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ABSTRACT 
Small bowel allograft recipients require multiple medications after transplant, many of 
which are orally administered cytochrome P450 3A (CYP3A) and/or p-glycoprotein (p-gp) 
substrates.  A previous study in dogs has shown that surgical manipulation of the intestine and 
ischemia-reperfusion injury lead to suppression of CYP3A and p-gp function in the early post-
transplant period, presumably due to release of pro-inflammatory cytokines, a suppression that 
diminished over time.  The work presented in this dissertation compares intestinal CYP3A (using 
midazolam) and p-gp (using fexofenadine) expression and function in small bowel transplant 
recipients in the early post-transplant period (the first 40 days after surgery, n=16) and later (four 
to 12 months) post transplant (n=10) as well as with age- and gender-matched (n=16) healthy 
control subjects.   
Oral AUC and oral bioavailability of midazolam were significantly higher in transplant 
subjects early post-transplant, but not different from controls at four to 12 months post-
transplant.  The oral AUC ratio of 1’hydroxymidazolam to midazolam, a measure of the extent 
of CYP3A-mediated metabolism, was significantly lower in the early post-transplant period 
compared with controls, but at the later period no difference was observed.  No difference in 
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fexofenadine AUC was observed between subject groups, and although Tmax of fexofenadine 
was significantly higher in transplant subjects at both time periods compared with healthy 
controls, AUC and Cmax were more influenced by route of administration (jejunostomy tube vs. 
oral) and transplant subtype (modified multivisceral vs. isolated intestine) than by ileal ABCB1 
expression.  Dose-normalized AUC0-7 and Cmax of oral tacrolimus (a CYP3A/p-gp substrate) 
were significantly higher early post transplant compared with later.   
Overall this work presents strong evidence for an early immune-mediated suppression of 
intestinal CYP3A that eventually returns to normal in stable intestinal transplant patients, 
indicating that bioavailability of highly soluble, highly permeable CYP3A substrates such as 
midazolam will be significantly higher early post-transplant, requiring caution in their dosing 
during this time and by extrapolation, during other times of high immune activation, such as 
acute rejection.  These findings have clinical relevance for appropriate medication use in small 
bowel transplant recipients. 
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1.0  INTRODUCTION 
1.1 FUNCTIONAL ANATOMY AND PHYSIOLOGY OF THE SMALL INTESTINE 
1.1.1 Structure 
The small intestine is the major site of drug absorption after oral administration. Therefore, an 
understanding of factors that affect its function is critical to comprehending changes in drug 
absorption after small bowel transplantation.  The small intestine is an organ approximately six 
meters in length that extends from the pyloric sphincter of the stomach to the ileocecal valve that 
marks the beginning of the colon.  It is composed of three parts:  the duodenum, approximately 
12 cm in length; the jejunum, approximately 2.5 m long, which is the major site of most drug and 
nutrient absorption due to the maximization of absorptive surface area resulting from the large 
number of folds and small, fingerlike structures called villi; and the ileum, approximately two to 
four meters long, narrower and containing fewer folds and villi(Rubin, 2009).   
The small intestine is composed of four layers: the serosa, the muscularis propria, the 
submucosa, and the mucosa (See Figure 1).  The serosa is the thin outermost layer, containing 
connective tissue and covered with a layer of mesothelial cells.  The next layer, the muscularis 
propria, contains two separate layers of smooth muscle cells—the outermost layer composed of 
cells arranged longitudinally and the thicker inner layer containing circular muscle cells.  
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Between the two sublayers lies the myenteric or Auerbach’s plexus, a nerve plexus composed of 
ganglia and connecting nerve fibers(Furness et al., 2009).  The muscularis propria is the layer 
mainly responsible for intestinal contractility(Kahn and Daum, 2010).   The next layer, the 
submucosa, is a dense layer that is highly vascularized and contains the Meissner plexus, a 
plexus of autonomic nerve fibers that communicates with the myenteric plexus to coordinate 
peristalsis(Rubin, 2009).   
The innermost layer of small intestine is the mucosa, which consists of a base layer of 
smooth muscle cells called the muscularis mucosae, a connective tissue layer called the lamina 
propria that contains many blood vessels, lymphoid tissue, lymphatic channels, additional nerve 
and muscle fibers, and fibroblasts, and lastly the single-layered epithelium, which is directly 
exposed to the lumen.  The lamina propria is the main site of the mucosa-associated lymphoid 
tissue (MALT), and is the location of T and B lymphocytes involved in intestinal immune 
responses.  Lining the lamina propria is a single layer of epithelial cells, mainly the absorptive, 
columnar cells called enterocytes but also the mucus-producing goblet cells and the microfold 
(M) cells that are located over lymphoid aggregates(Standring et al., 2008).   
The mucosa of the intestine is designed to maximize the surface area exposed to the 
lumen.  Ridges in the submucosa force the mucosa into circular folds, and the entire mucosal 
surface is covered with small projections called villi, each of which contains a lymphatic vessel 
called a lacteal as well as blood vessels, nerve cells, and smooth muscle cells.  Between and at 
the bases of the villi are indentations called crypts.  The crypts are the site of development of the 
enterocytes through stem cell mitosis.  The enterocytes mature as they migrate up the side of the 
villus and reach full maturity at the tip, where they undergo apoptosis and are shed into the 
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lumen.  The total lifespan of an enterocyte is approximately five days(Standring et al., 2008).  
The enterocyte is the key cell for intestinal drug absorption and metabolism. 
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Figure 1.  The architecture of an intestinal villus 
 
Reprinted from Healy et al. (Healy et al., 2005) with permission of Elsevier, Inc. 
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1.1.2 Gastrointestinal motility 
The distal portion of the stomach is responsible for the grinding of foods and regulation of the 
emptying of solids.  During times of fasting, a pattern of motor activity called the migrating 
motor complex (MMC) works to clear the stomach and upper intestine of any food residue 
and/or sloughed cells and mucus.  In a healthy person, the entire MMC cycle lasts approximately 
84-112 minutes and is comprised of three phases.  The first phase is a quiet period of slow 
pressure waves in which high-pressure contractions are entirely absent.  The second phase is 
marked by irregular contractions that increase in frequency.  The third and final phase, which 
lasts five to ten minutes, consists of intense contractions that typically start in the stomach and 
propagate sequentially down the gastrointestinal tract from the stomach to the colon.  Five to ten 
minutes after a meal, intermittent contractions of the stomach, similar to the second phase of the 
MMC, lead to emptying of the gastric contents(Hasler, 2009b).  It is important to note that the 
rate of gastric emptying depends strongly on the type of “meal” ingested.  Solids are emptied 
most slowly from the stomach, with a lag time of up to one hour.  Gastric emptying rates of 
liquids depend on the properties of the liquid.  Inert aqueous solutions are emptied most rapidly, 
with a half-life of approximately 8 to 18 minutes, in a process conforming to the principles of 
first order kinetics.  Particulate suspensions, high-fat, high-protein, and high-calorie liquids 
empty significantly more slowly, with an initial rapid phase of emptying followed by a slower 
phase exhibiting zero-order kinetics(Barrett, 2006; Hasler, 2009b). 
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Figure 2.  Gastric emptying times by content 
 
Reprinted from Barrett (Barrett, 2006) by permission of McGraw-Hill. 
 
After emptying into the small intestine, the stomach contents are mixed with bile and 
pancreatic enzymes and propelled through the gastrointestinal tract, largely by the circular 
muscle of the muscularis externa.  In a healthy person, the time of transit through the entire 
length of the small intestine is typically between 78 and 264 minutes(Hasler, 2009a; McConnell 
et al., 2008).   During this time the intestinal contents in the lumen come into contact with the 
enterocytes and absorption into the systemic circulation may occur. 
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1.1.3 Gastrointestinal transit of pharmaceutical dosage forms 
Gastric emptying rates for pharmaceutical dosage forms follow a pattern similar to those shown 
above for various meals.  Drugs in solution form and those containing small drug pellets (less 
than 2 mm) have been shown to empty from the stomach rapidly and largely unaffected by 
whether or not the subject is in the fasted or fed state.   Large, single unit dosage forms such as 
matrix tablets and osmotic pump tablets often exhibit rapid gastric emptying in the fasted state, 
but in the postprandial state emptying is delayed.  A light meal will delay emptying less than a 
heavy meal(Davis et al., 1986).   
Once the formulation has emptied from the stomach into the small intestine, however, 
there appears to be no difference in small intestinal transit times between solutions, small pellets, 
and large single unit dosage forms in healthy individuals.  In addition, the presence of food in the 
stomach does not affect small intestinal transit of drugs(Davis et al., 1986; McConnell et al., 
2008).  There is nevertheless considerable inter-individual and intraday variability in transit 
times, with usual estimates ranging from approximately one to six hours.  The correlation 
between the MMC and intestinal transit times through the jejunum and ileum has been shown to 
be high, with mean speeds of 4.2 to 5.6 cm per minute for a non-disintegrating capsule very 
similar to the recorded MMC velocity of 4.7 cm per minute.  Transit times are not uniform 
throughout the three segments of the small intestine.  Passage through the duodenum is the most 
rapid, with transit times of a few seconds to a few minutes.  Colonic transit times show the most 
variability, with estimates typically ranging between 6 and 48 hours(McConnell et al., 2008). 
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1.1.4 Drug absorption via the enterocyte 
1.1.4.1 Solubility 
A drug must be dissolved before absorption can occur.  Dissolution of solid drug depends 
mostly on the solubility properties of the drug molecule although the amount of fluid in the 
gastrointestinal tract also plays a role, especially for poorly water-soluble compounds.  
Measurements of the total amount of fluid in the small intestine of healthy volunteers at any 
given time have ranged from 10 mL to 350 mL, with average values of 90, 105, and 165 mL 
reported in three separate small studies.  In addition, discrete pockets of fluid have been found in 
separate areas throughout the small intestine, indicating that fluid volumes are not consistent 
throughout the lumen.  Poorly soluble drugs consequently have the propensity to undergo 
dissolution in some areas and re-precipitation in others, leading to erratic patterns of 
absorption(Sutton, 2009). 
1.1.4.2 Paracellular absorption 
Intestinal absorption of drugs through the epithelium can occur by different pathways.  
The enterocytes of the small intestine are epithelial cells of the simple columnar type, each 
containing approximately 1000 luminal protrusions called microvilli made primarily of actin 
filaments(Washington et al., 2003b). This single layer of epithelium is designed to protect the 
deeper layers of the intestine as well as the bloodstream from direct contact with the contents of 
the intestinal lumen.  Therefore, the enterocytes and other cells of the small intestinal epithelium 
are bonded closely together by several different types of junctions. The most prominent of these 
is the tight junction, a structure formed by proteins from adjacent cell membranes wrapping 
around the cells such as to effectively eliminate intercellular space (the cell membranes are 
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within two Å of each other), and sealing off the layers of the intestine below the epithelial cell 
layer.  Intact tight junctions are impermeable to most substances, including most drug molecules.  
The paracellular space left by tight junctions has been estimated at 0.8 nm in the jejunum and 0.3 
nm in the ileum(Washington et al., 2003a).  Despite this, a few drugs are absorbed via the 
paracellular pathway, through aqueous pores in tight junctions.  In general, these are hydrophilic 
molecules with a molecular weight less than 250(Reynolds et al., 2009). 
1.1.4.3 Transcellular absorption and permeability 
Most drugs are absorbed into the systemic circulation via the transcellular route (i.e. by 
entering the enterocyte via the plasma membrane on the luminal side and exiting via the 
basolateral). The plasma membrane, which is designed to hold the contents of the cell and act as 
a barrier to permeability, is essentially a bilayer of phospholipid surfactants in which various 
integral proteins are embedded. Drug molecules and other compounds may enter and exit 
through the membrane via diffusion or transport(Washington et al., 2003a).  In order to be 
absorbed, a drug must not only be dissolved in the fluid of the intestine, but must also be 
permeable through the enterocyte membrane.   
The pH of the intestinal milieu and the pKa will both affect the solubility and 
permeability of a drug.  The generally accepted pH partition hypothesis states that for organic 
molecules only the un-ionized form of the compound can penetrate the cell membrane and be 
absorbed.  According to this theory, the membrane permeation of a drug in any segment of the 
GI tract depends not only on the pH of the intestinal segment, but also on the pKa of the drug.  
Every drug will have a distribution coefficient, D, defined as: 
log D = log P + log fU = log P + log(1-fI) 
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where fU is the un-ionized fraction of the drug and fI the ionized fraction(Granero et al., 2003).  
The pH of the GI tract varies greatly between intestinal segments and between individuals, and 
also between health and disease.  However, in healthy people it is generally assumed that while 
the pH of gastric fluid is 1-2.5, the pH increases distally to approximately 5.5 in the duodenum, 
6.6 in the jejunum and 7.5 in the ileum(McConnell et al., 2008).   
Although the cell membrane is phospholipid-based and thus most accessible to 
hydrophobic and un-ionized molecules, in order to be absorbed a drug must also diffuse across 
the unstirred water layer (UWL), a stagnant coating approximately 30-100 µm in thickness and 
composed of water, mucus, and glycocalyx, that exists at the epithelial barrier(Lennernas, 1998; 
Reynolds et al., 2009).  Since solubility and permeability are the two driving forces behind drug 
absorption, a drug compound must be hydrophilic enough to be reasonably soluble in the 
relatively aqueous medium of the luminal contents (including the UWL), as well as lipophilic 
enough to cross the cell membrane.  Therefore, drugs with very high or very low octanol:water 
partition coefficient (LogP) values are not likely to be well absorbed.  In addition, the molecular 
weight of a drug will also affect its absorbability, since larger molecules diffuse more slowly 
across the membrane(Washington et al., 2003a).  
 Lipinski proposed the “rule of 5” to assess a drug’s likelihood of poor membrane 
permeability and thus poor oral absorption.  The rule states that low permeability is likely when 
the drug compound has a molecular weight greater than 500; contains more than five hydrogen-
bond donors (the sum of –OHs and -NHs); contains more than 10 hydrogen-bond acceptors (the 
sum of Ns and Os); and the calculated LogP is greater than five.  Although the rule was 
developed to aid in weeding out poor drug candidates in the drug development process, a few 
drugs that meet all of the rule of five criteria are still orally active and in use today, including 
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certain vitamins, cardiac glycosides, antibiotics and antifungals whose absorption is aided by 
transporter proteins.  Examples of currently-marketed drugs that meet the rule of five criteria for 
low permeability are azithromycin, cyclosporine, erythromycin, itraconazole, and 
methotrexate(Lipinski et al., 2001).  
1.1.4.4 The Biopharmaceutic Classification System 
With the understanding that the rate and extent of drug absorption depend largely on a 
drug molecule’s dissolution in intestinal fluid and permeability into the enterocyte, Amidon et al. 
extended this concept by the creation of the Biopharmaceutic Classification System (BCS), 
which assigns drug compounds to one of four classes based on the compound’s solubility and 
permeability.  The central premise of the BCS is based on Fick’s law of diffusion, JW = PW x CW, 
where JW is the drug flux through the intestinal wall, PW is the permeability of the membrane, 
and CW is the drug concentration at the membrane(Amidon et al., 1995).  Solubility of a drug is 
calculated in aqueous media at 37°C at several points in the pH range of 1 to 7.5, chosen 
depending on the pKa of the drug(FDA, 2000).  The four BCS classes are shown in figure 3. 
BCS class I compounds (high solubility, high permeability) are well absorbed through the 
enterocyte membrane.  High solubility is defined as the highest dose strength of the compound 
that is soluble in less than or equal to 250 mL of aqueous media over pH of 1 to 7.5.  Class I 
compounds dissolve rapidly in gastrointestinal fluid, and if contained in an immediate-release 
formulation, their absorption rate will be controlled primarily by the rate of gastric emptying.  In 
the fasted state in healthy people, the gastric emptying half life is 22 minutes for an administered 
volume of 200 mL(Amidon et al., 1995).  Examples of orally-administered BCS class I drugs 
include metoprolol (often used as a reference drug for permeability), midazolam, diltiazem, 
diphenhydramine, and valproic acid(Takagi et al., 2006).
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Figure 3.  The original Biopharmaceutic Classification Stystem as proposed by Amidon et al.   
For BCS class II compounds (low 
solubility, high permeability), drug dissolution 
throughout the segments of the intestine is the 
rate-limiting step for the absorption process, 
which tends to be slower and more variable than 
for class I compounds, as the compounds move 
through the varied pH, fluid, and absorptive 
conditions in the different sections of the GI tract(Amidon et al., 1995).  As noted previously, 
their low solubility may lead to pockets of drug precipitation and re-dissolution in various 
segments of the intestine according to fluid volume and composition, leading to erratic 
absorption profiles(Sutton, 2009).  Orally-administered members of BCS class II include 
tacrolimus, cyclosporine, phenytoin, sirolimus, voriconazole, and warfarin(Takagi et al., 2006). 
 Permeability through the cell membrane is the rate-limiting step in the absorption 
process for drugs in BCS class III (high solubility, low permeability).  Rate and extent of 
absorption may be quite variable for compounds in this category.  In the case of immediate-
release dosage forms, however, if dissolution is fast, variability in absorption will depend upon 
variations in intestinal transit times, composition of the luminal contents, and the ability of the 
drug to permeate the enterocyte membrane(Amidon et al., 1995).  Typical class III drugs include 
amoxicillin, doxycycline, fexofenadine, fluconazole, ganciclovir, lisinopril, and 
metformin(Takagi et al., 2006; Tannergren et al., 2002).   
BCS class IV drugs (low solubility, low permeability) are problematic in terms of oral 
absorption, and this class has the smallest number of members amongst currently marketed 
Class I 
High solubility 
High permeability 
Class II 
Low solubility 
High permeability 
Class III 
High solubility 
Low permeability 
Class IV 
Low solubility 
Low permeability 
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drugs.  However, some examples include nystatin, neomycin, amphotericin B, and 
colistin(Takagi et al., 2006), all of which are used clinically for gut decontamination prior to 
surgery, and in the case of nystatin and amphotericin B, for treatment or prevention of candida 
esophagitis in immunosuppressed patients.  In both these situations, the medications are used for 
their local effects after oral administration and absorption into the systemic circulation is not 
desired. 
1.1.5  Absorption via uptake transporters 
For many drugs, reaching the systemic circulation depends on more than solubility and 
permeability.  Many exogenous substances are actively transported across the enterocyte 
membrane by means of uptake transporter proteins.  Figure 2 is a simplified drawing of 
transporter locations at both the apical (luminal) and basolateral (blood) side of the enterocyte.  
Uptake transporters playing a significant role in drug disposition include the organic anion 
transporting polypeptides 1A2 and 2B1 (OATP1A2 and OATP2B1) and the peptide transport 
proteins PEPT1 and PEPT2.  Uptake transporters expressed on the apical side of the enterocyte 
membrane include the monocarboxylate transporter protein 1 (MCT1), the organic cation 
transporter 3 (OCT3), the apical sodium-dependent bile acid transporter (ASBT), the 
electroneutral organic cation transporters OCTN1 and OCTN2, and the concentrative nucleotide 
transporters CNT1 and CTN2(Klaasen and Aleksunes, 2010; Shugarts and Benet, 2009), while 
those expressed on the basolateral side include OATP3A1 and OATP4A1 and OCT1 and 
OCT2(Shugarts and Benet, 2009). 
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1.1.5.1 Organic anion transporting polypeptides 
The organic anion transporting polypeptides (OATPs) are a superfamily of uptake 
transporters expressed in many tissues, including the sinusoidal membrane of hepatocytes, the 
blood-brain barrier, and the apical and basolateral membranes of enterocytes.  The OATPs are 
encoded by SLCO gene family members located on chromosome 12(Hagenbuch and Gui, 2008).  
In general, OATPs assist in cellular uptake of many endogenous and exogenous compounds, 
including bile acids, thyroid hormones, HMG CoA-reductase inhibitors (statins) and angiotensin 
II receptor antagonists.  OATP1A2, OATP2A1, and OATP2B1 are expressed on the apical side 
of the enterocyte membrane(Kalliokoski and Niemi, 2009) and OATP3A1 and OATP4A1 on the 
basolateral side(Shugarts and Benet, 2009).  A study in healthy volunteers found no significant 
differences in OATP2B1 mRNA expression between duodenum, ileum, and the three segments 
of the colon in biopsies obtained from normal human intestine(Meier et al., 2007). 
1.1.5.2   Other uptake transporters 
The peptide uptake transporter PEPT1 is expressed in equal amounts in the three regions of the 
small intestine, but at significantly lower levels in the colon.  PEPT1 substrates include 
oseltamivir(Ogihara et al., 2009), ganciclovir(Sugawara et al., 2000), and some beta-lactam and 
cephalosporin antibiotics(Balimane et al., 1998).   The electroneutral organic cation uptake 
transporters OCTN1 and OCTN2 are expressed throughout the small intestine and colon, but 
with higher levels in the colon than the intestine.  The high affinity concentrative nucleoside 
transporters CNT1 and CNT2 were detectable in duodenum and ileum, but not in any colonic 
segment, whereas the equilibrative nucleoside transporters ENT1 and ENT2 were only detected 
in the colon and not in the small intestine.  The apical sodium-dependent bile acid transporter 
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(ASBT) has been found at higher levels in the ileum than in the duodenum, and has not been 
detected in the colon.   
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Figure 4.  Simplified drawing of enterocytes with membrane transporters 
 
 
 
 
Adapted from Shugarts and Benet(Shugarts and Benet, 2009).  Efflux transporters are in blue and uptake 
transporters in green. 
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1.1.6 Enterocyte barriers to absorption: Efflux transport and intestinal first-pass 
metabolism 
The oral bioavailability of a drug is defined as the amount of drug that reaches the systemic 
circulation after oral administration.  Substances absorbed via the intestine may undergo first-
pass metabolism in the enterocytes of the intestine or the hepatocytes of the liver, since the 
intestinal blood supply drains ultimately to the portal vein and liver before reaching the systemic 
circulation.  For drugs absorbed by the transcellular route, bioavailability is mainly dependent on 
the fraction of dose absorbed through the enterocyte membrane (Fa), the fraction of drug that 
escapes from intestinal first-pass metabolism (Fg), and the fraction of drug that escapes from 
hepatic first-pass metabolism (Fh)(Dahan and Amidon, 2009).  Once absorbed, some drugs will 
also be pumped out of the enterocyte back into the intestinal lumen by efflux transporters. 
 Efflux transporters expressed on the apical side of the enterocyte include p-glycoprotein 
(p-gp), multidrug resistance associated protein 2 (MRP2), breast cancer resistance protein 
(BCRP), and multidrug resistance associated protein 4 (MRP4).  MRP4 is also expressed on the 
basolateral side of the membrane, along with multidrug resistance associated proteins 1, 3 and 5 
(MRP1, MRP3, MRP5).  Other efflux transporters on the basolateral side are MCT1 and 
equilibrative nucleoside transporters 1 and 23 (ENT1 and ENT2)(Klaasen and Aleksunes, 2010; 
Shugarts and Benet, 2009).   
Drug-metabolizing enzymes such as cytochrome P450s, UDP-glucuronosyltransferases, 
glutathione-S-transferases, sulfotransferases, and esterases located within the enterocyte may 
also reduce the amount of drug reaching the systemic circulation.  Many drugs are substrates for 
both the efflux pump p-glycoprotein and the drug metabolizing enzyme cytochrome P450 3A 
(CYP3A).  P-gp and CYP3A are proposed to work synergistically in the gut to prevent systemic 
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absorption of xenobiotics, with p-gp effluxing substrates back into the intestinal lumen to keep 
CYP3A metabolism from becoming saturated(Christians et al., 2005). 
1.1.6.1 P-glycoprotein 
Of the efflux transporters known to be expressed on the apical side of the enterocyte, the 
best studied and most relevant for drug disposition is p-glycoprotein.  P-glycoprotein (p-gp) is an 
ATP-dependent efflux transporter with a wide distribution in the human body, including the 
brush border of the apical membrane of enterocytes, the bile canalicular membrane of 
hepatocytes, the apical membrane of renal proximal tubular cells, blood cells, and capillary 
endothelial cells of the blood-brain barrier(Canaparo et al., 2007).  P-gp is encoded by the 
ABCB1 gene located on chromosome 7 in humans and its expression is regulated by the 
pregnane X receptor (PXR), a nuclear receptor that acts as a ligand-activated transcription 
factor(Watkins et al., 2001). 
P-gp transports a wide variety of xenobiotics, including tacrolimus, cyclosporine, 
sirolimus, fexofenadine, digoxin, loperamide, ketoconazole, levofloxacin, and numerous 
others(Klaasen and Aleksunes, 2010).  The expression pattern of p-gp in the intestine is generally 
assumed to be lowest in the proximal small intestine, with expression levels increasing 
throughout the GI tract and peaking in the colon(Thӧrn et al., 2005), although one study found 
the highest expression in the jejunum as compared with the ileum and colon(Berggren et al., 
2006).  Small amounts of p-gp have also been found in gastric tissue(Canaparo et al., 2007; 
Thӧrn et al., 2005). 
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1.1.6.2 Breast cancer resistance protein (ABCG2) 
Breast cancer resistance protein (BCRP) is an efflux transporter expressed on the apical 
membrane of enterocytes as well as in breast tissue, the liver, kidney, and blood-brain 
barrier(Giacomini et al., 2010).  It is encoded by the ABCG2 gene, whose regulation has not been 
fully elucidated, although dexamethasone(Narang et al., 2008) and 2-
acetylaminofluorine(Anapolsky et al., 2006) have induced its upregulation, indicating roles for 
the glucocorticoid receptor and PXR, respectively.  Ciprofloxacin(Haslam et al., 2011), 
nitrofurantoin(Wright et al., 2011), imatinib(Krishnamurthy and Schuetz, 2006), and 
acyclovir(Gunness et al., 2011) are substrates of BCRP, among others. 
1.1.6.3 Multidrug resistance proteins 
Multidrug resistance protein 2 (MRP2) is an efflux protein located on the apical 
membrane of enterocytes as well as in the bile canalicular membrane of hepatocytes and the 
kidney proximal tubule(Takano et al., 2006).  It is encoded by the ABCC2 gene, which is 
regulated by the nuclear receptors PXR, constitutive androstane receptor (CAR) and farnesoid X 
receptor (FXR)(Choudhuri and Klaasen, 2006).  Substrates of MRP2 include methotrexate, 
various prostaglandins, and glucuronide conjugates such as conjugated bilirubin, estradiol 17-β-
D-glucuronide, acetaminophen-glucuronide, pravastatin, and ampicillin(Choudhuri and Klaasen, 
2006).  Its expression levels have been shown to be highest in the jejunum, decreasing to lowest 
levels in the colon(Berggren et al., 2006).  MRP3 (ABCC3) has much overlapping substrate 
specificity with MRP2, and has been shown to be regulated by PXR(Anapolsky et al., 2006) and 
CAR(Choudhuri and Klaasen, 2006). 
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1.1.6.4 Cytochrome P450 enzymes 
The cytochrome P450 (CYP) enzymes are a superfamily of heme-containing enzymes 
responsible for metabolism of many endogenous compounds as well as for the oxidative 
metabolism of as many as 80% of commonly used drugs(Wilkinson, 2005).  The CYP3A family 
accounts for approximately 50% of CYP content in the liver(Wilkinson, 2005) and 
approximately 82% of jejunal CYP content(Paine et al., 2006).  Of the other CYP enzymes 
expressed in the small intestine, CYP2C9 accounts for at most approximately 14%, and very 
small amounts of CYP2C19 (2%), CYP2D6 (0.7%), and CYP2J2 (approximately 1.4%) protein 
have also been detected(Paine et al., 2006). Although expression levels of CYP3A in the 
intestine are approximately 1% of those in the liver(Paine et al., 2006), intestinal CYP3A plays a 
vital role in intestinal first-pass metabolism of substrates after oral administration.  Examples of 
medications whose bioavailabilities are strongly affected by intestinal CYP3A content include 
the immunosuppressive medications tacrolimus and cyclosporine, calcium channel blocker 
antihypertensives, HIV protease inhibitors, and HMG-CoA reductase inhibitors.  The 
benzodiazepine sedative-hypnotic drug midazolam is metabolized nearly exclusively by CYP3A, 
and therefore is often used as a probe to assess CYP3A phenotype. 
There are two major CYP3A isoforms expressed in human adults, CYP3A4 and 
CYP3A5, and expression is regulated by PXR(Bertilsson et al., 1998; Lehmann et al., 1998).  
Although CYP3A is expressed throughout the small intestine, it is generally agreed that within 
the GI tract, CYP3A expression is highest in the duodenum and jejunum and gradually declines 
further along through the ileum, reaching its lowest levels in the colon(Berggren et al., 2006; 
Paine et al., 1997).  Small amounts of CYP3A4 and CYP3A5 mRNA and protein have also been 
detected in gastric tissue(Canaparo et al., 2007; Thӧrn et al., 2005). 
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1.1.6.5 UDP-glucuronosyltransferases  
The UDP-glucuronosyltransferases (UGTs) are a superfamily of conjugating enzymes 
widely distributed in the body, with several isoforms found in the small intestine, located on the 
endoplasmic reticulum of the enterocyte.  The UGTs use UDP-glucuronic acid as a co-substrate 
in glucuronidation reactions that make compounds more water soluble to facilitate renal 
excretion.  The UGTs form glucuronide conjugates of many drug metabolites created by CYP 
enzymatic reactions, but some endogenous and exogenous compounds undergo direct 
glucuronidation, including bilirubin, steroid hormones, morphine, and mycophenolic acid(Kiang 
et al., 2005).  The UGT isoenzymes known to be expressed in the GI tract are UGT 1A1, 1A3, 
1A4, 1A5, 1A6, 1A7, 1A8, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B28(Finel et al., 2005; Gregory 
et al., 2004).  Of these, UGT1A7, 1A8, and 1A10 are exclusively found in the GI tract, where 
their expression is regulated by cooperation of the transcription factors hepatocyte nuclear factor 
1 alpha (HNF1α) and caudal related homeodomain protein 2 (Cdx2)(Gregory et al., 2004).    
1.1.6.6 Other drug-metabolizing enzymes expressed in the enterocyte 
Other drug-metabolizing enzymes expressed in the enterocytes of the small intestine 
include glutathione-S-transferases (GSTs), sulfotransferases, and esterases.  GSTs are a family of 
enzymes that conjugate compounds with glutathione thus making them more water soluble and 
easily excreted, and for which azathioprine is a substrate.  GSTs of the alpha class have been 
found in the jejunum, ileum, and colon(Peters et al., 1989).    Sulfotransferases catalzye sulfation 
reactions that add sulfate to phenolic and hydroxyl functional groups and amines, including 
acetaminophen and terbutaline(Beaumont, 2003).  Lastly, esterases are responsible for catalyzing 
the hydrolysis of ester bonds.  Many prodrugs, including oseltamivir phosphate, valganciclovir, 
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olmesartan medoxomil, benazapril, and enalapril, are rapidly hydrolyzed to their active 
metabolites by esterases inside the enterocyte(Beaumont, 2003; Benet et al., 2011).   
1.1.6.7 The Biopharmaceutics Drug Disposition Classification System 
Further insight into bioavailability can be derived from consideration of the 
Biopharmaceutics Drug Disposition Classification System (BDDCS), which was developed by 
Wu and Benet to build upon the BCS.  Wu and Benet noted that the majority of BCS class I and 
II drugs (highly permeable) were extensively metabolized (many by CYP3A) and that the 
majority of class III and IV drugs were poorly metabolized with mostly renal and/or biliary 
excretion.  The BDDCS reflects the fact that although drug compound solubility is easy to 
measure in vitro, permeability is less so and values may vary depending on the system used.   
For drugs for which intestinal permeability is known from in vivo studies, a high 
correlation between jejunal permeability and metabolism is observed, which is higher than the                                                                                                                                        
observed correlation between jejunal permeability and LogP.  The fact that the BCS fails to take 
transporter effects into account is also an important consideration, for while in vitro-in vivo 
permeability measurements are highly correlated for drugs absorbed via passive diffusion, drugs 
absorbed via uptake transporters may deviate significantly from this relationship.  Some drugs, 
such as cefadroxil, levofloxacin, pregabalin, and sotalol, have shown low permeability but are 
well absorbed, probably due to uptake transporter effects(Lennernas and Abrahamsson, 2005).  
Given that most drugs on the market are substrates for enzymes and/or transporters, Benet et al. 
have now classified more than 900 drugs using the BDDCS (see figure 5)(Benet et al., 2011).  
Medications relevant to small bowel transplant recipients listed by BDDCS class appear in Table 
1 of this chapter and will be discussed in a future section.   
      
  23 
Figure 5. The Biopharmaceutics Drug Disposition Classification System as proposed by Wu and Benet 
 (Benet, 2009) 
Class I 
High solubility 
Extensive metabolism 
Transporter effects minimal in 
intestine and liver 
Class II 
Low solubility 
Extensive metabolism 
Efflux transporter effects 
predominate in intestine, but 
both uptake and efflux effects 
play a role in liver 
Class III 
High solubility 
Poor metabolism 
Uptake transporter effects 
predominate, but effects may be 
modulated by efflux transporters 
Class IV 
Low solubility 
Poor metabolism 
Uptake and efflux transporters 
may play role 
 
BDDCS class I drugs exhibit high solubility and are extensively (greater than 70%) 
metabolized.  Transporter effects are minimal for members of this class of compounds, even if a 
drug is a transporter substrate in vitro.  Class I includes many of the same compounds as class I 
of the BCS, including midazolam and metoprolol, as well as the prodrugs activated by intestinal 
esterases discussed previously.  These prodrugs such as enalapril are designed to reduce 
hydrophilicity of the active moiety and increase permeability across the intestinal wall.  
Members of BDDCS class II exhibit low solubility but are extensively (greater than 70%) 
metabolized.  If a class II compound is a transporter substrate, the effects of efflux transporters 
such as p-gp will predominate in the intestine, although both uptake and efflux transporters will 
affect its disposition in the liver.   
BDDCS class III drugs are highly soluble and poorly (less than 30%) metabolized.  Many 
members of this class depend on uptake transporters such as PEPT1 and PEPT2 and the OATPs 
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for absorption.  The active metabolites of the prodrugs mentioned in the previous section, 
including oseltamivir, ganciclovir, benazeprilat, enalaprilat, and olmesartan, all belong to class 
III of the BDDCS, as do fexofenadine, many of the cephalosporin antibiotics, digoxin, and 
famotidine.  Finally, BDDCS class IV compounds are poorly soluble and poorly metabolized, 
but their disposition may be affected by either uptake or efflux transporters to some extent.  
Examples of class IV compounds include acyclovir, atovaquone, ciprofloxacin, furosemide and 
valsartan(Benet, 2009; Benet et al., 2007; Benet et al., 2011).   
1.2 INTESTINAL FAILURE 
Intestinal failure is a serious condition in which the absorptive capacity of the intestine is 
severely impaired.  “Intestinal failure,” O’Keefe et al. state in their consensus document on short 
bowel syndrome and intestinal failure, “results from obstruction, dysmotility, surgical resection, 
congenital defect, or disease-associated loss of absorption and is characterized by the inability to 
maintain protein-energy, fluid, electrolyte, or micronutrient balance.”(O'Keefe et al., 2006).  
Some of the more common causes of intestinal failure include resections due to Crohn’s disease, 
intestinal trauma, or thrombosis of a superior mesenteric vein or artery, and conditions in which 
the full length of the non-functioning bowel often remains, including intestinal pseudo-
obstruction syndrome, radiation enteritis, or congenital villus atrophy(Buchman et al., 2003).  
Patients with intestinal failure are dependent on intravenous fluids and nutrition to sustain life.  
Daily dependence on total parenteral nutrition (TPN) is associated with significant health risks 
over time, including liver disease and sepsis due to line infection(Cavicchi et al., 2000; O'Keefe 
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et al., 1994).  Currently, intestinal transplantation is the only permanent treatment for irreversible 
intestinal failure. 
1.3 INTESTINAL TRANSPLANTATION 
The three main types of transplant that include a small intestine are the isolated intestinal 
transplant (Figure 6), in which the jejunoileum is transplanted; the combined liver-intestine 
transplant; and the multivisceral transplant, which includes the liver, stomach, duodenum, 
pancreas, and jejunoileum(Fishbein, 2009).  A subtype of multivisceral transplant, the modified 
multivisceral (Figure 7), includes all of the preceding except the liver.  In some cases of modified 
multivisceral transplantation, the native splenopancreaticoduodenal complex (native spleen, 
pancreas, and a portion of native duodenum) is retained, with the native segment of duodenum 
anastomosed to the transplanted duodenum in a side to side fashion(Cruz Jr et al., 2010), while in 
others the spleen is preserved but the native pancreaticoduodenal complex is removed(Cruz Jr et 
al., 2011).  In the latter case and in cases of modified multivisceral transplantation in which no 
native spleen or pancreaticoduodenal complex is retained, a T-tube is placed to connect the 
native and transplanted portions of the bile duct.  In addition, during multivisceral transplantation 
a pyloroplasty is performed on the transplanted stomach to facilitate gastric emptying(Cruz Jr et 
al., 2010). 
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1.3.1 Isolated intestinal transplant graft drainage 
In isolated intestinal transplant recipients, the venous outflow from the graft is sometimes 
arranged to drain directly into the systemic circulation via the vena cava rather than via the portal 
vein(Abu-Elmagd et al., 2009; Fishbein, 2009).  This is illustrated in the upper insert of Figure 6.  
This has occurred in 52% of the isolated intestinal transplants performed at the University of 
Pittsburgh Medical Center between July 2001 and November 2008(Abu-Elmagd et al., 2009).  
The presence of the caval graft drainage arrangement is an important consideration for drug 
dosing, since hepatic first-pass metabolism of orally administered highly metabolized drugs will 
be bypassed, leading to greater bioavailability.  In a study comparing the effects of portal 
systemic drainage (n=19 patients) with caval systemic drainage (n=18 patients), mean oral 
tacrolimus dosage requirements were nearly double in the patients with portal drainage as 
compared with the patients with systemic drainage (0.55±0.09 vs. 0.23±0.05 mg/kg/day, 
p=0.02), despite no significant difference in mean tacrolimus trough levels between the two 
groups (12.6 ±1.6 for portal vs. 12.0±1.3 ng/mL for systemic)(Berney et al., 2002).  This shows 
that the bioavailability and therefore the dosing requirements of orally-administered drugs in 
which first-pass metabolism plays an important role will be significantly increased in patients for 
whom the transplanted graft drains into the vena cava rather than the portal venous system.
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Figure 6.  Isolated intestinal transplantation 
 
Reprinted from Kocoshis et al. (Kocoshis et al., 1997) with permission of Springer Publishing. 
Isolated small bowel transplantation: (B) Recipient operation. Anastomosis of the full length of SMA to the aorta 
and the angled end of the SMV to the portal vein. In an alternative method the SMV is anastomosed to the recipient 
SMV inferior to the pancreas (lower insert). Option of SMV drainage into the inferior vena cava is shown in upper 
insert. 
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Figure 7.  Modified multivisceral transplantation 
 
Reprinted from Cruz et al. (Cruz Jr et al., 2010) with permission of Springer Publishing. 
 
1.3.2 Medication use after small bowel transplantation 
Small bowel transplant recipients require numerous medications after transplant.  In the first 
three or four days post-transplant, the recipient receives all medications intravenously, including 
the primary immunosuppressive drug tacrolimus.  After stabilization of the blood concentrations 
of tacrolimus at 10 to 15 ng/mL, tacrolimus and some other enteral medications are given via the 
jejunostomy tube (J-tube) placed during surgery.  These are mostly liquid formulations 
(tacrolimus suspension, sulfamethoxazole-trimethoprim solution) but in some cases tablets must 
be crushed and mixed with water before being administered via the tube.  At this point, the 
patient still has a nasogastric tube (NG tube) in place draining liquid from the stomach in order 
to prevent aspiration due to post-surgical gastroparesis. Medication administration via J-tube 
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allows delivery to the major site of intestinal medication absorption while bypassing the effects 
of impaired gastric emptying.   
When the NG tube is no longer draining significant amounts of liquid (usually within 14 
days post-transplant) it is removed and patients begin transitioning to taking medications by 
mouth.  These are usually solid dosage forms (tables or capsules) to allow the patient to learn 
about and recognize the oral medications and dosage forms they will be self-administering at 
home.  A typical outpatient oral medication regimen for a small bowel transplant patient includes 
the immunosuppressive drug tacrolimus, an oral corticosteroid such as hydrocortisone or 
prednisone, sulfamethoxazole-trimethoprim or dapsone for Pneumocystis carinii pneumonia 
prophylaxis, ganciclovir for cytomegalovirus prevention, and magnesium, calcium, vitamin B6, 
and vitamin D supplements.  In addition, many patients require oral psychotropic medications 
such as sertraline, haloperidol, mirtazepine, and trazodone, and perhaps zolpidem for sleep or 
hydromorphone or methadone for pain control.  Many also take oral antihypertensives such as 
calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin II 
receptor antagonists.  Most of these medications are substrates for CYP3A and/or transporters.  
Oral medications commonly used in small bowel transplant recipients, arranged by BDDCS 
class, are listed in Table 1. 
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Table 1.  Oral medications relevant to small bowel transplant recipients by BDDCS class 
Class I 
High Solubility 
High permeability/ 
metabolism 
If a substrate, transporter 
effects minimal  
Class II 
Low Solubility 
High permeability/ 
metabolism 
If a substrate, efflux 
transporter effects 
predominate in intestine 
Class III 
High Solubility 
Low permeability/ 
metabolism 
If a substrate, uptake 
transporter effects 
predominate over efflux 
Class IV 
Low Solubility 
Low permeability/ 
metabolism 
If a substrate, efflux and 
uptake transporters may 
play role 
Acetaminophen  
(UGT1A1, 1A6) 
Acitretin  
(p-gp) 
Adefovir  
(MRP1) 
Acyclovir  
(OCT1, BCRP) 
 
Amlodipine  
(CYP3A) 
Allopurinol Amoxicillin  (PEPT1, 2) Atovaquone 
 
Azathioprine  
(Glutathione-S-transferase) 
Amiodarone HCl  
(CYP2C8, 3A, p-gp) 
Ampicillin  
(MRP2, PEPT1, 2) Candesartan 
 
Benazepril 
(prodrug-hydrolysis to 
benazeprilat-see Class III) 
Calcitriol Atenolol (CYP2D6) Cefdinir 
Bupropion 
Carvedilol 
(CYP2D6, UGT1A1, 2B4, 
2B7, p-gp) 
Azithromycin  
(MRP2) 
Cefixime  
(PEPT2) 
Cholecalciferol (Vit. D3) 
(hydroxylation) 
 
Citalopram  
(CYP2C19) 
Benazaprilat (active 
metabolite) Cefpodoxime 
 
Clonazepam  
(CYP3A) 
Clofibrate  
(UGT1A3) Biotin Cefprozil 
Cyanocobalamin (Vit. B12) Clopidogrel busulfate (CYP2C19) Bumetanide 
Ceftibuten  
(PEPT1, 2) 
Desogestrel  
(CYP2C9) Clotrimazole 
Captopril  
(PEPT1, 2) 
 
Ciprofloxacin  
(OATP1A2, BCRP) 
 
Dextromethorphan HBr 
(CYP2D6, 3A) 
Cyclosporine  
(CYP3A, p-gp) 
Cefaclor 
(PEPT1, 2) Furosemide  
 
Diltiazem  
(CYP3A, p-gp) 
Dapsone  
(CYP3A) 
Cefadroxil  
(PEPT1, 2) Levonorgestrel 
 
Diphenhydramine  
(CYP2D6, UGT1A4) 
Ergocalciferol (Vit. D2) Cefamandole  (PEPT1, 2) 
Nitrofurantoin  
(BCRP) 
 
Enalapril  
(prodrug—converted to 
enalaprilat-see Class III) 
Ezetimibe  
(UGT1A1, 2B7) Cefazolin Penicillin V 
 
Escitalopram  
(CYP2C19, 3A) 
Felodipine  
(CYP3A) Cefuroxime Riboflavin (Vit. B2) 
 
Esomeprazole magnesium 
(CYP2C19, 3A) 
Folic acid  
(MRP1) 
Cephalexin  
(PEPT1, 2) Rifaximin 
 
Estradiol  
(CYP3A, UGT2B28) 
Gemfibrozil 
(UGT2B7) Cetirizine 
Valsartan  
(MRP2) 
 
Ethinyl Estradiol  
Glipizide  
(CYP2C9) Clavulanic acid  
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(UGT1A1) 
 
Fludrocortisone acetate 
 
Glyburide  
(CYP2C9, OATP2B1) 
 
Clonidine  
(CYP2D6) 
 
Fluoxetine  
(CYP2D6, p-gp) 
Haloperidol  
(CYP2D6, 3A) 
 
Digoxin  
(p-gp) 
 
Hydralazine HCl  
(acetylation – liver) 
Irbesartan  
(CYP2C9) 
 
Doxycycline  
(p-gp) 
 
Hydrocodone  
(CYP2D6) 
Isradipine  
(CYP3A) 
 
Enalaprilat (active metabolite) 
(PEPT1) 
 
Hydrocortisone  
(CYP3A, 2D6) 
Itraconazole  
(CYP3A, p-gp) 
 
Famotidine  
(p-gp, OCT2) 
 
Hydromorphone  
(UGT1A3, 2B7) 
Lansoprazole  
(CYP2C19, p-gp) Ferrous sulfate  
 
Labetalol  
(CYP2D6, UGT1A1, 2B7) 
Leflunomide Fexofenadine  (p-gp, OATP1A2, 2B1)  
 
Linezolid  
(oxidation-liver) 
Levothyroxine  
(OATP1A2, 3A1, 4A1) 
Fluconazole  
(p-gp)  
 
Methadone  
(CYP2D6, 3A, p-gp) 
Loratadine  
(CYP2D6, 3A) Gabapentin  
Methylphenidate Losartan potassium  (CYP2C9, p-gp) 
Ganciclovir sodium  
(PEPT1, OCT1)  
Metoprolol  
(CYP2D6) 
 
Nifedipine  
(CYP3A) 
Levetiracetam  
Metronidazole  
(CYP2C9)* 
 
Nimodipine  
(CYP3A) 
Levocetirizine  
 
Midazolam HCl  
(CYP3A) 
Nitrendipine  
(CYP3A) 
Levofloxacin  
(p-gp, OATP1A2)  
 
Mirtazapine  
(CYP2D6, 3A, 2C19) 
Norethindrone acetate Lisinopril  (PEPT1)  
Niacin, nicotinic acid Olanzapine  (UGT1A4) Loperamide (p-gp)  
Niacinamide, nicotinamide 
 
Paricalcitol  
(CYP24, 3A, UGT1A4) 
Metformin  
(OCT1, OCT2)  
Nicardipine  
(CYP3A, p-gp) 
 
Phenytoin sodium  
(CYP2C9, 2C19, 3A, p-gp) 
Metoclopramide (CYP2D6)  
Norethindrone  
(CYP3A) 
 
Prasugrel  
(GI hydrolysis, then CYP3A) 
Moxifloxacin HCl (p-gp)  
Norgestimate 
 
Prednisone  
(CYP3A, p-gp) 
Nystatin  
Norgestrel 
 
Progesterone  
(CYP2C19, 3A, p-gp) 
Olmesartan (active metabolite)  
Olmesartan medoxomil 
(prodrug—converted to 
olmesartan-see Class III) 
 
Quinapril  
(prodrug – hydrolysis to 
quinaprilat-see Class III) 
Oseltamivir (active metabolite) 
(PEPT1)  
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Omeprazole  
(CYP2C19) 
 
Sirolimus  
(CYP3A, p-gp) 
 
Potassium chloride  
 
Ondansetron  
(CYP2D6, 3A, p-gp) 
Sulfamethoxazole  
(N-acetyltransferase 1) 
Pravastatin  
(MRP2, OATP2B1)  
 
Oseltamivir phosphate 
(prodrug—converted to 
oseltamivir-see Class III) 
Tacrolimus  
(CYP3A, p-gp) 
Pregabalin 
(LAT-1)  
 
Oxybutynin  
(CYP3A) 
Telmisartan Quinaprilat (active metabolite)  
 
Oxycodone  
(CYP2D6) 
Trazodone  
(CYP3A) Sotalol  
 
Pantoprazole sodium 
(CYP2C19, BCRP) 
Ursodiol Tetracycline  (p-gp)  
 
Propranolol HCl  
(CYP2C19, 2D6, 3A) 
Vitamin A (retinol)  
(UGT2B7) Thiamine (Vit. B1)  
Pyridoxine 
 
Voriconazole  
(CYP2C19, 2C9, 3A4) 
Topiramate  
(p-gp)  
Quetiapine fumarate  
(CYP3A) 
 
Warfarin  
(CYP1A2, 2C9, 2C19) 
Trimethoprim  
Sertraline HCl  
(CYP2C19, 2D6, p-gp) 
 
Zaleplon  
(CYP3A) 
  
Sildenafil  
(CYP3A) 
 
Ziprasidone HCl  
(CYP3A) 
  
Sumatriptan succinate  
(MAO-A)    
Tamoxifen  
(CYP2C9, 2D6, 3A, UGT1A4)    
 
Tamsulosin  
(CYP2D6, 3A) 
   
 
Valganciclovir  
(prodrug--converted to 
ganciclovir-see Class III) 
   
 
Valproic acid  
(UGT1A3, 1A6) 
   
 
Venlafaxine HCl  
(CYP2D6) 
   
 
Zolpidem tartrate  
(CYP3A, 2D6) 
   
 
Table adapted from Benet et al. (Benet et al., 2011).  Relevant intestinal enzymes and transporters in parentheses.  
Liver/kidney/other non-intestinal transporters not included. 
Medications in bold are those examined in this work. 
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1.4 EFFECTS OF SMALL BOWEL TRANSPLANTATION ON INTESTINAL 
FUNCTION AND ORAL DRUG DISPOSITION 
Transplantation of a small intestine into a recipient involves a number of processes that may 
affect intestinal function as well as drug absorption, metabolism, and transport.  Anatomical 
changes include extrinsic denervation of the intestine, which affects motility, and severing of 
lymphatic channels, which affects fat absorption.  The intestinal microbiome after transplant is 
different than that of healthy persons in terms of relative populations of bacterial species and 
increased colony count.  Events causing inflammatory changes include intestinal manipulation 
during surgery, ischemia-reperfusion injury, and activation of cell-mediated and humoral 
immunity as donor immune cells come into contact with those of the recipient.  This immune 
activation and the associated inflammatory mediator production may suppress drug-metabolizing 
enzyme and transporter expression and function. 
1.4.1 Extrinsic denervation of the intestine 
Unless the recipient already has an ultra short intestine due to multiple resections, 
removal of the native intestine during transplant surgery severs the existing extrinsic nervous 
connections between the small intestine and the spinal cord.  During the multivisceral and 
modified multivisceral transplant procedure, the stomach also undergoes complete denervation, 
requiring a pyloroplasty to enable gastric emptying(Cruz Jr et al., 2010). 
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Under normal conditions, the jejunum and the ileum are innervated by both sympathetic 
and parasympathetic nerve fibers from the superior mesenteric plexus.  Movement of the small 
intestine results from a combination of contractions and relaxations of the circular and 
longitudinal muscles of the muscularis externa and of the muscularis mucosae(Furness et al., 
2009).  The sympathetic nerve fibers are inhibitory towards the muscle tissue of the jejunum and 
ileum and cause vasoconstriction of the surrounding blood vessels when activated(Standring et 
al., 2008), but they have little effect on intestinal motility under resting conditions(Furness et al., 
2009)  The parasympathetic nerve fibers travel via the vagus nerve and act as motor neurons in 
the muscularis externa and as secretomotor neurons in the mucosa(Standring et al., 2008).   
Normal activity of the enteric nervous system is modified by the central nervous system via 
extrinsic pathways, although it is capable of functioning on its own without external 
control(Furness et al., 2009).   
Denervation may cause impairments in gastric motility but increases in small intestinal 
motility and dysregulation of the MMC between segments.  In a study of denervation of the 
entire upper gastrointestinal tract in dogs, including stomach and small intestine, gastric motility 
during phase III of the MMC was decreased, and the duration between contractions 
increased(Tanaka et al., 2001).  In a dog model of selective neural isolation of the jejunoileum, a 
lack of coordination between phase III of the MMC between the duodenum and jejunum was 
observed, as was a decreased jejunal MMC period, and increased measures of motility through 
the jejunum(Behrns et al., 1996).  Similar patterns have been seen in a dog model of jejunoileal 
autotransplantation, which found recovery of MMC coordination between segments within one 
month in most dogs, but a persistent shortened intestinal transit time up to six months post-
surgery(Nakada et al., 1994). 
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 Eventual reinnervation of the transplanted intestine has been shown to occur by one year 
post-transplant in rat models of syngeneic intestinal transplantation, with spontaneous contractile 
activity of longitudinal muscle from the transplanted jejunum no different from that of 
nontransplanted control rats of the same age.    In addition, immunohistofluorescence staining for 
tyrosine hydroxylase, a substance found primarily in sympathetic neurons, was found to be 
identical in both duodenum and jejunum of transplanted and control rats, indicating intestinal 
reinnervation(Kasparek et al., 2008).   
1.4.2 Severing of lymphatics 
The lymphatic system of the small intestine is complex.  Each villus in the mucosa contains a 
fingerlike lymph channel projection called a lacteal.  These lacteals drain into a plexus of 
lymphatic channels in the submucosa, which in turn drain into larger mesenteric lymph nodes 
that often run alongside major arteries.  The larger mesenteric lymph nodes of the jejunum and 
ileum drain into superior mesenteric nodes that are located near the base of the superior 
mesenteric artery(Healy et al., 2005).  Dietary fats are normally absorbed as chylomicrons and 
very low density lipoproteins (VLDLs), which enter the lacteals inside the villi by diffusion and 
are transported through the branches of the intestinal lymphatic system into the circulatory 
system(Porter and Charman, 2001).  Small bowel graft harvesting necessitates severing of the 
lymphatics that drain the jejunum and ileum, and also – in the case of modified multivisceral 
transplantation – those that drain the stomach and duodenum. This process may lead to 
malabsorption of fats and the condition of chylous ascites, in which chyle (a combination of 
lymphatic fluid and fats produced by the intestine) enters peritoneal fluid(Weseman, 2007), as 
well as the disruption of lymphatic transport and decreased absorption of lipid drug formulations 
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into the circulation.  Some examples of lipid drug formulations now on the market include 
cyclosporine microemulsion (Neoral®)(Novartis, 2009), ritonavir (Norvir®)(Abbott, 2010), and 
saquinavir (Fortovase®)(Roche, 2003).  In a dog model of jejunoileal autotransplantation, 
cyclosporine absorption was severely diminished on post-transplant day 1, with a significantly 
lower AUC and Cmax and higher Tmax compared with normal control dogs.  On day 7, this 
difference remained, but was less pronounced.  By post-operative days 14 and 28, cyclosporine 
profiles were no different from control dogs(Ishikawa et al., 2003), indicating complete recovery 
of ability to absorb fats and fat-soluble compounds.   
In animal models, new lymphatic connections from the graft to outside lymphatic 
channels begin to be created by day 2 or 3 post-transplant, and are complete by post-operative 
days 8 to 21(Schmid et al., 1990; Üner et al., 2001), although regrowth patterns may be different 
than those prior to transplant.  Studies using dye have shown increased lymph channels around 
the vascular anastomosis extending into the retroperitoneal lymphatics(Winkelaar et al., 1997) as 
well as lymphatic vessels along the wall of the superior mesenteric artery draining via the 
testicular lymphatic channels to the thoracic lymph duct(Üner et al., 2001).   After 
lymphangiogenesis, fat absorption improves significantly.  Systemic absorption of a fatty acid 
emulsion containing medium and long chain fatty acids in rats six weeks after small bowel 
transplantation was similar to healthy control animals(Winkelaar et al., 1997).  Another study in 
dogs found no differences in the pharmacokinetic parameters of cyclosporine microemulsion 
between stable allotransplanted dogs and autotransplanted and control dogs after intensive blood 
sampling between post-operative days 110 and 196(Iwanami et al., 2003).    
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1.4.3 Changes in intestinal microflora 
The microbiome of the transplanted intestine is different from that observed in the healthy native 
intestine.  In the healthy gastrointestinal tract, bacterial colony numbers are low in the stomach 
and small intestine as compared with the colon.  Typical levels (expressed as colony forming 
units per gram of contents) are 1 x 103 in the stomach, 1 x 104 in the duodenum and jejunum, and 
1 x 106-107 in the ileum, whereas levels in the colon are reported as 1 x 1011 - 1012(McConnell et 
al., 2008).  In small bowel transplant recipients, impaired gastrointestinal motility and long-term 
use of proton pump inhibitors may lead to bacterial overgrowth, which carries a risk of bacterial 
translocation and systemic infection, and the bacterial species composition of the intestinal 
lumen is different due to gut decontamination prior to surgery, heavy antibiotic use, and presence 
of an ileostomy(Abu-Elmagd et al., 1994).  In subjects with an open ileostomy, Lactobacilli and 
Enterobacteria (facultative anaerobes) are more numerous than the obligate anaerobes of the 
Clostridia and Bacteroides families, a pattern opposite to that seen in most normal intestinal flora 
and similar to non-transplanted patients with ileostomies.  After ostomy closure, the 
microbiological pattern reverts back to a predominance of obligate anaerobes(Amarri et al., 
2002; Hartman et al., 2009).  Examples of drugs that undergo some degree of bacterial 
metabolism in the environment of the healthy intestine include clonazepam, metronidazole, 
omeprazole, and digoxin(Sousa et al., 2008).  The effects of altered microflora on intestinal drug 
metabolism in a small bowel transplant context are not understood at this time.   
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1.4.4 Effects of intestinal manipulation 
Surgical manipulation of the intestine impairs intestinal motility and gastric emptying 
even outside of a transplant context.  In a rat model of selective jejunal manipulation, GI transit 
of orally-administered FITC-labeled dextran over 30 minutes was significantly slowed in the 
manipulated animals 24 hours after manipulation, with fluorescent label peaks seen in the 
proximal half of the small intestine, with delays in the stomach.  In contrast, in control animals, 
30-minute label peaks occurred in the ileum.  In addition, jejunal circular muscle strips from 
manipulated animals showed a significant reduction in bethanechol-induced contractility 
compared with controls, and increases in leukocyte extravasation into the intestinal muscularis 
were seen.   These effects were partially, but not completely, ameliorated by pretreatment with 
dexamethasone (Schwarz et al., 2004). 
1.4.5 Ischemia-reperfusion injury 
After removal from the donor, the intestinal graft is placed in a preservation solution, typically 
University of Wisconsin (UW) solution, where it undergoes a period of cold ischemia time while 
it is in transit to the recipient.  Cold ischemia times vary, but Abu-Elmagd et al. report a mean of 
7.8 ±1.5 hours for transplants done at the University of Pittsburgh between July 2001 and 
November 2008(Abu-Elmagd et al., 2009).  Lack of oxygen during this time leads to tissue 
ischemia, cellular dysfunction, and cell death.  Restoration of blood flow to the organ during 
surgery and subsequent reoxygenation leads to the formation of reactive and cytotoxic oxygen 
species.  These cause leukocyte activation and adhesion to the endothelial lining of blood 
vessels.  Subsequent dysfunction of microcirculation and parenchymal cell damage ensues.  In 
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addition, CD4+ and CD8+ T cells are also recruited during ischemia-reperfusion, and lead to 
tissue infiltration by neutrophils and albumin extravasation(Vollmar and Menger, 2011). 
Intestinal ischemia-reperfusion results in immediate significant increases in plasma IL-6, 
IL-8, and TNF-α as well as elevated plasma levels of intestinal fatty acid binding protein (I-
FABP), a marker of enterocyte loss, and loss of tight junctions(Grootjans et al., 2010).  A case 
study of a human syngeneic small bowel transplant recipient (a situation that involves ischemia-
reperfusion without the additional immune factors of donor vs. recipient) showed peaks in serum 
I-FABP and IL-6 at 60 minutes after reperfusion but returning to baseline levels by 270 minutes 
after reperfusion.  In addition, IL-8 and IL-10 levels continuously rose for several days after 
surgery(Kadry et al., 2000).  
Intestinal ischemia-reperfusion has also been shown to suppress transporter expression 
and function.  Thirty minutes of induced intestinal ischemia in rats led to a significant reduction 
in p-gp and MRP2 mRNA expression in rat jejunum, six hours after reperfusion(Ogura et al., 
2008).  Similarly, another study found that 60 minutes of intestinal ischemia-reperfusion in the 
rat significantly decreased mRNA expression of p-gp in the ileum, as well as decreased p-gp 
function as measured by Rhodamine123 (a p-gp substrate) efflux(Tomita et al., 2008).  Most 
studies have examined intestinal ischemia-reperfusion in the short term, and the actual duration 
of effects is unknown, although it may last weeks to months.  A study in rats found continued 
impairment in intestinal morphology and function even after 90 days in rats that had undergone 
more than one 45-minute episode of intestinal ischemia-reperfusion, and the number of 
macrophages in the lamina propria remained significantly higher than in control rats, even after 
only a single 45-minute ischemia-reperfusion episode(Morini et al., 2010). 
 
  40 
 
1.5 ANIMAL AND HUMAN STUDIES OF SMALL BOWEL TRANSPLANTATION 
1.5.1 Vitamin deficiency after small bowel transplantation 
The majority of small bowel transplant recipients achieve nutritional autonomy after transplant, 
with weaning of TPN on average by post-transplant day 22 in one study(O'Keefe et al., 2007).     
After TPN weaning, serum vitamin levels are monitored regularly and supplementation 
administered in the case of deficiencies.  The most striking vitamin deficiency noted in adult 
small bowel transplant recipients is that of pyridoxyl-5’-phosphate (the active form of vitamin 
B6).  Although the exact mechanism of the deficiency is unknown, it has been observed in up to 
96 percent of small bowel transplant recipients in the first 30 days post-transplant(Matarese et 
al., 2009)   Deficiencies in zinc and red blood cell folate levels have been observed in pediatric 
intestinal transplant recipients at one year post-transplant(Rovera et al., 1998) and vitamin E 
deficiency has been reported in pediatric intestinal transplant recipients, especially in the first 
160 days post-transplant(Kaufman et al., 2000).   
1.5.2 Effects of small bowel transplantation on intestinal smooth muscle contractility  
Intestinal smooth muscle contractility is impaired in animal models of allogeneic small 
bowel transplantation, although this effect is partially ameliorated by immunosuppression.  In a 
rat model, rats treated with intramuscular tacrolimus or intraperitoneal sirolimus showed a 
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significant reduction in the number of apoptotic cells and leukocyte infiltration into the graft 
muscularis compared with untreated control animals at 24 hours and seven days post-transplant.  
In addition, smooth muscle strips from the graft in tacrolimus- and sirolimus-treated animals 
showed significantly better bethanechol-induced contractility as compared with untreated 
transplanted rats at 24 hours and seven days after surgery.  However, none of the groups of 
transplanted rats, including those under immunosuppression, had muscle contractility as high as 
untransplanted rats, indicating that some contractility impairment exists despite 
immunosuppressive treatment(Fujishiro et al., 2010).  Reductions in contractility may persist into 
the later post-transplant period.  In a dog model of small bowel allotransplantation, dose-
response curves of bethanechol-stimulated circular muscle contractility obtained between post-
transplant days 104 and 205 showed no difference in contractile function between 
autotransplanted dogs and controls, but a significant decrease in contractility was still observed 
in allotransplanted dogs as compared with control dogs(Iwanami et al., 2003). 
1.5.3 Gastric emptying and intestinal transit times after small bowel transplantation 
As mentioned in a previous section, denervation of the stomach leads to impaired phase 
III MMC contractions of that organ, and likely to impairment of gastric emptying.  This has been 
confirmed in human small bowel transplant recipients.  In a study of 16 transplant recipients (17 
allografts due to one retransplant), eight of whom were isolated intestine, six liver-intestine, and 
three multivisceral, contrast studies were performed using either diatrizoate or barium sulfate at 
1-2 weeks and 1-3, 6, 12, and 24 months after transplant.  Delays in gastric emptying (as 
measured by amount of liquid or food remaining in the stomach after overnight fasting as well as 
how much contrast material remained in the stomach after one hour as compared with five 
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minutes after administration) were noted in 76% of the contrast studies done within two months 
post-transplant.  At four months post-transplant, delayed emptying persisted in 33% of patients 
and by six months it was only present in 16% (Campbell et al., 1993).  Abnormally rapid gastric 
emptying may also be present in multivisceral transplant recipients, possibly due to the effects of 
pyloroplasty of the transplanted stomach.  A study of gastric emptying times of radiolabeled 
liquids and solids in small bowel transplant recipients found that three out of four multivisceral 
patients had rapid gastric emptying of solids and in one out of the four it was delayed.  By 
contrast, rapid emptying of liquid was observed in one multivisceral subject but in the rest it was 
normal.  By contrast, two out of the five isolated intestinal recipients had delayed gastric 
emptying of solids and one out of five had delayed emptying of liquids.  The rest were 
normal(Furukawa et al., 1994).     
As also mentioned previously, extrinsic denervation of the small intestine leads to a 
shortened intestinal transit time in dogs, but the contractile activity of intestinal smooth muscle is 
decreased secondary to infiltration of inflammatory mediators into the muscularis after small 
bowel transplantation.  In addition, severe acute rejection may lead to neuronal cell 
loss(Watanabe et al., 2008). Therefore, the motility effects of denervation and inflammation on 
the transplanted small bowel combine to varying degrees depending on the patient and the time 
post transplant.  In the aforementioned contrast study, small intestinal transit times were found to 
be variable and sometimes rapid: using barium they ranged from 0.2 to 17.8 hours (median of 2 
hours) and using diatrizoate they ranged from 0.25 to 7.75 hours (median of 0.5 hours).  
However, in this study intestinal transit times were not related to time post transplant, unlike 
gastric emptying(Campbell et al., 1993). 
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1.5.3.1 The MMC and postprandial motility after small bowel transplantation 
Phase III of the MMC in the transplanted intestine may be dissociated from the native 
intestine or absent in small bowel transplant recipients.  A study measured intestinal motility 
patterns via 8-channel catheters placed inside the lumen of the transplanted intestine in eight 
pediatric small bowel transplant recipients, ages 2 to 22 years old (2 isolated intestine, 5 liver 
intestine, and 1 multivisceral).  Time since transplant ranged from 3 to 23 months, with a mean 
of 12.5 months.  Intestinal motility was measured for three hours during a period of fasting and 
one hour after a feeding.  Normal MMC patterns were seen in the transplanted small intestine in 
5 of the 8 patients, although the phase III contractions were dissociated from the native 
remainder of the GI tract.  Two of the remaining patients only produced normal phase III 
patterns after injection of 1 µg/kg octreotide acetate, and the remaining patient, who had only 
recently recovered from severe exfoliative rejection, did not produce any phase III contractions.  
After feeding, normal post-prandial motility increases were observed only in the multivisceral 
transplant recipient(Mousa et al., 1998). 
1.5.4 Immune activity after small bowel transplantation 
The small intestine is a highly immunogenic organ, containing a large number of organized 
lymphoid tissues, including Peyer’s patches, mesenteric lymph nodes, and isolated lymphoid 
follicles. Immediately after transplantation, recipient T and B cells migrate rapidly into these 
lymphoid tissues and begin to proliferate, composing 50% of lymphocytes inside graft lymphoid 
tissues within 24 hours(Wang et al., 2006). A study of lymphocyte populations in drainage fluid 
from six isolated intestinal transplant recipients showed that on post-transplant days 1 to 2, 
recipient cells already made up slightly greater than 50% of the CD8+ lymphocyte population 
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draining from the graft.  By day 4, recipient cells accounted for 90%, and by day 11, 99%, of 
lymphocytes in the drainage(Meier et al., 2010).  During this time, immune activity and the risk 
of acute rejection are especially high. 
1.5.5 Inflammatory mediator expression after small bowel transplantation 
The increased trafficking of lymphocytes from the small intestine into the bloodstream via 
lymphatic channels leads to increases in pro-inflammatory cytokine concentrations in the 
systemic circulation as well as graft tissue.  Increases in serum concentrations of IL-2, IL-6, and 
TNF-α have been observed in the first 40 days after small bowel transplantation and during some 
episodes of acute rejection(Kita et al., 1996a; Noguchi et al., 1992).  Samples of intestine taken 
before and at various time points during the reperfusion phase during human small bowel 
transplantation show a 90.3-fold upregulation of IL-6 mRNA in the graft muscularis during the 
ischemic phase that rises to 371.8-fold during the first few hours of reperfusion(Tuler et al., 
2002).  A rat model of allogeneic intestinal transplantation under tacrolimus immunosuppression 
has shown increases in IL-6, IL-2, and IFN-γ mRNA transcripts in the graft muscularis, leading 
to impaired smooth muscle contractile function, up to seven days post-transplant(Fujishiro et al., 
2010).  It should also be noted that enterocytes are able to produce proinflammatory cytokines 
directly, including IL-1, IL-6, and TNF-α, at the epithelial level of the intestinal mucosa(Ogle et 
al., 1994; Pratt et al., 2000), although this has not been studied within a transplant context. 
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1.5.6 Effects of small bowel transplantation on CYP3A and p-gp expression and function 
Numerous studies have shown the suppression of CYP3A and transporter expression and 
function by pro-inflammatory cytokines.  These effects are mediated through inhibition of PXR, 
constitutive androstane receptor (CAR), and RXRα gene transcription, DNA binding, and 
CYP3A and transporter gene transcription(Assenat et al., 2004; Beigneux et al., 2002; Yang et 
al., 2010).  In particular, IL-1β(Aitken and Morgan, 2007; Assenat et al., 2004; Sukhai et al., 
2001), IL-6(Aitken and Morgan, 2007; Sukhai et al., 2001; Yang et al., 2010), TNF-α(Aitken 
and Morgan, 2007; Belliard et al., 2004), and IFN-γ(Aitken and Morgan, 2007) have shown 
significant inhibition of CYP3A and p-gp expression and function in vitro. 
Because of the inflammation and associated cytokine release caused by ischemia-
reperfusion injury and early immune activation, impairments in CYP3A and p-gp are expected to 
be present after small bowel transplantation, especially in the early post-transplant period.  This 
effect has been demonstrated in a dog model of intestinal autotransplantation.  Intestinal 
microsomal CYP3A4 activity (as measured by 6β-hydroxytestosterone formation) was 
significantly diminished 60 minutes after reperfusion as compared with microsomes taken from 
non-transplanted dogs as well as microsomes from tissue taken after organ preservation but 
before reperfusion.  P-glycoprotein expression levels 60 minutes after reperfusion (as measured 
by Western blot) were slightly decreased compared with expression levels before 
reperfusion(Ishikawa et al., 2003).  In addition, the AUC and Cmax of tacrolimus were 
significantly increased compared with control dogs at post-operative days 1 and 7, whereas there 
was no significant difference at days 14 and 28(Ishikawa et al., 2003), implying impaired 
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intestinal CYP3A and p-gp-mediated first-pass metabolism leading to increased bioavailability 
that returned to normal within the first month after transplant.   
Since these effects occurred in an autotransplant model, they reflect the effects of surgical 
manipulation and ischemia-reperfusion injury without the component of cell-mediated immunity.  
If different, the effects after allogeneic small bowel transplantation would be expected to be 
stronger and of longer duration post-transplant, but this not been studied.  However, several 
studies have shown that the pharmacokinetic parameters of tacrolimus are not significantly 
different from those seen in other transplant populations in clinically stable small bowel 
transplant patients two to 24 months post-transplant taken as a whole, although the effect of time 
post-transplant on recovery of intestinal CYP-mediated metabolism was not examined(Jain et al., 
1994; Jain et al., 1992; Schubert et al., 2004). 
1.6 HYPOTHESIS AND SPECIFIC AIMS OF THIS RESEARCH 
Small bowel transplant recipients take numerous medications, many of them by mouth, and a 
significant number of them CYP3A and/or transporter substrates.  Ischemia-reperfusion injury 
and immune activation within the transplanted organ lead to inflammatory mediator release both 
within the graft and into the systemic circulation.  In vitro studies have shown that pro-
inflammatory cytokines such as IL-1β, IL-6, TNF-α, and IFN-γ decrease CYP3A and transporter 
expression and function via suppression of gene transcription.  Clinical studies in other 
inflammatory conditions such as cancer and sepsis have shown the clinical correlation between 
inflammatory mediator expression and suppression of drug metabolism.  That these effects of 
cytokines on drug-metabolizing enzymes and transporters have clinical relevance in a transplant 
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setting is further evidenced by animal studies of small bowel transplantation that have shown not 
only impaired enzyme and transporter expression and function, but also impairments of intestinal 
first pass metabolism of the widely-used immunosuppressive drug tacrolimus, in the first two 
weeks after transplant, returning to normal approximately one month after surgery.  Whether or 
not these changes are seen in intestinal transplant patients and when the functional recovery 
occurs are key questions.  As mentioned earlier, the pharmacokinetic parameters of tacrolimus, a 
CYP3A and p-gp substrate, in clinically stable small bowel transplant recipients several months 
to years after transplant are similar to those seen in other transplant populations, implying 
eventual recovery of intestinal CYP3A and p-gp function. 
Based on these observations, the central hypothesis of this study is that intestinal CYP3A 
and transporter expression and function in small bowel transplant recipients will be suppressed in 
the early post-transplant period (estimated at approximately the first 30 to 40 days after 
transplant), but will be similar to that seen in healthy control subjects in stable patients without 
evidence of rejection in the later post-transplant period (by four to six months post-transplant).  
In order to examine the effects of the transplanted intestine without the confounding variable of 
the transplanted liver, only isolated intestinal and modified multivisceral transplant recipients 
were included in the study. 
The study therefore has the following specific aims: 
1. To measure intestinal CYP3A expression and function (chapter 5) in 
stable small bowel transplant recipients in the early post-transplant 
period and late post-transplant period in comparison to CYP3A 
activity in healthy control subjects. 
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a. This will be accomplished by characterizing the pharmacokinetics 
of oral and intravenous midazolam, administered as a probe drug 
for assessment of intestinal and hepatic CYP3A, within 40 days 
post-transplant and approximately four to 12 months post-
transplant in transplant recipients as well as in healthy control 
subjects.  In addition, in transplant subjects, mRNA transcripts of 
CYP3A4, CYP3A5, and NR1I2 (PXR) will be measured in ileal 
mucosal biopsy samples taken within 48 hours of each midazolam 
study and compared between time periods. 
b. It is predicted that the oral AUC and bioavailability of midazolam 
in the small bowel transplant recipients in the early post-transplant 
period will be significantly higher, and the AUC ratio of 
1’hydroxymidazolam to midazolam significantly lower, than that 
seen in age- and gender-matched healthy control subjects and also 
significantly different than the same subjects in the later post-
transplant period.  In the later post-transplant period it is predicted 
that the pharmacokinetic parameters of oral midazolam will be no 
different than those seen in healthy controls.  In addition, 
expression levels of CYP3A4 and CYP3A5 will be significantly 
lower in the early post-transplant period as compared with the 
later. 
2. To measure intestinal transporter expression and function (chapter 6) 
in stable small bowel transplant recipients in the early post-transplant 
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period and later post-transplant period in comparison to transporter 
activity in normal healthy control subjects.   
a. This will be accomplished by the characterization of the 
pharmacokinetics of oral fexofenadine as a probe drug for 
transporter function assessment, within 40 days post-transplant and 
approximately four to 12 months post-transplant.  In addition, in 
transplant subjects, mRNA transcripts of ABCB1 (p-gp), SLCO1A2 
(OATP1A2), and SLCO2B1 (OATP2B1) will be measured in ileal 
mucosal biopsy samples taken within 48 hours of each 
fexofenadine study and compared between time periods. 
b. It is predicted that the oral AUC of fexofenadine in small bowel 
transplant recipients in the early post-transplant period will be 
significantly higher than that seen in age- and gender-matched 
healthy control subjects and also significantly different than the 
same subjects in the later post-transplant period.  In the later post-
transplant period, it is predicted that the pharmacokinetic 
parameters of fexofenadine will be no different from those seen in 
healthy controls.  In addition, expression levels of the above-
mentioned transporters will be significantly lower in the early post-
transplant period as compared with the later. 
3. To characterize the pattern and magnitude of inflammatory mediator 
expression in plasma in the early and later post-transplant periods as 
compared to that seen in healthy control subjects (chapter 4). 
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a. This will be accomplished by the measurement of plasma IL-1β, 
IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IFN-γ, and TNF-α at both the 
early post-transplant study session and the later.  Plasma 
concentration of each cytokine will be compared between 
transplant subjects at each study session as well as with the group 
of healthy control subjects.  In addition, in transplant subjects, 
mRNA transcripts of IL-1β, IL-2, IL-6, TNF-α, and IFN-γ genes 
will be measured in ileal biopsy samples taken within 48 hours of 
each study session and compared between time periods. 
4. To assess the correlation between plasma concentrations of 
inflammatory mediators and the expression and function of CYP3A 
and transporters (chapters 4, 5, and 6). 
a. This will be accomplished by correlation analysis between 
pharmacokinetic parameters of midazolam and fexofenadine and 
plasma cytokine concentrations, between plasma cytokine 
concentrations and ileal CYP3A and transporter gene expression, 
between ileal CYP3A expression and pharmacokinetic parameters 
of midazolam, and between ileal ABCB1, SLCO1A2, and 
SLCO2B1 gene expression and pharmacokinetic parameters of 
fexofenadine. 
5. To characterize the pharmacokinetics of oral tacrolimus, a CYP3A and 
p-gp substrate, in small bowel transplant recipients in the first 40 days 
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post-transplant as compared with the later post-transplant period (four 
to 12 months post-transplant) (chapter 7) 
a. This will be accomplished by measurement of whole blood 
tacrolimus concentrations in blood samples taken at the time of the 
early and late post-transplant study sessions mentioned previously.  
Tacrolimus dose-adjusted AUC will be compared between the 
early and later post-transplant periods. 
b. It is predicted that the dose-adjusted AUC of tacrolimus will be 
significantly higher in small bowel transplant recipients at the early 
post-transplant period than during the later period. 
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2.0  MATERIALS AND METHODS 
This chapter outlines the materials and methods used for the studies described in this document. 
2.1 STUDY DESIGN 
The study protocol was approved by the University of Pittsburgh Institutional Review Board and 
informed consent was obtained from all subjects before any study procedures were performed.   
2.1.1 Subject recruitment – transplant subjects 
Transplant recipients were recruited prior to transplant, either in the outpatient transplant clinic 
or as inpatients during hospital admissions not related to transplant.  Inclusion criteria for 
transplant recipients were age 18 to 65, listed for isolated small bowel or modified multivisceral 
transplant, and weight within 30 percent of ideal body weight.  Candidates were excluded if they 
were scheduled to get any other organ transplanted other than small intestine, stomach, or 
pancreas.  In addition, transplant candidates were excluded before transplant if they had a history 
of previous organ transplant, a creatinine clearance less than 30 mL/minute, hemoglobin less 
than 8.5 gm/dL, were a smoker, or had any known allergy to midazolam or fexofenadine.  
Transplanted subjects were not studied after transplant if they required supplemental oxygen, 
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were receiving a non-standard immunosuppression protocol, had an ostomy output of greater 
than 2500 mL per day, were taking any major CYP3A or p-gp inhibitors or inducers or had 
clinical or histological evidence of acute or chronic rejection.   
2.1.2 Subject recruitment – control subjects 
Age (±5 years)- and gender-matched healthy subjects were recruited as a control group for 
comparison with the transplant patients.  Inclusion criteria for control subjects were age between 
18 and 65 years, weight within 30 percent of ideal body weight, and normal renal and hepatic 
function (as measured by total bilirubin, AST, ALT, BUN, and serum creatinine within normal 
limits).  Exclusion criteria for control subjects were smoking, history of bariatric surgery or 
intestinal resection, intestinal disease (i.e. Crohn’s disease or ulcerative colitis), any other 
condition, such as diabetes mellitus, which might affect gastrointestinal motility, use of major 
CYP3A or p-gp inhibitors or inducers (oral contraceptives were allowed), and for females, 
pregnancy or nursing.  Control subjects underwent a physical examination and ECG as part of 
the screening process.  All female subjects of childbearing age were given a urine pregnancy test 
during the screening and on the day of the study session before any study procedures were 
performed.   
2.1.3 Study procedure 
Transplant subjects underwent two separate pharmacokinetic study sessions, one in the early 
post-transplant period while patients were still in the hospital after surgery (PK session 1) and 
one four to 14 months after transplant, but prior to ostomy closure (PK session 2).    Healthy 
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control subjects underwent one pharmacokinetic study session after a screening session.    
Subjects were required to abstain from all fruits and fruit juices for at least 72 hours before the 
start of the study session due to the well-documented effects of certain juices on fexofenadine 
pharmacokinetics.  (A study in healthy volunteers found that consumption of grapefruit juice 
with an oral dose of fexofenadine or 2 hours before the dose reduced fexofenadine AUC0-8 by 
52%, possibly via inhibition of OATP1A2-mediated uptake(Glaeser et al., 2007).  Another study 
observed a 30 to 40% decrease in AUC and Cmax of oral fexofenadine after consumption of 
grapefruit, orange, and apple juice(Dresser et al., 2002), and a third noted a large and significant 
decrease in mean AUC in subjects administered apple juice with fexofenadine compared to those 
given the drug with water alone (1342 vs. 284 ng*hr/mL)(Imanaga et al., 2011).)  In addition, 
study subjects were asked to avoid caffeine for 48 hours before the session, and required to fast 
after midnight on the day of the study session (water was allowed). 
On the morning of the study session, two blood samples were taken immediately prior to 
study drug administration: one whole blood sample for genotyping purposes and one sample for 
time zero drug concentration measurement.   Five mg (2.5 mL) of oral midazolam syrup (Roxane 
Laboratories, Columbus, OH) was administered enterally via an oral syringe.  To make sure that 
no drug was sticking to the syringe, the syringe was refilled with water twice, which was given 
to the subject.  The subject then drank approximately four ounces of water.  Sixty minutes after 
administration of oral midazolam, a 60 mg tablet of fexofenadine (Teva Pharmaceuticals, North 
Wales, PA) was given to the subject with four ounces of water.  Subjects were required to remain 
in bed with the head of the bed set to a 60-degree angle for six hours after oral midazolam 
administration.  At the 7-hour timepoint, 2 mg of intravenous midazolam (Bedford Laboratories, 
Bedford, OH) in 120 mL of normal saline was given as an infusion over 30 minutes.  Subjects 
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were given a meal two hours after administration of oral midazolam, but were required to fast for 
30 minutes before and one hour after administration of IV midazolam.  Blood samples (3 mL) 
were drawn into EDTA tubes at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 7, 7.25, 7.5, 8, 10, 12, and 20 
hours after oral administration of midazolam.  Blood samples were spun down and plasma stored 
at -80 degrees Celsius until analysis.  
Subjects were monitored by the principal investigator and the nursing staff during the 
study sessions.  Subjects remained in bed for six hours after each administration of midazolam, 
with bathroom privileges with assistance after two hours.  Blood pressure, pulse, and oxygen 
saturation were measured every 15 minutes for the first two hours after each administration of 
midazolam and additionally as deemed necessary.  Supplemental oxygen was administered for 
an oxygen saturation less than 94%.  A study physician was required to be notified if 
supplemental oxygen failed to improve saturation, if the oxygen saturation was below 90% at 
any time, in the event of any changes in blood pressure greater than 20 mm Hg from baseline, or 
they exhibited any other signs or symptoms of adverse effects of any kind. 
2.1.4 Ileal biopsy sampling in transplant subjects 
Small bowel transplant recipients undergo routine biopsies of intestinal mucosa.  For this study, 
two extra tissue samples (in addition to the two or three taken for clinical purposes) were taken 
during the routine biopsy session closest to the study date.  This was often done on the same day 
as the PK study session, but could be ± 2 days apart from the session.  All biopsy samples were 
taken from 4 to 13 cm inside the proximal ileum.  Samples were placed on dry ice immediately 
after removal from the subject, and stored at -80 degrees Celsius until analysis of mRNA 
expression of enzymes, transporters, and cytokines by RT-PCR.  
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2.2 MEASUREMENT OF MIDAZOLAM, 1’HYDROXYMIDAZOLAM, AND 
FEXOFENADINE IN PLASMA BY LC-MS 
2.2.1 Materials 
Midazolam, 1’hydroxymidazolam, midazolam-D5 (internal standard), and fexofenadine-D6 
(internal standard) were purchased from Toronto Research Chemicals (North York, Ontario, 
Canada).  Fexofenadine was purchased from the United States Pharmacopeia (Rockville, MD).  
HPLC-grade methanol and water were purchased from Fisher Scientific (Pittsburgh, PA). 
2.2.2 Sample preparation 
Frozen plasma samples were thawed at room temperature and vortexed for 30 seconds.  Each 
aliquot of 0.4 mL of plasma was mixed with 0.6 mL of HPLC-grade water (Fisher Scientific, 
Pittsburgh, PA), 50 µL of five percent ammonium hydroxide, and 25 µL of midazolam-d5 (2 
µg/mL, internal standard).  After vortexing for 30 seconds, solid phase extraction (SPE) was 
performed using Oasis® HLB extraction cartridges (Waters Corporation, Milford, MA) that had 
been conditioned with one mL of HPLC-grade methanol (Fisher Scientific, Pittsburgh, PA) 
followed by one mL of HPLC-grade water.  Samples were loaded onto cartridges and the plasma 
mixture allowed to filter through.  After filtration, each cartridge was washed with one mL of 
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water.  Samples were eluted with one mL of methanol and dried under air.  The resulting residue 
was reconstituted with 150 µL of mobile phase mixture (described below). 
2.2.3 Sample analysis 
Plasma samples were analyzed by LC-MS, using a system consisting of a Waters model 2795 
separations module (Waters Corporation, Milford, MA), a Waters Micromass Quattro Micro 
triple quadrupole mass spectrometer (Waters Corporation, Milford, MA), and MassLynx 4.1 
software (Waters Corporation, Milford, MA).  HPLC conditions included a Symmetry C18 (3.5 
µm 2.1 x 50 mm) column with guard (Waters Corporation, Milford, MA) and mobile phase 
components consisting of mixture A: 2 mM ammonium acetate, 0.1 percent formic acid, and 5 
percent methanol in water and B: 2 mM ammonium acetate and 0.1 percent formic acid in 100 
percent methanol running at a flow rate of 0.3 mL/minute.  A gradient procedure was used for 
the mobile phase mixture proportions throughout the ten-minute run time.   The ratios of A:B 
were as follows: 0-1.5 minutes, 70:30; 1.5-1.55 minutes, 50:50, 1.55-3.1minutes, 10:90; 3.1-10 
minutes, 70:30.   
    Mass spectrometry parameters for the assay were as follows: Capillary voltage, 0.8 kV; 
source temperature, 100°C; desolvation temperature, 500°C; desolvation gas flow, 550 L/hr; 
cone gas flow, 50 L/hr; argon pressure, 20 ± 10 psig; nitrogen pressure, 100 ± psig.  Multiple 
reaction monitoring parameters and conditions for midazolam were m/z of 326>295.97, for 
1’hydroxymidazolam 342>323.9, and for midazolam-d5 331.09>295.97.  Multiple reaction 
monitoring parameters and conditions for fexofenadine were m/z of 502.25>466.12 and for 
fexofenadine-d6 508.17>472.23.   
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Standard curves were generated, using the ratio of drug peak height to that of internal 
standard, with every batch analyzed using seven concentrations of each analyte and were 
accepted if the corresponding r2 value was 0.990 or greater.  The standard curve was linear 
between 0.5 and 75 ng/mL for midazolam, 0.25 to 50 ng/mL for 1’hydroxymidazolam, and 1 and 
225 ng/mL for fexofenadine.  Three quality control (QC) samples were also run with each batch.  
%CVs were less than 20% for the low range, and less than 15% for the medium and high ranges.   
2.3 MEASUREMENT OF TACROLIMUS IN WHOLE BLOOD BY LC-MS 
2.3.1 Sample preparation 
Whole blood samples were gently mixed by placing on a Thermolyne speci-mix rocker (Sybron, 
Milwaukee, WI).  After mixing, 50 µL of each sample was placed into a microcentrifuge tube 
with 0.2 mL of 0.1M zinc sulfate heptahydrate solution (Fisher Scientific, Pittsburgh, PA) and 
0.5 mL of 1.75 ng/mL ascomycin internal standard (Sigma-Aldrich, St. Louis, MO).  Tubes were 
vortexed on speed 10 for 60 seconds using a multi-tube vortexer (VWR, Radnor, PA), then 
centrifuged.  The resulting supernatant was placed into a vial and loaded into the mass 
spectrometer unit. 
2.3.2 Sample analysis 
Tacrolimus concentrations were measured in whole blood by LC-MS, using a system consisting 
of a model 2795 separations module (Waters Corporation, Milford, MA), a Micromass Quattro 
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Micro API mass spectrometer (Waters Corporation), and MassLynx 4.1 software (Waters 
Corporation).  HPLC conditions included a Nova-Pak® C18 2.1 x 10 mm column (Waters 
Corporation) and mobile phase components consisting of equal amounts of mixture A: 1L 
HPLC-grade water to which 2 mL of 1M ammonium acid (Fisher Scientific, Pittsburgh, PA) and 
1 mL of formic acid (Fisher Scientific) were added and mixture B: 1L HPLC-grade methanol to 
which 2 mL of 1M ammonium acid (Fisher Scientific, Pittsburgh, PA) and 1 mL of formic acid 
(Fisher Scientific) were added, running at a flow rate of 0.6 mL/minute.     
Mass spectrometry parameters for the assay were as follows: Capillary voltage, 1.00 kV; 
cone voltage, 30.00 V; source temperature, 140°C; desolvation temperature, 350°C; desolvation 
gas flow, 600 L/hr.   Mass to charge ratio of tacrolimus was 821.4→768.3 and of ascomycin 
809.5→756.3.  Standard curves consisting of six standard concentrations were calculated using 
the ratio of drug peak height to that of internal standard.  Curves were accepted if the r2 was 
0.990 or greater.  The standard curve was linear within the range of 2.0 to 40.0 ng/mL.  Samples 
with concentrations above 40.0 ng/mL were diluted and re-analyzed.  Three whole blood quality 
control (QC) samples (Tri-level immunosuppressants, UTAK Laboratories, Valencia, CA) were 
run with each batch of patient samples.  Low QC was 4 ng/mL, medium QC was 15 ng/mL, and 
high QC was 25 ng/mL.  QC readings had to be within ±15% of the verified value given by the 
manufacturer for each batch in order for the results to be accepted.  %CVs were 9.3% in the low 
range, 9.9% in the medium range, and 7.5% in the high range. 
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2.4 ANALYSIS OF CYP3A4/5 AND TRANSPORTER EXPRESSION IN ILEAL 
BIOPSY SAMPLES 
2.4.1 Materials 
DEPC water, chloroform, isopropyl alcohol, and 75% ethanol were purchased from Sigma-
Aldrich (St. Louis, MO).  Trizol® reagent was purchased from Invitrogen (Carlsbad, CA).  RQ1 
DNAse, RQ1 DNase buffer, RQ1 DNase stop solution, random primers, M-MLV reverse 
transcriptase, M-MLV RT buffer, dNTPs, and RNase inhibitor (rRNasin®) were all purchased 
from Promega (Madison, WI).  TaqMan® gene expression assays for CYP3A4 
(Hs00604506_m1), CYP3A5 (Hs00241417_m1), ABCB1 (Hs00184500_m1), MRP2 
(Hs00166123_m1), BCRP (ABCG2) (Hs00184979_m1), PXR (NR1I2) ((Hs00243666_m1), 
SLCO1A2 (Hs00245360_m1), SLCO2A1 (Hs00194554_m1), SLCO2B1 (Hs00200670_m1), IL-
1β (Hs00174097_m1), IL-2 (Hs99999150_m1), IL-6 (Hs00985639_m1), TNF-α 
(Hs00174128_m1), and IFN-γ (Hs00989291_m1) were purchased from Applied Biosystems 
(Foster City, CA).  TaqMan® Universal PCR MasterMix was also purchased from Applied 
Biosystems. 
2.4.2 RNA extraction 
Frozen biopsy samples were thawed and placed in polypropylene tubes.  To each sample 
(weighing 25-50 mg), 0.5 mL of Trizol® reagent was added and the tissue crushed and stirred 
with a pestle.  Samples were incubated for five minutes at room temperature, then 0.1 mL 
chloroform was added.  Sample tubes were then shaken vigorously for 15 seconds, incubated at 
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room temperature for two to three minutes, and centrifuged at 12,000 x g for 15 minutes at 4 
degrees Celsius.  The resulting top layer (aqueous phase) in each tube was transferred to a fresh 
tube and 0.25 mL of isopropyl alcohol added.  Tubes were then incubated at room temperature 
for ten minutes, and centrifuged at 12,000 x g for ten minutes at 4 degrees Celsius.  At this point, 
a small white pellet of RNA could be seen at the bottom of each tube.  Supernatant was removed, 
and pellets were washed with approximately 0.5 mL of 75 percent ethanol.  After removal of the 
ethanol, pellets were air dried, then reconstituted with 20 µL of DEPC water.   
2.4.3 cDNA synthesis 
After reconstitution to 5 µL with DEPC water according to concentrations obtained from OD 
measurement, each RNA sample was used to create a cDNA sample according to the following 
procedure.  A 5 µL mixture of 1µL DNase buffer, 2 µL DNase I and 2 µL DEPC water was 
added to each 5 µL RNA sample.  Samples were then incubated at 37° C for 30 minutes in a 
thermal cycler (PCR Express, ThermoHybaid, Pittsburgh, PA).  Samples were then placed on ice 
and 1 µL stop solution was added to each and samples reincubated at 65°C for 10 minutes.  
Afterwards, samples were removed and placed on ice, and 1 µL of random primers was added to 
each and samples placed in the thermal cycler at 70°C for 10 minutes.  Samples were then 
removed and 13 µL of a mixture containing 5 µL reverse transcriptase buffer, 1 µL reverse 
transcriptase, 1.25 µL dNTPs, 0.65 µL RNase inhibitor, and 5.1 µL DEPC water was added to 
each.  Samples were then incubated at 37°C for 60 minutes followed immediately by 70°C for 10 
minutes.  After removal from the thermal cycler, 200 µL of DEPC water was added to each 
cDNA sample and samples were frozen at -20°C until use.   
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2.4.4 RT-PCR procedure 
In each well of a 96-well plate, 5 µL of cDNA solution was combined with 12.5 µL of master 
mix, 6.25 µL DEPC water, and 1.25 µL of the relevant gene expression assay.  All samples were 
assayed in triplicate.  After preparation, plates were covered and centrifuged at 600 rpm for 10 
seconds to remove droplets from the sides of wells and any air bubbles.  Cyclophilin A, a 
housekeeping gene, was used as the reference gene. 
Plates were placed in an ABI PRISM® 7000 sequence detection system (Applied 
Biosystems).  Corresponding 7000 system sequence detection software version 1.2.3 (Applied 
Biosystems) was used for sample analysis.  Thermal cycler settings consisted of three stages as 
follows:  Stage 1, 50°C for 2 minutes (one rep); Stage 2, 95°C for 10 minutes (one rep); Stage 3, 
95°C for 15 seconds followed by 60°C for 60 seconds (45 reps).  Gene expression levels are 
given relative to cyclophilin.  Integrity of PCR products was verified by gel electrophoresis.  
2.5 ANALYSIS OF PLASMA CYTOKINE CONCENTRATIONS 
2.5.1 Materials 
Interleukin-1β (IL-1β), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-12 (IL-12), interferon-γ (IFN-γ), and 
tumor necrosis factor-α (TNF-α) were measured in plasma using a MILLIPLEX® MAP High 
Sensitivity Human Cytokine Multiplex Panel kit (#HSCYTO-60SK, Millipore, Billerica, MA).  
Reagents included in the kit were a high sensitivity human cytokine standard, high sensitivity 
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human cytokine quality controls 1 and 2, serum matrix containing 0.08% sodium azide, 96-well 
filter plate with sealers, 10X wash buffer containing 0.05% Proclin, high sensitivity human 
cytokine detection antibodies, and streptavidin-phycoerythrin (reporter molecule) solution. 
2.5.2 Assay method 
Frozen plasma samples were thawed, mixed, and centrifuged to remove particulate matter.  
Antibody beads were mixed and quality controls and serum matrix were reconstituted according 
to manufacturers directions.  The manufacturer-supplied standard was reconstituted to a 
concentration of 2,000 pg/mL, then serially diluted to make standards of 400, 80, 16, 3.2, 0.64, 
and 0.13 pg/mL.  The filter plate was prewetted by the addition of 200 µL of 1X wash buffer to 
each well.  After the plate was shaken for ten minutes, the wash buffer was removed from the 
wells.  After sonicating the bead bottle for 30 seconds and vortexing for one minute, 25 µL of 
premixed beads were added to each well.  After removal of excess liquid from wells, 50 µL of 
each of the standards and quality controls 1 and 2 were added to the designated wells along with 
50 µL of serum matrix.  Subsequently, 50 µL of assay buffer was added to each of the sample 
wells, followed by 50 µL of sample.  Filled plates were sealed and incubated overnight on a plate 
shaker at 4°C.   
The next day, fluid was removed from each well by vacuum and wells were each washed 
twice with 200 µL of wash buffer.  Fifty µL of detection antibodies were added to each well and 
the plates resealed and incubated at room temperature for one hour on a plate shaker.  After 
incubation, 50 µL of streptavidin-phycoerythrin (reporter molecule) was added to each well and 
the plates sealed and reincubated on a plate shaker for 30 minutes at room temperature.  After 
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removal of liquid by vacuum, each well was washed twice with 200 µL of wash buffer. One 
hundred µL of sheath fluid was added to each well in which the beads were resuspended on a 
plate shaker for five minutes.   
The plates were read on a Luminex® 100™ analyzer (Luminex Corporation, Austin, TX).  
Fluorescent intensity (FI) output was analyzed using Bio-Plex Manager™ software (Bio-Rad 
Laboratories, Hercules, CA).  A minimum of five points were used to generate each standard 
curve.  Points were excluded from the curve if the (observed concentration/expected 
concentration)*100 was less than 70 or greater than 130.  Two plates were run, with the within-
range standard curve ranges for each plate as follows: 
IL-1β:  Plate 1: 0.13 - 359.86 pg/mL  Plate 2: 0.79 -  334.65 pg/mL 
IL-2: Plate 1: 0.13 – 2122.24 pg/mL  Plate 2: 0.77 – 2395.94 pg/mL 
IL-4: Plate 1: 3.72 – 2002.91 pg/mL  Plate 2: 3.02 – 2000.03 pg/mL 
IL-6: Plate 1: 0.14 – 2156.73 pg/mL  Plate 2: 0.79 – 343.75 pg/mL 
IL-8: Plate 1: 0.13 – 1721.55 pg/mL  Plate 2: 0.13 – 2308.77 pg/mL 
IL-10: Plate 1: 3.25 – 2019.26 pg/mL  Plate 2: 3.08 – 2018.59 pg/mL 
IL-12: Plate 1: 0.72 – 2034.93 pg/mL  Plate 2: 0.83 – 2050.18 pg/mL 
TNF-α: Plate 1: 0.13 – 2286. 95 pg/mL  Plate 2: 0.14 – 366.14 pg/mL 
IFN-γ: Plate 1: 0.16 – 2010.6 pg/mL  Plate 2: 4.15 – 2027.17 pg/mL 
2.6 PHARMACOKINETIC DATA ANALYSIS 
Pharmacokinetic parameters of midazolam and fexofenadine were calculated by 
noncompartmental analysis using WinNonLin software, version 6.1 (Pharsight Corporation, St. 
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Louis, MO).  At least three points were used to calculate the terminal disposition rate constant 
(λz) by log regression using uniform weighting.  The bioavailability (F) of midazolam was 
calculated using the formula F = (AUCpo × DOSEIV)/(AUCIV × DOSEpo).  Areas under the curve 
(AUCs) were calculated using the linear trapezoidal method, and Tmax and Cmax were obtained 
from visual inspection of the data.  AUC of midazolam after IV administration (AUCIV) was 
calculated by calculating the AUC from the start of the intravenous infusion to infinity, then 
subtracting the remaining AUC from the oral dose (the last concentration before administration 
of the IV divided by the slope of the intravenous elimination curve (C7/λz)).  Clearance (CL), 
apparent oral clearance (CL/F), volume of distribution (Vz), and apparent volume of distribution 
(Vz/F) were normalized to subject weight in kg. 
2.7 STATISTICAL ANALYSIS 
2.7.1 Sample size calculation 
The required sample size for the study was calculated based on a main outcome measure, the oral 
AUC of midazolam (a measure of systemic exposure to the drug and hence CYP3A activity).  
Calculation of the necessary sample size to have a power of 0.80 of observing a 50% difference 
in the oral AUC of midazolam between transplant subjects and controls using a two-sided test 
with a significance level of α=0.05 was performed using the following equation(Rosner, 2006): 
€ 
n =
σ1
2 +σ2
2( ) z1−α / 2 + z1−β( )
Δ2
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Estimates of the likely mean of the AUC of 5 mg oral midazolam in healthy volunteers was 
taken from Lee et al. (Lee et al., 2002) and was 4124 ng*min/mL with a standard deviation of 
2018 ng*min/mL.  No midazolam data from small bowel transplant populations is available in 
the literature, so mean oral AUC in transplant subjects was predicted to be 50% higher (6186 
ng*min/mL).  The calculated sample size needed to fulfill the above requirements was 15 
subjects in each group. 
2.7.2 Comparison of pharmacokinetic parameters and plasma cytokine concentrations 
between subject groups 
Since the pharmacokinetic parameters of midazolam, fexofenadine, and tacrolimus as well as 
plasma cytokine concentrations were not normally distributed, they were compared between 
transplant groups using the Wilcoxon matched-pairs signed rank test.  Transplant session one 
parameters were compared with controls and transplant session two with controls using the 
Mann-Whitney U test, as were pharmacokinetic parameters between enteral routes of 
administration and transplant subtype.   A two-tailed p value of less than 0.05 was considered 
statistically significant for these comparisons.   
Plasma concentrations of several cytokines were below the lower limit of detection of the 
assay.  These included: 
• 4 Tx1 samples below the standard curve range for IL-1β 
• 3 Tx1 samples below the standard curve range for IL-2 
• 5 Tx1 samples below the standard curve range for IL-4 
• 5 Tx1 samples below the standard curve range for IL-12  
• 2 Tx1 samples below the standard curve range for IFN-γ 
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• 2 Tx2 samples below the standard curve range for IL-4 
• 1 Tx2 sample below the standard curve range for IL-12 
• 3 control samples below the standard curve range for IL-12 
These samples were assigned a concentration of 0.13 pg/mL, the concentration of the lowest 
point on the standard curve of each cytokine’s assay.  Because this point fell out of range 
((observed concentration/expected concentration)*100 was less than 70 or greater than 130) in 8 
out of the 18 standard curves generated, 0.13 pg/mL was chosen rather than the LLOD/2, since 
the actual concentration could be above or below 0.13 pg/mL depending on the direction of the 
%CV. 
2.7.3 Correlation analysis 
Individual correlations between pharmacokinetic parameters of study drugs, CYP3A and 
transporter expression, and plasma cytokine concentrations were analyzed by Spearman rank 
correlations.    A two-tailed p-value less than 0.10 was considered statistically significant.  
Separate correlations were performed for study sessions 1 and 2.  In addition, within-subject 
correlation was calculated for the 10 subjects who completed both study sessions, based on a 
method proposed by Bland and Altman (Bland and Altman, 1995).  Since there were two 
observations per subject, correlation analysis was performed on the difference in values between 
study sessions 1 and 2. 
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3.0  SUBJECT DEMOGRAPHICS 
Sixteen small bowel transplant recipients (12 isolated small bowel, 4 modified multivisceral) 
underwent study session 1 between post-transplant day 10 and 40 (median day 19) and ten were 
studied a second time between post-transplant day 125 and 428 (median day 239).  Out of the 
sixteen transplant subjects who underwent study session 1, six were men and ten were women.  
Of these, five men and five women returned for the second study session.   Sixteen healthy age- 
and gender-matched control subjects (six men and ten women) were also studied.   There was no 
significant difference in ages or weights between the transplant subjects at session one and the 
control subjects, nor any significant difference in weight between transplant subjects at session 
two and control subjects (see Table 2).  However, the ten transplant subjects who underwent the 
second study session had significantly higher body weight than at the first study session (median 
weight 62.8 vs. 72.8 kg, p=0.0059).  This was due to the fact that most of the transplant subjects 
were somewhat underweight prior to transplant secondary to intestinal failure and had significant 
improvements in nutritional autonomy afterwards, resulting in weight gain.   Total bilirubin, 
ALT, and AST were within normal limits in all subjects on the days of study sessions, although 
all transplant subjects showed some degree of hepatic disease on pre-transplant liver biopsy.  
Estimates of steatosis ranged from less than 5% to 60% of the lobule biopsied, which may 
negatively affect hepatic CYP3A protein expression and function(Fisher et al., 2009).  All 
subjects had some degree of fibrosis, ranging from “minimal” or “early” to severe (3-4/4) with 
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bridging.  Three out of the sixteen subjects showed significant cholestasis.  Median total bilirubin 
at the time of transplant was 2.3 mg/dL (25th percentile: 1.55 mg/dL, 75th percentile: 3.35 mg/dL) 
but typically decreased to within normal limits (less than 1.5 mg/dL) in the first week after 
transplant.    Bilirubin levels were within normal limits in all subjects on the day of 
pharmacokinetic study.  
Creatinine clearance (CrCL) was calculated for all subjects using the Modification of 
Diet in Renal Disease (MDRD) formula of CrCL (in mL/min/1.73m2) = 186.3 x SCr-1.154 x (Age 
in years)-0.203 x 1.212 (if African-American) x 0.742 (if female).  There was no difference in 
CrCL between transplant session 1 and control subjects (91.5 vs. 99.0 mL/min/1.73m2, p=0.98).  
However, CrCL was significantly lower at the second study session as compared with the first 
(55.5 vs. 94.0 mL/min/1.73m2, p=0.0098) and with controls (55.5 vs. 99.0 mL/min/1.73m2, 
p=0.0054).  This may have been due to the nephrotoxic effects in some subjects of several 
months to a year of tacrolimus therapy, and the nephrotoxic potential of certain other drugs that 
may have been used such as aminoglycosides and vancomycin. 
All of the transplant recipients were Caucasian, as were 12 out of the 16 donors.  Of the 
remaining donors, three were African-American and one was categorized as Caucasian/Asian.  
Of the sixteen control subjects, fourteen were Caucasian and two were African-American.  Four 
of the transplant subjects were receiving medications via jejunostomy tube (J-tube) at the time of 
the first study session; In those subjects, the midazolam syrup was administered directly into the 
J-tube followed by two oral syringe rinses of 2.5 mL and one chaser of four ounces of water.  
The fexofenadine tablet was crushed to a powder and mixed with four ounces of water before 
administration via the tube.  After drug administration the tube was flushed twice with four 
ounces of water. 
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Table 2.  Subject demographics 
 
Transplant 
Subjects 
Session 1 
(n=16)  
Transplant 
Subjects 
Session 2 
(n=10) 
Control 
Subjects 
(n=16) 
P value* 
Tx1 vs. 
Tx2 
P value§ 
Tx1 vs. C 
P value§ 
Tx2 vs. C 
Males/Females 6/10 5/5 6/10 n/a n/a n/a 
Age (yr) 45.5 (27.3,55.5) 
48.0 
(27.3,55.5) 
40.5 
(22.5,53.5) n/a 0.36 0.33 
Body weight (kg) 63.0 (52.6,81.0) 
72.8 
(66.3,94.5) 
68.0 
(53.8,80.2) 0.0059 0.69 0.18 
Post-tx day studied 19.0 (13,23) 213 (178,256) n/a n/a n/a n/a 
Race (African-
American/Caucasian) 
Recipients: 0/16 
Donors: 3/12a 2/14 n/a n/a n/a 
Creatinine clearance 
(mL/min/1.73m2)b 
91.5 
(79.5, 136.5) 
55.5 
(46.8, 62.5) 
99.0 
(79.5, 121) 0.0098 0.98 0.0054 
Age, body weight, post-tx day, and creatinine clearance are expressed as median (25th, 75th percentile) 
*Comparisons between  transplant sessions 1 and 2 made using the Wilcoxon matched-pairs signed rank test on ten 
matched pairs.  §Comparisons between transplant session 1 and controls and transplant session 2 and controls made 
using the Mann-Whitney U test.  Two-tailed p values reported.  aOne donor was categorized as Caucasian/Asian.  
bCreatinine clearance was calculated using the MDRD formula:  186.3 x SCr-1.154 x (Age in years)-0.203 x 1.212 (if 
African-American) x 0.742 (if female). 
 
Median cold ischemia time of the transplanted organs was 6.5 hours (6.1, 7.5).  Primary 
reasons for intestinal failure in the transplant subjects included SMA and/or SMV thrombosis 
(n=4), desmoid tumors (n=3), Crohn’s disease (n=3), complications of gastric bypass (n=2), 
trauma due to motor vehicle accident (n=1), radiation enteritis (n=2), and intestinal pseudo-
obstruction (n=1).  Fifteen out of the 16 transplant subjects had graft drainage via the superior 
mesenteric vein connected to the native hepatic portal venous system.  One of the isolated 
intestinal transplant patients had the superior mesenteric vein of the graft connected to the 
inferior vena cava, bypassing the hepatic portal system.  All of the four modified multivisceral 
transplant recipients had undergone pyloroplasty (surgical widening of the pylorus of the 
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transplanted stomach) during the transplant surgery to facilitate gastric emptying.  One modified 
multivisceral transplant recipient had preservation of the native spleen, pancreas, and a small 
portion of duodenum with a side-to-side anastomosis to the transplanted duodenum.  Two of the 
remaining three had preservation of the native spleen without the pancreaticoduodenal complex, 
and one had no preservation of spleen, pancreas, or native duodenum.  These three subjects had 
T-tubes placed during transplant surgery to connect the common bile duct. 
All of the transplant subjects had ileostomies at the time of both study sessions.  Five out 
of the sixteen transplant subjects had a permanent end ileostomy after transplant, with the result 
that small intestinal contents could only exit the body via the ostomy bag.  The remaining 11 had 
chimney (n=8) or loop (n=3) ileostomies placed with an additional anastomosis with remaining 
colon and/or rectum.  Of these, five subjects had ileotransverse anastomoses, two had 
ileosigmoid anastomoses, three had ileorectal anastomoses, and one had a colocolonic 
anastomosis.  In the three subjects with ileorectal anastomoses, intestinal contents could exit the 
body either via the ileostomy or via the rectum with no colon involved.  However, in the 
remaining eight subjects with the intestinal graft connected to some portion of colon, intestinal 
contents could exit via the ileostomy or travel through the remaining colon.   
There were no unanticipated adverse events during the study.  One transplant subject 
required temporary supplemental oxygen for an oxygen saturation below 94%, and in two cases 
(1 transplant subject and 1 control subject) administration of IV midazolam was delayed by 
approximately one hour due to temporary decreases in blood pressure requiring consultation with 
study physicians.  In one transplant subject, the dose of IV midazolam was reduced to 1 mg after 
physician consult due to concerns about sustained blood pressure decreases since the patient had 
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just taken a dose of metoprolol.  In one control subject, the dose of IV midazolam was not given 
because of sustained decreases in blood pressure after oral midazolam. 
3.1.1 Other medications taken by transplant subjects 
None of the study subjects, controls or transplant, were taking moderate or strong 
CYP3A or p-gp inhibitors or inducers at the time of study sessions.  However, some of the 
transplant subjects required concurrent therapy with medications that may have weak CYP3A 
inhibitory or induction effects. Small bowel transplant recipients require acid suppression 
therapy after transplant to prevent ulcers and bleeds in the delicate newly transplanted graft.  All 
transplant subjects except one were taking proton pump inhibitors (PPIs) during the study 
sessions. Lansoprazole, pantoprazole, or omeprazole were given, typically once per day.  All of 
the PPIs are known to be weak inhibitors of CYP3A4 in vitro to varying degrees.  Ki values of 
42 µM for omeprazole and 22 µM for pantoprazole with regards to 1’hydroxymidazolam 
formation have been seen in in vitro.  Lansoprazole has been shown to have extremely weak 
(practically negligible) CYP3A4 inhibitory activity in vitro (IC50 of >200 µM)(Li et al., 2004).  
These Ki values for the PPIs are significantly higher than, for example, the Ki of 0.0052 µM for 
the prototypical CYP3A4 inhibitor ketoconazole.   Considering that typical Cmax values of 20 
mg omeprazole at steady state are 1.6 µM, for 40 mg pantoprazole 5.4 µM, and 30 mg 
lansoprazole 2.2 µM(Li et al., 2004), the risk of interactions in vivo between these PPIs and the 
CYP3A substrates midazolam and tacrolimus is low.    
In particular, the risk of interaction with omeprazole appears low.  Another in vitro study 
calculated a Ki of 367.5 µM for omeprazole inhibition of nifedipine oxidation, another marker of 
CYP3A4 function(Furuta et al., 2001).  In addition, Katsakiori et al. found no difference in 
  73 
tacrolimus pharmacokinetics in renal transplant patients during omeprazole treatment versus 
without omeprazole(Katsakiori et al., 2010).  It has been suggested that any interaction between 
tacrolimus and lansoprazole is mediated via p-glycoprotein rather than CYP3A4, since 
lansoprazole is a p-gp substrate(Miura et al., 2007a).  Therefore, given the low risk of 
interactions between PPIs and study drugs, the clinical need for PPI therapy in the transplant 
recipients, and the risk of gastric acid rebound if the drugs were discontinued, transplant subjects 
remained on PPI therapy during the study period.   
All of the 16 transplant subjects required corticosteroid treatment at some point either 
during or after transplant, either for adrenal insufficiency or rejection treatment.  Most of the 
corticosteroids now on the market are inducers of CYP3A to some degree, but level of induction 
depends on the steroid, with the most potent inducer being dexamethasone, which was not used 
in any of the subjects(El-Sankary et al., 2000; Pascussi et al., 2000).  Methylprednisolone has 
been shown to have no significant effect on CYP3A in vitro or in vivo(El-Sankary et al., 2000; 
Pichard et al., 1992; Villikka et al., 2001) but may be an inducer of p-glycoprotein at very high 
doses(Konishi et al., 2004).  Prednisolone is also been shown not to significantly induce 
CYP3A(Pichard et al., 1992), but hydrocortisone and prednisone have induced CYP3A in in 
vitro systems via regulation of PXR, CAR, and the glucocorticoid receptor(El-Sankary et al., 
2000; Pascussi et al., 2000; Pichard et al., 1992).   A clinical study in kidney transplant recipients 
found that daily tacrolimus dose requirements were significantly higher, and concentration/dose 
ratios significantly lower, in patients taking 0.25 mg/kg/day or greater of oral prednisone as 
compared with those taking less than 0.15 mg/kg/day(Anglicheau et al., 2003). 
Steroid doses could not be withheld in the transplant subjects without significant patient 
discomfort and risk, and drug choice and doses were individualized based on steroid use prior to 
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transplant, degree of adrenal insufficiency, and risk of rejection.  All subjects received a bolus of 
1 to 3 mg of methylprednisolone intravenously for induction immediately before or during 
surgery, then an IV methylprednisolone taper after surgery in which the drug was tapered from 
60 mg IV four times a day to 20 mg IV every 12 hours.   At the time of study session 1, 
transplant subjects were receiving methylprednisolone IV, hydrocortisone IV, hydrocortisone by 
mouth, or prednisone by mouth.  In addition, single bolus doses of 1000 or 2000 mg of 
methylprednisolone were administered to some transplant subjects during episodes of suspected 
immune activation or risk of rejection.  All of these bolus doses occurred at least three days prior 
to the study session (2 subjects) and most were many days before (see table 4).  At the time of 
study session 2, all transplant subjects were receiving either oral hydrocortisone or prednisone.  
Steroid and PPI doses in transplant subjects on study session days are listed in table 3. 
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Table 3.  Proton pump inhibitor and corticosteroid doses in transplant subjects at both study sessions 
PPI dose Steroid dose Transplant 
Subject Session 1 Session 2 Session 1 Session 2 
1 Lans 30 mg JT qd n/a HC 50 mg IV q8h n/a 
2 Lans 30 mg JT qd Pant 40 mg po qd MP 20 mg IV q12h HC 15 mg po q8h 
3 Lans 30 mg JT qd n/a MP 20 mg IV q12h n/a 
4 Lans 30 mg JT qd Pant 40 mg po qd HC 50 mg IV q8h HC 20 mg po qAM/ 10 mg po qPM 
5 none none PD 20 mg po BID PD 5 mg po BID 
6 Pant 40 mg IV qd Pant 40 mg po BID MP 20 mg IV q12h HC 25 mg po q8h 
7 Pant 40 mg po qd Pant 40 mg po qd HC 40 mg IV q8h HC 20 mg po qAM/ 10 mg po qPM 
8 none Omep 20 mg po qd MP 20 mg IV q8h HC 15 mg po q8h 
9 Omep 20 mg po qd none HC 50 mg IV q8h HC 15 mg po q8h 
10 Lans 30 mg po qd n/a MP 20 mg IV q8h n/a 
11 Lans 30 mg po qd n/a HC 50 mg IV q8h n/a 
12 none Pant 40 mg po BID MP 20 mg IV q12h PD 5 mg po BID 
13 Omep 20 mg po qd Omep 20 mg po qd HC 30 mg IV q8h HC 15 mg po q8h 
14 Lans 30 mg po qd n/a HC 50 mg IV q8h n/a 
15 Omep 20 mg po qd Omep 40 mg po qd HC 50 mg IV q8h HC 30 mg po q8h 
16 Omep 20 mg po qd n/a HC 50 mg po q8h n/a 
Lans=lansoprazole, Pant=pantoprazole, Omep=omeprazole 
MP=methylprednisolone sodium succinate (Solu-Medrol®) 
HC=hydrocortisone sodium succinate (Solu-Cortef® IV) or hydrocortisone tablets (po) 
PD=prednisone tablets 
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Table 4.  High-dose corticosteroid boluses in transplant subjects prior to study session 1 
Transplant Subject Steroid Bolus Days before study session 1 
1 none n/a 
2 MP 1 gm IV x 1 10 
3 MP 1 gm IV x 1 11 
4 MP 1 gm IV x 1 10 
5 MP 1 gm IV x 1 MP 2 gm IV x 1 
18 
12 
6 MP 1 gm IV x 1 12 
7 
MP 1 gm IV x 1 
MP 2 gm IV x 1 
MP 2 gm IV x 1 
34 
23 
19 
8 
MP 1 gm IV x 1 
MP 2 gm IV x 1 
MP 1 gm IV x 1 
20 
6 
3 
9 MP 2 gm IV x 1 10 
10 MP 1 gm IV x 1 MP 0.5 gm IV x 1 
16 
15 
11 MP 2 gm IV x 1 12 
12 
MP 1 gm IV x 1 
MP 2 gm IV x 1 
MP 1 gm IV x 1 
18 
13 
6 
13 MP 1 gm IV x 1 26 
14 MP 1 gm IV x 1 19 
15 MP 1 gm IV x 1 MP 2 gm IV x 1 
18 
3 
16 MP 1 gm IV x 1 21 
MP=methylprednisolone sodium succinate (Solu-Medrol®) 
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  Transplant subjects also received 300 mg oral ursodiol (ursodeoxycholic acid) three 
times a day at session 1 to encourage bile flow.  Ursodiol has been shown to weakly induce 
CYP3A in vitro by induction of PXR(Becquemont et al., 2006).  A study in rats found that 
although the AUC and Cmax of midazolam were significantly increased by a single dose of 300 
mg/kg ursodiol, repeated dosing of 300 mg/kg/day had no discernable effect on the 
pharmacokinetics of either oral or IV midazolam.  In addition, the repeated dosing had no effect 
on CYP3A1 or 3A2 mRNA expression in rat liver(Kurosawa et al., 2009).  In addition, a study in 
eight healthy human volunteers given oral midazolam before and after a 14 day course of 13 
mg/kg/day oral ursodiol in divided doses found no difference in midazolam disposition before 
and after the therapy.   Gene expression levels of CYP3A4 and ABCB1 in duodenal biopsy 
samples from the subjects also showed no difference between before and after ursodiol 
treatment.  There was, however, a small but statistically significant decrease in the bioavailability 
of oral digoxin seen after ursodiol treatment.  It may be that ursodiol is a weak inducer of p-
glycoprotein, but the risk of interaction was considered low(Becquemont et al., 2006). 
Subjects used nystatin swish and swallow for candida esophagitis prevention.  Nystatin 
does not affect CYP3A4 or transporters.  Clotrimazole troches were not allowed because 
clotrimazole, although poorly absorbed when taken orally, is a CYP3A4 inhibitor and has been 
shown to significantly decrease the oral clearance of midazolam in healthy volunteers(Shord et 
al., 2010).  All subjects received sulfamethoxazole/trimethoprim 400/80 mg tablet by mouth 
three times a week for prevention of Pneumocystis carinii (PCP) pneumonia.  At the first study 
session, 12 subjects were still receiving ganciclovir IV and four had been switched to oral 
ganciclovir for cytomegalovirus (CMV) prophylaxis. 
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Some transplant subjects were receiving medications that could affect gastrointestinal 
motility.  Before and after the first study session, seven out of 16 subjects were receiving 
metoclopramide (six IV and one by mouth) three times a day to encourage more rapid gastric 
emptying and to prevent nausea.  Because of the prokinetic effects of metoclopramide and the 
fact that not all subjects required it, the drug was held for 24 hours during the study sessions.    In 
addition, at the first study session two subjects were receiving low doses of hydromorphone by 
mouth (2 mg) and three received one or two doses of hydromorphone 0.5 mg IV for pain during 
the study session.  Two subjects were wearing fentanyl transdermal patches for pain control at 
the first study session, and four at the second.  Transdermal fentanyl doses ranged from 25 
mcg/hr to 75 mcg/hr.   
 Transplant subjects received other medications, including antihypertensives, 
antidepressants, warfarin, vitamin supplements, and others.  These are listed in table 5.  Median 
number of oral medications taken by transplant subjects at session 1 was seven (range 4 to 11) 
and at session 2 was 14 (10 to 22).   
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Table 5.  Other miscellaneous oral medications taken by small bowel transplant recipients 
Number of transplant subjects taking drug Drug Session 1 Session 2 
Metoprolol  2 3 
Amlodipine  0 1 
Warfarin  0 6 
Sertraline 3 2 
Trazodone 1 0 
Mirtazepine 3 0 
Bupropion 0 1 
Hydromorphone 3 0 
Loperamide 0 4 
Diphenoxylate/atropine 0 4 
Ganciclovir 4 2 
Acyclovir 0 4 
Valganciclovir 1 4 
Clonazepam 5 6 
Zolpidem 0 1 
Sodium bicarbonate 1 7 
Magnesium gluconate 11 8 
Pyridoxine 1 7 
Cholecalciferol 0 3 
Calcium citrate + Vit. D 0 4 
Folic acid 0 1 
Ferrous gluconate 0 2 
Zinc sulfate 0 4 
Riboflavin 0 1 
Methylphenidate 0 1 
Leviracetam 0 1 
Pravastatin 1 0 
   
Median number of daily oral 
medications not including 
tacrolimus (range) 
7 (4 – 11) 14 (10 – 22) 
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3.1.2 Crossmatch and donor-specific antibodies prior to transplant and induction therapy 
at time of transplant 
All transplant subjects except one received an intravenous methylprednisolone bolus as part of 
induction therapy before and during transplant surgery.  Twelve out of the 16 subjects also 
received alemtuzumab (Campath®, Genzyme, Cambridge, MA) 30 mg IV immediately before 
transplant surgery as induction therapy.  Three out of the 16 transplant subjects showed a strong 
positive crossmatch upon pre-transplant testing and received 3 gm of methylprednisolone IV and 
2 gm/kg intravenous immunoglobulin in addition to alemtuzumab.  Four of the 16 transplant 
subjects exhibited donor-specific antibodies upon pre-transplant testing: two had class I only, 
one had class II only and one had both class I and class II.  One of these subjects received 
bortezomib (Velcade®, Millenium Pharmaceuticals, Cambridge, MA) intravenously during the 
transplant surgery and several times in the early post-transplant period in response to donor-
specific antibody formation. 
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3.1.3 Intestinal morphology and biopsy results at time of pharmacokinetic study sessions 
Intestinal biopsy pathology reports at the times of each study session are summarized in tables 6 
and 7.   
Table 6.  Intestinal biopsy results at time of study session 1 
Subject Mucosal Architecture 
Apoptotic bodies/10 
crypts 
Other comments by 
pathologist 
1 intact 0-1 no ACR 
2 intact 1 no ACR 
3 focal crypt loss 6-8 mild ACR 
4 intact 2-3 no ACR, mild LP inflammation 
5  1-2 mild nonspecific infiltrate 
6 intact 1-2 focal, mild LP inflammation 
7 intact 1  
8 intact, some focal crypt loss 1-2 
mild nonspecific LP 
inflammation 
9 intact 1-2 no ACR 
10  1-2 mild infiltrate 
11 mostly intact, mild crypt loss 2 mild regenerative changes 
12 intact 1  
13 intact 2  
14 intact 1-2  
15 intact 1-2  
16 intact 0-1  
 
Table 7.  Intestinal biopsy results at time of study session 2 
Subject Mucosal Architecture 
Apoptotic bodies/10 
crypts Other comments by pathologist 
2 intact 1  
4 intact 2 mild chronic nonspecific inflammation 
5  1-3 mild lymphoplasmacytic inflammation 
6 intact 0-1  
7  2 mild lymphoplasmacytic infiltrate 
8 intact 2-3  
9 intact 1-2 no ACR 
12 intact 2 mild LP congestion 
13 intact 2 mild LP inflammation 
15 intact 2  
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4.0  EXPRESSION OF INFLAMMATORY MEDIATORS AFTER SMALL BOWEL 
AND MODIFIED MULTIVISCERAL TRANSPLANTATION 
4.1 OBJECTIVES 
Since the suppressive effects of pro-inflammatory cytokines on CYP3A and p-gp expression and 
function have been well characterized, the objective of this component of the study is to assess 
the plasma concentrations of inflammatory mediators in small bowel and modified multivisceral 
transplant recipients in the early post-transplant period as compared with the concentrations 
observed in the later post-transplant period and in healthy controls.   Two secondary objectives 
are to examine the correlation between ileal mRNA expression of CYP3A and ABCB1 and 
plasma cytokine concentrations and to measure cytokine mRNA transcripts in the ileal mucosa 
of small bowel and modified multivisceral transplant recipients.  
4.2 METHODS AND DEMOGRAPHICS 
The study design, methodology and demographics of the recruited subjects have been described 
in detail in chapters 2 and 3 of this dissertation.  Briefly, this study was approved by the 
University of Pittsburgh Institutional Review Board and informed consent was obtained from all 
subjects before any study procedures were performed.  Sixteen small bowel transplant recipients 
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(12 isolated intestine and 4 modified multivisceral) and 16 age-and-gender-matched healthy 
control subjects were recruited and studied.  Transplant subjects were studied twice: once within 
the first 40 days post-transplant (median day–19, range–10 to 40 days); and again four to 
fourteen months post-transplant (median day–239, range–125 to 428 days).  Sixteen transplant 
subjects (ten women and six men) underwent the first study session and ten (five women and five 
men) returned for the second.  Control subjects underwent one study session.  A time zero 
plasma sample from the associated pharmacokinetic analysis was used for measurement of 
cytokine concentrations.  
Interleukin-1β (IL-1β), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-12 (IL-12), interferon-γ (IFN-γ), and 
tumor necrosis factor-α (TNF-α) were measured in plasma using a MILLIPLEX® MAP High 
Sensitivity Human Cytokine Multiplex Panel kit (#HSCYTO-60SK, Millipore, Billerica, MA).   
The concentrations of each cytokine were compared between transplant subjects at the two study 
sessions using the Wilcoxon matched pairs signed-rank test, and between each transplant group 
and controls using the Mann-Whitney U test.  In addition, mucosal biopsy samples from the 
transplanted ileum of the transplant subjects were obtained during routine intestinal biopsies 
done to monitor the graft for rejection. They were typically taken on the same day as the 
pharmacokinetic study session, although they were allowed to be within ±48 hours of the study 
session. These mucosal biopsy samples were subsequently analyzed for IL-1β, IL-2, IL-6, IFN-γ, 
and TNF-α gene expression by RT-PCR.  
Plasma concentrations of several cytokines were below the lower limit of detection of the 
assay.  These included: 
• 4 Tx1 samples below the standard curve range for IL-1β 
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• 3 Tx1 samples below the standard curve range for IL-2 
• 5 Tx1 samples below the standard curve range for IL-4 
• 5 Tx1 samples below the standard curve range for IL-12  
• 2 Tx1 samples below the standard curve range for IFN-γ 
• 2 Tx2 samples below the standard curve range for IL-4 
• 1 Tx2 sample below the standard curve range for IL-12 
• 3 control samples below the standard curve range for IL-12 
These samples were assigned a concentration of 0.13 pg/mL, the concentration of the lowest 
point on the standard curve of each cytokine’s assay.  Because this point fell out of range 
((observed concentration/expected concentration)*100 was less than 70 or greater than 130) in 8 
out of the 18 standard curves generated, 0.13 pg/mL was chosen rather than the LLOD/2, since 
the actual concentration could be above or below 0.13 pg/mL depending on the direction of the 
%CV. 
4.3 INDIVIDUAL CYTOKINES AND THEIR CONCENTRATION IN PLASMA 
Cytokines are proteins having autocrine, paracrine, and endocrine functions, and are produced by 
a number of different cell types.  They are secreted by immune cells such as macrophages and 
lymphocytes, as well as by non-immune cells such as epithelial cells, fibroblasts, endothelial 
cells, and smooth muscle cells.  They play a role in various types of immune activities, including 
the acute phase response, antibody synthesis, and cell-mediated immunity, among 
others(Blumberg and Stenson, 2003).   
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The amount of leukocyte traffic through the small intestine exceeds that of all other 
organs, even in healthy persons.  As mentioned in chapter 1, recipient lymphocytes rapidly 
repopulate the lymphoid tissue of the transplanted small intestine where they undergo activation.  
Activated T and B lymphocytes migrate out of the intestine lymphoid follicles into afferent 
lymphatic channels and thence into mesenteric lymph nodes.  These lymphocytes then pass 
through the thoracic duct into the bloodstream, returning to the lamina propria via endothelial 
cells of small intestinal venules(Blumberg and Stenson, 2003).     
4.3.1 Interleukin- 1β  
IL-1β is secreted by macrophages and acts on receptors as a costimulator of T cells and B cells, 
as well as on endothelial cells and hepatocytes, as a mediator of the acute phase 
response(Blumberg and Stenson, 2003).   IL-1β has been shown to down-regulate mRNA 
expression of CYP3A4(Aitken and Morgan, 2007; Assenat et al., 2004), SLCO2B1 (OATP2B1), 
ABCG2 (BCRP), MRP2, MRP3, and MRP4 (Le Vee et al., 2008) as well as CYP3A4 protein 
expression(Aitken and Morgan, 2007) in human hepatocytes and p-glycoprotein expression and 
function in rat hepatocytes(Sukhai et al., 2001).  In the absence of inflammation, IL-1β 
concentrations in plasma are low, with a mean concentration of 0.96 ±0.12 pg/mL reported in a 
group of healthy female control subjects(Scully et al., 2010). 
4.3.2 Interleukin-2 
IL-2 is secreted by Th1 cells and acts on T and B cells to support the events leading to IgG1 
production and cell-mediated immunity(Blumberg and Stenson, 2003).  IL-2 has been shown to 
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suppress p-gp transport of rhodamine 123 and ABCB1 mRNA production in Caco-2 
cells(Belliard et al., 2002).   IL-2 concentrations in plasma were significantly elevated in the first 
1 to 2 days post transplant but decreased sharply by days 4 to 6 in a study of 52 cadaveric renal 
transplant recipients over the first 10 days post-transplant(Sadeghi et al., 2003a).   IL-2 levels are 
typically low in healthy persons, with one study finding a mean plasma IL-2 concentration of 0.3 
±1.4 pg/mL (range 0-7) in a group of 37 healthy control subjects(Daniel et al., 2005). 
4.3.3 Interleukin-4 
IL-4 is produced by CD4 T cells and stimulates undifferentiated Th cells to become Th2 by 
activation of the transcription factor GATA-3.  Th2 cells then proceed to secrete more IL-4 in 
addition to other cytokines(Blumberg and Stenson, 2003).  A study of 52 cadaveric renal 
transplant recipients over the first 10 days post-transplant observed stability in mean IL-4 
concentrations of 6 ±2 pg/mL on both days 1-2 and days 4-6, with a mean concentration of 6±3 
pg/mL on days 8-10(Sadeghi et al., 2003a).  IL-4 concentrations in plasma are variable, even in 
healthy persons.  One study found a mean IL-4 concentration of 6 ±17 pg/mL in a group of 40 
healthy control subjects(Sadeghi et al., 2003b), while another reported a mean plasma IL-4 
concentration of 1.4 ±5.4 pg/mL (range 0-27) in a group of 37 healthy control subjects(Daniel et 
al., 2005). 
4.3.4 Interleukin-6 
IL-6 is produced by macrophages, endothelial cells, and Th2 cells, and plays a role in the acute 
phase response as well as in T and B cell growth(Blumberg and Stenson, 2003).  IL-6 has been 
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shown to suppress CYP3A4 mRNA and protein expression and activity in human 
hepatocytes(Aitken and Morgan, 2007; Yang et al., 2010).  In Caco-2 cells, incubation with IL-6 
has been shown to disrupt cell integrity, but have no effect on PEPT1-mediated uptake(Foster et 
al., 2009).  IL-6 has been shown to decrease p-glycoprotein expression and function in rat 
hepatocytes(Sukhai et al., 2001).   
Plasma concentrations of IL-6 have been positively correlated with lactulose-mannitol 
absorption (a measure of gut barrier permeability) after severe trauma in patients with and 
without multiple organ failure (r=0.43, p<0.03)(Spindler-Vesel et al., 2006) and negatively 
correlated with caffeine (a CYP1A2 probe) metabolism (rs=-0.56, p=0.0235) and CYP2C19 
activity (as measured by urinary recovery of 4’OH-mephenytoin after mephenytoin 
administration)(rs=-0.63, p=0.0094) in a group of congestive heart failure patients(Frye et al., 
2002).  IL-6 in plasma is also highly correlated with C-reactive protein, a marker of systemic 
inflammation, which has in turn been associated with suppression of CYP3A4-mediated 
metabolism in cancer patients(Rivory et al., 2002).  Several studies in liver, liver-intestine, 
kidney, and isolated intestinal transplant patients have shown spikes in serum IL-6 
concentrations immediately before or during episodes of rejection in some patients(Kita et al., 
1994; Kita et al., 1996a; Kita et al., 1996b).  A study in 81 stable cadaveric renal transplant 
recipients without infection or rejection reported that the median plasma IL-6 concentrations of 
patients taking tacrolimus were 3.9 pg/mL (range 3.9 to 6.1 pg/mL) at three months post-
transplant and 3.2 pg/mL (2.5 to 3.7 pg/mL) at 12 months post-transplant(Lauzurica et al., 2007).  
Plasma IL-6 concentrations are typically low but variable in healthy subjects.  One study 
found a mean plasma IL-6 concentration of 2 ±12 pg/mL in a group of 40 healthy control 
subjects(Sadeghi et al., 2003b), while another study reported a mean plasma IL-6 concentration 
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of 1.2 ±2.4 pg/mL (range 0-9) in a group of 37 healthy control subjects(Daniel et al., 2005).  A 
third study found a mean plasma IL-6 concentration of 1.90 ±0.28 pg/mL in a group of healthy 
females(Scully et al., 2010). 
4.3.5 Interleukin-8 
IL-8 is a chemokine produced by macrophages and epithelial cells.  It activates neutrophils and 
encourages their chemotaxis to sites of inflammation or infection(Blumberg and Stenson, 2003; 
Tixier et al., 2005).  IL-8 concentrations increase rapidly during the reperfusion phase during 
lung(Mathur et al., 2006) and liver transplantation(Wen et al., 2004), and remained elevated but 
stable over the first seven days in a liver transplant population(Kubala et al., 2001).     Mean 
plasma IL-8 concentrations of 9.76 ±1.31 pg/mL were seen in a group of healthy female 
controls(Scully et al., 2010). 
 
4.3.6 Interleukin-10 
IL-10 is produced by CD4 T cells and acts on other T cells to suppress cytokine 
production(Blumberg and Stenson, 2003).  IL-10 has been shown to improve Caco-2 cell 
monolayer integrity and ameliorate the destructive effects of IL-6 and TNF-α on integrity(Foster 
et al., 2009). Plasma IL-10 levels have been shown to peak sharply at 2500% of baseline 
immediately after reperfusion during liver transplant surgery, and remain elevated but stable 
through post-transplant day 7(Kubala et al., 2001).  A study of 52 cadaveric renal transplant 
recipients over the first 10 days post-transplant observed mean IL-10 concentrations of 38 ±13 
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pg/mL on days 1-2, 19±9 pg/mL on days 4-6, and 14±3 pg/mL on days 8-10(Sadeghi et al., 
2003a).  At 30 days post-transplant, a mean plasma IL-10 concentration of 3.47 pg/mL was 
observed in a group of 77 liver, heart, liver-kidney, and heart-kidney transplant 
recipients(Cervera et al., 2007).  Plasma IL-10 concentrations in healthy subjects appear variable, 
with one study finding a mean plasma IL-10 concentration of 6.4 ±15.0 pg/mL (range 0-76) in a 
group of 37 healthy control subjects(Daniel et al., 2005). 
4.3.7 Interleukin-12 
IL-12 is produced by macrophages and stimulates the T-bet transcription factor to drive 
undifferentiated Th cells to become Th1, leading to further T and B cell development and cell-
mediated immunity(Blumberg and Stenson, 2003).  IL-12 concentrations in healthy persons are 
typically low—one study found a mean plasma IL-12 concentration of less than 10 pg/mL in a 
group of healthy female controls(Scully et al., 2010). 
 
4.3.8 Tumor necrosis factor-α  
TNF-α is secreted by macrophages, T cells, natural killer cells, and mast cells and acts on 
neutrophils and endothelial cells(Blumberg and Stenson, 2003).  TNF-α has been shown to 
decrease CYP3A4 mRNA and protein expression(Aitken and Morgan, 2007) in human 
hepatocytes as well as decrease ABCB1 mRNA expression and p-glycoprotein transport(Belliard 
et al., 2004) in Caco-2 cells.  A significant negative correlation between CYP2C19 activity (as 
measured by urinary recovery of 4’OH-mephenytoin after mephenytoin administration) and 
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plasma TNF-α (rs=-0.61, p=0.0118) was observed in a group of 16 congestive heart failure 
patients(Frye et al., 2002).   
A study of 52 cadaveric renal transplant recipients over the first 10 days post-transplant 
found that plasma TNF-α concentrations peaked between day 8 and day 10, with a mean 
concentration of 57 ±17 pg/mL on days 1-2, 115±56 pg/mL on days 4-6, and 155±46 pg/mL on 
days 8-10(Sadeghi et al., 2003a).  At 30 days post-transplant, a mean plasma TNF-α 
concentration of 12.71 pg/mL was observed in a group of 77 liver, heart, liver-kidney, and heart-
kidney transplant recipients(Cervera et al., 2007).  A study in 81 stable cadaveric renal transplant 
recipients without infection or rejection reported median TNF-α concentrations of 10.2 pg/mL 
(range 7.8 to 13 pg/mL) at three months and 10.6 pg/mL (range 6.6 to 13.2 pg/mL) at 12 
months(Lauzurica et al., 2007).  In healthy subjects, a mean plasma TNF-α concentration of 1.3 
±2.6 pg/mL (range 0-14) has been reported(Daniel et al., 2005).  
4.3.9 Interferon-γ  
IFN-γ is produced by T cells and natural killer cells, and acts on macrophages, endothelial cells, 
natural killer cells, and epithelial cells(Blumberg and Stenson, 2003), and has been shown to 
significantly suppress CYP3A mRNA expression in human hepatocytes(Aitken and Morgan, 
2007).  IFN-γ concentrations in plasma have been shown to spike to high concentrations three to 
six days before and during episodes of rejection in the first month after transplant in kidney 
transplant patients(Sadeghi et al., 2003b).  Plasma concentrations of IFN-γ are typically low in 
healthy persons.  One study found a mean plasma IFN-γ concentration of less than 5 pg/mL in a 
group of healthy female controls(Scully et al., 2010). 
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4.4 COMPARISON OF PLASMA CYTOKINE CONCENTRATIONS ON THE DAY 
OF STUDY SESSION IN THE THREE STUDY GROUPS 
Plasma samples were analyzed for cytokine concentrations from each study session in all 
subjects.  Median cytokine concentrations (in pg/mL) are presented in Table 8.  Only those 
samples with a concentration falling within the plate-specific standard curve were included in the 
analysis.   
IL-6 and TNF-α concentrations were elevated during the early post-transplant period 
(Tx1), and remained elevated in the later period (Tx2) compared with controls.  Concentrations 
of IL-6 in transplant patients were significantly higher at study session 1 than at study session 2 
(13.5 pg/mL vs. 3.90 pg/mL, p=0.049), and were also higher in Tx1 than in controls (13.8 pg/mL 
vs. 1.21 pg/mL, p<0.0001) and in Tx2 than in controls (3.90 pg/mL vs. 1.21 pg/mL, p=0.0014).  
Similarly, TNF-α concentrations were significantly higher in Tx1 than in Tx2 (4.00 pg/mL vs. 
3.13 pg/mL, p=0.020), higher in Tx1 than in controls (4.10 pg/mL vs. 1.37 pg/mL, p<0.0001), 
and higher in Tx2 than in controls (3.13 pg/mL vs. 1.37 pg/mL, p=0.0004).   
Concentrations of the anti-inflammatory cytokine IL-10 were elevated during the early 
post-transplant period, but were no different from controls in the later period.  Concentrations 
were significantly higher in Tx1 than in Tx2 (47.4 pg/mL vs. 10.8 pg/mL, p=0.0059) and higher 
in Tx1 than in controls (45.9 pg/mL vs. 5.98 pg/mL, p<0.0001).  However, there was no 
significant difference in IL-10 between Tx2 and controls (10.8 pg/mL vs. 5.98 pg/mL, p=0.078).  
IL-8 concentrations did not differ between the early and later post-transplant periods (8.38 
pg/mL vs. 3.40 pg/mL, p=0.11), but were significantly higher in the early period than in controls 
(12.7 pg/mL vs. 1.51 pg/mL, p<0.0001) and in the later period than in controls (3.40 pg/mL vs. 
1.51 pg/mL, p=0.0048).   No significant differences in median plasma concentrations of IL-1β, 
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IL-2, IL-4, IL-12, and IFN-γ were observed between any of the three groups, although a fairly 
wide variability in IL-12 and IFN-γ was noted in the transplant subjects at session 1.  
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Table 8.  Plasma cytokine concentrations on study session days 
Plasma 
cytokine 
(pg/mL) 
Transplant 
Session 1 
(n=16)* 
Transplant 
Session 2 
(n=10) 
Control 
Subjects 
(n=16) 
P value* 
Tx1 vs. Tx2 
P value§ Tx1 
vs. C 
P value§ Tx2 
vs. C 
IL-1β 0.490 (0.198,1.54) 
0.550 
(0.458,1.26) 
0.640 
(0.428,1.60) 0.92
 0.31 0.58 
IL-2 0.705 (0.335,1.08) 
0.720 
(0.608,1.16) 
0.635 
(0.470,1.38) 0.63 0.63 0.60 
IL-4 5.57 (0.130,10.5) 
6.23 
(4.31,10.3) 
5.05 
(1.81,10.4) 0.91 0.46 0.98 
IL-6 13.8
 
(5.22,29.0) 
3.90 
(1.98,5.70) 
1.21 
(0.763,1.61) 0.049 <0.0001 0.0014 
IL-8 12.7 (5.18,17.1) 
3.40 
(2.36,5.62) 
1.51 
(1.33,1.97) 0.11 <0.0001 0.0048 
IL-10 45.9 (25.5,52.9) 
10.8 
(5.54,14.5) 
5.98 
(2.70,7.85) 0.0059 <0.0001 0.078 
IL-12 0.790 (0.130,2.17) 
1.18 
(0.703,2.76) 
0.880 
(0.225,2.22) 0.49 0.88 0.56 
IFN-γ 4.30 (0.633,9.13) 
3.30 
(1.58,5.76) 
2.84 
(1.47,4.51) 1.0 0.84 0.92 
TNF-α 4.10 (2.67,5.18) 
3.13 
(2.85,3.46) 
1.37 
(1.01,1.69) 0.020 <0.0001 0.0004 
Concentrations are median (25th, 75th percentile) 
*Comparisons between transplant sessions 1 and 2 made using the Wilcoxon matched-pairs signed rank 
test on matched pairs.  Numbers in first column are median (25th, 75th percentile) for all 16 transplant session 1 
subjects.  Median concentrations in the Tx1 subjects used in the paired analysis only are reported in the text as 
appropriate.  §Comparisons between transplant session 1 and controls and transplant session 2 and controls made 
using the Mann-Whitney U test.  Two-tailed p values reported.  
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4.5 CORRELATION BETWEEN PLASMA CYTOKINE CONCENTRATIONS AND 
ILEAL CYP3A AND TRANSPORTER GENE EXPRESSION 
4.5.1 Relationship between plasma cytokines and ileal CYP3A expression in transplant 
subjects at study session 1 
Significant correlations between CYP3A expression and plasma cytokine concentrations are 
shown in figures 8 through 12.  There was a strong negative correlation between relative CYP3A 
mRNA expression in ileal biopsy samples and plasma IL-2 (rs=-0.58, p=0.036), IL-4 (rs=-0.53, 
p=0.062), IL-12 (rs=-0.51, p=0.077), and IFN-γ (rs=-0.53, p=0.062) concentrations at study 
session 1.  There was a significant positive correlation between CYP3A mRNA and plasma IL-8 
concentrations (rs=0.62, p=0.025). 
 
Figure 8.  Correlation between ileal CYP3A expression and plasma IL-2 in transplant subjects at study 
session 1. 
 
 
rs = -0.58, p = 0.036 
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Figure 9.  Correlation between ileal CYP3A expression and plasma IL-4 in transplant subjects at study 
session 1. 
 
 
Figure 10.  Correlation between ileal CYP3A expression and plasma IL-8 in transplant subjects at study 
session 1. 
 
 
 
 
rs = -0.53, p = 0.062 
rs = 0.62, p = 0.025 
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Figure 11.  Correlation between ileal CYP3A expression and plasma IL-12 in transplant subjects at study 
session 1. 
 
 
 
 
Figure 12.  Correlation between ileal CYP3A expression and plasma IFN-γ  in transplant subjects at study 
session 1. 
 
 
 
rs = -0.51, p = 0.077 
rs = -0.53, p = 0.062 
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In addition, at study session 1 there was a negative correlation between total CYP3A 
expression and plasma IL-1β (rs=-0.33, p=0.27) and TNF-α (rs=-0.19, p=0.53).  All correlations 
between ileal CYP3A4 and total CYP3A and plasma cytokine concentrations are listed in Table 
34 of Appendix A.  
4.5.2 Relationship between plasma cytokines and CYP3A in transplant subjects at study 
session 2 
A strong negative correlation was observed between ileal CYP3A4  expression and plasma IL-10 
concentrations in transplant subjects at study session 2 (rx=-0.65, p=0.049).  This relationship is 
shown in figure 13.  Similarly, a negative correlation was seen between ileal CYP3A expression 
and plasma IL-12 concentrations (rx=-0.62, p=0.060), shown in figure 14. 
 
Figure 13.  Correlation between ileal CYP3A4 expression and plasma IL-10 in transplant subjects at study 
session 2 
 
 
rs = -0.65, p = 0.049 
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Figure 14.  Correlation between ileal CYP3A expression and plasma IL-12 in transplant subjects at study 
session 2 
 
 
In addition, at study session 2 negative correlations between total CYP3A expression and 
IL-2 (rs=-0.49, p=0.15), IL-4 (rs=-0.34, p=0.33), IFN-γ (rs=-0.54, p=0.11), and TNF-α (rs=-0.30, 
p=0.41) were observed. 
4.6 ASSOCIATION OF PLASMA CYTOKINE CONCENTRATIONS WITH 
EPISODES OF ACUTE REJECTION EARLY POST-TRANSPLANT 
 
 
 
 
rs = -0.62, p = 0.060 
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Figure 15.  Plasma cytokine profile in subject with acute rejection on biopsy 
 
Biopsy taken on day 12 showed acute rejection with 6-7 apoptotic bodies per 10 crypts.  2 methylprednisolone IV x 
1 was given on day 12 and OKT3 was started on day 13.  
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Figure 16.  Plasma cytokine profiles in two subjects with clinical signs of rejection 
 
 
One subject received 1 gm IV methylprednisolone x 1 and one received 2 gm IV methylprednisolone x 1 on day 15 
for clinical symptoms.  Biopsies turned out to be normal.  Areas of rejection may be focal/patchy. 
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4.7 RELATIONSHIP BETWEEN PLASMA IL-6 CONCENTRATIONS AND PRE-
TRANSPLANT DONOR-SPECIFIC ANTIBODIES AND CROSSMATCH 
There was no observed association between plasma cytokine concentrations on the day of study 
and the presence of strong positive crossmatch, donor-specific antibodies, or use of alemtuzumab 
as induction therapy in the transplant subjects. 
 
Figure 17.  Plasma IL-6 concentrations in transplant subjects at study session 1 by presence of crossmatch 
 
p=NS 
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Figure 18.  Plasma IL-6 concentrations in transplant subjects at study session 1 by presence of donor-specific 
antibodies 
 
 
 
Figure 19.  Plasma IL-6 concentrations in transplant subjects at study session 1 by crossmatch and/or donor-
specific antibodies 
 
 
p=NS 
p=NS 
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Figure 20.  Plasma IL-6 concentrations in transplant subjects at study session 1 by alemtuzumab induction 
 
 
 
4.8 CYTOKINE GENE TRANSCRIPTS IN ILEAL BIOPSY SAMPLES 
Low amounts of cytokine mRNA transcripts in ileal biopsy tissue were detected in all but one of 
the transplant subjects at session 1, and all but two at session 2.  Transcript amounts relative to 
cyclophilin are shown in Tables 7 and 8.  IL-1β was the most widely expressed cytokine in the 
transplanted mucosa, detected in 12 out of 13 biopsies at session 1 and six out of ten at session 2.  
TNF-α was the second most ubiquitous, expressed in 11 out of 13 subjects at session 1, and 
seven out of ten at session 2.   IFN-γ was expressed in eight out of 13 at session 1, but only three 
out of ten at session 2.  IL-2 was detected in nine out of 13 at session 1, but only two out of ten at 
session 2.  IL-6 was the least widely detected, being found in only five out of 13 at session 1 and 
two out of ten at session 2.
p=NS 
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Table 9.  Cytokine gene expression in ileal biopsy samples - Session 1 
Subject IL-1β  IL-6 IFN-γ  TNF-α  IL-2 
1 0.00105 0.000170 0.000332 0.00142 0.00213 
3 0.00105 0.000130 0.000373 0.00121 0.000279 
4 0.00109 nd 0.0000671 0.000201 0.00109 
5 0.00725 0.000240 nd 0.000660 0.00134 
6 nd nd nd nd nd 
7 0.000668 nd 0.0000475 0.000421 0.0000855 
8 0.000578 0.00015 nd 0.000608 nd 
9 0.0370 nd nd nd nd 
10 0.00141 nd 0.000705 0.00135 0.000321 
11 0.000372 nd nd 0.000573 0.000149 
13 0.00101 nd 0.00526 0.00102 0.0000920 
14 0.000917 nd nd 0.00220 nd 
15 0.00697 0.00984 0.000820 0.00410 nd 
16 0.000684 nd 0.00312 0.00109 0.00404 
Amounts are expressed relative to cyclophilin, a housekeeping gene 
 
Table 10.  Cytokine gene expression in ileal biopsy samples - Session 2 
Subject IL-1β  IL-6 IFN-γ  TNF-α  IL-2 
2 0.00326 0.000410 0.000192 0.00134 0.00292 
4 nd nd nd nd nd 
5 0.00355 0.0000160 0.000542 0.00110 nd 
6 0.00172 nd nd 0.000944 nd 
7 0.00109 nd nd 0.00218 nd 
8 0.00613 nd 0.000452 0.00258 nd 
9 nd nd nd nd nd 
12 0.00765 nd nd 0.00594 0.000119 
13 nd nd nd nd nd 
15 nd nd nd 0.00862 nd 
Amounts are expressed relative to cyclophilin, a housekeeping gene 
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4.9 DISCUSSION 
 
 
The results presented in this chapter demonstrate that, even in the absence of rejection, 
inflammatory mediators are significantly elevated in the first 40 days after small bowel 
transplantation.   In addition, these results provide evidence that some pro-inflammatory 
cytokines remain elevated above normal even in stable small bowel transplant recipients four 
months to one year post-transplant.  IL-6, IL-8, IL-10, and TNF-α were significantly elevated in 
transplant subjects during the early post-transplant period as compared to the later period and 
with controls and concentrations of IL-6, IL-8, and TNF-α remained significantly higher than 
controls in the later post-transplant period.  IL-1β, IL-2, IL-4, IL-12, and IFN-γ concentrations 
showed no significant difference between groups.  These results, accompanied by the detection 
of cytokine mRNA transcripts in most of the ileal biopsy samples, provide evidence of immune 
activation in small bowel transplant recipients that is higher in the early post-transplant period, 
but that may persist in the long term, even in stable patients with no signs or symptoms of 
rejection or infection.  Furthermore, the significant negative correlations seen between ileal 
CYP3A expression and plasma levels of IL-2, IL-4, IL-10, IL-12, and IFN-γ are consistent with 
previous reports of suppression of CYP3A by pro-inflammatory cytokines in vitro and in vivo, 
and indicate that this immune activity may significantly affect intestinal drug metabolism and 
transport in this study population.  This will be evaluated in the following chapters.  
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5.0  CYTOCHROME P450 3A FUNCTION AFTER SMALL BOWEL AND 
MODIFIED MULTIVISCERAL TRANSPLANTATION  
5.1 BACKGROUND 
5.1.1 Hypothesis and objectives 
Small bowel transplant recipients take numerous medications, many of them by mouth, and a 
significant number of them are CYP3A substrates.  Ischemia-reperfusion injury and immune 
activation within the transplanted organ lead to inflammatory mediator release both within the 
graft and into the systemic circulation.  In vitro studies have shown that pro-inflammatory 
cytokines such as IL-1β, IL-6, TNF-α, and IFN-γ decrease CYP3A expression and function via 
suppression of gene transcription.  Clinical studies in other inflammatory conditions such as 
cancer and sepsis have shown the clinical correlation between inflammatory mediator expression 
and suppression of drug metabolism.   Whereas animal studies have shown suppression of 
CYP3A expression and function in the first 14 days after small bowel transplantation, the 
pharmacokinetics of the CYP3A/p-gp substrate tacrolimus appear no different in stable small 
bowel transplant patients months to years post-transplant. 
In addition, in the previous chapter it has been shown that plasma concentrations of the 
pro-inflammatory cytokines IL-6 and TNF-α were significantly elevated in the early post-
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transplant period (study session 1) as compared with the later post-transplant period (study 
session 2) and with healthy controls.  Significant negative correlations were also seen between 
ileal CYP3A mRNA expression and plasma concentrations of the pro-inflammatory cytokines IL-
2, IL-4, IL-10, IL-12, and IFN-γ, indicating post-transplant inflammation associated with 
decreases in intestinal CYP3A expression.  
Based on these observations, the central hypothesis of this chapter is that intestinal 
CYP3A expression and function in small bowel transplant recipients will be suppressed in the 
early post-transplant period (estimated at approximately the first 30 to 40 days after transplant), 
but will be similar to that seen in healthy control subjects in stable patients without evidence of 
rejection in the later post-transplant period (by four to six months post-transplant).  In order to 
examine the effects of the transplanted intestine without the confounding variable of the 
transplanted liver, only isolated intestinal and modified multivisceral transplant recipients were 
included in the study. 
This chapter therefore has the following specific aim: 
1. To measure intestinal CYP3A expression and function in stable small 
bowel transplant recipients in the early post-transplant period and late 
post-transplant period in comparison to CYP3A activity in healthy 
control subjects. 
a. This will be accomplished by characterizing the pharmacokinetics 
of oral and intravenous midazolam, administered as a probe drug 
for assessment of intestinal and hepatic CYP3A, within 40 days 
post-transplant and approximately four to 12 months post-
transplant in transplant recipients as well as in healthy control 
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subjects.  In addition, in transplant subjects, mRNA transcripts of 
CYP3A4, CYP3A5, and NR1I2 (PXR) will be measured in ileal 
mucosal biopsy samples taken within 48 hours of each midazolam 
study and compared between time periods. 
b. It is predicted that the oral AUC and bioavailability of midazolam 
in the small bowel transplant recipients in the early post-transplant 
period will be significantly higher, and the AUC ratio of 
1’hydroxymidazolam to midazolam significantly lower, than that 
seen in age- and gender-matched healthy control subjects and also 
significantly different than the same subjects in the later post-
transplant period.  In the later post-transplant period it is predicted 
that the pharmacokinetic parameters of oral midazolam will be no 
different than those seen in healthy controls.  In addition, 
expression levels of CYP3A4 and CYP3A5 will be significantly 
lower in the early post-transplant period as compared with the 
later. 
5.1.2 Use of midazolam as a probe drug for CYP3A phenotyping 
Midazolam is a short-acting benzodiazepine sedative-hypnotic, approved by the FDA for use in 
induction of anesthesia and for sedation, especially in critical care units or prior to procedures 
such as endoscopy(APP, 2003).  It is usually administered as an intravenous bolus or infusion, 
although an oral solution formulation is commercially available and is typically used in pediatric 
populations.  Midazolam is metabolized by CYP3A4 and CYP3A5 (if present) to two primary 
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hydroxylated metabolites, 1’hydroxymidazolam (1’OH-MDZ) and 4’hydroxymidazolam, which 
respectively account for approximately 75% and 5%, of biotransformation products(APP, 2003).  
Each of these metabolites is produced by binding to a different site on the CYP3A4 
enzyme(Kapelyukh et al., 2008; Khan et al., 2002).  In addition, very small amounts of parent 
drug are transformed to a third (dihydroxy) metabolite by CYP3A, and to a direct N-glucuronide 
conjugate by UDP-glucuronosyltransferase 1A4 (UGT1A4)(Klieber et al., 2008).  The hydroxy 
and dihydroxy metabolites undergo Phase II biotransformation via glucuronidation and are 
excreted in the urine(APP, 2003).  Midazolam is not a 
substrate of any known transporter in vivo.   
 
Figure 21.  Chemical structure of midazolam 
 
Midazolam is rapidly and completely absorbed 
via the transcellular route after oral administration(Paine 
et al., 2006) and undergoes significant first-pass 
metabolism by intestinal CYP3A(Paine et al., 1996), 
leading to average bioavailability estimates of between 19% to 38% in healthy volunteers(Lee et 
al., 2002; Link et al., 2008; Pentikainen et al., 1989).  Midazolam is highly soluble, highly 
permeable through the enterocyte membrane, and extensively metabolized; as such, it is 
categorized as a class I compound in both the BCS and BDDCS(Takagi et al., 2006).  Typical 
volume of distribution in healthy subjects ranges from 1 to 3.1 L/kg and the average half-life is 
around three hours(APP, 2003).  Clearance of midazolam is diminished in patients with liver 
disease(APP, 2003; Pentikainen et al., 1989; Shelly et al., 1989).  Midazolam is >97% bound to 
plasma proteins, mainly albumin(APP, 2003). 
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Because of its nearly complete metabolism by CYP3A and its lack of affinity for 
transporters, as well as its short half-life and favorable safety profile, midazolam has frequently 
been used as a probe drug to assess CYP3A function in healthy subjects(Chaobal and Kharasch, 
2005; Katzenmaier et al., 2010; Kirby et al., 2006; Lee et al., 2002; Lee et al., 2006; Link et al., 
2008), patients with renal failure(Dowling et al., 2003; Kirwan et al., 2009), liver 
cirrhosis(Chalasani et al., 2001), and in liver transplant recipients(Thummel et al., 1994a; 
Thummel et al., 1994b).  While disposition of intravenous midazolam is used as a marker for 
hepatic CYP3A function, disposition of oral midazolam reflects both intestinal and hepatic 
CYP3A activity.   
Although CYP3A4 and CYP3A5 are both genetically polymorphic in their expression 
and function, the effects of these polymorphisms on the in vivo disposition of CYP3A substrates 
such as midazolam are uncertain.  Intrinsic clearance of midazolam by CYP3A5 has been shown 
to be essentially equal to that mediated by CYP3A4(Soars et al., 2006), so it would be reasonable 
to assume that the presence of genetic polymorphisms of such alleles as CYP3A5*3 would lead 
to significant differences in midazolam clearance compared with carriers of the CYP3A5*1 
allele.  However, this has not always or even typically been the case either in vitro or in vivo.   
The relationship between 1’hydroxymidazolam formation rate and CYP3A 
polymorphisms was examined in human liver microsomes from 54 different donors, with no 
relationship found between midazolam 1’hydroxylation activity and any of the genotypes or 
haplotypes tested, including the relatively common CYP3A5*1 and *3(He et al., 2006).  Studies 
done in healthy human subjects have shown no relationship between oral midazolam AUC0-∞ and 
the presence of CYP3A5*3, CYP3A5*6, CYP3A4*1B, and CYP3A4*1F alleles(Eap et al., 2004), 
between oral and IV midazolam clearance and CYP3A5*3 and CYP3A4*1B alleles(Miao et al., 
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2009), between oral and IV midazolam clearance and CYP3A5*1, *3, *6, and *7 
alleles(Kharasch et al., 2007), and between oral midazolam bioavailability, oral and IV 
midazolam clearance, and the presence of CYP3A5*1 and CYP3A5*3 alleles(Tomalik-Scharte et 
al., 2008). 
Although the relationship between genetic polymorphisms of CYP3A4 and CYP3A5 and 
midazolam disposition has not been shown consistently in vivo, the relationship between 
intestinal CYP3A4 and CYP3A5 mRNA and protein expression and disposition of CYP3A 
substrates has been demonstrated.  1’hydroxylation rates of midazolam were significantly 
correlated to hepatic microsomal CYP3A4 protein content (rs=0.92, p<0.001) as well as 
CYP3A5 protein content, although to a lesser degree (rs=0.60, p<0.001).  Although homozygous 
carriers of the CYP3A5*3 gene had significantly less CYP3A5 protein expression than non-
carriers, this did not affect hepatic CYP3A activity(He et al., 2006). 
A correlation between intestinal CYP3A mRNA expression and pharmacokinetic 
parameters of oral CYP3A substrates has been shown with budesonide, saquinavir, and 
felodipine.  Rectosigmoidal CYP3A4 mRNA expression levels in healthy volunteers were found 
to correlate significantly with the partial metabolic clearances of the two major metabolites of 
budesonide, 16-OH-prednisolone (r2=0.30, p=0.010) and 6-OH-budesonide (r2=0.25, p=0.016).  
CYP3A4 expression was also significantly negatively correlated with the metabolic ratios of 
budesonide and 16-OH-prednisolone (r2=0.34, p=0.006) and budesonide and 6-OH-budesonide 
(r2=0.16, p=0.048), as well as with budesonide AUC0-24(r2=0.18, p=0.040)(Ufer et al., 2008). 
In a study of 20 healthy volunteers administered oral saquinavir, in the six subjects in 
whom CYP3A5 was detected there was a significant positive correlation between saquinavir 
CL/F and CYP3A5 mRNA expression (r2=0.58, p=0.05)(Mouly et al., 2005).  Similarly, a 
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significant negative correlation between duodenal and colonic CYP3A4 expression and Cmax of 
the orally administered CYP3A substrate felodipine was observed in a study of ten healthy male 
volunteers(Lown et al., 1997). 
5.1.2.1 Midazolam disposition in inflammation  
The effects of inflammatory mediators on CYP3A expression have been discussed 
previously.  Consistent with those results, it has also been shown that inflammation and immune 
activation may decrease midazolam 1’hydroxylation via CYP3A.  In a study of rats administered 
a single dose of lipopolysaccharide (LPS) from E. coli, it was found that hepatic microsomal 
expression of CYP3A2 (the rat analog of human CYP3A4) was significantly decreased for five 
days.  In addition, plasma levels of TNF-α and IL-1β were both significantly increased in LPS-
treated rats as compared with control rats at three and six hours after administration (and also at 
nine hours in the case of IL-1β), but concentrations of both were similar to those found in control 
rats by 24 hours.  In addition, the AUC of 1’hydroxymidazolam was significantly lower in LPS-
treated rats on day one after treatment as compared with control rats (421±105 vs. 151±78.6 
ng*min/mL, p<0.01) (Kato et al., 2008).  Midazolam 1’hydroxylation activities of intestinal 
microsomes taken from rats with adjuvant arthritis (AA), an animal model of rheumatoid arthritis 
(a disease of chronic systemic inflammation), were significantly diminished as compared with 
those taken from healthy rats(Uno et al., 2007).        
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5.2 METHODS AND SUBJECT DEMOGRAPHICS 
The study design, methodology and demographics of the recruited subjects have been described 
in detail in chapters 2 and 3 of this dissertation.  Briefly, this study was approved by the 
University of Pittsburgh Institutional Review Board and informed consent was obtained from all 
subjects before any study procedures were performed.  Sixteen small bowel transplant recipients 
(12 isolated intestine and 4 modified multivisceral) and 16 age- and gender-matched healthy 
control subjects were recruited and studied.  Transplant subjects were studied twice: once within 
the first 40 days post-transplant (median day–19, range–10 to 40 days); and again four to 
fourteen months post-transplant (median day–239, range–125 to 428 days).  Sixteen transplant 
subjects (ten women and six men) underwent the first study session and ten (five women and five 
men) returned for the second sesson.  Control subjects underwent one study session. 
At each study session, following an overnight fast, the subject was administered 
5mg/2.5mL of midazolam syrup orally using an oral syringe.  The used oral syringe was then 
flushed twice with 2.5 mL of water, which was administered to the subject, and the subject was 
immediately given an additional four ounces of water to drink.  In the four transplant subjects 
who were receiving medications by jejunostomy tube (J-tube) at the time of the first study 
session, the syrup was administered through the J-tube, together with the two tube rinses and an 
additional four ounces of water.  The J-tube was then clamped.  Seven hours after the oral dose, 
2 mg of midazolam in 150 mL of normal saline was administered intravenously over 30 minutes.  
Blood samples were taken at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 7, 7.25, 7.5, 8, 10, 12, and 20 hours 
after administration of oral midazolam.  Subjects remained in bed for six hours after each 
midazolam administration, with the head of the bed at a 60-degree angle. 
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In addition, tissue samples from the transplanted ileum of the transplant subjects were 
obtained during routine intestinal biopsies performed to monitor the graft for rejection.  They 
were typically taken on the same day as the pharmacokinetic study session, although they were 
allowed to be within ±48 hours of the study session. These mucosal biopsy samples were 
subsequently analyzed for CYP3A4, CYP3A5, and NR1I2 (PXR) gene expression by RT-PCR.   
Midazolam and 1’hydroxymidazolam were measured in plasma by LC-MS as previously 
described. The pharmacokinetic parameters of midazolam were calculated using 
noncompartmental analysis.  Pharmacokinetic parameters and mRNA expression of genes 
between study sessions for transplant subjects were compared using the Wilcoxon matched pairs 
signed rank test.  Transplant session 1 and 2 pharmacokinetic parameters were each compared 
with control subjects and within transplant patients by transplant type and route of administration 
using the Mann-Whitney U test, with a two-sided p value less than 0.05 considered statistically 
significant.  Correlations between CYP3A4 and CYP3A5 ileal gene expression and 
pharmacokinetic parameters of oral midazolam were analyzed in transplant subjects using 
Spearman’s rank correlations, with a one-tailed p value less than 0.05 considered a significant 
correlation. 
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5.3 RESULTS OF PHARMACOKINETIC ANALYSES 
5.3.1 Composite analysis of pharmacokinetic parameters between subject groups 
The pharmacokinetic parameters of intravenous midazolam are presented in Table 9.   
There were no significant differences in parameters between subject groups.   
 
Table 11.  Pharmacokinetic parameters of midazolam after IV administration 
 
Transplant 
Session 1 
(n=16) 
Transplant 
Session 2 
(n=10) 
Control 
Subjects  
(n=16) 
P value* 
Tx1 vs. Tx2 
P value§ 
Tx1 vs. C 
P value§ 
Tx2 vs. C 
MDZ 
AUCIV 
(mcg*hr/L) 
54.4 
(41.4,74.7) 
84.6 
(56.0,182) 
76.3a 
(61.3,124) 0.074
b 0.093 0.68 
CLIV 
(L/hr/kg) 
0.480 
(0.290,0.580) 
0.210 
(0.190,0.425) 
0.420 
(0.230,0.500) 0.068 0.34 0.15 
Vz (L/kg) 1.40 (1.13,1.83) 
1.62 
(1.38,2.15) 
1.36 
(0.860,2.21) 0.077 0.71 0.55 
1’OHMDZ 
AUCIV 
(mcg*hr/L) 
8.22 
(4.42,10.6) 
9.08 
(5.08,11.3) 
8.41a 
(4.97,19.6) 1.0
b 0.51 0.85 
1’OHMDZ/
MDZ AUC 
ratioIV 
0.117 
(0.0875,0.134) 
0.0860 
(0.0615,0.123) 
0.0990a 
(0.0600,0.135) 0.48
b 0.77 0.47 
Parameters are median (25th, 75th percentile).  *Comparisons between transplant sessions 1 and 2 made using the 
Wilcoxon matched-pairs signed rank test on ten matched pairs.  Numbers in first column are median (25th, 75th 
percentile) for all 16 transplant session 1 subjects.  Median concentrations in the 10 Tx1 subjects used in the paired 
analysis only are reported in the text as appropriate.  §Comparisons between transplant session 1 and controls and 
transplant session 2 and controls made using the Mann-Whitney U test.  Two-tailed p values reported.  an=15 for 
controls (one subject was not given midazolam IV).  bTest performed on 9 pairs because one subject only received 1 
mg midazolam IV. 
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The pharmacokinetic parameters of midazolam after oral administration are presented in 
Table 10.  Midazolam oral solution was rapidly absorbed in all subject groups.  However, control 
subjects reached Tmax significantly more quickly than transplant subjects at session 1 (Tx1) or 
session 2 (Tx2), with a median of 0.5 hr in controls compared with 1.0 hr in Tx1 (p=0.020) and 
0.75 hr in Tx2 (p=0.0055).  There was no significant difference in median oral Cmax between 
the three groups, but the AUC of midazolam was significantly higher in Tx1 compared with Tx2 
(65.4 mcg*hr/L vs. 46.4 mcg*hr/L, p=0.0020), as well as Tx1 compared to controls (52.1 
mcg*hr/L vs. 39.3 mcg*hr/L, p=0.037).  There was no significant difference in AUC between 
Tx2 and controls (46.4 mcg*hr/L vs. 39.3 mcg*hr/L, p=0.48).  A similar trend was observed for 
bioavailability (F), which was significantly higher in Tx1 than in Tx2 (0.600 vs. 0.285, 
p=0.0059) and Tx1 compared with controls (0.565 vs. 0.220, p=0.0010), but not significantly 
different between Tx2 and controls (0.285 vs. 0.220, p=0.45).  Weight-adjusted apparent oral 
clearance (CL/F) was not significantly different between Tx1 and Tx2 (1.07 L/hr/kg vs. 1.12 
L/hr/kg, p=0.38) nor between Tx2 and controls (1.12 L/hr/kg vs. 1.85 L/hr/kg, p=0.14).  
However, CL/F was significantly higher in control subjects as compared with Tx1 (1.85 L/hr/kg 
vs. 1.07 L/hr/kg, p=0.019).  Similarly, weight-adjusted apparent volume of distribution (Vz/F) 
was significantly higher in controls than in Tx1 (7.10 L/kg vs. 4.78 L/kg, p=0.050).  Moreover, 
Vz/F came close to statistical significance in a comparison of controls with Tx2 (7.10 L/kg vs. 
4.53 L/kg, p=0.054) but not in a comparison of Tx1 with Tx2 (4.32 L/kg vs. 4.53 L/kg, p=0.065).  
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Table 12.  Pharmacokinetic parameters of midazolam after oral administration 
 
Transplant 
Session 1 
(n=16) 
Transplant 
Session 2 
(n=10) 
Control 
Subjects 
(n=16) 
P value* 
Tx1 vs. Tx2 
P value§ 
Tx1 vs. C 
P value§ 
Tx2 vs. C 
Cmaxpo (mcg/L) 
19.8 
(13.8,32.6) 
16.9 
(12.0,25.5) 
24.7 
(16.0,31.8) 0.38 0.61 0.22 
Tmaxpo (hr) 
1.00 
(0.500,1.50) 
0.750 
(0.500,1.63) 
0.500 
(0.313,0.500) 0.68 0.020 0.0055 
MDZ AUCpo 
(mcg*hr/L) 
52.1 
(41.5,79.5) 
46.4 
(30.2,64.1) 
39.3 
(27.1,50.7) 0.0020 0.037 0.48 
F 0.565 (0.370,0.698) 
0.285 
(0.0850,0.360) 
0.220a 
(0.150,0.290) 0.0059 0.0010 0.45 
CL/F (L/hr/kg) 1.07 (0.733,1.52) 
1.12 
(0.655,1.99) 
1.85 
(1.05,2.62) 0.38 0.019 0.14 
Vz/F (L/kg) 4.78 (2.99,6.61) 
4.53 
(3.76,6.34) 
7.10 
(4.60,9.09) 0.065 0.050 0.054 
MRTlast (hr) 2.48 (2.02,3.00) 
2.46 
(1.88,2.68) 
1.83 
(1.51,2.08) 0.36 0.0014 0.0027 
1’OHMDZ 
AUCpo 
(mcg*hr/L) 
14.5 
(11.2,19.3) 
14.2 
(10.4,29.8) 
19.0 
(13.9,26.9) 0.49 0.086 0.33 
1’OHMDZ/MDZ 
AUC ratiopo 
0.255 
(0.183,0.386) 
0.290 
(0.243,0.843) 
0.549 
(0.342,0.725) 0.11 0.00070 0.13 
Parameters are median (25th, 75th percentile).  *Comparisons between transplant sessions 1 and 2 made using the 
Wilcoxon matched-pairs signed rank test on ten matched pairs.  §Comparisons between transplant session 1 and 
controls and transplant session 2 and controls made using the Mann-Whitney U test.  Numbers in first column are 
median (25th, 75th percentile) for all 16 transplant session 1 subjects.  Median concentrations in the 10 Tx1 subjects 
used in the paired analysis only are reported in the text as appropriate.  Two-tailed p values reported.  an=15 for 
controls (one subject was not given midazolam IV).  bTest performed on 9 pairs because one subject only received 1 
mg midazolam IV. 
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Figure 22.  Midazolam bioavailability between transplant sessions 1 and 2 
 
Dashed line represents medians 
 
There was no significant difference between the AUC of 1’OHMDZ between Tx1 and 
Tx2 (14.5 mcg*hr/L vs. 14.2 mcg*hr/L, p=0.49); between Tx1 and controls (14.5 mcg*hr/L vs. 
19.0 mcg*hr/L, p=0.086); or between Tx2 and controls (14.2 mcg*hr/L vs. 19.0 mcg*hr/L, 
p=0.33).  However, the 1’OHMDZ/MDZ AUC ratio was significantly higher in control subjects 
compared to Tx1 (0.549 vs. 0.255, p=0.00070); although not between Tx1 and Tx2 (0.244 vs. 
0.290, p=0.11) or between Tx2 and controls (0.290 vs. 0.549, p=0.13). 
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Figure 23.  Midazolam concentration vs. time profiles in transplant subjects at Sessions 1 and 2 
 
 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
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Figure 24.  Midazolam concentration vs. time in control subjects 
 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
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Figure 25.  Oral midazolam profiles in all three subject groups 
 
 
Figure 26.  1'hydroxymidazolam profiles after oral midazolam 
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5.3.2 Comparison of J-tube and oral administration in transplant subjects at the first 
study session 
There were no differences in the pharmacokinetic parameters of midazolam and 
1’hydroxymidazolam between subjects receiving medications via jejunostomy tube (J-tube, n=4) 
or by mouth (n=12).  There was a trend towards a higher Vz/F in the J-tube group (6.48 vs. 4.32 
L/kg, p=0.060) but no significant difference in F (0.615 vs. 0.520, p=0.47); Cmax (19.5 vs. 19.8 
mcg/L, p=0.95); Tmax (0.500 vs. 1.00 hr, p=0.54); oral AUC (48.5 vs. 55.6 mcg*hr/L, p=0.50); 
or CL/F (0.975 vs. 1.07 L/hr/kg, p=0.86) between the two routes of administration.  There was 
also no observed difference in 1’hydroxymidazolam oral AUC (16.8 vs. 14.5 mcg*hr/L, p=0.95) 
or 1’hydroxymidazolam/midazolam ratio (0.338 vs. 0.215, p=0.59) between midazolam 
administration by the J-tube or oral route. 
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Table 13.  Pharmacokinetic parameters of oral midazolam by route of administration 
 J-tube (n=4) 
PO 
(n=12) 
P value* 
JT vs. PO 
Cmaxpo (mcg/L) 
19.5 
(13.4,41.1) 
19.8 
(13.8, 32.6) 0.95 
Tmaxpo (hr) 
0.500 
(0.500,1.25) 
1.00 
(0.313,1.88) 0.54 
MDZ AUCpo 
(mcg*hr/L) 
48.5 
(32.8,73.8) 55.6 (41.5,93.4) 0.50 
F 0.615 (0.450,0.758) 
0.520 
(0.248,0.698) 0.47 
CL/F (L/hr/kg) 0.975 (0.780,2.02) 
1.07 
(0.668,1.52) 0.86 
Vz/F (L/kg) 6.48 (4.89,12.6) 4.32 (2.49,5.69) 0.060 
MRTlast (hr) 2.35 (1.88,2.97) 
2.48 
(2.07,3.08) 0.76 
1’OHMDZ 
AUCpo 
(mcg*hr/L) 
16.8 (9.43,20.4) 14.5 (11.2,18.0) 0.95 
1’OHMDZ/MDZ 
AUC ratiopo 
0.338 
(0.198,0.432) 
0.215 
(0.183,0.363) 0.59 
Parameters are median (25th, 75th percentile).  *Comparisons made using the Mann-Whitney U test.  Two-tailed p 
values reported. 
  124 
 
Figure 27.  Oral midazolam concentration-time profiles by route of administration – Session 1 
 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
 
5.3.3 Comparison of pharmacokinetics of oral midazolam in isolated intestinal (II) and 
modified multivisceral (MM) recipients 
There were no significant differences in the pharmacokinetic parameters of midazolam after oral 
administration between modified multivisceral (MM, n=4) and isolated small bowel (II, n=12) 
recipients at either study session 1 or 2 (See figure 4).    There was a trend towards a lower Cmax 
in MM vs. II (17.6 vs. 19.8 mcg/L, p=0.50) as well as a higher Tmax (1.25 vs. 0.750 hr, p=0.71) 
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median Cmax of 13.4 mcg/L in MM vs. 23.9 mcg/L in II (0.38).   Median Tmax was also higher 
in MM vs. II (1.00 vs. 0.500, p=0.46), but the difference did not reach statistical significance. 
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Table 14.  Pharmacokinetic parameters of oral midazolam by transplant type at Session 1 
Session 1 MM (n=4) 
II 
(n=12) 
P value* 
MM vs. II 
Cmaxpo (mcg/L) 
17.6 
(9.43,32.5) 
19.8 
(16.2,35.9) 0.50 
Tmaxpo (hr) 
1.25 
(0.438,1.88) 
0.750 
(0.500,1.50) 0.71 
MDZ AUCpo 
(mcg*hr/L) 
52.1 
(43.2,152.3) 
53.1 
(39.2,78.5) 0.76 
F 0.570 (0.458,0.750) 
0.565 
(0.248,0.698) 0.67 
CL/F (L/hr/kg) 0.895 (0.260,1.45) 
1.07 
(0.780,1.52) 0.50 
Vz/F (L/kg) 4.54 (2.20,6.35) 4.79 (2.99,7.31) 0.59 
MRT (hr) 3.15 (2.21,3.50) 
2.44 
(2.02,2.58) 0.16 
1’OHMDZ 
AUCpo 
(mcg*hr/L) 
16.1 (9.35,23.6) 14.5 (11.2,18.0) 0.76 
1’OHMDZ/MDZ 
AUC ratiopo 
0.298 
(0.102,0.445) 
0.255 
(0.183,0.363) 0.86 
*Comparisons made using the Mann-Whitney U test.  Numbers are median (25th, 75th percentile).   Two-tailed p 
values reported. 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
  127 
 
 
Table 15.  Pharmacokinetic parameters of oral midazolam by transplant type at Session 2 
Session 2 MM (n=3) 
II 
(n=7) 
P value* 
MM vs. II 
Cmaxpo (mcg/L) 
13.4 
(11.5,17.6) 
23.9 
(12.1,29.9) 0.38 
Tmaxpo (hr) 
1.00 
(0.500,3.00) 
0.500 
(0.500,1.00) 0.46 
MDZ AUCpo 
(mcg*hr/L) 
43.1 
(30.5,60.2) 
49.6  
(29.3,75.7) 1.0 
F 0.350 (0.230,0.390) 
0.280 
(0.070,0.340) 0.36 
CL/F (L/hr/kg) 0.830 (0.640,2.16) 
1.40 
(0.660,1.93) 1.0 
Vz/F (L/kg) 3.82  (3.56,6.07) 
5.05 
(3.99,7.15) 0.52 
MRTlast (hr) 2.64 (1.88,3.48) 
2.46 
(1.87,2.60) 0.36 
1’OHMDZ 
AUCpo 
(mcg*hr/L) 
12.6  
(8.79,15.0) 
16.9  
(10.7,47.3) 0.27 
1’OHMDZ/MDZ 
AUC ratiopo 
0.288 
(0.249,0.291) 
0.310 
(0.224,0.916) 0.67 
Parameters are median (25th, 75th percentile).  *Comparisons made using the Mann-Whitney U test.  Two-tailed p 
values reported. 
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5.4 RT-PCR RESULTS 
5.4.1 Biopsy tissues obtained 
Two ileal mucosal biopsy samples were obtained from 15 of the 16 transplant subjects 
undergoing study session 1 and 10 of the 10 transplant subjects undergoing study session 2.  The 
two samples per session (together weighing approximately 25 mg) were combined for PCR 
analysis.  Of the samples collected from the 15 subjects at the time of study session 1, two 
yielded insufficient mRNA for analysis, which was consequently performed on 13 biopsy 
samples taken at study session 1 and 10 samples taken at study session 2.   Since the three 
missing values in the Tx1 group (one biopsy not done, two with insufficient RNA) belonged to 
subjects who returned for study session 2, paired analysis could only be performed on seven 
pairs.   
 
5.4.2 Expression levels of CYP3A4 and CYP3A5 
Expression levels of CYP3A4 and CYP3A5, and total CYP3A mRNA are shown in tables 16 and 
17.  Median (25th, 75th percentile) expression levels of CYP3A4 relative to cyclophilin were 
0.182 (0.0630,0.846) at Tx1 and 0.536 (0.300, 0.937) at Tx2 (p=0.16); levels of CYP3A5 were 
0.0360 (0.0130,0.0780) at Tx1 and 0.109 (0.0100,0.241) at Tx2 (p=0.078); and levels of total 
CYP3A were 0.261 (0.0990,0.956) at Tx1 and 0.561 (0.356,1.15) at Tx2 (p=0.078).  
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Table 16.  Paired comparison of ileal CYP3A and PXR expression 
mRNA Transplant Session 1 (n=7) 
Transplant Session 2 
(n=7) 
P value 
Tx1 vs. Tx2 
CYP3A4 0.182 (0.0630,0.846) 
0.536 
(0.300,0.937) 0.16 
CYP3A5 0.0360 (0.0130,0.0780) 
0.109 
(0.0100,0.241) 0.078 
Total CYP3A 0.261 (0.0990,0.956) 
0.561 
(0.356,1.15) 0.078 
NR1I2 (PXR) 0.157  (0.096,0.283) 
0.183  
(0.174,0.195) 1.0 
Amounts are relative to cyclophilin and are expressed as median (25th, 75th percentile).  Comparison made using the 
Wilcoxon matched-pairs signed-rank test.  Two-tailed p values reported. 
 
Table 17.  Ileal CYP3A and PXR expression in all transplant subjects 
mRNA Transplant Session 1 (n=13) 
Transplant Session 2 
(n=10) 
CYP3A4 0.450 (0.159,0.722) 
0.591 
(0.272,0.898) 
CYP3A5 0.0470 (0.0155,0.0945) 
0.0825 
(0.00975,0.190) 
Total CYP3A 0.516 (0.200,0.848) 
0.610 
(0.315,1.08) 
NR1I2 (PXR) 0.142  (0.0972,0.212) 
0.186  
(0.169,0.193) 
Amounts are relative to cyclophilin and are expressed as median (25th, 75th percentile) 
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5.5 CORRELATION BETWEEN PLASMA CYTOKINE CONCENTRATIONS AND 
PHARMACOKINETIC PARAMETERS OF MIDAZOLAM 
5.5.1 Study session 1 
At study session 1, a strong correlation was observed between AUC of midazolam and plasma 
TNF-α concentrations (rs=0.71, p=0.0021) and IL-10 concentrations (rs=0.53, p=0.036) .   This is 
shown in Figures 28 and 29.   
 
Figure 28.  Correlation between oral midazolam AUC and plasma TNF-α in transplant subjects at study 
session 1 
 
 
rs = 0.71, p=0.0021 
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Figure 29.  Correlation between midazolam oral AUC and plasma IL-10 concentrations in transplant subjects 
at study session 1 
 
 
 
In addition, significant correlations between oral bioavailability of midazolam and 
plasma IL-2 (rs=0.42, p=0.10), plasma IL-6 (rs=0.67, p=0.0081), and plasma IFN-γ (rs=0.56, 
p=0.026) were observed.  These correlations are shown in figures 30, 31, and 32. 
 
 
 
 
 
 
 
 
 
 
rs = 0.53, p=0.036 
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Figure 30.  Correlation between midazolam bioavailability and plasma IL-2 in transplant subjects at study 
session 1 
 
 
Figure 31.  Correlation between midazolam bioavailability and plasma IL-6 concentrations in transplant 
subjects at studys session 1 
 
 
 
rs = 0.42, p=0.10 
rs = 0.67, p=0.0081 
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Figure 32.  Correlation between midazolam bioavailability and plasma IFN-γ  in transplant subjects at study 
session 1 
 
 
 
 
 
Figure 33.  Correlation between 1’OHMDZ/MDZ oral AUC ratio and plasma TNF-α  in transplant subjects 
at study session 1 
 
 
rs = 0.56, p=0.026 
rs = -0.53, p=0.036 
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Figure 34.  Correlation between midazolam CL/F/kg and plasma TNF-alpha concentrations in transplant 
subjects at study session 1 
 
 
 
 
 
 
Figure 35.  Correlation between difference in 1’OHMDZ/MDZ oral AUC ratio and difference in plasma IL-
10 levels between study sessions in transplant subjects 
 
 
 
rs = 0.59, p=0.081 
rs = 0.57, p=0.021 
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Figure 36.  Correlation between difference in 1’OHMDZ/MDZ oral AUC ratio and difference in plasma IFN-
γ  levels between study sessions in transplant subjects 
 
 
 
5.5.2 Relationship between % hepatic steatosis and IV AUC of midazolam 
There was no correlation observed between degree of hepatic steatosis on pre-transplant liver 
biopsy and AUC of IV midazolam at study session 1 (Figure 36).   
rs = -0.76, p=0.015 
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Figure 37.  Relationship between pre-transplant % hepatic steatosis and IV midazolam AUC at study session 
1 
 
5.6 DISCUSSION 
These results show distinctive differences in intestinal absorption and first-pass metabolism of 
oral midazolam, both between transplant sessions 1 and 2 and between transplant groups and 
control subjects.  The similarity in midazolam disposition between groups after IV 
administration indicates that the differences seen are occurring at the level of the transplanted 
intestine and not the native liver.  These data also show clear differences in rate and extent of 
absorption of midazolam as well as the extent of metabolism between transplant subjects at 
different timepoints and between transplant subjects and control subjects.   
Midazolam is a BCS and BDDCS class I drug(Amidon et al., 1995; Benet et al., 2011), 
highly soluble (and in this case administered in solution form), readily absorbed through the 
enterocyte membrane, and extensively metabolized.  Therefore, the absorption rate (reflected in 
rs=0.14, p=0.67 
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Tmax and to some extent Cmax) after oral administration will depend largely on the gastric 
emptying rate(Amidon et al., 1995), which under normal circumstances for a liquid is extremely 
rapid.  Gastric emptying may be delayed in small bowel transplant recipients(Campbell et al., 
1993; Furukawa et al., 1994), and this is reflected in the presented data by the significantly 
higher Tmax in transplant subjects – both early and late post-transplant – as compared with 
control subjects.  This data provides evidence that slower gastric emptying persists long term 
even in clinically stable small bowel transplant recipients. 
The area under the concentration-time curve (AUC) after oral administration and 
bioavailability (F) reflect the degree both of absorption and first-pass metabolism of the drug.  
Both AUC and F were significantly higher in the early post-transplant period as compared with 
the later post-transplant period, and in the early period as compared with control subjects.  
However, there was no significant difference in AUC or F between the later post-transplant 
period and healthy control subjects.  This is an indication that more midazolam was reaching the 
systemic circulation after oral administration early post-transplant as compared with later post-
transplant and with controls.  Particularly striking is the fact that midazolam F was higher in the 
early post-transplant period as opposed to the later post-transplant in every transplant subject 
who underwent both study sessions as shown in Figure 14.  Since Vz and CL after IV midazolam 
showed no difference between groups, it is likely that the lower CL/F and Vz/F values seen in 
transplant subjects in the early post-transplant period as compared with controls are due to the 
higher bioavailability (F) in transplant subjects.   
Although it is possible that the increases in AUC and F of midazolam early post-
transplant are at least in part a consequence of increased intestinal permeability due to altered 
epithelial barrier integrity or alterations in motility leading to increased contact of the drug with 
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the enterocyte membrane, the additional evidence favors impairment of CYP-mediated intestinal 
first-pass metabolism as the most likely cause of the observation.  The ratio of the oral AUC of 
1’hydroxymidazolam to midazolam (a measure of the extent of first-pass metabolism by 
CYP3A) was significantly lower in transplant subjects early post-transplant as compared with 
controls.  The ratio of the concentration of 1’hydroxymidazolam/midazolam at a single 
timepoint, usually either 20 or 30 minutes after IV administration, has been proposed by some as 
a marker of hepatic CYP3A metabolic activity that correlates strongly with midazolam 
clearance, but results have been mixed(Link et al., 2008; Rogers et al., 2002).  The ratio of AUCs 
is presented here since it takes the entire sampling interval into account rather than simply 
relying on a single point estimate.    
Another reason the differences in AUC and F are likely to be due to impaired metabolism 
is the difference in ileal mRNA expression of CYP3A4 and CYP3A5 between transplant subjects, 
early and late post-transplant.  Although the difference did not reach statistical significance, 
probably due to the small number of paired samples available (n=7), the median CYP3A4, 
CYP3A5, and total CYP3A expression was lower at the early post-transplant session as compared 
with the later post-transplant session.  It should also be noted that there was a significant 
negative relationship between CYP3A4 expression and the AUC after oral midazolam.  This is 
most likely the first study to assess the correlation between the pharmacokinetics of midazolam 
and intestinal CYP3A expression in vivo.   
Interestingly, there was no significant effect resulting from differences in the route of 
administration (JT vs. PO) at transplant session 1 and between transplant types (MM vs. II) at 
either study session on the pharmacokinetics of oral midazolam.  The only difference seen 
between routes of administration in Figure 19 is a slightly lower median Tmax in the JT group, a 
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difference that was not statistically significant (p=0.54).  Although this may be due to the small 
number of subjects, especially in the JT and MM groups, the lack of difference implies that for 
highly soluble and highly permeable BCS/BDDCS class I drugs such as midazolam, enteral route 
of administration does not have a significant effect on the absorption of the drug.  Administration 
via J-tube bypasses the stomach and thus gastric emptying has no effect on the absorption rate, 
but it also bypasses the duodenum and a small portion of jejunum, and therefore the available 
absorptive surface area is less, possibly leading to a smaller AUC for poorly absorbed drugs.  
However, for a highly permeable drug such as midazolam, the difference was minimal.   
The pharmacokinetics of midazolam were also only minimally affected by transplant 
subtype in the subjects studied.  Upon examination of Figure 19, a higher Tmax (i.e. decrease in 
rate of absorption) can be seen in the MM subjects as compared with the II at session 1, but this 
does not translate to any difference in AUC (p=0.76) or F (p=0.67).  This higher Tmax in MM 
subjects could be due to a slower rate of gastric emptying in the MM subjects.  Although MM 
patients have been demonstrated in one study to be more likely to have rapid gastric emptying 
due to pyloroplasty, there may still be a degree of impairment in emptying, especially in the early 
post-transplant period in the presence of increased immune activity.  At study session 2, the 
median Tmax was still higher in the MM subjects as compared with II, and the median AUC and 
Cmax were smaller, but as with session 1, the differences did not reach statistical significance.  
This finding warrants further investigation with a larger group of both MM and II patients, since 
the small number of subjects in each group at session 2 (II=7 and MM=3) make it difficult to 
detect any but the most dramatic differences in parameters with any certainty.  However, these 
results do imply motility and/or absorption differences between MM and II patients that persist 
into the later post-transplant period, even in clinically stable small bowel allograft recipients. 
  140 
The effects of graft drainage to the caval rather than the portal circulation should be 
mentioned.  As noted in the demographics chapter, only one of the 16 transplant subjects had this 
anatomical arrangement after isolated intestinal transplant, a number which did not allow for an 
evaluation of the differences in first-pass metabolism with caval drainage.  This subject only 
underwent study session 1, where his pharmacokinetic profile of midazolam was unremarkable, 
showing a bioavailability of 0.36, midazolam oral AUC of 34.2 mcg*hr/L, and an oral 
1’hydroxymidazolam/midazolam ratio of 0.523.  This bioavailability and AUC are lower than 
the medians of 0.570 and 52.1 mcg*hr/L in II subjects at session 1, and the AUC ratio is higher 
than the median of 0.298.  But it should also be noted that the donor of this subject’s graft was 
African-American, and it is known that African-Americans are significantly more likely than 
Caucasians to be expressers of the CYP3A5*1 allele, which leads to production of a functional 
CYP3A5 enzyme and is associated with enhanced CYP3A-mediated metabolism and lower 
bioavailability of tacrolimus.   
Although the amount of tissue retrieved during ileal biopsies was not enough to do 
genotyping of the graft (which, it should be remembered, may be different from the genotype of 
the recipient), the fact that this subject’s relative CYP3A5 expression level was 0.225, nearly four 
times the median of 0.047 seen in session 1, is a strong indicator that the subject was at least 
heterozygous for the CYP3A5*1 allele, and the presence of a functional intestinal CYP3A5 
enzyme may have compensated for the absence of hepatic first-pass metabolism.  The PCR 
primer used in this study will only amplify the functional form of the enzyme.  However, 
homozygous carriers of the CYP3A5*3 allele will produce very small amounts of the functional 
enzyme in addition to the truncated form, leading to detection of small amounts of CYP3A5 
mRNA by RT-PCR.  It should also be noted that the two other transplant subjects who had 
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African-American donors had AUC ratios of 0.445 and 0.392, higher than the median.  One of 
these also had a CYP3A5 expression level of 0.111 at the first study session and 0.241 at the 
second, but the remaining subject had a low relative CYP3A5 expression level of 0.018.  Hence, 
pharmacokinetic studies should always take the graft drainage arrangement into account when 
analyzing small bowel transplant pharmacokinetic data, although graft genotype and intestinal 
CYP3A expression levels may compensate for the lack of hepatic first-pass metabolism. 
This is the first study to assess intestinal CYP3A function and expression in the 
transplanted small bowel and it has demonstrated a significant reduction in the extent of 
metabolism of the CYP3A probe substrate midazolam in the early post-transplant period.  These 
results have clinical ramifications for small bowel transplant recipients.  As discussed in the 
introduction, small bowel transplant recipients receive numerous oral CYP3A substrates after 
transplant, some of which have narrow therapeutic indices and are not easily assayed in blood or 
plasma.  These results reveal that intestinal CYP3A metabolism is impaired in the early post-
transplant period, and that extra caution should be used when dosing oral CYP3A substrates. 
While these results have ramifications for the dosing of all oral CYP3A substrates in 
small bowel transplant recipients, they are not translatable to all drugs, given that – as discussed 
earlier – the biopharmaceutical characteristics of the drug also play a role in oral disposition.  
However, these results with midazolam are highly relevant to BCS/BDDCS class I CYP3A 
substrates, for example amlodipine, clonazepam, diltiazem, estradiol, nicardipine, oxybutynin, 
quetiapine, and sildenafil, that undergo rapid absorption and extensive metabolism.   These 
results indicate that disposition of highly soluble and highly permeable drugs such as midazolam 
will be only minimally affected by enteral route of administration and transplant subtype, but 
highly affected by intestinal CYP3A expression and function.  If there is a concern for about 
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excessive bioavailability of these drugs, especially in the early post-transplant period, clinicians 
should dose cautiously and drug concentrations should be measured in blood or plasma 
whenever assays are available,  and pharmacodynamic monitoring (i.e. blood pressure and pulse 
for antihypertensives, level of sedation for clonazepam) should performed more frequently in 
these patients until the desired pharmacologic effects are attained in the absence of toxicity. 
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6.0  INTESTINAL DRUG TRANSPORTER EXPRESSION AND FUNCTION AFTER 
SMALL BOWEL AND MODIFIED MULTIVISCERAL TRANSPLANTATION 
 
6.1 BACKGROUND 
6.1.1 Objectives of this study 
Small bowel transplant recipients take numerous medications, many of them by mouth, and a 
significant number of them are substrates for intestinal transporters such as p-glycoprotein (p-
gp).  Ischemia-reperfusion injury and immune activation within the transplanted organ lead to 
inflammatory mediator release both within the graft and into the systemic circulation.  In vitro 
studies have shown that pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, and IFN-γ 
decrease p-gp expression and function via suppression of gene transcription.  That these effects 
of cytokines on transporters may have clinical relevance in a transplant setting is further 
evidenced by animal studies of small bowel transplantation that shown not only impaired 
enzyme and transporter expression and function, but also impairments of intestinal first pass 
metabolism and transport of the widely-used immunosuppressive drug tacrolimus, in the first 
two weeks after transplant, returning to normal approximately one month after surgery.  Whether 
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or not these changes are seen in intestinal transplant patients and when the functional recovery 
occurs are key questions.  As mentioned earlier, the pharmacokinetic parameters of tacrolimus, a 
CYP3A and p-gp substrate, in clinically stable small bowel transplant recipients several months 
to years after transplant are similar to those seen in other transplant populations, implying 
eventual recovery of intestinal CYP3A and p-gp function. 
Based on these observations, the central hypothesis of this chapter is that intestinal 
transporter expression and function in small bowel transplant recipients will be suppressed in the 
early post-transplant period (estimated at approximately the first 30 to 40 days after transplant), 
but will be similar to that seen in healthy control subjects in stable patients without evidence of 
rejection in the later post-transplant period (by four to six months post-transplant).  In order to 
examine the effects of the transplanted intestine without the confounding variable of the 
transplanted liver, only isolated intestinal and modified multivisceral transplant recipients were 
included in the study.  The specific aim of this study is as follows: 
1. To measure intestinal transporter expression and function in stable 
small bowel transplant recipients in the early post-transplant period 
and later post-transplant period in comparison to transporter activity in 
normal healthy control subjects.   
a. This will be accomplished by the characterization of the 
pharmacokinetics of oral fexofenadine as a probe drug for 
transporter function assessment, within 40 days post-transplant and 
approximately four to 12 months post-transplant.  In addition, in 
transplant subjects, mRNA transcripts of ABCB1 (p-gp), SLCO1A2 
(OATP1A2), and SLCO2B1 (OATP2B1) will be measured in ileal 
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mucosal biopsy samples taken within 48 hours of each 
fexofenadine study and compared between study sessions in the 
transplant subjects. 
b. It is predicted that the oral AUC of fexofenadine in small bowel 
transplant recipients in the early post-transplant period will be 
significantly higher than that seen in age- and gender-matched 
healthy control subjects and also significantly different than the 
same subjects in the later post-transplant period.  In the later post-
transplant period, it is predicted that the pharmacokinetic 
parameters of fexofenadine will be no different from those seen in 
healthy controls.  In addition, expression levels of the above-
mentioned transporters will be significantly lower in the early post-
transplant period as compared with the later. 
 
6.1.2 Oral fexofenadine as a probe drug to assess transporter function 
Fexofenadine is a histamine H1receptor antagonist that is FDA-approved for the treatment of 
seasonal allergic rhinitis and chronic idiopathic urticaria(sanofi-aventis, 2007).  It is a moderately 
lipophilic zwitterionic molecule that is an active metabolite of terfenadine, another antihistamine 
no longer marketed in the US.  Fexofenadine has good water solubility (0.81 mg/mL in 
phosphate buffer) but a low partition coefficient (LogP) of approximately 0.3 at neutral pH.  The 
carboxylic acid functional group on the molecule has a pKa of 4.25 and the piperidine moiety a 
pKa of 9.53(Chen, 2007).  
  146 
 
Figure 38.  Chemical structure of fexofenadine 
 
  
After oral administration of the immediate release tablet formulation, average Tmax 
estimates of fexofenadine in healthy volunteers range from 1.42(Robbins et al., 1998) to 2.7 
hours(Lappin et al., 2010).  Mean elimination half-life is 14.4 hours, and most of the drug is 
eliminated unchanged in the urine (8 to 18%)(Russell et al., 1998) and feces (80%, mainly due to 
biliary secretion), with less than 5% undergoing metabolism(sanofi-aventis, 2007).  Binding to 
plasma proteins is low at 60 to 70%(sanofi-aventis, 2007).   Although not marketed in an 
intravenous formulation, the mean bioavailability of fexofenadine was calculated at 0.30 in a 
study in which an intravenous microdose of 100 µg was administered to healthy volunteers.  A 
mean volume of distribution of 116 L and clearance of 13 L/hr were reported after IV 
administration(Lappin et al., 2010).  In a study of 24 healthy male volunteers, a single oral dose 
of 60 mg fexofenadine resulted in a mean AUC0-∞ of 1348 ng*hr/mL, Cmax of 209 ng/mL, Tmax 
of 1.42 hours, CL/F of 50.6 L/hr, and half life of 13.1 hours(Robbins et al., 1998). 
Fexofenadine is a substrate for several drug transporters found in the intestine, including 
p-gp, OATP2B1, and OATP1A2(Cvetkovic et al., 1999; Ma et al., 2010; Shimizu et al., 2005).  
Fexofenadine is also a substrate for hepatic transporters, including the uptake transporters 
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OATP1B1 and OATP1B3(Shimizu et al., 2005).  In addition, the bile salt export pump (BSEP) 
and MRP3 play a role in efflux of fexofenadine into bile(Matsushima et al., 2008).  Fexofenadine 
is most likely not a substrate of BCRP(Matsushima et al., 2008; Shimizu et al., 2005; Swift et al., 
2009), MRP4(Matsushima et al., 2008), or OCT1(Cvetkovic et al., 1999), and the role of MRP2 
in its intestinal efflux and biliary excretion is under debate(Matsushima et al., 2008; Petri et al., 
2004; Tahara et al., 2005).  It is preferentially absorbed in the proximal small intestine 
(duodenum and upper jejunum) as compared with the distal (lower jejunum and ileum), probably 
due to the increased p-gp-mediated efflux in the distal intestine(Ujie et al., 2008).  Overall 
effective permeability of fexofenadine from the lumen to the bloodstream in the jejunum is poor 
at a mean of 0.11±0.11 cm/second(Tannergren et al., 2002).   
Although fexofenadine is a substrate for OATP uptake transporters as well as the p-gp 
efflux transporter, animal studies have demonstrated that efflux transporter effects predominate 
over uptake during the absorption process in the intestine.  Rat studies have shown that oatp2b1 
(the rat analog to the human uptake transporter OATP2B1) expression level patterns in the 
intestinal segments are very similar to those of p-gp, with lowest levels in the duodenum, 
followed by jejunum, ileum, and highest levels in the colon(MacLean et al., 2010).  Another 
study found that permeability of fexofenadine from the serosal to mucosal side of rat ileal 
segments was 18-fold greater than its mucosal to serosal permeability, also indicating 
predominance of efflux over uptake(Ujie et al., 2008).  It is possible that given the much lower 
relative expression of OATP transporters as compared with p-gp(Glaeser et al., 2007) that OATP 
transporters become saturated at clinically relevant luminal concentrations of fexofenadine.  It is 
likely that passive diffusion also plays a role in its absorption. 
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Fexofenadine has been used in a number of studies as a p-gp phenotyping probe drug to 
assess p-gp function(Dresser et al., 2002; Glaeser et al., 2007; Kharasch et al., 2005; Xie et al., 
2005).  The advantages of fexofenadine as a probe drug for p-gp include its very favorable safety 
profile(sanofi-aventis, 2007), lack of metabolism by intestinal or hepatic enzymes(Miura et al., 
2007b; sanofi-aventis, 2007), easy detection in plasma by LC-MS even at the lowest 
commercially available dose of 60 mg, and linear pharmacokinetics up to doses of 240 
mg(Robbins et al., 1998).  Drawbacks to its use as a probe include the lack of an FDA-approved 
intravenous formulation (without which, true oral bioavailability cannot be calculated), and its 
lack of selectivity for p-glycoprotein.  However, evidence suggests that p-gp does not play a 
significant role in the biliary excretion of fexofenadine(Tahara et al., 2005), indicating that with 
regards to p-gp, its disposition after oral administration largely reflects that of the intestine, with 
a lesser contribution from intestinal OATP1A2 and OATP2B1 due to their lower expression and 
saturability.  Disposition of fexofenadine also reflects the function of BSEP, MRP3, and 
OATP1B1 and OATP1B3 in the liver, as well as transporter function in the kidneys.   
6.1.3 Effects of inflammation on fexofenadine pharmacokinetics 
It has been previously noted in the introduction that inflammatory mediators secreted during 
immune activation may have suppressive effects on p-gp expression and function(Belliard et al., 
2004; Belliard et al., 2002) as well as increase intestinal permeability(Kuebler et al., 2003; 
Nagpal et al., 2006; Welcker et al., 2004).  Administration of lipopolysaccharide (LPS) to rats 
found a higher AUC0-∞ (13.9 ±9.76 vs. 5.53 ± 1.12 mcg*hr/mL, p<0.05) and bioavailability 
(0.030 ± 0.021 vs. 0.012 ± 0.002) of oral fexofenadine as compared with control rats, but no 
significant effects on the pharmacokinetics of IV fexofenadine (mainly a reflection of biliary 
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excretion and some renal elimination)(Jaisue et al., 2010).  Although cytokines were not 
measured in the animals, the systemic response to LPS is well characterized, and includes 
increases in circulating IL-1β and IL-6.  The increase in fexofenadine bioavailability was not 
accompanied by a decrease in clearance, indicating a likely localization of the LPS effects to the 
level of the intestine, possibly via suppression of p-gp efflux, loosening of tight junctions, or 
both. 
6.2 METHODS AND SUBJECT DEMOGRAPHICS 
The study design and methodology as well as demographics of the recruited subjects have been 
described in detail in chapters 2 and 3.  This study was approved by the University of Pittsburgh 
Institutional Review Board and informed consent was obtained from all subjects before any 
study procedures were performed.  Sixteen small bowel transplant recipients (12 isolated 
intestine, 4 modified multivisceral) and 16 age and gender matched healthy control subjects were 
recruited and studied.  Transplant subjects were studied twice; once within the first 40 days post-
transplant (median day 19, range days 10 to 40) and again four to fourteen months post-
transplant (median day 239, range days 125 to 428).  Sixteen transplant subjects (ten women, six 
men) participated in the first study session and ten (five women, five men) returned for the 
second.  Control subjects participated in one study session. 
At each study session, after an overnight fast, the subject was administered a single 60 
mg immediate-release tablet of fexofenadine with four ounces of water.   In the four transplant 
subjects who were receiving medications by jejunostomy tube (J-tube) at the time of the study 
session, the tablet was crushed completely to a powder, mixed with approximately 10 mL of 
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water and drawn up into an oral syringe.  The syringe contents were then administered through 
the J-tube and followed by two tube rinses of water and another four ounces of water.  The J-tube 
was then clamped.  Blood samples (3 mL) were drawn into EDTA tubes at 0, 0.5, 1, 2, 3, 4, 6, 
6.25, 6.5, 7, 9, 11, and 19 hours after administration of fexofenadine.  Subjects remained in bed 
for five hours after fexofenadine administration, with the head of the bed at a 60-degree angle. 
In addition, in the transplant subjects, mucosal biopsy samples from the transplanted 
ileum were analyzed for ABCB1, MRP2, ABCG2, SLCO1A2, SLCO2A1, and SLCO2B1 gene 
expression by RT-PCR.  Tissue samples were obtained during routine intestinal biopsies done to 
monitor the graft for rejection.  They were typically taken on the same day as the 
pharmacokinetic study session, although they were allowed to be within ±48 hours of the study 
session. 
Fexofenadine was measured in plasma by LC-MS as described previously.  
Pharmacokinetic parameters of fexofenadine were calculated using noncompartmental analysis.  
Parameters and mRNA expression of genes were compared between study sessions for transplant 
subjects using the Wilcoxon matched pairs signed rank test, and transplant session 1 and 2 
results, including biopsies, were each compared with control subjects and transplant patients by 
transplant type and route of administration using the Mann-Whitney U test.  A two-sided p value 
<0.05 was considered statistically significant.  Correlations between ileal transporter gene 
expression and pharmacokinetic parameters of fexofenadine were analyzed in transplant subjects 
using Spearman’s rank correlations, with a one-tailed p value less than 0.05 considered a 
significant correlation. 
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6.3 RESULTS OF PHARMACOKINETIC ANALYSES 
6.3.1 Composite analysis of pharmacokinetic parameters between subject groups 
Concentration-time profiles of fexofenadine in the three study groups are shown in Figures 31 to 
34.  The most striking differences between the groups were seen in Tmax, with both transplant 
groups showing a higher median Tmax than controls.  Median Tmax of subjects at study session 
1 (Tx1) was 10.0 hours in the paired analysis compared with 3.00 hours for those at study 
session 2 (Tx2) (p=0.050) and compared with 2.00 hours for controls (p=0.0007).  Tx2 was also 
significantly higher than controls (p=0.0021).  Median Cmax of fexofenadine was not 
significantly different between Tx1 and Tx2 (80.3 vs. 122 mcg/L, p=0.16) nor between Tx2 and 
controls (122 vs. 119 mcg/L, p=0.87) and Tx1 vs. controls (86.5 vs. 119 mcg/L, p=0.052).  There 
were no significant differences in median AUC0-11 or AUC0-19 between the three groups, 
although there was a trend towards a lower AUC0-11 in the Tx1 subjects as compared with Tx2 
(492 vs. 738 mcg*hr/L, p=0.16).  CL/F and Vz/F could only be calculated in seven Tx1 subjects 
because the elimination phase could not be clearly characterized in nine of the subjects.  Of the 
seven subjects in whom these parameters could be calculated, there was no difference between 
Tx1 and Tx2 (1.12 vs. 1.04 L/hr/kg, p=0.49), Tx1 and controls (1.08 vs. 1.23 L/hr/kg, p=0.57) 
and Tx2 and controls (1.04 vs. 1.23 L/hr/kg, p=0.29).  Vz/F was not significantly different 
between Tx1 and Tx2 (9.61 vs. 7.14 L/kg, p=0.38) nor between Tx1 and controls (7.96 vs. 10.3 
L/kg, p=0.19).  However, median Vz/F values were significantly lower in Tx2 compared with 
controls (7.14 vs. 10.3 L/kg, p=0.043).  MRTlast was significantly higher in Tx1 as compared 
with controls (7.46 vs. 4.80 hr, p=0.012). 
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Table 18.  Pharmacokinetic parameters of oral fexofenadine 
Parameter 
Transplant 
Session 1 
(n=16) 
Transplant 
Session 2 
(n=10) 
Control 
Subjects 
(n=16) 
p value 
Tx1 vs. Tx2 
p value 
Tx1 vs. C 
p value 
Tx2 vs. C 
Cmax 
(mcg/L) 
86.5 
(50.4,130) 
122 
(81.7,196) 
119 
(91.6,186) 0.16 0.052 0.87 
Tmax 
(hr) 
6.00 
(3.00,11.0) 
3.00 
(2.75,6.00) 
2.00 
(1.25,2.75) 0.050 0.0007 0.0021 
AUC0-11 
(mcg*hr/L) 
496 
(284,823) 
738 
(401,941) 
618 
(375,838) 0.16 0.49 0.65 
AUC0-19 
(mcg*hr/L) 
604 
(333,1140) 
871 
(456,1160) 
692 
(415,965) 0.84 0.88 0.44 
CL/F 
(L/hr/kg) 
1.08* 
(0.910,1.16) 
1.04 
(0.630,1.48) 
1.23 
(0.960,1.93) 0.49 0.57 0.29 
V/F 
(L/kg) 
7.96* 
(4.30,10.2) 
7.14 
(4.12,8.78) 
10.3 
(7.40,13.3) 0.38 0.19 0.043 
MRTlast 
(hr) 
7.46 
(4.92,11.3) 
6.49 
(4.61,7.59) 
4.80 
(4.60,5.23) 0.065 0.012 0.068 
Parameters are median (25th, 75th percentile) *CL/F and V/F could only be calculated in 7 out of 16 transplant 
subjects at session 1.  *Comparisons between transplant sessions 1 and 2 made using the Wilcoxon matched-pairs 
signed rank test on ten matched pairs, except for CL/F and V/F.  Numbers in first column are median (25th, 75th 
percentile) for all 16 transplant session 1 subjects.  Median concentrations in the 10 Tx1 subjects used in the paired 
analysis only are reported in the text as appropriate.  §Comparisons between transplant session 1 and controls and 
transplant session 2 and controls made using the Mann-Whitney U test.  Two-tailed p values reported. 
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Figure 39.  Fexofenadine concentration vs. time in transplant subjects at session 1 
 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
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Figure 40.  Fexofenadine concentration vs. time in transplant subjects at Session 2 
 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
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Figure 41.  Fexofenadine concentration vs. time in control subjects 
 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
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Figure 42.  Fexofenadine concentration vs. time - all subject groups 
 
6.3.2 Comparison of J-tube and oral administration in transplant subjects at the first 
study session 
Pharmacokinetics of fexofenadine compared between those who received the medication via 
jejunostomy tube (JT, n=4) and by mouth (PO, n=12) are shown in Table 17 and the 
concentration-time profiles in Figure 35.  There was a trend towards a higher Cmax (123 vs. 80.3 
mcg/L, p=0.25) and AUC0-11 (786 vs. 492 mcg*hr/L, p=0.16) in the JT group, as well as a trend 
towards a lower Tmax (3.00 vs. 10.0, p=0.26) and Vz/F (4.30 vs. 9.61 L/kg, p=0.057).  MRT 
was significantly lower in the JT group as compared with PO (4.48 vs. 10.3 hours, p=0.034). 
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Table 19.  Pharmacokinetic parameters of fexofenadine in transplant subjects by route of administration at 
session 1 
Parameter J-tube (n=4) 
PO 
(n=12) 
p value 
JT vs. PO 
Cmax 
(mcg/L) 
123 
(71.2,260) 
80.3 
(48.2,125) 0.25 
Tmax 
(hr) 
3.00 
(1.50,9.00) 
10.0 
(3.00,17.0) 0.26 
AUC0-11 
(mcg*hr/L) 
786 
(439,1270) 
492 
(186,552) 0.16 
CL/F 
(L/hr/kg) 
1.12* 
(1.07,3.22) 
0.910§ 
(0.680,1.12) 0.23 
V/F 
(L/kg) 
4.30* 
(3.08,7.12) 
9.61§ 
(8.23,16.8) 0.057 
MRTlast 
(hr) 
4.48 
(3.75,6.45) 
10.3 
(6.53,11.6) 0.034 
Parameters are median (25th, 75th percentile).  Medians were compared using the Mann-Whitney U test.  A two-
sided p value was considered statistically significant. 
 
Figure 43.  Fexofenadine concentration vs. time profile by route of administration - transplant session 1 
 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
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6.3.3 Comparison of pharmacokinetics of oral fexofenadine in isolated intestinal (II) and 
modified multivisceral (MM) recipients 
6.3.3.1 Study session 1 
Pharmacokinetic parameters of fexofenadine in modified multivisceral (MM) transplant 
subjects as compared with isolated intestinal (II) transplant subjects at study session 1 are listed 
in Table 18 and the concentration-time profile is shown in Figure 36.  Median Cmax was 
significantly lower in MM as compared with II (35.0 vs. 114 mcg/L, p=0.0064), as were AUC0-
11(150 vs. 534 mcg*hr/L, p=0.0064) and AUC0-19(282 vs. 1040 mcg*hr/L, p=0.018).  Tmax was 
significantly higher in MM as compared with II (19.0 vs. 3.00, p=0.0062).  There was a trend 
towards a longer MRT in MM as compared with II (12.0 vs. 6.55, p=0.060).  CL/F and Vz/F 
could not be compared between transplant groups at this session because those parameters could 
not be calculated in any of the Tx1 MM patients due to the difficulty in characterizing an 
elimination phase within the 19 hour sampling period.  Comparisons of II with controls, 
however, showed no significant differences between parameters except for Tmax, which was still 
higher in Tx1 (p=0.0071). 
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Table 20.  Pharmacokinetic parameters of fexofenadine by transplant type at session 1 
Session 1 MM (n=4) 
II 
(n=12) 
Control 
Subjects 
(n=16) 
p value 
MM vs. II 
p value 
II vs. C 
Cmax 
(mcg/L) 
35.0 
(19.8,52.6) 
114 
(79.1,137) 
119 
(91.6,186) 0.0064 0.37 
Tmax 
(hr) 
19.0 
(13.0,19.0) 
3.00 
(2.25,10.5) 
2.00 
(1.25,2.75) 0.0062 0.0071 
AUC0-11 
(mcg*hr/L) 
150 
(85.5,301) 534 (490,912) 
618 
(375,838) 0.0064 0.66 
AUC0-19 
(mcg*hr/L) 282 (254,428) 
1040 
(594,1370) 
692 
(415,965) 0.0182 0.19 
MRTlast 
(hr) 
12.0 
(8.03,13.6) 
6.55 
(4.48,10.9) 
4.80 
(4.60,5.23) 0.060 0.11 
Parameters are median (25th, 75th percentile) Comparisons between MM and II and and II and controls made using 
the Mann-Whitney U test.  Two-tailed p values reported. 
 
Figure 44.  Fexofenadine concentration vs. time profiles by transplant type - session 1 
 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
 
0	  20	  
40	  60	  
80	  100	  
120	  140	  
160	  180	  
200	  
0	   5	   10	   15	   20	  
FE
X	  
co
nc
	  (m
cg
/L
)	  
Time	  (hr)	  
Fexofenadine	  Session	  1	  -­‐	  ModiUied	  Multivisceral	  (n=4)	  
and	  Isolated	  Intestine	  (n=12)	  
MM	  II	  
  160 
 
6.3.3.2 Study session 2 
Pharmacokinetic parameters of fexofenadine in modified multivisceral (MM) transplant 
subjects as compared with isolated intestinal (II) transplant subjects at study session 2 are listed 
in Table 19 and the concentration-time profiles are shown in Figure 37.  At this later session, no 
significant differences in Tmax (3.00 vs. 3.00 hours, p=0.90) or MRT (5.29 vs. 6.78 hours, 
p=0.52) were seen.  However, differences in AUC0-11 and AUC0-19 between the two groups 
remained.  Both AUC0-11 (385 vs. 831 mcg*hr/L, p=0.033) and AUC0-19 (417 vs. 1160 
mcg*hr/L, p=0.017) were still significantly lower in MM than II.   In addition, both CL/F (2.03 
vs. 0.720 L/hr/kg, p=0.033) and Vz/F (9.75 vs. 6.60 L/kg, p=0.017) were significantly higher in 
MM as compared with II.  
 
Table 21.  Pharmacokinetic parameters of fexofenadine by transplant type at session 2 
Session 2 MM (n=3) 
II 
(n=7) 
Control 
Subjects 
(n=16) 
p value 
MM vs. II 
p value 
II vs. C 
Cmax 
(mcg/L) 
88.1 
(34.6,114) 158 (118,215) 
119 
(91.6,186) 0.067 0.50 
Tmax 
(hr) 
3.00 
(3.00,6.00) 
3.00 
(2.00,6.00) 
2.00 
(1.25,2.75) 0.90 0.012 
AUC0-11 
(mcg*hr/L) 385 (205,410) 831 (687,957) 
618 
(375,838) 0.033 0.10 
AUC0-19 
(mcg*hr/L) 417 (242,468) 
1160 
(753,1160) 
692 
(415,965) 0.0167 0.042 
CL/F 
(L/hr/kg) 
2.03 
(1.15,2.73) 
0.720 
(0.570,1.12) 
1.23 
(0.960,1.93) 0.033 0.035 
V/F 
(L/kg) 
9.75 
(8.46,15.2) 
6.60 
(3.86,7.15) 
10.3 
(7.40,13.3) 0.017 0.0068 
MRTlast 
(hr) 
5.29 
(4.71,6.72) 
6.78 
(4.31,8.23) 
4.80 
(4.60,5.23) 0.52 0.12 
Parameters are median (25th, 75th percentile)  Comparisons between MM and II and II and controls made using the 
Mann-Whitney U test.  Two-tailed p values reported. 
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Figure 45.  Fexofenadine concentration vs. time profiles by transplant type - session 2 
 
Median concentrations shown with + error bar 75th percentile, - error bar 25th percentile 
 
6.3.4 Effects of renal function on the pharmacokinetics of fexofenadine in transplant 
subjects 
As noted in chapter 3, creatinine clearance was significantly lower in transplant subjects at 
session 2 as compared with session 1 (55.5 vs. 94.0 mL/min/1.73 m2, p=0.0098) and as 
compared with control subjects (55.5 vs. 99.0 mL/min/1.73 m2, p=0.0054).  There was no 
difference in creatinine clearance between Tx1 and controls (91.5 vs. 99.0 mL/min/1.73 m2, 
p=0.98).  A decrease in creatinine clearance of greater than 50% was observed in six out of the 
ten transplant subjects who returned for session 2.  In the other four subjects, the creatinine 
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clearance had changed 15% or less from baseline.  Approximately 11% of an administered dose 
of fexofenadine is excreted in the urine, and Cmax was 87% greater and elimination half-life 
59% longer, in subjects with mild to moderate renal impairment (CrCL 41-80 mL/min)(sanofi-
aventis, 2007).  Therefore, the relationship between creatinine clearance and fexofenadine AUC, 
CL/F, MRT, and Cmax was examined in transplant subjects at session 1, session 2, and both 
sessions combined.  There was no correlation observed between creatinine clearance and 
fexofenadine AUC, CL/F, and Cmax.  However, there was a significant negative correlation 
observed between creatinine clearance and MRT at session 1.  Results of correlation analysis are 
listed in Table 20. 
Table 22.  Relationship between creatinine clearance and fexofenadine disposition in transplant subjects 
Session Fex AUC0-11 Fex AUC0-19 CL/F Cmax MRTlast 
1 rs=0.17 p=0.27 
rs=0.021 
p=0.47 
rs=-0.50* 
p=0.13 
rs=0.090 
p=0.37 
rs=-0.50 
p=0.025 
2 rs=-0.16 p=0.33 
rs=-0.079 
p=0.42 
rs=0.15 
p=0.34 
rs=-0.13 
p=0.37 
rs=-0.018 
p=0.49 
All rs=-0.060 p=0.39 
rs=-0.071 
p=0.38 
rs=0.16 
p=0.27 
rs=-0.17 
p=0.21 
rs=-0.16 
p=0.22 
*n=7 because fexofenadine CL/F could only be calculated in 7 transplant subjects at session 1 
 
6.4 RT-PCR RESULTS 
6.4.1 Ileal mRNA expression of transporters 
The relative expression levels of the six transporters tested are listed in tables 21 and 22.  
Because of poor mRNA yield in two samples and one sample not obtainable (all from session 1) 
analysis was performed on seven pairs of samples.  Although median ABCB1 (p-gp) and ABCG2 
(BCRP) transcript levels were lower at session 1 as compared with session 2, the difference did 
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not reach statistical significance.  However, MRP2 levels were significantly lower at session 1 
than session 2 in the paired analysis (0.0202 vs 0.0778, p=0.031).  The expression levels of 
SLCO2A1 (OATP2A1) and SLCO2B1 (OATP2B1) were nearly identical between study sessions.  
mRNA expression of SLCO1A2 (OATP1A2), thought to be the main uptake transporter for 
fexofenadine, was not detected in any of the 23 samples evaluated. 
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Table 23.  Paired comparison of ileal transporter expression 
mRNA Transplant Session 1 (n=7) 
Transplant Session 2 
(n=7) 
P value* Tx1 
vs. Tx2 
ABCB1 (P-gp) 0.114 (0.0920, 0.261) 0.226 (0.0860, 0.351) 0.30 
MRP2 0.0202 (0.00397,0.0411) 0.0778 (0.0386,0.0925) 0.031 
ABCG2 
(BCRP) 0.334 (0.165,0.554) 0.616 (0.586,0.788) 0.078 
SLCO1A2 
(OATP1A2) not detected not detected n/a 
SLCO2A1 
(OATP2A1) 0.0111 (0.00389,0.0368) 0.0108 (0.00565,0.0180) 0.58 
SLCO2B1 
(OATP2B1) 0.0111 (0.00710,0.0128) 0.0123 (0.00988,0.0146) 0.84 
Amounts are relative to cyclophilin and are expressed as median (25th, 75th percentile)  Comparisons made using the 
Wilcoxon matched-pairs signed rank test.  Two-tailed p values reported. 
 
Table 24.  Ileal transporter expression in all transplant subjects 
mRNA Transplant Session 1 (n=13) 
Transplant Session 2 
(n=10) 
ABCB1 (p-gp) 0.125 (0.0960, 0.212) 0.281 (0.0733,0.361) 
MRP2 0.0294 (0.0202,0.0440) 0.0844 (0.0354,0.101) 
ABCG2 
(BCRP) 0.302 (0.262,0.476) 0.661 (0.572,0.848) 
SLCO1A2 
(OATP1A2) not detected not detected 
SLCO2A1 
(OATP2A1) 0.0106 (0.00455,0.0221) 0.0108 (0.00580,0.0275) 
SLCO2B1 
(OATP2B1) 0.0120 (0.00911,0.0131) 0.0124 (0.0102,0.0157) 
Amounts are relative to cyclophilin and are expressed as median (25th, 75th percentile) 
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6.4.2 Transporter mRNA expression and pharmacokinetic parameters of fexofenadine 
There were no statistically significant correlations between the pharmacokinetic parameters of 
fexofenadine (Cmax, Tmax, AUC0-11, AUC0-19, CL/F, and MRT) and relative ABCB1 mRNA 
expression in the samples taken as a whole.  However, there was a statistically significant 
negative correlation between ABCB1 expression and Cmax (rs=-0.52, p=0.071) at Tx1 only.  
There was no relationship observed between SLCO2B1 (OATP2B1) expression and fexofenadine 
AUC, Cmax, CL/F, or MRT either by study session or with both sessions combined.  Correlation 
between fexofenadine parameters and SLCO1A2 expression could not be performed because that 
transporter was not detected in any of the samples. 
6.4.3 Fexofenadine pharmacokinetics and plasma cytokine concentrations 
Figure 46.  Correlation between fexofenadine Cmax and plasma ileal ABCB1 expression in transplant 
subjects at study session 1 
 
 
rs = -0.52, p=0.071 
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Figure 47.  Correlation between fexofenadine CL/F/kg and plasma IL-12 concentration in transplant subjects 
at study session 1 
 
 
 
 
Figure 48.  Correlation between fexofenadine AUC0-11 and plasma IL-4 concentration in transplant subjects 
at study session 2 
 
 
 
rs = -0.67, p=0.039 
rs = 0.75, p=0.066 
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Figure 49.  Correlation between fexofenadine Cmax and plasma IL-4 concentration in transplant subjects at 
study session 2 
 
 
Figure 50.  Correlation between fexofenadine CL/F/kg and plasma IL-8 concentration in transplant subjects 
at study session 2 
 
 
 
 
rs = -0.58, p=0.088 
rs = -0.65, p=0.049 
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Figure 51.  Correlation between fexofenadine MRTlast and plasma IL-6 concentration in transplant subjects 
at study session 2 
 
 
Figure 52.  Correlation between difference in fexofenadine Cmax and plasma IL-4 concentrations in 
transplant subjects between study sessions 
 
 
 
 
rs = 0.73, p=0.020 
rs = -0.62, p=0.060 
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Figure 53.  Correlation between difference in fexofenadine Tmax and plasma IL-6 concentrations in 
transplant subjects between study sessions 
 
 
 
Figure 54.  Correlation between difference in fexofenadine Tmax and plasma IL-8 concentrations in 
transplant subjects between study sessions 
 
 
 
 
rs = 0.77, p=0.013 
rs = 0.63, p=0.060 
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Figure 55.  Correlation between difference in fexofenadine AUC0-19 and plasma IL-12 concentrations in 
transplant subjects between study sessions 
 
6.5 DISCUSSION 
This work has examined the rate of absorption (as measured by Tmax and Cmax) and extent of 
absorption (as measured by AUC and also Cmax) of the BCS/BDDCS class III drug 
fexofenadine, a substrate for intestinal p-gp and OATP1A2 and OATP2B1 transporters, in small 
bowel transplant recipients and healthy control subjects.     
The significantly increased median Tmax, and somewhat decreased median Cmax, seen 
in the transplant subjects at session 1 as compared with session 2 and with controls reflects a 
greatly slowed rate of absorption of fexofenadine in the early post-transplant period that has not 
recovered to normal even in the later post-transplant period in this group of stable transplant 
subjects.  However, the overall extent of systemic exposure (as measured by AUC) is not 
significantly different between the groups.  CL/F was also not different between the groups, but 
rs = 0.79, p=0.028 
  171 
could not be measured in nine out of 16 transplant subjects at session 1, and without intravenous 
dosing it is impossible to evaluate the relative contribution of CL and F.  Despite this, given the 
low intestinal permeability of fexofenadine, it is possible that bioavailability (F) is reduced in 
these patients, especially at session 1, due to incomplete absorption.  Overall, at the second study 
session all the parameters tended to more closely approach those of control subjects. 
Unfortunately, full concentration-time profiles could not be characterized in nine of the 
transplant subjects at session 1 within the 19-hour sampling interval. These results were 
unexpected at the time of study design.  While 19 hours was sufficient to evaluate the profiles of 
control subjects as well as transplant subjects at session 2, increasing the sampling interval to 36 
or even 48 hours would have allowed for characterization of the true AUC, Cmax and clearance, 
especially in the transplant subjects at session 1 whose Cmax based on these profiles occurred at 
11 or 19 hours post-dose.  While in most of the subjects Cmax had been reached much earlier 
than 11 hours, in that particular group of subjects the true Cmax may even have occurred 
between 11 and 19 hours and been missed, leading to underestimation of the AUC.  And if blood 
sampling had occurred until plasma concentrations were very low, the full AUC to infinity in 
these subjects might have been discovered to be significantly higher than those seen at session 2 
and in control subjects, confirming the initial prediction of the study.  Therefore, the lack of 
difference between fexofenadine Cmax and AUC at session 1 as compared with the other groups 
may have been an artifact of abnormal absorption and study design.  Future pharmacokinetic 
studies of highly soluble but poorly permeable and slowly absorbed drugs such as fexofenadine 
in small bowel transplant patients should make sure that the duration of sampling is at least 36 
hours. 
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In addition, a decreased intestinal surface area due to ileostomy may have led to 
decreases in absorption.  A pharmacokinetic study of oral and IV azithromycin (a BDDCS class 
III drug that is a substrate for MRP2 efflux in the intestine and liver) in subjects with ileostomies 
showed that 37% of the oral dose was recovered from the ileostomy output in the six hours after 
dosing and 47% in the first 24 hours.  After IV administration, only 13% was recovered in the 
ileostomy bag after 24 hours.  Since azithromycin, like fexofenadine, is preferentially absorbed 
in the duodenum and upper jejunum, recovery of a large amount of unchanged drug after passage 
through this segment of intestine is likely due to incomplete absorption.  This argument was 
further strengthened by the finding that bioavailability of azithromycin was 16.2% in the 
ileostomy subjects, approximately half that seen in subjects with an intact intestine(Luke and 
Foulds, 1997).  It is possible that significant amounts of fexofenadine were washed out into the 
ostomy bag, especially in those subjects with an especially rapid intestinal transit time.  In the 
case of fexofenadine, however, measurement of drug in ostomy output would have been 
confounded by its lack of metabolism and the high excretion of unchanged drug in the bile.  It 
should be noted, however, that undissolved fexofenadine tablets were not observed to come out 
into the ostomy bag undissolved in any case, although this could have been missed amongst 
ostomy bag contents. 
Abete et al. described the pharmacokinetics of 5 mg/kg IV ganciclovir followed by 900 
mg oral valganciclovir (rapidly converted to ganciclovir, a BDDCS class III PEPT1 substrate, in 
the intestine) in an adult small bowel transplant recipient two months after transplant.  AUC0-24, 
Cmax, and bioavailability of ganciclovir after oral valganciclovir were similar to the values seen 
in other transplant populations.  However, ganciclovir Tmax at 6 hours was significantly higher 
than the typical 1 to 3 hours expected, suggesting absorption rate differences between small 
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bowel transplant recipients and other patients(Abete et al., 2004).  Whether the difference is due 
to impaired intestinal hydrolysis to ganciclovir by esterases, impaired PEPT1 uptake, or delays in 
gastric emptying is unknown, but this report also provides evidence of delayed absorption of a 
highly soluble, poorly permeable drug in the setting of small bowel transplantation. 
Small bowel transplant recipients often display delays in gastric emptying combined with 
reduced intestinal transit times.  Once the stomach empties into the proximal small intestine (the 
optimal site of fexofenadine absorption) if transit time is rapid the exposure of the drug to the 
enterocyte membrane will be limited.  The drug compound will also spend longer in the jejunum 
and ileum than the duodenum due to the greater length and although fexofenadine absorption is 
normally lower in those segments due to p-gp efflux, p-gp expression may be suppressed leading 
to increased absorption from the ileum.  It is also possible that the absence of ileal OATP1A2 
expression observed in all the transplant subjects, thought to be the primary uptake transporter 
for fexofenadine, in the ileal biopsy samples may have also played a role in reducing 
fexofenadine absorption in the proximal small intestine. 
The significantly higher Tmax after oral as compared with J-tube administration also 
suggests delays in gastric emptying in the transplant subjects in the early post-transplant period.  
J-tube administration bypasses the effects of the stomach (and gastric emptying times) and 
although it also bypasses some of the supposed optimal absorption window for fexofenadine, the 
reduced expression of p-gp (and MRP2, if it is indeed an efflux transporter of fexofenadine) in 
the transplanted ileum may lead to improved absorption there.  It is also possible that crushing 
the fexofenadine tablet prior to J-tube administration improved the dissolution profile of the drug 
thus leading to more rapid absorption.  However, given that it was an immediate-release 
formulation of a drug with high solubility, the effects of dissolution time should have been 
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negligible unless intestinal fluid content was significantly reduced in the transplant subjects at 
session 1.  This is a possibility, since intestinal transplant recipients are sometimes under oral 
fluid restrictions in the first few weeks after surgery.  However, the unusual absorption patterns 
with extremely high Tmax were unrelated to time post-transplant at study session 1 and were 
observed up to studies on post-transplant days 32 and 40 in subjects who had been receiving oral 
medications for some time and who were eating a normal diet.   
In addition to being enteral route-dependent, the disposition of fexofenadine in the 
transplant subjects was also strongly dependent on transplant subtype, especially at session 1, 
with modified multivisceral transplanted subjects showing significantly higher Tmax and 
significantly lower Cmax and AUC as compared with isolated intestinal transplant subjects in the 
early post-transplant period, showing decreased rate and extent of absorption.  As with the 
analysis of the transplant groups as a whole, the sampling time of 19 hours is not enough in the 
modified multivisceral subgroup to fully characterize AUC to infinity and therefore the true 
difference in AUC cannot be adequately described.  However, the similarities between the 
profiles between the 11 and 19 hour time points suggest that the main differences are occurring 
during the absorption phase.  At session 2, the extent of absorption, as measured by AUC, is still 
significantly decreased in MM subjects as compared with II, although differences in median 
Tmax have disappeared. These results, particularly at session 2, are difficult to explain, and may 
relate either to a recovery of impairments in gastric emptying in the MM subjects combined with 
a more rapid intestinal transit time or merely to the small number of subjects in the subgroup 
analysis, with only three in the MM group in the later post-transplant period. 
Overall, the results of this study do not provide complete support for the main hypothesis 
that intestinal transporter expression and function are suppressed in the early post-transplant 
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period as compared with later post-transplant and control subjects.  Firstly, these results do not 
demonstrate that the AUC of fexofenadine is significantly higher in the early post-transplant 
period as opposed to the later, due perhaps in part to the study sampling interval of 19 hours 
being insufficient to characterize the elimination phase in nine out of the 16 subjects at session 1.  
Secondly, although relative ileal mucosal expression of ABCB1 (although not significantly) and 
MRP2 were lower in the early post-transplant period compared with later there were no 
significant correlations observed between the pharmacokinetic parameters of fexofenadine and 
either ABCB1 and SLCO2B1 ileal gene expression, in sharp contrast to the results seen with 
midazolam and CYP3A expression.    There was no correlation between fexofenadine AUC or 
Cmax and plasma cytokine concentrations in the subjects taken as a whole, although there was a 
significant correlation between Tmax and several cytokines.  Although again the lack of 
correlation of cytokine concentration with extent of absorption may have been influenced by the 
duration of sampling it could point to an effect of inflammation on motility or gastric emptying.   
Overall, these results demonstrate a stronger effect of enteral route of administration and 
transplant subtype on fexofenadine pharmacokinetics than ileal transporter expression, a result 
that casts doubt on the appropriateness of fexofenadine as a p-gp probe in patient populations 
with impaired gastrointestinal motility, due to its poor absorption profile.  These results also 
recommend caution on the part of clinicians when dosing poorly permeable BCS/BDDCS class 
III substrates in small bowel transplant patients, since they demonstrate that rate and, in some 
cases, extent of absorption of these drugs will be significantly decreased, even in the later post-
transplant period in stable patients.  This may be an especially important consideration for the 
use of oral antibiotics in the case of infection.  Amoxicillin, azithromycin, many of the oral 
cephalosporins, doxycycline, fluconazole, levofloxacin, moxifloxacin, tetracycline, and 
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trimethoprim are all BDDCS class III drugs, and may exhibit some of the same impairments in 
rate and extent of absorption as fexofenadine, particularly in the early post-transplant period. 
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7.0  PHARMACOKINETICS OF TACROLIMUS AFTER SMALL BOWEL AND 
MODIFIED MULTIVISCERAL TRANSPLANTATION 
7.1 BACKGROUND 
7.1.1 Hypothesis and objectives of this study 
Small bowel transplant recipients take numerous medications, many of them by mouth, and a 
significant number of them CYP3A and/or transporter substrates.  Ischemia-reperfusion injury 
and immune activation within the transplanted organ lead to inflammatory mediator release both 
within the graft and into the systemic circulation.  In vitro studies have shown that pro-
inflammatory cytokines such as IL-1β, IL-6, TNF-α, and IFN-γ decrease CYP3A and transporter 
expression and function via suppression of gene transcription.  Clinical studies in other 
inflammatory conditions such as cancer and sepsis have shown the clinical correlation between 
inflammatory mediator expression and suppression of drug metabolism.  That these effects of 
cytokines on drug-metabolizing enzymes and transporters have clinical relevance in a transplant 
setting is further evidenced by animal studies of small bowel transplantation that shown not only 
impaired enzyme and transporter expression and function, but also impairments of intestinal first 
pass metabolism of the widely-used immunosuppressive drug tacrolimus, in the first two weeks 
after transplant, returning to normal approximately one month after surgery.  Whether or not 
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these changes are seen in intestinal transplant patients and when the functional recovery occurs 
are key questions.  As mentioned earlier, the pharmacokinetic parameters of tacrolimus, a 
CYP3A and p-gp substrate, in clinically stable small bowel transplant recipients several months 
to years after transplant are similar to those seen in other transplant populations, implying 
eventual recovery of intestinal CYP3A and p-gp function. 
Based on these observations, the central hypothesis of this chapter is that intestinal 
CYP3A and transporter expression and function in small bowel transplant recipients will be 
suppressed in the early post-transplant period (estimated at approximately the first 30 to 40 days 
after transplant), but will be similar to that seen in healthy control subjects in stable patients 
without evidence of rejection in the later post-transplant period (by four to six months post-
transplant).  In order to examine the effects of the transplanted intestine without the confounding 
variable of the transplanted liver, only isolated intestinal and modified multivisceral transplant 
recipients were included in the study.  This chapter has the following aim: 
1. To characterize the pharmacokinetics of oral tacrolimus, a CYP3A and 
p-gp substrate, in small bowel transplant recipients in the first 40 days 
post-transplant as compared with the later post-transplant period (four 
to 12 months post-transplant)  
a. This will be accomplished by measurement of whole blood 
tacrolimus concentrations in blood samples taken at the time of the 
early and late post-transplant study sessions mentioned previously.  
Tacrolimus dose-adjusted AUC will be compared between the 
early and later post-transplant periods. 
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It is predicted that the dose-adjusted AUC of tacrolimus will be significantly higher in 
small bowel transplant recipients at the early post-transplant period than the later. 
 
7.1.2 Pharmacokinetic properties of tacrolimus 
Tacrolimus is a macrolide immunosuppressant drug produced by the actinobacterium species 
Streptomyces tsukubaensis.  It suppresses T-cell activation via calcineurin phosphatase 
inhibition, most likely through binding to an intracellular protein called FKBP-12.  Once bound, 
the tacrolimus-FKBP-12 forms a complex with calcium, calmodulin, and calcineurin that inhibits 
the phosphatase activity of calcineurin.  This is thought to inhibit gene transcription for 
Figure 56.  Chemical structure of tacrolimus 
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production of cytokines such as IL-2 and IFN-γ.  Consequently, its main effect is to suppress 
cell-mediated immunity, although animal studies have also shown it to have some effect on 
humoral immunity(Astellas, September 2011). 
Tacrolimus is a BCS/BDDCS class II drug with very low solubility but good 
permeability(Takagi et al., 2006) and a high extent of metabolism in both the liver and intestine, 
where it is a substrate for both CYP3A4, 3A5, and p-glycoprotein (p-gp)(Lampen et al., 1995).  
Tacrolimus exhibits higher systemic absorption in the jejunum as compared to the duodenum and 
ileum, most likely because CYP3A is highest in the duodenum and upper jejunum, while p-gp 
expression is highest in the ileum(Shimomura et al., 2002; Tamura et al., 2003).  Because of poor 
solubility and extensive first-pass metabolism, the bioavailability of tacrolimus is highly 
variable, with estimates ranging from 5% to 93% in small bowel transplant patients(Jain et al., 
1992), while Tmax is typically between 1 and 4 hours in transplant populations 
generally(Venkataramanan et al., 1990).  It has been noted since the earliest days of the clinical 
use of tacrolimus that in some patients the drug is rapidly absorbed after oral adminstration, with 
Tmax reached within 30 minutes, but in others the concentration-time profile is relatively 
flat(Venkataramanan et al., 1991a).  Multiple peaks have also been noted in the concentration-
time profiles in both dog and human studies(Venkataramanan et al., 1990).  Figure 46 shows the 
unusual concentration-time profiles seen in four different liver transplant patients after an oral 
dose of 9 mg tacrolimus.  
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Figure 57.  Plasma tacrolimus concentration vs. time curves after administration of 9 mg by mouth to four 
liver transplant patients 
 
Reprinted from Venkataramanan et al.(Venkataramanan et al., 1990) with permission of Elsevier, Inc. 
 
There may be as many as 15 metabolites of tacrolimus, none of which have significant 
activity(Lampen et al., 1995; Staatz and Tett, 2004).  Tacrolimus has also been shown to be a 
weak inhibitor of CYP3A4 and CYP3A5 in vitro(Amundsen et al., 2011), although a study in 
kidney transplant patients between one and five years post-transplant receiving tacrolimus 
reported no difference in IV clearance or apparent oral clearance of midazolam from healthy 
control subjects (de Jonge et al., 2011).  High interindividual variability exists in the clearance of 
tacrolimus after both IV and oral administration, largely due to wide differences in CYP3A4 and 
CYP3A5 expression and function between individuals.  The mean clearance of tacrolimus after 
IV administration has been shown to be 0.040 L/hr/kg in healthy control subjects, 0.083 L/hr/kg 
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in adult kidney transplant recipients, and 0.053 L/hr/kg in adult liver transplant 
recipients(Astellas, September 2011). 
In healthy volunteers, tacrolimus has been shown to have a mean volume of distribution 
of 1.91 ± 0.31 L/kg after IV administration, while in a study of IV tacrolimus in 17 liver 
transplant recipients, the mean volume of distribution was reported to be 0.85 ±0.30 L/kg.  
Tacrolimus is approximately 99% bound to plasma proteins, mainly albumin and alpha-1-acid 
glycoprotein, and partitions into erythrocytes, with a mean whole blood to plasma ratio of 35.  
For this reason, it is customary to measure whole blood concentrations of tacrolimus rather than 
plasma concentrations(Astellas, September 2011).  Tacrolimus half-life estimates have been 
reported to range from 11.7 to 34.8 hours(Astellas, September 2011), and, since it is typically 
dosed every 12 hours, significant accumulation occurs in body tissues after repeated dosing 
every 12 hours (see Figure 47)(Venkataramanan et al., 1990). 
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Figure 58.  Tissue concentrations of tacrolimus in rat after 14 days of 1.28 mg/kg/day IM 
 
Reprinted from Venkataramanan et al.(Venkataramanan et al., 1990) with permission of Elsevier, Inc. 
 
A dose of tacrolimus undergoes almost total metabolism, with less than 5% of the drug 
appearing unchanged in bile, and less than 1% excreted unchanged in the urine(Venkataramanan 
et al., 1991a).  Most metabolites of tacrolimus are excreted in bile via the feces, although small 
amounts of glucuronide conjugates may be excreted in the urine(Venkataramanan et al., 1991a; 
Venkataramanan et al., 1991b).   
Despite the unpredictability of tacrolimus concentration-time profiles, many studies have 
found a strong correlation between tacrolimus AUC and the corresponding minimum 
concentration C0 or Clast.  A study in kidney transplant patients found a correlation between 
AUC from 0 to 10 hours and Cmin or 0 to 12 hours and Cmin of 0.93(Astellas, September 2011).  
Another study in kidney transplant patients reported an r2 of 0.79 (although it was only 0.67 
during the first two weeks after transplant)(Scholten et al., 2005).  However, in a third study 
there was a very poor correlation of r = 0.34, with an r2 of 0.11 and a study in liver transplant 
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patients found an r2 of 0.639.(Dansirikul et al., 2004).  Overall, however, the correlation between 
tacrolimus AUC and trough has been found to be high, and for this reason trough concentration 
monitoring alone (as a surrogate for AUC) is typically performed for tacrolimus in clinical 
settings. 
7.1.3 Tacrolimus use in small bowel transplant populations 
Tacrolimus is a mainstay of immunosuppression after small bowel transplantation at 
many transplant centers(Fishbein, 2009).  At the University of Pittsburgh, goal whole blood 
trough concentrations of tacrolimus for the first three months postoperatively are set at 10-15 
ng/mL.  Subsequently, and in the absence of rejection, concentrations are titrated to between 5 
and 10 ng/mL.  In stable patients, weaning of immunosuppression – involving reduction of the 
tacrolimus dose to daily, every other day, three times a week, or twice a week, is attempted(Abu-
Elmagd et al., 2009). 
The first study describing the pharmacokinetics of IV and oral tacrolimus in small bowel 
transplant recipients was a case series of five patients (two adult and three pediatric), four of 
whom had also received a liver transplant in conjunction with small bowel.  Intensive 
pharmacokinetic sampling was done between 2 and 12 months post-transplant, with reported 
bioavailabilities ranging from 0.05 to 0.93, and lowest in the two patients with open ostomies.  In 
those patients in whom the ostomy had been closed and the intestine reconnected to colon, the 
bioavailability of the drug ranged from 0.16 to 0.93 (mean 0.43) and Tmax from 0.5 to 5 hours 
(mean 2.8 hours).  The investigators concluded that in their sample of patients the 
pharmacokinetic parameters of tacrolimus were not significantly different from those seen in 
other transplant populations(Jain et al., 1992).  This was confirmed in a subsequent study of 21 
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small bowel transplant recipients (both with and without transplanted liver) also between 2 and 
12 months post-transplant.  The mean tacrolimus bioavailability in the adult subjects was 0.19 
±0.087 and time to maximal concentration (Tmax) was 2.9 ±2.2 hours(Jain et al., 1994).  
A study comparing the steady-state pharmacokinetics of oral tacrolimus between 
clinically stable pediatric small bowel transplant recipients and pediatric liver transplant 
recipients observed no significant differences in the half-life, mean residence time (MRT), AUC, 
or oral clearance (CL/F) of tacrolimus between groups.  The only significant difference between 
transplant groups was that the small bowel transplant recipients had a lower mean daily dose 
requirement than the liver transplant recipients (4.8±3.3 mg vs. 8.0 ±5.2, p=0.01), indicating a 
possible higher bioavailability of tacrolimus through the transplanted small bowel, but the 
influence of post-transplant time on dose requirement was not formally evaluated(Schubert et al., 
2004). 
7.2 METHODS AND SUBJECT DEMOGRAPHICS 
As described in chapter 2, daily tacrolimus doses and whole blood trough concentrations were 
recorded in sixteen small bowel transplant patients (12 isolated intestinal and 4 modified 
multivisceral) starting on the day of transplant and continuing up to 40 days post-transplant.  
Subjects were started on tacrolimus continuous IV infusion (Prograf® injection, Astellas 
Pharma, Deerfield, IL) at a rate of 41.3 mcg/hr (approximately 1 mg over 24 hours) immediately 
upon arrival in the transplant ICU after surgery and infusion rates were increased if necessary to 
achieve target blood concentrations within the first few days after surgery.  Subjects were begun 
on a low dose (typically 1 mg or 2 mg twice a day) regimen tacrolimus suspension administered 
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via jejunostomy tube on a median of post-transplant day three (range–three to six days), with the 
IV infusion discontinued from 12 to 24 hours later.  This suspension was compounded by the 
hospital pharmacy by opening tacrolimus capsules (Prograf®, Astellas Pharma, Deerfield, IL) 
and mixing the contents with a suspending agent.  A switch to the capsule formulation (Prograf® 
capsules, Astellas Pharma, Deerfield, IL) by mouth occurred on a median of post-transplant day 
16 (range–12 to 27 days).   
Doses were adjusted based on daily trough concentrations, but these concentrations were 
usually not true 12-hour troughs, since they were drawn between 4:00 am and 6:00 am (more 
typically around 4:00 am).  Evening doses were typically scheduled for 9:00 pm.  Therefore, 
even if the doses were given on time, the concentrations were no more than seven hour to 10 
hour trough levels.  Actual (rather than prescribed) dosing times were recorded for each day from 
electronic barcode administration records.  The subjects, none of whom were taking aluminum or 
magnesium hydroxide at the time of study, took tacrolimus on an empty stomach and were not 
allowed grapefruit or grapefruit juice at any time during their hospitalization (and were 
instructed to avoid them at home). 
On the day of each pharmacokinetic study session (as described in previous chapters), 
tacrolimus concentrations were measured in whole blood taken from each pharmacokinetic study 
sample before it was centrifuged to obtain the plasma.  Samples were drawn at 0, 0.25, 0.5, 1, 
1.5, 2, 3, 4, 5, 7, 7.25, 7.5, 8, 10, 12, and 20 hours after oral midazolam administration.  In many 
cases at study session 1, however, the administration of tacrolimus did not occur at time zero of 
the study session because the pharmacokinetic study sessions often began before the physicians 
had rounded on the patient and assessed whether or not the dose should be changed based on the 
concentration measured that morning.  Therefore, intensive sampling over a full 12-hour dosing 
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interval and calculation of clearance by standard compartmental or noncompartmental methods 
was impossible in most subjects.   AUC0-7 was estimable in all subjects and calculated by the 
linear trapezoidal method, and Cmax and Tmax were estimated from visual inspection of 
concentration-time profiles.  These three parameters were compared between study sessions, 
route of administration, and transplant subtype using the Mann-Whitney U test.  A two-tailed p 
value of less than 0.05 was considered statistically significant.  Spearman correlations were used 
to examine the relationship between these three parameters and plasma cytokine concentrations 
and ileal CYP3A4, CYP3A5, and ABCB1 gene expression.  A one-sided p value of less than 0.05 
was considered statistically significant for the correlations. 
Since subjects were taking a range of doses, and doses were not changed for the purposes 
of the study, all three parameters were normalized to that morning’s tacrolimus dose, Median 
morning dose at session 1 was 4 mg (range – 1 mg to 10 mg) and at session 2 was 6 mg (range – 
3 mg to 7 mg). In two subjects, the morning tacrolimus dose was held because of high trough 
concentrations in the early morning. These subjects were excluded from pharmacokinetic 
analysis.  Many subjects were not at steady state on the day of pharmacokinetic session 1, 
because of frequent dose changes in the first 40 days post-transplant, but assuming adherence to 
their prescribed regimens (they were outpatients at the time), all subjects were at steady state at 
session 2.   For the comparisons of dose-normalized trough concentrations between IV, J-tube, 
and oral administration, only steady state concentrations were used (assumed if the subject had 
been on the same dose for at least 48 hours before the trough was drawn), with concentrations 
measured during biopsy-proven rejection episodes excluded from analysis.  All whole blood 
tacrolimus concentrations were measured by LC-MS.   
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7.3 PHARMACOKINETIC ANALYSIS OF TACROLIMUS 
7.3.1 Composite analysis of all subjects 
Dose-adjusted tacrolimus concentration-time profiles for session 1 are shown in Figure 48 and 
for session 2 are shown in Figure 49, while pharmacokinetic parameters are shown in table 23.  
Tmax was significantly higher at session 1 as compared with session 2 (3.00 vs. 1.50 hours, 
p=0.036), as was dose-adjusted AUC0-7 (28.9 vs. 20.9 [mcg*hr/L]/dose in mg, p=0.0078).  
Although median dose-adjusted Cmax was higher at session 1 than session 2 (6.37 vs. 4.14 
[mcg/L]/mg dose) the difference did not reach statistical significance. 
 
Figure 59.  Dose-adjusted concentration vs. time profiles at session 1 
 
 
0	  2	  
4	  6	  
8	  10	  
12	  14	  
16	  
0	   2	   4	   6	   8	   10	   12	  
Co
nc
en
tr
at
io
n	  
(m
cg
/L
)/
do
se
	  
Time	  (hr)	  
Dose-­‐adjusted	  tacrolimus	  concentration	  vs.	  time	  
-­‐	  Session	  1	   1	  2	  3	  4	  5	  7	  9	  10	  11	  13	  14	  15	  
  189 
Figure 60.  Dose-adjusted tacrolimus concentration vs. time profiles at session 2 
 
 
 
Table 25.  Pharmacokinetic parameters of tacrolimus by study session 
Tacrolimus parameter Session 1 Session 2 p value Session 1 vs. 2 
Dose-adjusted Cmax 
(mcg/L)/mg dose 6.37 (4.33,9.35) 4.14 (3.22,7.78) 0.43 
Tmax (hr) 3.00 (2.25, 6.13) 1.50 (1.00, 2.00) 0.036 
Dose-adjusted AUC0-7 
(mcg*hr/L)/mg dose 28.9 (21.7,47.4) 20.9 (18.6,28.7) 0.0078 
Results shown are median (25th, 75th percentile).  Session 1 and session 2 were compared using the Mann-Whitney 
U test.  Two-tailed p values are reported. 
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7.3.2 Multiple peak phenomenon 
All subjects showed at least two peaks in their concentration vs. time profiles at both study 
sessions.  Five subjects at study session 1 and five at study session 2 had three peaks during the 
sampling interval, and four subjects – one at session 1 and three at session 2 – had four peaks.  
There was no apparent correlation within subjects between the number of peaks at session 1 and 
at session 2.  Peak 1 was usually the highest and occurred at a median of 2 hours (range–1 hour 
to 4.25 hours), while Peak 2 occurred at a median of 6.5 hours (range–2.5 to 10.5 hours) and 
Peak 3 at a median of 7.5 hours (range–7 to 9 hours).  If a fourth peak was present, it was 
reported at a median of 11 hours (range–9 to 11.5 hours).  In 15 out of the 26 intensive sampling 
profiles of tacrolimus, a secondary peak occurred during or within 30 minutes following the 
midazolam IV infusion.   Interestingly, this phenomenon included two subjects in whom the 
morning dose of tacrolimus had been held on the study day due to a supratherapeutic trough 
concentration that same morning.  Tacrolimus concentration-time profiles for these two subjects 
are shown in Figure 50. 
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Figure 61.  Tacrolimus concentration vs. time profiles in two subjects after morning dose was held 
 
 
7.3.3 Effect of route of administration on tacrolimus pharmacokinetics 
Dose-adjusted steady state tacrolimus trough concentrations during the period of IV, J-
tube, and oral administration are shown in Table 24.  Not surprisingly, concentration/dose ratios 
during IV infusion therapy on post-transplant days 3 to 5 were significantly higher than those 
observed after either J-tube or oral administration.  There was no difference in dose-adjusted 
concentrations during J-tube administration on days 7 to 14 as compared to oral administration 
on days 18 to 30. 
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Table 26.  Tacrolimus dose-adjusted trough concentrations in the first 30 days post-transplant by route of 
administration 
 IV infusion Post-transplant days 3-5 
Twice daily J-tube 
administration 
Post-transplant days 7-14 
Twice daily oral 
administration 
Post-transplant days 18-30 
Steady-state dose-
normalized tacrolimus 
concentration 
(mcg/L)/mg 
5.95 (4.68,8.18) 1.74 (1.51,1.96) 1.43 (1.05,2.03) 
Results shown are median (25th, 75th percentile).   
 
Table 25 compares the parameters of tacrolimus between the two enteral routes of 
administration.  There was no significant difference in Tmax, dose-adjusted Cmax, or dose-
adjusted AUC0-7 between the two groups. 
Table 27.  Pharmacokinetic parameters of tacrolimus by route of administration 
Tacrolimus parameter JT PO p value JT vs. PO 
Dose-adjusted Cmax 
(mcg/L)/mg dose 4.86 (3.85,5.59) 4.55 (4.22,9.41) 0.76 
Tmax (hr) 1.75 (1.38, 3.25) 2.50 (2.50, 4.13) 0.32 
Dose-adjusted AUC0-7 
(mcg*hr/L)/mg dose 24.6 (17.6,29.1) 23.2 (20.1,47.7) 0.43 
Results shown are median (25th, 75th percentile).  JT and PO were compared using the Mann-Whitney U test.  Two-
tailed p values are reported. 
 
Figure 51 provides dose-adjusted tacrolimus concentration-time profiles after J-tube 
administration in four subjects at session 1.  Three out of the four profiles are relatively smooth, 
with a median Tmax of 1.75 hours.  One subject has the appearance of a slight double peak 
during the absorption phase, while another has a relatively flat profile, except for a small peak at 
7 hours. In three of the four subjects, a secondary peak (preceded by a slight dip) in 
concentration is apparent at that same time point.   In subjects 1 and 4, this peak occurred in the 
30 minutes before the IV midazolam was given, while in subject 2 it occurred one hour after the 
end of the infusion, and in subject 3 at the end of the infusion.  
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Figure 62.  Dose-adjusted tacrolimus concentration vs. time profiles after J-tube administration at session 1 
 
 
Figure 52 shows the dose-adjusted tacrolimus concentration-time profiles after oral 
administration in nine subjects at session 1.  Five out of the nine subjects exhibited profiles with 
a clear Tmax (even though combined with a low Cmax in two) between 1 and 3 hours post-
administration, followed by a clear elimination phase, although with one or more smaller 
secondary peaks.  The remaining four subjects showed a relatively flat profile, punctuated by one 
or more small peaks.  In six out of the nine subjects, small peaks occurred during or immediately 
after the end of the IV midazolam infusion.  In the three other subjects, secondary tacrolimus 
peaks occurred three hours after the end of the infusion. 
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Figure 63.  Dose-adjusted concentration vs. time profiles after oral administration at session 1 
 
7.3.4 Effect of transplant type on tacrolimus pharmacokinetics 
A comparison of pharmacokinetic parameters between transplant types is shown in table 
26.  Although median dose-adjusted Cmax was higher in the modified multivisceral (MM) group 
as compared with isolated intestinal (II) (7.38 vs. 4.58 [mcg/L]/mg dose) as was the Tmax (4.38 
vs. 2.50 hr) and the dose-adjusted AUC0-7 (36.1 vs. 21.5 [mcg*hr/L]/dose, these differences did 
not reach statistical significance.   
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Table 28.  Pharmacokinetic parameters of tacrolimus by transplant type at session 1 
Session 1 MM (n=4) II (n=12) p value MM vs. II 
Dose-adjusted Cmax 
(mcg/L)/mg dose 7.38 (3.79,11.5) 4.58 (4.29,6.85) 0.67 
Tmax (hr) 4.38 (2.38, 6.44) 2.50 (1.63, 3.75) 0.25 
Dose-adjusted AUC0-7 
(mcg*hr/L)/mg dose 36.1 (21.0,56.2) 21.5 (19.8,32.8) 0.59 
Results shown are median (25th, 75th percentile).  MM and II were compared using the Mann-Whitney U test.  Two-
tailed p values are reported. 
 
Dose-adjusted tacrolimus concentration-time profiles in modified multivisceral transplant 
subjects at session 1 are presented in Figure 53.  Two out of the four subjects exhibit relatively 
typical drug concentration-time profiles, with a Tmax between 2 and 3 hours, and a relatively 
smooth elimination phase. The remaining two subjects exhibit relatively flat profiles. All 
subjects, however, exhibit a small peak occurring between six and seven hours post-dose.  In 
subjects 7, 9, and 11, this peak occurred during or immediately after the end of the midazolam 
infusion, while in subject 4, it occurred immediately before the start of the infusion. 
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Figure 64.  Dose-adjusted tacrolimus concentration vs. time profiles in modified multivisceral transplant 
recipients at session 1 
 
 
 
Dose-adjusted tacrolimus concentration-time profiles in isolated intestinal transplant 
recipients at session 1 are reported in figure 54.  In this group, three out of nine subjects had 
relatively flat profiles, and the remaining six had a Tmax of between 1 and 4 hours.  All had at 
least one secondary peak.  In five out of the nine subjects, a small secondary peak occurred either 
during or immediately after the IV midazolam infusion: in one subject, this peak occurred 30 
minutes before the infusion; in a second, it occurred one hour after the end of the infusion; while 
in three other subjects, it occurred three hours after the end of the infusion. 
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Figure 65.  Dose-adjusted tacrolimus concentration vs. time profiles in isolated intestine recipients at session 1 
 
 
Table 27 lists the Tmax, dose-adjusted Cmax, and dose-adjusted AUC0-7 for both 
transplant types at session 2.  There were no significant differences between groups with respect 
to any of the three parameters. 
 
Table 29.  Pharmacokinetic parameters of tacrolimus by transplant type at session 2 
Session 2 MM (n=3) II (n=7) p value MM vs. II 
Dose-adjusted Cmax 
(mcg/L)/mg dose 4.14 (2.87,6.18) 4.44 (3.29,7.18) 0.90 
Tmax (hr) 2.00 (1.75, 3.00) 1.25 (1.00,1.88) 0.18 
Dose-adjusted AUC0-7 
(mcg*hr/L)/mg dose 20.9 (14.3,25.3) 20.7 (18.9,26.9) 1.0 
Results shown are median (25th, 75th percentile).  MM and II were compared using the Mann-Whitney U test.  Two-
tailed p values are reported. 
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Dose-adjusted concentration-time profiles for the three out of four modified multivisceral 
transplant subjects who returned for the second study session appear in Figure 55.  Interestingly, 
each subject’s profile pattern is quite similar to that from the first study session, with subject 7 
showing a sharp Tmax at 1.5 hours and a smooth elimination phase, except for a very tiny peak 
at 7.25 hours during the IV midazolam infusion.  Subject 4 again shows a fairly flat profile, 
although with a small peak during and immediately after the midazolam IV.  Finally, subject 9, 
who was known to have impaired motility, even in the later post-transplant period, shows a 
similar irregular profile, with a decrease in tacrolimus concentration during the infusion followed 
by a peak at its end.  
  
Figure 66.  Dose-adjusted tacrolimus concentration vs. time profiles in modified multivisceral recipients at 
session 2 
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Dose-adjusted tacrolimus concentration-time profiles in isolated intestine recipients at 
session 2 are shown in figure 56.  All subjects had an easily discernable initial peak, with a Tmax 
of between 1 hour and 3 hours.  Dose-adjusted Cmax was widely variable, ranging from 3.10 to 
11.5 [mcg/L]/mg dose, with a median of 4.44 [mcg/L]/mg dose.  Four out of the six subjects 
exhibited a small peak during or immediately following the midazolam IV infusion, while one 
revealed a peak at one hour after the end of infusion, and another at three hours after the end of 
the infusion. 
 
Figure 67.  Dose-adjusted tacrolimus concentration vs. time profiles in isolated intestine recipients at session 2 
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7.3.5 Correlation between tacrolimus pharmacokinetics, intestinal CYP3A and ABCB1 
expression, and plasma cytokine concentrations 
There was no correlation observed between dose-adjusted AUC0-7, dose-adjusted Cmax, or Tmax 
of tacrolimus and plasma concentrations of IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12, TNF-α, or IFN-
γ.  There was also no correlation observed between pharmacokinetic parameters of tacrolimus 
and ileal CYP3A4 or ABCB1 expression.  There was, however, a significant negative correlation 
between dose-adjusted AUC0-7 and CYP3A5 expression (rs=-0.47, p=0.015). 
7.3.6 Relationship between tacrolimus trough levels and AUC 
In order to compare the relationship between tacrolimus trough concentrations and AUC 
in this study population of small bowel and modified multivisceral transplant recipients to those 
seen in other transplant populations, the relationship between tacrolimus trough concentrations at 
the end of the sampling interval and the AUC of that interval were assessed by correlation 
analysis and are displayed in Figures 58, 59, and 60.  There was a significant correlation between 
trough and AUC at session 1 (rs=0.55, p=0.041) and in the subjects as a whole (rs=0.57, 
p=0.0047). 
 
  201 
 
Figure 68.  Relationship between tacrolimus Cmin and AUC in transplant subjects at study session 1 
 
 
 
Figure 69.  Relationship between tacrolimus Cmin and AUC in transplant subjects at study session 2 
 
 
rs=0.55, p=0.041 
rs=0.56, p=0.060 
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7.3.7 Relationship between midazolam and tacrolimus oral AUC 
Figure 70.  Relationship between midazolam oral AUC and dose-normalized tacrolimus AUC in transplant 
subjects at study session 1 
 
rs=0.018, p=0.95 
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Figure 71.  Relationship between midazolam oral AUC and dose-normalized tacrolimus AUC in transplant 
subjects at study session 2 
 
 
 
 
7.4 DISCUSSION 
These results overall support the prediction that tacrolimus AUC will be higher in small bowel 
transplant recipients in the early post-transplant period as compared with later post-transplant.  
However, similar to studies in other transplant populations, multiple peak profiles were reported 
in many patients, sometimes with secondary peaks corresponding to intravenous administration 
of midazolam with regards to timing.  The reason for these peaks is unknown but there are a 
number of possibilities, based on existing knowledge of tacrolimus.  Multiple peaks in 
rs=-0.37, p=0.34 
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tacrolimus profiles have been noted since the drug was first in development(Venkataramanan et 
al., 1990), but  are unlikely to be due to enterohepatic recirculation, since tacrolimus is not 
secreted in bile to any significant degree.  Therefore, the peaks are more likely to reflect regional 
differences in solubility in the segments of the small intestine (most likely) and/or a 
pharmacokinetic interaction with midazolam (less likely).   
A pharmacokinetic interaction between tacrolimus and midazolam is a possibility, but 
seems more likely after oral – rather than intravenous – administration of midazolam.  Tamura et 
al. found that when midazolam was coperfused with tacrolimus in the rat intestinal lumen, 
tacrolimus absorption was enhanced in the jejunum but not in the ileum, suggesting some kind of 
inhibitory effect of midazolam on intestinal CYP3A at luminal concentrations(Tamura et al., 
2003).  It is possible that when the two drugs are present in the intestine at the same time, they 
may compete for the available CYP3A enzyme.  This could also occur at the level of the liver, 
but is less likely, since both drugs are highly protein bound and the free fraction available to the 
hepatic CYP3A enzymes might be too low for this effect to occur.  The sharp decrease in 
tacrolimus concentration that was observed in some cases before the secondary peak could also 
have been due to dilution of the blood samples, but this is unlikely, given that the IV was only 
120 mL and was administered in the opposite arm from the site of blood draws.  Furthermore, 
120 mL would be unlikely to cause a significant increase in intestinal fluid content leading to 
improved solubility of tacrolimus in the intestine. 
Instead, the poor solubility of the drug may have lead to dissolution and re-precipitation 
of the drug at various points in the GI tract.  As has been noted previously, it is thought that 
much of the intestinal fluid content is contained in pockets throughout the intestine rather than 
being evenly distributed(Sutton, 2009).  In six of the seven oral concentration-time profiles of 
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tacrolimus shown in the papers by Venkataramanan et al., similar multiple peaks were observed.   
Secondary peaks were visible at three and six hours in one patient, four and six hours in the 
second, four hours in the third and fourth, five hours in the fifth, and 6.5 hours in the sixth.  In 
addition, secondary peaks were observed at five and 12 hours in a dog and at four and six hours 
in two human patients after intravenous dosing.  It is quite possible that the timing of some of the 
smaller secondary peaks corresponded to the midazolam IV administration by coincidence, since 
the administration of the IV always occurred at the 7 hour timepoint of the study session and, for 
the most part, tacrolimus doses were administered in the morning, one or two hours after the oral 
midazolam dose.   
Interestingly, multiple peaks were also observed in the profiles of two isolated intestinal 
transplant recipients at session 1 in whom the morning dose had been held due to high trough 
concentration.  Not only were peaks observed, they occurred in a very similar pattern.  One 
possible explanation for this is that small amounts of precipitated tacrolimus remained in the 
small intestine even after greater than 12 hours since the last dose due to slowed transit, and that 
these particles continued to be re-dissolved in fluid pockets at various points along the intestine 
and were absorbed, even in the absence of recent oral doses.  Another explanation could be that 
as blood concentrations decline, accumulated drug begins to be released from tissues back into 
the systemic circulation. 
The lack of correlation between ileal ABCB1 mRNA expression and AUC, Cmax, and 
Tmax of tacrolimus was somewhat surprising, since a case of an adult small bowel transplant 
recipient (exact time post-transplant was not given) with very high dosing requirements for oral 
tacrolimus and cyclosporine despite apparently normal graft function demonstrated high levels of 
p-glycoprotein relative to duodenal mucosal samples taken from healthy subjects on Western 
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blot.  Protein expression of CYP3A4 was also measured but found to be consistent with the 
amounts in the normal duodenal samples(Kaplan et al., 1999).  A second study described a 
significant correlation between dose-normalized oral tacrolimus trough concentrations and ileal 
mucosal ABCB1 mRNA expression in two pediatric small bowel transplant recipients.  Similar to 
the results shown in this work, no significant correlation was observed between ileal CYP3A4 
expression and dose-normalized tacrolimus concentrations(Masuda et al., 2004).  The finding in 
this study’s population of small bowel recipients of a significant negative correlation between 
tacrolimus AUC and ileal CYP3A5 expression is consistent with the finding that in CYP3A5*1 
expressors, CYP3A5 plays a larger role than CYP3A4 in tacrolimus metabolism.   
The lack of a demonstrated dependence of tacrolimus AUC, Cmax, and Tmax on enteral 
route of administration or transplant subtype also points to the likelihood of the patterns seen 
being the result of solubility rather than motility.  The reasonably high correlations seen in this 
study between tacrolimus AUC and trough concentrations also imply consistency in profile 
patterns with other transplant populations.  Suppression of intestinal CYP3A function and 
expression in this population in the early post-transplant period was shown in chapter 5 by the 
increased oral bioavailability of midazolam, the decreased 1’hydroxymidazolam/midazolam oral 
AUC ratio, and the lower expression levels of ileal CYP3A.   The increased AUC and Cmax of 
tacrolimus seen in the early post-transplant period as opposed to the later, in addition to the lack 
of association of absorption patterns with enteral route of administration or transplant subtype, 
imply that, similar to other transplant populations, solubility in the various regions of the small 
intestine is the main factor controlling the absorption of tacrolimus in small bowel transplant 
recipients, although when in soluble form, extent of absorption may be increased by lower 
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expression of intestinal CYP3A and p-gp, as this data has shown in the early post-transplant 
period.    
This concept is likely translatable to other poorly soluble but highly permeable 
BCS/BDDCS class II substrates used in small bowel transplant recipients.  Figure 61 shows 
concentration-time profiles of the antifungal medication voriconazole, also a class II drug, after 
oral dosing in four small bowel transplant recipients (three isolated intestinal and one full 
multivisceral) who were greater than nine months post-transplant.  A second peak in the profile 
is observable in three of the four subjects, including one subject (an isolated intestinal recipient) 
in whom the profile is relatively flat(Choudry et al., 2007).  Similar to the tacrolimus data 
presented earlier, there is no obvious association between small bowel transplant subtype and 
profile pattern in these voriconazole profiles.   
 
 
 
 
 
 
 
 
 
 
 
From Choudry et al. (Choudry et al., 2007) 
 
Conc. (mg/L) 
Figure 72.  Oral voriconazole concentration vs. time profiles in four small bowel transplant 
recipients 
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Overall, these results suggest that overall oral absorption of poorly soluble but highly permeable 
BCS/BDDCS class II CYP3A/p-gp substrates may be higher in the early post-transplant period 
as compared with later due to initial suppression and eventual recovery of CYP3A and p-gp 
expression and function.  However, concentration-time profiles over a dosing interval may be 
erratic, and this effect does not appear to depend on transplant subtype, but on solubility.  These 
effects may be translatable in small bowel transplant recipients to other class III CYP3A/p-gp 
substrates such as sirolimus, dapsone, and nifedipine, but further studies with a larger number of 
subjects are required. 
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8.0  SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
8.1 SUMMARY 
The transplanted intestinal graft undergoes many changes during removal from the donor and 
placement in the recipient, including ischemia and subsequent reperfusion injury and activation 
of cell-mediated immunity, leading to the local and systemic upregulation of inflammatory 
mediators, especially in the first few weeks after surgery.  Since small bowel transplant 
recipients receive numerous medications after transplant, many by the oral route, the effects of 
transplantation of the intestine on drug absorption and intestinal first-pass metabolism and 
transport are of key clinical importance. 
The intestine contains significant amounts of cytochrome P450 3A (CYP3A) and 
transporters such as p-glycoprotein (p-gp) that limit the oral bioavailability of substrate drugs. 
The suppressive effects of inflammation and inflammatory mediators on CYP450 and drug 
transporter gene expression and function have been well characterized.  In addition, dog models 
of intestinal transplantation have shown increased availability of tacrolimus (a CYP3A and p-gp 
substrate) in the first 14 days post-transplant that returns to normal by day 28.  Moreover, 
tacrolimus pharmacokinetics in stable small bowel transplant recipients months to years post-
transplant are not significantly different than in other transplant populations, likely indicating 
eventual recovery of CYP3A and p-gp function.   
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The major hypothesis of this work is that intestinal CYP3A and p-gp expression and 
function would be impaired in the early post-transplant period but that it will be no different than 
that of healthy control subjects in the later post-transplant period in stable patients without 
rejection.  To examine this, 16 small bowel transplant recipients (12 isolated intestine and 4 
modified multivisceral) were studied in the first 40 days post-transplant (median day 19, range 
day 10 to 40) and ten returned for a second study session between day 125 and 428 (median day 
239).  Sixteen age- and gender-matched control subjects were also administered study drugs for 
comparison purposes. The major findings of this work are as follows:  
1.  Midazolam (a highly soluble, highly permeable probe for CYP3A) oral bioavailability 
(p=0.0059) and oral AUC (p=0.0020), two measures of the extent of systemic absorption, were 
significantly higher in transplant subjects at the early study session, but no different from 
controls at the later study session.  The AUC ratio of 1’hydroxymidazolam to midazolam, a 
measure of the extent of CYP3A-mediated metabolism, was significantly lower in the early 
period compared with controls (p=0.00070), but at the later period there was no difference with 
controls (p=0.13).  There were no observed differences in the pharmacokinetics of oral 
midazolam between routes of administration (jejunostomy tube vs. oral) or between transplant 
subtype (modified multivisceral vs. isolated intestine).   CYP3A4 and CYP3A5 gene transcripts 
were also lower in ileal biopsy samples in the early post-transplant period as compared with the 
later, and there was a positive correlation in the early post-transplant period between plasma 
TNF-α and midazolam oral AUC (rs=0.71, p=0.0021).  There was also a significant positive 
correlation at study session 1 between plasma IL-6 concentrations and midazolam bioavailability 
(rs=0.67, p=0.0081).   There were significant negative correlations observed early post-transplant 
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between ileal CYP3A4 expression and plasma concentrations of IL-2 (rs=-0.58, p=0.036), IL-4 
(rs=-0.53, p=0.062), IFN-γ (rs=-0.53, p=0.062) and IL-12 (rs=-0.51, p=0.077). 
2.  Oral AUC of fexofenadine (a highly soluble but poorly permeable probe for p-gp) was 
no different between study groups taken as a whole, but Tmax was significantly higher at the 
early study session as compared with the later (p=0.050), and remained higher than controls at 
the second study session as well (p=0.0021).  There were trends towards a higher Cmax, lower 
Tmax, and higher AUC after administration via jejunostomy tube as compared with oral 
administration, but the differences did not reach statistical significance.  When analyzed by 
transplant subtype, at the early study session modified multivisceral transplant recipients had a 
significantly lower fexofenadine Cmax (p=0.0064) and AUC (p=0.018) and higher Tmax 
(p=0.0062) than isolated intestinal transplant recipients.  This difference in AUC persisted into 
the later post-transplant period (p=0.0167), although Tmax became similar between the two 
groups (p=0.90).  Ileal transcript levels of the transporters ABCB1 (p-gp), MRP2, and ABCG2 
(BCRP) were all lower in ileal biopsy samples in the early post-transplant period as compared 
with later, with a statistically significant difference in the case of MRP2 (p=0.031).  A significant 
positive correlation was observed between fexofenadine Cmax and ileal ABCB1 expression (rs= -
0.52, p=0.071). 
3.  Tacrolimus (a poorly soluble, highly permeable CYP3A and p-gp substrate) dose-
adjusted oral AUC0-7, and Tmax were significantly higher in the early post-transplant period than 
in the later period (p=0.0078 and p=0.036, respectively).  No significant effect of route of 
administration or transplant subtype on tacrolimus pharmacokinetics was observed.  Absorption 
patterns of tacrolimus were erratic, with a range of two to four peaks seen on concentration-time 
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profiles.   No significant effects of enteral route of administration or transplant subtype on 
tacrolimus dose-adjusted AUC0-7, dose-adjusted Cmax, and Tmax were seen. 
8.2 CONCLUSIONS 
1. Intestinal CYP3A expression and function are impaired in the early post-operative 
period after small bowel transplantation 
With regards to intestinal CYP3A expression and function after small bowel 
transplantation, these results clearly show diminished CYP3A activity and expression in the 
early post-transplant period as compared with the later period.  Although there was a somewhat 
slower rate of absorption of midazolam seen in the transplant subjects as compared with controls, 
likely due to impaired gastric emptying, the pharmacokinetics of this highly soluble and highly 
permeable drug were not significantly affected by enteral route of administration or presence of 
transplanted stomach and duodenum, as in the case of modified multivisceral recipients.  
Therefore, the differences in pharmacokinetic parameters of oral midazolam between transplant 
subjects as a whole and controls may be assumed to be due for the most part to differences in 
CYP3A function.  The decreased ileal mRNA expression of CYP3A4 and CYP3A5 in the early 
post-transplant period as compared with later, and the strong correlation between midazolam oral 
AUC and CYP3A expression provide further evidence for the suppression of intestinal CYP3A in 
the early post-transplant period.  The strong inverse correlation between CYP3A expression and 
plasma cytokines, as well as the positive correlation between midazolam bioavailability and oral 
AUC and cytokines, provide evidence that this suppression is the result of the increased immune 
activity in the early post-transplant period. 
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2. Intestinal CYP3A function is not significantly different from that seen in healthy 
persons four to 12 months post-transplant in small bowel transplant recipients 
The fact that oral midazolam Cmax, AUC, bioavailability, and 
1’hydroxymidazolam/midazolam AUC ratio in stable small bowel transplant recipients in the 
later post-transplant period were no different from those seen in healthy controls indicates that 
intestinal CYP3A function returned to normal in the later post-transplant period.  In addition, the 
increased CYP3A4 and CYP3A5 mRNA expression levels in ileal mucosa and lower plasma 
cytokine concentrations in the later post-transplant period as compared with earlier support the 
hypothesis that CYP3A expression and function recover with time. 
3.  For highly soluble but poorly permeable transporter substrates such as fexofenadine, 
factors such as gastric and small intestinal motility may override the effects of transporters on 
oral absorption  
These results also showed that absorption of the highly soluble but poorly permeable p-
gp substrate fexofenadine was more dependent on route of administration and transplant subtype 
than ileal ABCB1 expression.  The significantly increased Tmax in the MM recipients as 
compared with II at both study sessions and the significantly improved rate and extent of 
absorption when the drug was administered by the jejunostomy tube, a route of administration 
that bypasses the effects of gastric emptying, as compared with oral administration, all indicate 
that alterations in gastric emptying rate and intestinal motility may reduce the time that this 
poorly permeable drug spends in the proximal small intestine, its optimal site of absorption.  This 
argument is strengthened by the lack of correlation between pharmacokinetic parameters of 
fexofenadine and ileal ABCB1 expression.  The diminished transporter gene expression in the 
early post-transplant period as compared with the later, and the significant inverse correlation 
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between plasma IFN-γ and ABCB1 expression, as well as the positive correlation between 
plasma IL-6 and IL-8 and fexofenadine Tmax, indicate that immune activation may still be 
affecting absorption, but at the level of intestinal motility as much as transporter expression in 
the case of poorly permeable drugs. 
4.  For poorly soluble but highly permeable CYP3A and p-gp substrates such as 
tacrolimus, solubility limitations will lead to erratic absorption patterns in small bowel 
transplant recipients, but when in soluble form in the intestine, systemic absorption of tacrolimus 
in the early post-transplant period will be increased due to impairments in intestinal CYP3A and 
p-gp.  In the later post-transplant period, erratic absorption patterns and poor solubility persist, 
but intestinal CYP3A and p-gp suppression will no longer be present.  
The previous indications of the relationship between markers of inflammation and 
CYP3A and p-gp expression provide evidence that the increased tacrolimus dose-adjusted AUC0-
7, dose-adjusted Cmax, and Tmax seen in the early post-transplant period as compared with the 
later in the transplant groups as a whole likely reflect early immune-mediated suppression of 
CYP3A and p-gp.  As a highly permeable but poorly soluble drug, the disposition of tacrolimus 
was not significantly affected by enteral route of administration or transplant subtype in this 
study population.  Although a great deal of variability and multiple peaks were seen in 
concentration-time profiles, patterns could not be generalized to any particular transplant 
subgroup or post-transplant period with any certainty.  A larger study with more subjects in the 
jejunostomy tube and modified multivisceral subgroups might elucidate trends further.   Since 
the unusual and erratic concentration-time profiles seen in some of these subjects have also been 
seen in other transplant populations, the most likely explanation is that as a poorly soluble drug, 
tacrolimus undergoes repeated dissolution, absorption, and precipitation amongst the irregular 
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fluid volumes of the small intestine, and when in its soluble form, is highly susceptible to the 
amount of intestinal CYP3A and p-gp present at the site of absorption. 
6. Taken as a whole, these results suggest that while CYP3A and transporter expression 
and function are suppressed early after transplant in small bowel transplant recipients, the 
solubility and permeability properties of a particular drug will determine the effect that this 
suppression has on the drug’s disposition.   
Highly soluble, highly permeable CYP3A substrate drugs such as midazolam are so 
readily absorbed that CYP3A metabolism will be the main determinant of their disposition.  
Drugs of this type, especially in solution form, can be expected to be rapidly and well absorbed 
by small bowel transplant patients.  Clinicians taking care of these patients should choose 
BCS/BDDCS class I drugs whenever possible, although with the caveat that bioavailability may 
be enhanced in the early post-transplant period and during times of immune activation, such as 
rejection, if the drug is a CYP3A substrate.   
This caveat also holds for poorly soluble but highly permeable BCS/BDDCS class II 
drugs such as tacrolimus, for although their absorption patterns will depend largely on solubility, 
when in soluble form their systemic absorption will also be affected by CYP3A and p-gp 
function, and increases in bioavailability may be seen in the early transplant period and during 
times of rejection, as has been shown in other studies.  By contrast, factors such as gastric 
emptying and intestinal motility will have more significant effects on the systemic absorption of 
highly soluble but poorly permeable BCS/BDDCS class III drugs such as fexofenadine that are 
absorbed slowly even in healthy subjects.  These motility effects may outweigh the effects of p-
gp expression and function, a concept that casts doubt on the appropriateness of fexofenadine as 
a p-gp probe drug in populations with impaired intestinal motility. 
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8.3 FUTURE DIRECTIONS 
This work offers important insights into drug absorption and intestinal first-pass 
metabolism and transport in small bowel transplant recipients, and offers proof that rates, 
patterns, and extents of absorption of midazolam, fexofenadine, and tacrolimus are different in 
small bowel transplant recipients than in healthy subjects.  This work also offers strong evidence 
that immune activity is higher in the early post-transplant period after transplantation of the small 
bowel, and that this inflammation is at least partly responsible for the decreased CYP3A and 
transporter expression and the changes in pharmacokinetic parameters of the three drugs early 
post-transplant.  However, larger studies are required to elucidate the mechanisms behind these 
changes and assess the relationship between the many patient variables that may affect drug 
disposition in this complex population and the pharmacokinetics of these or other oral drugs.  
Suggestions for future studies include: 
• Population pharmacokinetic analysis  The information presented in this work, 
especially the tacrolimus data with the large number of trough concentrations and 
rich but inconsistent intensive sampling, lends itself well to a population 
pharmacokinetic approach that examines the effects of covariates such as route of 
administration, transplant subtype, post-transplant day, intestinal CYP3A and 
transporter expression, corticosteroid dose, proton pump inhibitor use, creatinine 
clearance, and plasma cytokine concentrations on clearance, volume of 
distribution, and bioavailability.  This work is currently in process in our lab, as is 
the genotyping of subject blood samples to assess the effects of recipient CYP3A5 
and ABCB1 polymorphisms on the disposition of the study drugs.  With a larger 
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group of subjects, enough carriers of the CYP3A5*1 allele would be present to 
assess its effect on CYP3A-mediated metabolism. 
• Further study of gastric emptying rates and intestinal transit times after small 
bowel and modified multivisceral transplantation  Gastric emptying and intestinal 
transit times in the small bowel and modified multivisceral transplant populations 
need further study, both in patients with and without ileostomy. Concurrent 
objective measures of gastric emptying and intestinal transit times in the 
transplant subjects in this study would have been very valuable to the full 
understanding of their contribution to the absorption profiles observed, 
particularly of fexofenadine.  In addition, a larger study at set timepoints early and 
later post transplant by oral administration and subsequent recovery of a non-
disintegrating capsule would provide valuable insight into the fate of all orally 
administered medications after small bowel transplantation.  
• Assessment of the effects of ileostomy and ileostomy closure on the 
pharmacokinetics of BCS/BDDCS class II/III drugs  All transplant subjects were 
studied while the ileostomy was present, for maximum consistency.  However, the 
effects of the presence or absence of the additional absorptive surface area of the 
colon would be useful to understand, especially for poorly permeable drugs such 
as fexofenadine.  In addition, since tacrolimus bioavailability was noted in a 
previous study to be lower in patients with open ileostomy, and since tacrolimus 
is not secreted unchanged in bile to any significant degree, measurement of 
tacrolimus recovery in ostomy output would be a useful adjunct to future studies 
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of tacrolimus pharmacokinetics in small bowel transplant recipients, to assess 
how much drug is passing through the intestine unabsorbed. 
• Measurement of intestinal CYP3A and transporter protein expression in addition 
to mRNA expression The small amount of mucosal tissue yielded by biopsy 
precluded the performance of Western blot analysis of CYP3A and transporter 
protein expression, which in some cases is a more reliable indicator of functional 
tissue protein content than mRNA levels.  Although high correlations between 
CYP3A4 mRNA and CYP3A4 protein expression have been reported, at least two 
studies have reported a poor correlation between ABCB1 mRNA and p-gp protein 
expression.  It is possible that this accounts for the lack of correlation between the 
pharmacokinetic parameters of fexofenadine and tacrolimus and ABCB1 mRNA 
expression that were seen in this work. 
• Assessment of passive intestinal permeability in the early vs. later post-transplant 
periods  This work could not assess the contribution of passive permeability to the 
oral bioavailability of midazolam or the absorption profiles of fexofenadine and 
tacrolimus.  As described in the introduction, pro-inflammatory mediators may 
loosen tight junctions between enterocytes leading to increased paracellular 
permeability.  In addition, severe immune activation may cause mucosal 
sloughing and disruption of villus morphology, another mechanism of potential 
increased permeability.  Although transplant subjects did not have biopsy-proven 
rejection at the time of study, it is possible that patchy areas of sloughing and 
blunted villi may have been present contributing to the enhanced bioavailability 
of midazolam in the early post-transplant period. 
  219 
Despite the continued knowledge gaps, it is to be hoped that this study provides a 
preliminary understanding of intestinal drug absorption, metabolism, and transport after small 
bowel and modified multivisceral transplantation, and will encourage further study of drug 
disposition in this unique and complex patient population.  
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APPENDIX A 
CORRELATION ANALYSIS TABLES 
A.1 CORRELATIONS BETWEEN CYP3A EXPRESSION AND 
PHARMACOKINETIC PARAMETERS OF ORAL MIDAZOLAM 
Table 30.  Spearman correlation coefficients for midazolam pharmacokinetics and CYP3A expression 
  Spearman r CYP3A4 P value 
Spearman r 
Total CYP3A P value 
Tx 1 (n=13) -0.43 0.14 -0.40 0.18 
Tx 2 (n=10) -0.35 0.33 -0.22 0.54 MDZpo AUC 
(mcg*hr/L) 
Tx 2-Tx 1 
(n=7) -0.071 0.91 -0.25 0.59 
Tx 1 (n=13) -0.12 0.71 -0.23 0.45 
Tx 2 (n=10) -0.33 0.17 -0.21 0.56 MDZ 
Bioavailability 
Tx 2-Tx 1 
(n=7) -0.29 0.56 -0.32 0.50 
Tx 1 (n=13) 0.35 0.24 0.32 0.28 
Tx 2 (n=10) 0.091 0.81 -0.0061 1.0 1’OHMDZ/MDZ 
AUCpo ratio 
Tx 2-Tx 1 
(n=7) -0.11 0.84 -0.29 0.56 
Tx 1 (n=13) 0.23 0.46 0.32 0.28 
Tx 2 (n=10) 0.52 0.13 0.44 0.20 MDZ CL/F 
(L/hr/kg) 
Tx 2-Tx 1 
(n=7) 0.14 0.78 0.36 0.44 
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A.2 CORRELATIONS BETWEEN MDR1 EXPRESSION AND 
PHARMACOKINETIC PARAMETERS OF ORAL FEXOFENADINE 
 
Table 31.  Spearman correlation coefficients for fexofenadine parameters and ABCB1 expression 
  Spearman r ABCB1 P value 
Tx 1 (n=13) -0.52 0.071 
Tx 2 (n=10) -0.042 0.92 FEX Cmax (mcg/L) 
Tx 2-Tx 1 
(n=7) 
-0.75 0.066 
Tx 1 (n=13) 0.47 0.10 
Tx 2 (n=10) -0.078 0.84 FEX Tmax (hr) 
Tx 2-Tx 1 
(n=7) 
0.071 0.91 
Tx 1 (n=13) -0.57 0.040 
Tx 2 (n=10) -0.079 0.84 FEX AUC0-11 (mcg*hr/L) 
Tx 2-Tx 1 
(n=7) 
-0.68 0.11 
Tx 1 (n=13) -0.45 0.19 
Tx 2 (n=10) -0.16 0.66 FEX AUC0-19 (mcg*hr/L) 
Tx 2-Tx 1 
(n=7) 
-0.31 0.56 
Tx 1 (n=13) -0.60 0.35 
Tx 2 (n=10) 0.15 0.68 FEX CL/F (L/hr/kg) 
Tx 2-Tx 1 
(n=3) 
1.0 0.33 
Tx 1 (n=13) 0.23 0.44 
Tx 2 (n=10) -0.35 0.33 FEX MRT (hr) 
Tx 2-Tx 1 
(n=7) 
-0.046 0.92 
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A.3 CORRELATIONS BETWEEN PLASMA CYTOKINE CONCENTRATIONS AND 
PHARMACOKINETIC PARAMETERS OF ORAL MIDAZOLAM 
 
Table 32.  Spearman correlation coefficients for plasma cytokines and pharmacokinetic parameters of 
midazolam.  2-sided p values given. 
  MDZpo 
AUC 
(mcg*hr/L) 
p 
1’OHMDZ/
MDZ 
AUCpo 
ratio 
p MDZ F p 
MDZ 
CL/F 
(L/hr/kg) 
p 
Tx1 (n=16) -0.28 0.30 0.27 0.32 0.31 0.25 -0.057 0.83 
Tx2 (n=10) -0.26 0.46 0.18 0.64 -0.15 0.68 0.19 0.60 IL-1β Tx2-Tx1 
(n=10) 
-0.079 0.84 -0.36 0.31 0.43 0.22 0.53 0.12 
Tx1 (n=16) -0.035 0.90 -0.13 0.64 0.42 0.10 -0.27 0.31 
Tx2 (n=10) -0.16 0.66 -0.44 0.20 -0.46 0.18 0.049 0.90 IL-2 Tx2-Tx1 
(n=10) 
-0.33 0.35 -0.38 0.28 -0.055 0.89 0.44 0.20 
Tx1 (n=16) -0.081 0.77 0.0090 0.97 0.21 0.44 -0.093 0.73 
Tx2 (n=10) 0.036 0.92 -0.16 0.66 0.21 0.56 0.018 0.97 IL-4 Tx2-Tx1 
(n=10) 
-0.32 0.37 -0.45 0.19 0.079 0.84 0.42 0.23 
Tx1 (n=16) 0.11 0.70 0.055 0.86 0.67 0.0082 -0.29 0.32 
Tx2 (n=10) 0.50 0.14 -0.52 0.13 0.12 0.76 -0.38 0.28 IL-6 Tx2-Tx1 
(n=10) 
0.37 0.30 0.042 0.92 0.31 0.39 -0.13 0.73 
Tx1 (n=16) 0.05 0.86 0.14 0.60 -0.11 0.68 -0.24 0.38 
Tx2 (n=10) 0.27 0.22 0.33 0.17 0.28 0.21 0.030 0.47 IL-8 Tx2-Tx1 
(n=10) 
0.31 0.37 0.52 0.13 -0.018 0.97 -0.20 0.58 
Tx1 (n=16) 0.53 0.036 -0.39 0.14 -0.043 0.88 -0.32 0.22 
Tx2 (n=10) 0.018 0.98 -0.50 0.14 -0.24 0.52 -0.13 0.74 IL-10 Tx2-Tx1 
(n=10) 
-0.12 0.38 0.59 0.081 -0.042 0.92 -0.018 0.97 
Tx1 (n=16) -0.29 0.27 0.12 0.66 0.20 0.46 -0.070 0.80 
Tx2 (n=10) 0.042 0.92 -0.43 0.21 -0.15 0.68 -0.26 0.47 IL-12 Tx2-Tx1 
(n=10) 
0.091 0.81 -0.48 0.17 -0.33 0.35 -0.22 0.54 
Tx1 (n=16) 0.24 0.37 -0.25 0.35 0.56 0.026 -0.27 0.32 
Tx2 (n=10) -0.018 0.98 -0.47 0.18 -0.18 0.64 -0.21 0.56 IFNγ Tx2-Tx1 
(n=10) 
0.0061 1.0 -0.76 0.015 -0.067 0.87 0.054 0.89 
Tx1 (n=16) 0.71 0.0021 -0.53 0.036 0.11 0.68 -0.57 0.021 
Tx2 (n=10) 0.44 0.20 0.10 0.78 0.21 0.56 -0.42 0.24 TNF-α Tx2-Tx1 
(n=10) 
0.030 0.95 -0.33 0.35 0.018 0.97 -0.19 0.61 
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A.4 CORRELATIONS BETWEEN PLASMA CYTOKINE CONCENTRATIONS AND 
PHARMACOKINETIC PARAMETERS OF ORAL FEXOFENADINE 
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Table 33.  Spearman correlation coefficients for plasma cytokines and pharmacokinetic parameters of fexofenadine 
  
FEX 
Cmax 
(mcg/L) 
p 
FEX 
Tmax 
(hr) 
p 
FEX 
MRT 
(hr) 
p 
FEX AUC 
0-11 
(mcg*hr/L
) 
p 
FEX AUC 0-
19 
(mcg*hr/L) 
p 
FEX 
CL/F 
(L/hr/kg
) 
p 
Tx 1 (n=16) 
(N(n=160 
0.095 0.73 -0.21 0.43 -0.41 0.11 0.030 0.91 -0.12 0.71 0.43 0.35 
Tx 2 (n=10) -0.055 0.90 -0.48 0.16 -0.14 0.70 -0.27 0.44 -0.13 0.72 0.055 0.90 IL-1β 
Tx2-Tx1 (n=10) -0.33 0.35 -0.27 0.45 -0.30 0.41 0.13 0.73 0.19 0.66 0.40 0.75 
Tx 1 (n=16) 
(N(n=160 
0.086 0.75 -0.24 0.37 -0.38 0.14 0.00 1.0 -0.11 0.72 0.50 0.27 
Tx 2 (n=10) -0.073 0.84 0.23 0.52 0.22 0.54 -0.23 0.52 -0.012 0.98 -0.15 0.68 IL-2 
Tx2-Tx1 (n=10) -0.18 0.63 -0.30 0.39 -0.32 0.37 0.45 0.19 0.47 0.24 0.20 0.92 
Tx 1 (n=16) 
(N(n=160 
0.087 0.75 -0.22 0.42 -0.26 0.34 -0.024 0.93 -0.0070 0.98 0.64 0.14 
Tx 2 (n=10) -0.58 0.088 0.013 0.97 -0.030 0.95 -0.67 0.039 -0.53 0.12 -0.53 0.12 IL-4 
Tx2-Tx1 (n=10) -0.62 0.060 -0.47 0.17 0.30 0.41 -0.21 0.56 -0.071 0.88 0.80 0.33 
Tx 1 (n=16) 
(N(n=160 
-0.11 0.70 0.37 0.16 0.23 0.39 -0.14 0.60 -0.049 0.88 0.11 0.84 
Tx 2 (n=10) 0.042 0.92 0.22 0.54 0.73 0.020 0.30 0.40 0.53 0.12 -0.65 0.049 IL-6 
Tx2-Tx1 (n=10) 0.0061 1.0 0.77 0.013 0.45 0.19 0.10 0.79 0.48 0.24 0.0 1.1 
Tx 1 (n=16) 
(N(n=160 
-0.25 0.34 0.48 0.056 0.48 0.060 -0.21 0.42 -0.084 0.80 -0.32 0.50 
Tx 2 (n=10) 0.31 0.38 -0.10 0.78 0.079 0.84 0.55 0.10 0.44 0.20 -0.20 0.58 IL-8 
Tx2-Tx1 (n=10) 0.31 0.39 0.63 0.060 0.37 0.30 -0.079 0.84 0.086 0.84 0.0 1.1 
Tx 1 (n=16) 
(N(n=160 
-0.076 0.78 0.14 0.60 0.28 0.30 -0.13 0.64 0.00 1.00 -0.18 0.72 
Tx 2 (n=10) -0.21 0.56 0.27 0.44 0.26 0.46 -0.26 0.46 -0.055 0.90 0.030 0.94 IL-10 
Tx2-Tx1 (n=10) 0.25 0.49 0.24 0.51 0.067 0.87 0.13 0.73 -0.40 0.33 0.20 0.92 
Tx 1 (n=16) 
(N(n=160 
0.084 0.76 -0.23 0.39 -0.37 0.15 0.094 0.73 -0.064 0.84 0.75 0.067 
Tx 2 (n=10) -0.26 0.51 0.078 0.84 0.28 0.43 -0.36 0.31 -0.12 0.76 -0.12 0.76 IL-12 
Tx2-Tx1 (n=10) -0.43 0.22 0.049 0.89 0.20 0.58 0.0061 1.0 0.79 0.028 -0.40 0.75 
Tx 1 (n=16) 
(N(n=160 
-0.0015 1.0 -0.073 0.79 -0.095 0.73 -0.13 0.62 -0.21 0.51 0.37 0.50 
Tx 2 (n=10) -0.30 0.40 0.12 0.76 0.25 0.50 -0.42 0.24 -0.19 0.60 -0.067 0.86 IFNγ 
Tx2-Tx1 (n=10) -0.26 0.47 0.018 0.97 0.12 0.76 0.15 0.68 0.43 0.30 -0.40 0.75 
Tx 1 (n=16) 
(N(n=160 
0.012 0.96 0.20 0.46 0.44 0.10 0.074 0.78 0.16 0.62 0.00 1.00 
Tx 2 (n=10) 0.26 0.46 0.11 0.76 0.32 0.38 0.38 0.28 0.38 0.28 -0.41 0.24 TNF-α 
Tx2-Tx1 (n=10) 0.16 0.66 0.27 0.45 0.19 0.61 0.26 0.47 0.45 0.27 0.0 1.1 
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A.5 CORRELATIONS BETWEEN PLASMA CYTOKINE CONCENTRATIONS AND 
CYP3A EXPRESSION 
 
Table 34.  Spearman correlation coefficients for plasma cytokines and CYP3A expression 
  Spearman r CYP3A4 P value 
Spearman r 
Total CYP3A P value 
Tx 1 (n=13) -0.22 0.48 -0.33 0.27 
Tx 2 (n=10) 0.042 0.92 -0.19 0.61 IL-1β 
Tx2-Tx1 (n=7) 0.32 0.50 0.59 0.16 
Tx 1 (n=13) -0.48 0.10 -0.58 0.036 
Tx 2 (n=10) -0.48 0.17 -0.49 0.15 IL-2 
 Tx2-Tx1 (n=7) 0.39 0.40 0.54 0.24 
Tx 1 (n=13) -0.49 0.088 -0.53 0.062 
Tx 2 (n=10) -0.13 0.73 -0.34 0.33 IL-4 
Tx2-Tx1 (n=7) 0.21 0.66 0.39 0.40 
Tx 1 (n=13) 0.41 0.17 0.33 0.28 
Tx 2 (n=10) -0.079 0.84 -0.042 0.92 IL-6 
Tx2-Tx1 (n=7) 0.61 0.17 0.50 0.27 
Tx 1 (n=13) 0.62 0.025 0.62 0.026 
Tx 2 (n=10) 0.44 0.20 0.47 0.18 IL-8 
Tx2-Tx1 (n=7) 0.036 0.96 -0.11 0.84 
Tx 1 (n=13) 0.18 0.55 0.12 0.70 
Tx 2 (n=10) -0.65 0.049 -0.59 0.081 IL-10 
Tx2-Tx1 (n=7) 0.14 0.78 -0.036 0.96 
Tx 1 (n=13) -0.39 0.19 -0.51 0.077 
Tx 2 (n=10) -0.58 0.088 -0.62 0.060 IL-12 
Tx2-Tx1 (n=7) -0.11 0.84 -0.18 0.71 
Tx 1 (n=13) -0.48 0.098 -0.53 0.062 
Tx 2 (n=10) -0.49 0.15 -0.54 0.11 IFN-γ 
Tx2-Tx1 (n=7) 0.25 0.59 0.39 0.40 
Tx 1 (n=13) -0.16 0.60 -0.19 0.53 
Tx 2 (n=10) -0.33 0.35 -0.30 0.41 TNF-α 
Tx2-Tx1 (n=7) 0.32 0.50 0.29 0.56 
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A.6 CORRELATIONS BETWEEN PLASMA CYTOKINE CONCENTRATIONS AND 
ABCB1 EXPRESSION 
 
Table 35.  Spearman correlation coefficients for plasma cytokines and ABCB1 expression 
  Spearman r ABCB1 P value 
Tx 1 (n=13) -0.34 0.26 
Tx 2 (n=10) 0.36 0.31 IL-1β 
Tx2-Tx1 (n=7) 0.14 0.78 
Tx 1 (n=13) -0.40 0.18 
Tx 2 (n=10) -0.22 0.54 IL-2 
Tx2-Tx1 (n=7) 0.29 0.56 
Tx 1 (n=13) -0.18 0.56 
Tx 2 (n=10) 0.11 0.76 IL-4 
Tx2-Tx1 (n=7) 0.54 0.24 
Tx 1 (n=13) 0.033 0.91 
Tx 2 (n=10) -0.055 0.89 IL-6 
Tx2-Tx1 (n=7) -0.36 0.44 
Tx 1 (n=13) 0.23 0.46 
Tx 2 (n=10) 0.37 0.30 IL-8 
Tx2-Tx1 (n=7) -0.64 0.14 
Tx 1 (n=13) 0.16 0.59 
Tx 2 (n=10) -0.54 0.11 IL-10 
Tx2-Tx1 (n=7) 0.036 0.96 
Tx 1 (n=13) -0.26 0.38 
Tx 2 (n=10) -0.37 0.30 IL-12 
Tx2-Tx1 (n=7) 0.25 0.59 
Tx 1 (n=13) -0.41 0.16 
Tx 2 (n=10) -0.32 0.37 IFN-γ 
Tx2-Tx1 (n=7) 0.61 0.17 
Tx 1 (n=13) -0.27 0.37 
Tx 2 (n=10) -0.14 0.71 TNF-α 
Tx2-Tx1 (n=7) 0.57 0.20 
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APPENDIX B 
PLASMA CYTOKINE CONCENTRATIONS IN THE FIRST 21 DAYS POST-
TRANSPLANT 
B.1 PLASMA CYTOKINE TRENDS IN THE FIRST 21 DAYS POST-TRANSPLANT 
Figure 73.  Plasma IL-1beta vs. time
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Figure 74.  Plasma IL-2 vs. time 
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Figure 75. Plasma IL-4 vs. time 
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Figure 76. Plasma IL-6 vs. time 
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Figure 77. Plasma IL-8 vs. time 
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Figure 78. Plasma IL-10 vs. time
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Figure 79. Plasma IL-12 vs. time 
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Figure 80. Plasma TNF-alpha vs. time 
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Figure 81. Plasma IFN-gamma vs. time 
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APPENDIX C 
PROTOCOL AND CONSENT FORMS 
C.1 PROTOCOL 
TITLE: EVALUATION OF INTESTINAL CYP3A4/5 AND P-GLYCOPROTEIN IN 
SMALL BOWEL TRANSPLANT RECIPIENTS (IRB#PRO07050246) 
Principal Investigator:  
Jennifer Bonner, PharmD 
731 Salk Hall 
School of Pharmacy 
3501 Terrace St, Pittsburgh, PA 15261 
 
Co-investigators: 
Kareem Abu-Elmagd, MD, PhD 
Geoffrey Bond, MD 
Guilherme Costa, MD 
Hossam Kandil, MD, PhD 
Darlene Koritsky, RN 
Stephen O’Keefe, MD 
Raman Venkataramanan, PhD 
 
 
Abstract: 
 
The small intestine is involved in uptake, metabolism and efflux of many endogenous and 
exogenous compounds. Drug uptake transporters, drug metabolizing enzymes such as 
cytochrome P450 3A4/5 (CYP3A45), and drug efflux transporters such as p-glycoprotein (pgp) 
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play an important role in the oral bioavailability of many currently marketed drugs, including 
most of the narrow therapeutic index immunosuppressive drugs used in transplant patients, such 
as tacrolimus, sirolimus, and cyclosporine. This is a single center study to evaluate the intestinal 
(and hepatic) CYP3A4/5 and p-gp activity in recipients of isolated small bowel transplants, small 
bowel-pancreas transplants, and modified multivisceral transplants (stomach-small intestine-
pancreas), early postoperatively and at four to nine months after transplant surgery, in 
comparison to that of normal healthy adults. We hypothesize that in the early post operative time 
period, intestinal CYP3A4/5 and p-gp activity will be lower due to the effects of ischemia-
reperfusion injury and the inflammatory and immunologic insult to the transplanted graft, as 
compared to the control subjects. After four to nine months there will be no significant difference 
between the two groups as the graft would have recovered completely from the aforementioned 
injuries associated with the transplant surgery. Twenty-five patients who undergo small bowel, 
small bowel and pancreas, or modified multivisceral transplantation at the Thomas E. Starzl 
Transplantation Institute at the University of Pittsburgh Medical Center will participate in a 
screening session and two study sessions approximately four to nine months apart. Control 
subjects will undergo a screening session and only one pharmacokinetic study session. During 
pharmacokinetic study sessions, we will administer midazolam intravenously (IV) and orally to 
determine its bioavailability as a marker for CYP3A4/5 activity in the gut, and administer 
fexofenadine orally and determine the area under the plasma-concentration time curve as a 
measure of p-gp activity. Each subject will receive a dose of midazolam orally and one hour later 
a dose of fexofenadine orally, followed by an IV dose of midazolam six hours after the oral dose 
of fexofenadine. Blood samples will be taken for 20 hours after start of the study and plasma 
midazolam and fexofenadine levels will be measured by high performance liquid 
chromatography/mass spectrometry (LC/MS). In addition, blood concentrations of tacrolimus 
(an immunosuppressive drug that is a substrate for both CYP3A4/5 and p-gp, given to all small 
bowel transplant patients as standard of care) will also be measured in the same blood samples. 
We will also determine the concentrations of several cytokines and C-reactive protein (CRP) in 
plasma, and CYP3A and p-gp proteins in graft tissue from biopsies, whenever available during 
the first 21 days post-transplant and at a time point approximately four to nine months (a the time 
of the second study) after transplant in the transplant recipients. Cytokine and CRP levels will be 
measured in the healthy control subjects during each study period. We predict that plasma 
midazolam, fexofenadine, and tacrolimus levels will be significantly higher in the transplant 
patients at the earlier time point, but that levels will be significantly decreased to what is 
observed in normal healthy adults at about four to six months and that these changes will be 
associated with decreases in cytokine and CRP levels in blood and intestinal mucosa. We will 
also assess the contribution of CYP3A5/MDR1 polymorphisms on drug exposure in small bowel 
transplant recipients and normal healthy controls (a pilot study). Understanding the regulation of 
and changes in CYP3A4/5 and p-gp after small bowel transplantation will enable us to optimize 
drug therapy in this unique patient population. 
1. Objectives, Aims, Background and Significance 
1.1 Objective: What is the overall purpose of this research study? 
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The primary objectives of this study are to determine the intestinal metabolic capacity as 
measured by CYP3A4/5 and intestinal efflux transport as measured by p-gp expression and 
activity in small bowel transplant recipients early and late after transplant surgery and to 
compare the intestinal CYP3A4/5 and first pass p-gp activity in small bowel transplant patients 
to that in normal healthy adults. We will also evaluate the cytokine profiles and C-reactive 
protein (CRP) expression in these patients during the early post operative period and at a later 
time point and correlate with the functional activity of CYP3A and P-gp. The secondary 
objective of this study (as a pilot study) is to assess the effect of CYP3A5/MDR1 polymorphisms 
on the oral availability of CYP3A4/5 and p-gp substrates in small bowel transplant patients. Our 
central hypothesis is that small intestinal transplant patients will have altered intestinal function 
during the early post operative period, but will have normal intestinal function when they are 
clinically stable, as measured by CYP3A and Pgp expression and activity. 
 
1.2 Specific Aims: List the goals of the proposed study (e.g., describe the relevant 
hypotheses or the specific problems or issues that will be addressed by the study). 
 
Question #1: What is the expression and functional activity of intestinal CYP3A4/5 and 
p-gp in the early post-transplant period? 
Specific Aim #1: To determine the activity of intestinal CYP3A4/5 and p-gp in the early 
posttransplant period by measurement of the area under the curve (AUC—a measure of exposure 
to the drug) and the oral clearance of midazolam, a substrate for CYP3A4/5, oral fexofenadine, a 
substrate for p-gp. In the transplant subjects only, tacrolimus (a substrate for both CYP3A4/5 and 
p-gp given to all small bowel transplant recipients as standard of care) levels will also be 
measured using the same blood samples taken for the study. This aim will be accomplished by 
administration of a single dose of oral midazolam followed by a single dose of oral fexofenadine 
60 minutes later, followed by a dose of intravenous midazolam, six hours later. Plasma levels of 
midazolam and fexofenadine and whole blood levels of tacrolimus (in the transplant patients) 
will be measured for 20 hours starting with the oral dose of midazolam. Various pharmacokinetic 
parameters will be determined for each subject and compared between groups. This study will 
allow for a better understanding of the dosing of CYP3A4/5 and p-gp substrates in the early post-
operative period after small bowel transplantation. 
Hypothesis #1: We hypothesize that intestinal transplantation leads to a transitory 
increase in expression of inflammatory and anti-inflammatory cytokines, which in turn leads to 
decreased expression and impairment of CYP3A4/5-mediated intestinal first-pass metabolism 
and p-gp-mediated intestinal efflux transport in the early postoperative period. This will then 
lead to a correspondingly increased AUC and bioavailability of orally administered CYP3A4/5 
and p-gp substrates. 
 
Question #2: What is the expression and functional activity of CYP3A4/5 and p-gp in the 
later post-transplant period? 
Specific Aim #2: To determine the activity of intestinal CYP3A4/5 and p-gp in the later 
posttransplant period (approximately four to nine months post-surgery) by measurement of oral 
bioavailability of midazolam and AUC of oral fexofenadine. This aim will be accomplished by 
administration of a single dose of oral midazolam followed by a single dose of oral fexofenadine 
60 minutes later, followed by a single dose of intravenous midazolam 6 hours later. Plasma 
concentrations of midazolam and fexofenadine and whole blood levels of tacrolimus (in the 
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transplant subjects only) will be measured for 20 hours starting with the dose of oral midazolam. 
Various pharmacokinetic parameters will be determined for each subject and compared between 
subjects and between groups. This will allow for a better understanding of dosing of CYP3A4/5 
and p-gp substrates in the later post-operative period after small bowel transplantation. 
Hypothesis #2: We hypothesize that the functional capacity (as measured by CYP3A4/5 
and p-gp activity) of the intestine in clinically stable intestinal transplant patients (about four 
months after transplantation) will be no different than the functional capacity of the intestine in 
non-transplanted healthy adults. 
 
Question #3: What is the time course of the concentration of inflammatory mediators 
such as cytokines and CRP after small bowel transplantation? 
Specific Aim #3: To determine the expression pattern of various cytokines (including those 
associated with inflammation, ischemia-reperfusion injury, and inhibitory effects on CYP 
enzymes and p-gp) as well as CRP in the first 21 days after surgery and approximately four to 
nine months after surgery. This aim will be accomplished by measurement of serum cytokine 
and CRP levels, as well as graft cytokine levels (whenever graft tissue is available) in small 
bowel transplant patients during the first 21 days after surgery. This will allow for a better 
understanding of the expression of inflammatory and anti-inflammatory mediators immediately 
after small bowel transplantation. These mediators have been known to alter the expression of 
certain drug metabolizing enzymes and transporters. 
Hypothesis #3: We hypothesize that graft ischemia, intestinal manipulation secondary to 
surgery, and ischemia-reperfusion injury will lead to increases in cytokine and CRP expression 
levels in blood and intestinal mucosa during the first three weeks after surgery. We hypothesize 
that these protein levels will decline over the course of time post-surgery. In addition, we 
hypothesize that these increased cytokine levels will result in decreased expression of CYP3A 
and p-gp proteins in small intestinal mucosal tissue. 
 
Question #4: What are the effects of graft and native CYP3A4/5 and MDR1 variant 
genotypes on the bioavailability of orally administered CYP3A4/5 and p-gp substrates after 
small bowel transplantation? 
Specific Aim #4: The purpose of this aim is to obtain pilot data on the effects of graft and 
native CYP3A4/5 and MDR1 variant genotypes on the bioavailability of CYP3A4/5 and p-gp 
substrates after small bowel transplantation. This aim will be accomplished in the transplant 
patients by genotyping of small bowel grafts using tissue samples taken from routine biopsies. In 
addition, we will use peripheral blood cells to determine native genotype in the small bowel 
transplant patients and healthy controls. We will then assess the relationship between genotype 
and pharmacokinetic parameters in the study subjects. This will provide pilot data towards a 
future study. 
Hypothesis #4: Graft and native CYP3A4/5 and MDR1 variant genotypes are associated 
with alterations in the first pass metabolism of CYP3A4/5 and p-gp substrates, and will 
contribute to the variability in drug levels in small bowel transplant recipients and healthy 
controls. 
 
1.3 Background: Briefly describe previous findings or observations that provide the 
background leading to this proposal. 
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Small bowel transplantation is an increasingly viable alternative to chronic intravenous 
nutrition in patients with intestinal failure. However, despite the importance of the small intestine 
in the absorption (uptake), metabolism and efflux of endogenous and exogenous materials, little 
is known about the time course of recovery of these functions in the graft, and whether the graft 
function recovers to what is normally observed in normal healthy subjects, in small bowel 
transplant patients. Earlier studies in our laboratory has shown that the AUC of tacrolimus after 
oral administration was higher during the early post operative period, compared to late 
postoperative period in dogs after small bowel transplantation. The AUC of tacrolimus was, 
however, similar between small bowel transplanted dogs and control non-transplanted dogs 
during the late post operative period (about 4 to 7 months) (Ishikawa et al. 2003). Other studies 
by our group have shown evidence of complete recovery of intestinal metabolic function in 
stable small bowel transplant patients a few months after transplantation. We have shown that 
the dose normalized trough concentration of tacrolimus (a substrate for CYP3A4/5 and p-gp) in 
clinically stable small bowel transplant patients (5 ng/ml/mg dose) is similar to that observed in 
other transplant (liver) patients (4.6 ng/ml/mg dose) at six months after transplant surgery (Jain 
et al. 1992; Jain et al. 1994). In clinically stable pediatric small bowel and liver transplant 
patients, the pharmacokinetic profile of tacrolimus was similar to that observed in pediatric liver 
transplant patients (Schubert et al. 2004). The blood concentration versus time profile of 
sirolimus (substrate for CYP3A4/5 and Pgp) in clinically stable small bowel transplant patients is 
similar to that observed in other transplant (liver) patients (Schubert et al. 2004). All of the above 
observations point to altered functional activity early post transplantation that completely 
recovers with time (in about 4-6 months) after transplantation. 
Small bowel grafts are subjected to several types of injury leading to the release of 
inflammatory mediators such as interleukin-6 (IL-6) and tumor necrosis factor-alpha 
(TNFalpha), which may adversely affect the intestinal function in the early post-transplant period 
(Kadry et al. 2000; Tuler et al. 2002). Cytokines such as TNF-alpha and IL-6 have been shown to 
inhibit gene expression of various drug-metabolizing enzymes and drug transporters, including 
the key cytochrome P450 enzyme, CYP3A4, and p-glycoprotein, a key drug transporter. 
(Morgan et al. 1994; Carlson and Billings 1996; Pascussi et al. 2000; Bertilsson et al. 2001; 
Sukhai et al. 2001; Belliard et al. 2002; Belliard et al. 2004; Fernandez et al. 2004). These early 
post-operative changes are of concern in the setting of small bowel transplantation because the 
small intestine is the primary site of absorption of drugs. The enterocytes lining this organ 
contain CYP3A4/5 enzymes in their endoplasmic reticulum as well as p-gp transporters on their 
brush border, both of which contribute significantly to intestinal first-pass metabolism of orally 
administered medications. Many clinically used drugs, including the immunosuppressive 
medications tacrolimus, sirolimus, and cyclosporine, are given orally and are substrates for both 
CYP3A4/5 and p-gp. Earlier studies carried out in our lab have shown that intestinal metabolism 
plays an important role in the bioavailability of the CYP3A and p-gp substrate cyclosporine 
(Schwinghammer et al. 1991). Given the important role of CYP3A and pGP it is important to 
understand their activity in small bowel transplant patients. 
In addition, genetic factors may also play a role in the pharmacokinetics of CYP3A4/5 
and pgp substrates in small bowel transplant patients. Although inter-individual variability in 
CYP3A4 levels and CYP3A4-mediated metabolism has been noted in patients, of the 38 allelic 
variants of the CYP3A4 gene that have been described, only one has been found to cause 
alterations in metabolism (CYP3A4*20) and this variant is extremely rare (Westlind-Johnsson et 
al. 2006). In contrast, polymorphic differences in the CYP3A5 protein, an enzyme with substrate 
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specificity overlapping that of CYP3A4, are common in the U.S. population. It has been 
estimated that up to 90 percent of Caucasians express a nonfunctional version of this enzyme 
(CYP3A5*3) while up to 50 percent of African-Americans express a functional version of the 
enzyme (most commonly CYP3A5*1). CYP3A5 is the most predominant extrahepatic CYP3A 
isoform. Patients heterozygous and homozygous for the *1 allele have been shown in some 
studies to have decreased trough levels of tacrolimus, implying increased first-pass metabolism 
by CYP3A5 in the intestine (Lamba et al. 2002; Daly 2006). MDR1 (the gene encoding the p-gp 
protein) polymorphisms are also common and may cause alterations in the bioavailability of p-gp 
substrates after oral administration. Although study results have been conflicting, the C3435T 
and G2677T/A variants have been associated with decreased p-gp expression and function and 
increased bioavailability of p-gp substrates (Pauli-Magnus and Kroetz 2004; Yi et al. 2004). The 
genotype of the graft may therefore play a role in the pharmacokinetics of CYP3A4/5 and p-gp 
substrates in small bowel transplant patients. 
 
1.4 Significance: Why is it important that this research be conducted? What gaps in 
existing information or knowledge is this research intended to fill? 
 
A thorough understanding of the functional activity and time course of recovery of 
CYP3A4/5 and p-gp in small bowel transplant patients is important to optimize drug therapy in 
this population. Due to the increasing number of intestinal transplants performed for treatment of 
intestinal failure, the complicated biochemical changes that occur in both the recipient and the 
graft over time, the large number of drugs used in this patients, the importance of the small 
intestine in absorption and metabolism of drugs, a better understanding of the regulation of the 
metabolic and transport function of the transplanted gut in these patients is essential. This study 
will also evaluate the clinical utility of serum CRP and cytokine measurement and CYP3A and 
p-gp tissue protein measurement in the post-transplant period as ways of gauging the amount of 
systemic and graft inflammation in the recipient and its potential effect on drug disposition. 
Finally, with the growing awareness of the importance of genetic variants on drug metabolism, 
more information is needed on the effects of CYP3A4/5 and MDR1 variants on bioavailability of 
drugs in this unique patient population. Transplantation of a small bowel also potentially creates 
a situation where the liver and intestinal CYP3A4/5 and/or MDR1 polymorphisms may be 
different between native and transplanted organ. Given the importance of the small intestine to 
drug metabolism, it is crucial to investigate the pharmacokinetic consequences of such a 
situation. 
2. Research Design and Methods 
2.1 Does this research study involve the use or evaluation of a drug, biological, or 
nutritional (e.g., herbal or dietary) supplement? 
 
yes 
 
2.1.1 Does this research study involve an evaluation of the safety and/or effectiveness 
of one or more marketed nutritional (e.g., herbal or dietary) supplements for the diagnosis, 
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prevention, mitigation or treatment of a specific disease or condition or symptoms 
characteristic of a specific disease or condition? 
 
no 
 
2.1.2 Does this research study involve the use or evaluation of one or more drugs or 
biologicals not currently approved by the FDA for general marketing? 
 
no 
 
2.1.3 Does this research involve an evaluation of the effectiveness and/or safety of 
one or more drugs or biologicals currently approved by the FDA for general marketing? 
 
no 
 
2.2 Will this research evaluate the safety and/or effectiveness of one or more 
devices? 
 
no 
 
2.3 Summarize the general classification (e.g., descriptive, experimental) and 
methodological design (e.g., observational, cross-sectional, longitudinal, randomized, open-
label single-blind, double-blind, placebo-controlled, active treatment controlled, parallel 
arm, cross-over arm) of the proposed research study, as applicable. 
 
This is an open-label pharmacokinetic study. 
This is a single center pharmacokinetic study of oral and IV midazolam (a CYP3A4/5 
substrate) and oral fexofenadine (a p-gp substrate) in patients who undergo isolated small bowel, 
small bowel-pancreas, or modified multivisceral transplantation for end stage intestinal failure at 
the Thomas E. Starzl Transplantation Institute at the University of Pittsburgh Medical Center, 
Pittsburgh, PA and in healthy controls. An appropriately signed informed consent will be 
obtained from each transplant patient once transplant candidacy is established and prior to any 
study-related procedures. No standard of care is being withheld by patient participation in this 
study. Similarly, an appropriately signed informed consent will be obtained from healthy control 
subjects before any study-related procedures are performed. Up to 50 subjects who have signed 
the informed consent and who continue to meet entry criteria will be enrolled and eligible for 
participation in the study sessions. 
For transplant patients, the study consists of three phases: a screening visit and two study 
visits. For controls, the study consists of one screening visit and one study visit. Subject 
participation in the study will last for approximately 120-180 days from the day of 
transplantation (for transplant patients) or day of enrollment (healthy controls). For the transplant 
recipients, the first study session will be while they are still hospitalized after transplant surgery. 
However, for the second study session the transplant patients may be required to make a separate 
visit for study purposes alone, and the control subjects will make two separate visits to the study 
facility for study purposes alone. We will attempt to prescreen potential control subjects by 
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telephone so that they are an appropriate match for the small bowel transplant patients (see 
recruitment section). 
 
2.3.1 Does this research study involve a placebo-controlled arm? 
 
no 
 
2.4 Will any research subjects be withdrawn from known effective therapy for the 
purpose of participating in this research study? 
 
no 
 
2.5 Will screening procedures (i.e., procedures to determine research subject 
eligibility) be performed specifically for the purpose of this research study? 
 
yes 
 
2.5.1 List the screening procedures that will be performed for the purpose of this 
research study. 
 
The investigators involved in the study are clinicians who are normally involved in the 
routine clinical care of the patients. These clinicians will be involved in screening the subjects 
for the study. Transplant patients (Screening will be done in transplant ICU after transplant): 
Medical history (including medical conditions and drug allergies) 
Volume of transplanted intestinal graft output 
Total bilirubin 
AST/ALT 
gamma-glutamyl transferase 
BUN/Cr 
serum albumin 
alkaline phosphatase 
electrolyte panel and calcium, magnesium, phosphorus 
CBC with differential 
platelet count 
ECG 
hemoglobin/hematocrit 
demographics (age, gender, height, weight, percent of ideal body weight) 
indication for transplant 
degree of hepatic steatosis/fibrosis from pre-transplant liver biopsy report 
CMV status of donor and recipient 
HLA mismatch 
Control subjects (Screening will be done in Montefiore CTRC): 
All of the above, except indication for transplant, pre-transplant liver biopsy report, CMV 
status, and HLA mismatch since these are N/A to controls. 
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2.5.2 What steps will be taken in the event that a clinically significant, unexpected 
disease or condition is identified during the conduct of the screening procedures? 
 
If a clinically significant, unanticipated disease or condition is identified during the 
conduct of these screening procedures the subject will be excluded from the study and given a 
referral to a physician who specializes in the condition identified. 
 
2.6 Provide a detailed description of all research activities (e.g., all drugs or devices; 
psychosocial interventions or measures) that will be performed for the purpose of this 
research study. This description of activities should be complete and of sufficient detail to 
permit an adequate assessment of associated risks. At a minimum this should include: 
personnel performing the procedures 
location of procedures 
duration of procedures 
timeline of study procedures 
 
Study Visit 1 (Screening): Eligible small bowel, small bowel-pancreas, and modified 
multivisceral transplant recipients will be given the opportunity to sign informed consent for the 
study as soon as transplant candidacy is confirmed. Healthy control subjects will be recruited as 
the study subjects are recruited so that we are able to match based on demographics such as age, 
race, and gender. All patients who have signed the consent form and been enrolled in the study 
will undergo a preliminary screening lasting for approximately two hours. For the transplant 
subjects, the screening will take place in the transplant ICU after the transplant. The control 
subjects will have their screening visits at the Clinical and Translational Research Center 
(CTRC) at Montefiore hospital. The initial screening of subjects will include a medical history 
and the following clinical laboratory tests: serum bilirubin, alanineaminotrasferease, (ALT), 
aspartateaminotransferase (AST), serum creatinine (Scr), blood urea nitrogen (BUN), serum 
albumin, alkaline phosphatase, phosphorus, calcium, magnesium, an electrolyte panel, glucose, 
PT/PTT/INR, complete blood count with differential (CBC), platelets, as well as demographics 
(including age, gender, race, weight, and height).  In the case of the transplant recipients, the 
indication for transplant and HLA mismatch will also be recorded as well as the cytomegalovirus 
(CMV) status of both the donor and the recipient. In addition, for the transplant subjects, gamma-
glutamyltransferase will be measured in serum, output from the transplanted graft will be 
recorded, and the degree of hepatic steatosis and/or fibrosis from pre-transplant liver biopsy 
reports will be noted. If any subjects do not meet the inclusion criteria or meet any of the 
exclusion criteria based on the results of this screening session, they will be excluded from the 
study before any study procedures have been performed. If a clinically significant, unanticipated 
disease or condition is identified during the conduct of these screening procedures the subject 
will be excluded from the study and given a referral to physician who specializes in the condition 
identified.  
Transplant recipients will also have serum cytokine (including TNF-alpha, IL-6, IL-
1beta) and C-reactive protein (CRP) levels measured every other day from the day of transplant 
up until the second study session before post-transplant day 21. This range was chosen because 
we would like to do the study within a week of the patient being able to tolerate oral medications 
and enteral feedings, but we recognize that there is wide inter-individual variability in this. 
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Female subjects of childbearing age will undergo a urinary pregnancy testing at this phase prior 
to administration of any study medications. 
Study Visits 2 and 3: For the transplant patients, the second study session will be between 
2 and 4 days after the patient is able to tolerate enteral intake (usually within the first 2 weeks 
after surgery) and the third session will be approximately four to nine months after 
transplantation (120-240 days post-transplant). For the control subjects, the single study session 
will take place as soon as possible after enrollment and will be in the CTRC at UPMC 
Montefiore. In order to participate in the second and third study sessions, the transplant patients 
must be able to take medications orally. If greater than 30 days has elapsed since a control 
subject had labs done during the screening session, then the control will have the following labs 
drawn prior to the administration of study drugs: total bilirubin, AST/ALT, BUN/SCr, serum 
albumin, phosphorus, magnesium, alkaline phosphatase, and electrolyte panel. Transplant 
subjects will have these labs drawn daily or weekly as standard of care and those values will be 
used. During the pharmacokinetic study sessions, subjects will receive an oral dose of 5 mg 
midazolam, an oral dose of 60 mg fexofenadine 60 minutes later, and about 6 hours later an 
intravenous dose of 2 mg midazolam. Transplant subjects may receive the oral medications via 
jejunostomy tube at the earlier study session. Subjects will be monitored with an automated 
blood pressure cuff and pulse oximetry for two hours after each drug administration. The mean 
elimination half-life of midazolam in patients with normal hepatic and renal function is 
approximately 3 hours (range 1.8 to 6.4 hours). The semisimultaneous bioavailability approach 
will be used to characterize the pharmacokinetic parameters after midazolam administration. 
This method allows for administration of a second dose of midazolam while some of the first 
dose remains in the circulation, and the drug concentration-time profile is fitted to a 
mathematical model using nonlinear regression (Karlsson, 1989). The half life of fexofenadine is 
about 12 hours. However, the plasma concentration of fexofenadine is very low by 20 hrs after 
drug administration and correspondingly the AUC from 0-20 after fexofenadine administration 
will approximate the AUC from 0-infinity. Therefore in a total study time period of 20 hours we 
expect to capture a significant portion of the AUC for fexofenadine and adequately characterize 
the pharmacokinetic parameters of midazolam. Control subjects at all study sessions and 
transplant subjects at the later study session will be given a breakfast two hours after the dose of 
oral midazolam in the morning and will be given a lunch one hour after the dose of intravenous 
midazolam, followed by a dinner near the end of the session. Transplant subjects at the earlier 
study session will remain on their standard enteral feeding schedule. Any patients who 
experience emesis within four hours after oral administration of study drugs will be removed 
from the study, as full absorption of drug may not have taken place. Subjects will stay overnight 
after study sessions 2 and 3 either in their hospital bed (if inpatient transplant subjects) or the 
CTRC (if outpatient and/or control subjects). As an additional safety measure, all subjects will be 
required to remain in bed for six hours after each dose of midazolam, although they will be 
allowed bathroom privileges with assistance. The Observer's Assessment of Alertness/Sedation 
(OAA/S) scale will be used by the investigators to assess alertness and level of sedation. This 
assessment will be administered at baseline (before administration of study drug), and at 15, 30, 
45, 60, and 120 minutes after each dose of midazolam. 
Multiple blood samples (3 ml each) will be obtained in a purple top vacutainer from an 
indwelling catheter over a 12 hr time period. The sampling time points will include 0, 0.25, 0.5, 
1.0, 1.5, 2, 3, 4, 5, 7, 7.25, 7.5, 8, 10, 12, and 20 hours after the start of oral dosing for 
measurement of the concentration of drugs under study. One additional 3 ml blood sample will 
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be drawn to measure cytokine and CRP levels at time zero. Total blood volume removed during 
the study visits will be 51 mL, unless a control subject requires labs, in which case the total 
amount drawn will be 54 mL. 
Urine samples will be taken at 1, 3, 5, 7, 9, and 12 hours in the transplant patients at the 
first pharmacokinetic study session and at 1, 3, 5, 7, 9, 12 and 20 hours at the second 
pharmacokinetic study session and also in controls, in order to measure levels of midazolam, 
1'hydroxymidazolam, and 1'hydroxymidazolam glucuronide. Measurement of these compounds 
in the urine will allow for the characterization of formation clearance of the 1'hydroxymidazolam 
metabolite as well as other pharmacokinetic parameters such as renal clearance of unchanged 
drug (midazolam) as well as metabolite. 
Blood samples will be centrifuged at 3000 rpm for 10 minutes immediately to obtain 
plasma and plasma and urine samples will be frozen at –70 degrees until analysis. Plasma and 
urine samples will be assayed for midazolam, 1'hydroxymidazolam, 1'hydroxymidazolam 
glucuronide, and fexofenadine concentrations by LC/MS in the PI’s laboratory. Whole blood 
concentrations of tacrolimus will be measured by HPLC-MS. 
Subjects will be asked not to consume grapefruit or grapefruit juice or cranberry juice 
(which contain known inhibitors of intestinal CYP3A4) or apple or orange juice (which may 
decrease fexofenadine concentrations) for 3 days before and during study visits 2 and 3. In 
addition, subjects will be asked not to consume caffeine-containing beverages for 72 hours prior 
to the study session, since caffeine is a weak CYP3A inhibitor. Subjects will be asked to abstain 
from consuming food and other beverages (except water) after midnight prior to the study day. 
Transplant patients will be allowed to take their routine medications at least two hours before 
administration of the study medications. 
All transplant patients will receive tacrolimus for routine immunosuppression. 
Tacrolimus dose and blood levels that are routinely measured in the patients will be collected, as 
a measure of a combined measure of CYP3A and pgp activity. 
Small intestinal mucosal tissue samples that are taken from the transplant recipients 
during two routine intestinal biopsies (one in the early post-transplant period and one 
approximately 4-9 months post-transplant around the time of the third study session) will be 
genotyped for the presence of the CYP3A5*1 and CYP3A5*3 alleles, as well as for the C3435T 
and G2677T/A variants of the MDR1 gene. Levels of cytokine and CRP mRNA expression in 
the tissue sample will also be measured whenever tissue samples from routine biopsies become 
available. Markers of ischemia and reperfusion injury may also be assessed. A peripheral blood 
sample from each subject (transplant patients and controls) will also be genotyped for the above 
polymorphisms. Finally, CYP3A and p-gp protein levels will be measured in routine biopsy 
samples by Western blot and immunohistochemical staining, using antibodies specific for 
CYP3A and p-gp. Two additional mucosal tissue samples (beyond the three typically taken 
during a routine biopsy in these patients) will be taken during each of the two biopsy sessions in 
order to have enough tissue for the PCR and Western blot procedures. 
 
2.7 Will follow-up procedures be performed specifically for research purposes? 
Followup procedures may include phone calls, interviews, biomedical tests or other 
monitoring procedures. 
 
yes 
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1) Transplant subjects at study session 2 will be in monitored hospital beds as standard of 
their post-operative care, and will be supervised by medical and nursing staff for the duration of 
the session. 
2) Session 2 for control subjects and session 3 for transplant subjects will take place at 
the University of Pittsburgh Clinical and Translational Research Center (CTRC) at Montefiore 
hospital. The following precautions will be taken after drug administration: 
a) Subjects will lie supine and have blood pressure, respiratory rate and heart rate 
measured every 15 minutes for two hours after study drug administration. 
b) Subjects will wear a pulse oximeter continuously for two hours after study drug 
administration. Supplemental oxygen will be administered for oxygen saturations less than 94%. 
c) Subjects will be required to remain in bed for six hours after each dose of midazolam, 
but will be allowed bathroom privileges with assistance. 
d) Level of sedation will be assessed using the Observer's Assessment of 
Alertness/Sedation scale at baseline and 15, 30, 60, and 120 minutes after each dose of 
midazolam. 
If this fails to increase the saturation or if the pulse ox is less than 90 percent, a physician 
will be called. In addition, a physician will be called if the blood pressure goes above 140/90 or 
below 90/60, depending on the patient’s baseline blood pressure (the physician would of course 
be called for any dramatic increases or decreases). 
e) Subjects will remain overnight in the CTRC to ensure that all study drugs are washed 
out of the system. In addition, CTRC nursing staff will assess level of sedation, blood pressure, 
and pulse ox before the subject is allowed to leave on the morning after the study session. 
 
2.8 Does this research study involve the use of any questionnaires or survey 
instruments not listed in Appendix G of the IRB Reference Manual? 
 
yes 
 
2.9 If subjects are also patients, will any clinical procedures that are being used for 
their conventional medical care also be used for research purposes? 
 
yes 
 
If Yes, describe the clinical procedures (and, if applicable, their frequency) that will be 
used for research purposes: 
 
1) In the potential transplant subjects, all labs used for screening purposes are drawn 
daily as part of routine clinical care--no extra labs will be drawn for screening in these subjects. 
2) In the transplant subjects, all intestinal tissue biopsies are done as part of routine 
clinical care--no additional biopsies will be scheduled in these subjects for study purposes. 
3) For control subjects, none of the procedures associated with any portion of the study 
are considered routine clinical care and thus all costs associated with their participation in the 
study will be paid for by the study and not billed to them or to their insurance (this is indicated in 
the fiscal review form). 
 
2.10 Will blood samples be obtained as part of this research study? 
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yes 
 
If Yes, address the frequency, volume per withdrawal, the total volume per visit, and the 
qualifications of the individual performing the procedure: 
 
During the screening session, control subjects will have one 3 mL sample of blood 
collected to measure various biochemical parameters. Transplant patients will have blood drawn 
and labs done daily as part of routine clinical care so no additional blood draws will be required 
during screening for the transplant group. 
During participation in each of the two pharmacokinetic study sessions, a total of 17 
blood samples of 3 mL each will be collected for a total of 51 mL (approximately 3 
tablespoonfuls). Research subjects will participate in no more than one screening session and two 
pharmacokinetic study sessions (one for controls) for a maximum total of 102 mL of blood 
collected at all study sessions combined. No additional blood will be drawn for genotyping since 
1 mL of blood taken from study session 2 will be used for this purpose in both study groups. 
 
2.11 What is the total duration of the subject's participation in this research study 
across all visits, including follow-up surveillance? 
 
Approximately four to nine months 
 
2.12 Does this research study involve any type of planned deception? 
 
no 
 
2.13 Does this research study involve the use of UPMC/Pitt protected health 
information that will be de-identified by an IRB approved "honest broker" system? 
 
no 
 
2.14 Will protected health information (PHI) from a UPMC/Pitt HIPAA covered 
entity be obtained for research purposes or will research data be placed in the UPMC/Pitt 
medical record? 
 
no 
 
2.14.1 Will protected health information from a non-UPMC/Pitt HIPAA covered 
entity be obtained for research purposes or will research data be placed in the non- 
UPMC/Pitt medical record? 
 
no 
 
2.15 Does this research study involve the long-term storage (banking) of biological 
specimens? 
 
  250 
yes 
 
2.15.1 Broadly describe the intended future use of the banked biological specimens: 
 
1) Peripheral blood samples drawn from subjects in both the transplant and control 
groups will be genotyped for the presence of CYP3A5*1 and CYP3A5*3 alleles and the C3435T 
and G2677T/A variants of the MDR1 gene. 
2) Intestinal tissue taken during biopsies performed as part of routine clinical care in the 
transplant subjects will also be genotyped for the above polymorphisms as well as analyzed for 
cytokine, CYP3A4/5, and p-gp levels. 
 
2.15.2 Indicate the planned length of storage of the banked biological specimens: 
 
indefinite 
 
2.15.3 Will the biological specimens be de-identified prior to making these 
specimens available for use in this research study? 
 
no 
 
2.15.4 Will subjects (including family members, if applicable) be informed of their 
personal results from analyses performed on their biological specimens? 
 
yes 
 
2.15.4.2 Indicate when personal results will be disclosed. 
 
Only upon the request of a research subject 
 
2.15.4.3 Indicate how subjects will be informed of their personal results. 
 
Information on the blood concentration time profile of tacrolimus and other drugs tested 
may be shown to the subjects. Since the implications of the initial results will not be clear no 
changes in routine management of the subjects will be made if any, until the completion of the 
study. 
 
2.15.4.4 When will the results be disclosed? 
 
At the conclusion of the research study 
 
2.15.4.5 Describe potential risks associated with disclosure of personal results. 
 
While the investigators will have procedures in place to ensure that all subject 
information is kept strictly confidential, there is the possibility that if genotype results became 
generally known, this information could have an impact on a subject’s future insurability, 
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employability, reproductive plans, or could have a negative impact on family relationships, or 
could result in paternity suits or stigmatization. 
 
2.15.4.5.1 Is germ-line genetic research being conducted on the banked biological 
specimens? 
 
no 
 
2.15.4.6 Is the laboratory performing the analyses on the biological specimens CLIA 
certified? 
 
yes 
 
2.15.4.7 Describe the procedures that will be employed to protect the confidentiality 
of subjects' private information associated with use of biological specimens: 
 
All patient/subject data obtained over the course of this study will remain strictly 
confidential. Specimens collected will be coded and kept in the laboratory of the Principal 
Investigator. Only authorized personnel will have access to the specimens. All specimens will be 
labeled with a code and will not be identifiable by patient name, initials, social security number, 
or any other identifier that could be traced back to the patient. The list of codes linking 
specimens and identifiable patient information will be kept in a locked cabinet in the Principal 
Investigator’s office. Only investigators in this study will have access to this information. 
 
2.15.4.8 Will the banked biological specimens or data derived from them be 
provided with subject identifiers to any secondary investigators or external entities? 
 
no 
 
2.15.4.9 Will research subjects be remunerated in the event of the future 
commercial development of inventions or products based on the research use of their 
biological specimens? 
 
no 
 
2.16 Will research participants be asked to provide information about their family 
members or acquaintances? 
 
no 
 
2.17 What are the main outcome variables that will be evaluated in this study? 
 
The functional activity of CYP3A and P-gp will be assessed from the concentration vs. 
time profile of midazolam, fexofenadine and tacrolimus.  Pharmacokinetic data will be analyzed 
by noncompartmental methods. Plasma concentration versus time curves will be generated for 
each subject and the area under the plasma concentration versus time curve (AUC), which is the 
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primary outcome measure since it is a measure of drug exposure, will be calculated. Other 
pharmacokinetic parameters including disposition rate constant, disposition half life, mean 
residence time, clearance, and volume of distribution will be calculated after IV administration; 
and absorption rate constant, elimination rate constant, absorption half life, elimination half life, 
bioavailability, Cmax (maximum concentration), and Tmax (time of maximum concentration) 
will be calculated after oral administration of the study drugs.  For tacrolimus, in addition, the 
ratio of the trough blood concentration vs. time will be evaluated over the entire study period. 
 
2.18 Describe the statistical approaches that will be used to analyze the study data. 
 
Various weight-normalized pharmacokinetic parameters will be compared between 
groups of patients at each time point (i.e. between transplant patients and controls) and within 
groups (between time points) by the use of a two-sample t test and two way ANOVA. A 
comparison of the systemic clearance and oral clearance of midazolam will provide information 
on the drug’s intestinal clearance.  Oral clearance and AUC of fexofenadine will be used as a 
measure of p-gp activity. AUC of tacrolimus will be used as a measure of combined CYP3A and 
Pgp activity.  Trends in cytokine levels will be evaluated over time. Mean serum cytokine and 
CRP levels will be compared between the transplant patients and controls at both time points 
using the Wilcoxon rank-sum test, and correlated with various pharmacokinetic parameters. 
Descriptive plots of cytokine and CRP levels over time will also be created.  Time course of the 
ratio of blood concentration to dose will be evaluated.  In addition, in the statistical analysis of 
pharmacokinetic parameters within and between groups, subjects will be subdivided by presence 
or absence of CYP3A5 protein, and by CYP3A5 and MDR1 polymorphism and parameters 
compared by polymorphism.  We will also use the genotype as a covariate in the population 
pharmacokinetic analysis (NONMEM software available in our department) of the data. 
Although these comparisons will not be likely to reach statistical significance due to the small 
sample size and unknown genetic makeup of the future groups, this information will nevertheless 
allow us to better understand the contribution of some of the more common CYP3A5 and MDR1 
genotypes to intestinal first-pass metabolism in small bowel transplant recipients and healthy 
subjects and provide pilot data needed for future studies. 
 
2.19 Will this research be conducted in a foreign country or at a site where the 
cultural background of the subject population differs substantially from that of Pittsburgh 
and its surrounding communities? 
 
no 
 
2.20 Will the Principal Investigator for this project be responsible for some or all 
research activities at other sites? 
 
no 
 
2.21 Will this research study be conducted within a nursing home located in 
Pennsylvania? 
 
no 
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3. Human Subjects 
3.1 What is the age range of the subject population? 
 
18-65 
 
3.2 What is their gender? 
 
Both males and females 
 
3.3 Will any racial or ethnic subgroups be explicitly excluded from participation? 
 
no 
 
3.4 For studies conducted in the U.S., do you expect that all subjects will be able to 
comprehend English? 
 
yes 
 
3.5 Participation of Children: Will children less than 18 years of age be studied? 
 
no 
 
If No, provide a justification for excluding children: 
 
There will be no children included in the study. The large number of blood samples 
needed in this study for pharmacokinetic analysis would not be practical in pediatric patients. 
 
3.6 Does this research study involve prisoners, or is it anticipated that the research 
study may involve prisoners? 
 
no 
 
3.7 Will pregnant women be knowingly and purposely be included in this research 
study? 
 
no 
 
3.8 Does this research study involve neonates? 
 
no 
 
3.9 Fetal Tissues: Does this research involve the use of fetal tissues or organs? 
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no 
 
3.10 What is the total number of subjects to be studied at this site, including subjects 
to be screened for eligibility? 
 
50 
 
3.11 Identify each of the disease or condition specific subgroups (include healthy 
volunteers, if applicable) that will be studied. 
 
Subgroup Number to undergo research procedures 
Number to undergo screening 
procedures 
Small bowel transplant 20 25 
Healthy controls 20 25 
 
 
3.12 Provide a statistical justification for the total number of subjects to be enrolled 
into this research study at the multicenter sites or this site. 
 
Sample size calculations for this study were performed to determine the appropriate 
sample size to ensure an 80 percent chance of finding a significant difference using a two-sided 
significance test with an alpha of 0.05. Data from the studies by Kirby et al. and Kharasch et al. 
were used as estimates of arithmetic AUC means and standard deviations for each drug in 
healthy subjects. The mean AUC values for small bowel transplant patients are not available in 
the literature but are predicted to be 25 percent higher than in controls, but standard deviations 
are predicted to be equal. Therefore, we estimate that 20 patients will be needed in each group to 
show a 25 percent difference in midazolam and fexofenadine AUCs between the transplant 
patients at two different time points and between transplant patients and controls. However, 
based on the survival, rejection incidence, and other possible complications we predict that some 
of the small bowel transplant patients in the study will not return for the second and/or third 
study sessions. Similarly, not all of the controls will be expected to complete the study. 
Therefore, a sample size of 25 in each group should provide an adequate number to account for 
dropouts. 
 
3.13 Inclusion Criteria: List the specific criteria for inclusion of potential subjects. 
 
Inclusion criteria (transplant patients and controls): 
 
To be included in the study, a transplant patient must: 
• Have signed appropriate informed consent 
• Be between 18 and 65 years of age 
• Have been accepted as an isolated small bowel, modified multivisceral, or small bowel-
pancreas transplant candidate at the University of Pittsburgh Medical Center 
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• Be treated in accordance with the standard of care protocol(s) currently in effect for 
small bowel transplant recipients at the University of Pittsburgh Medical Center, including 
immunosuppression and other elements of pre- and post-operative care 
• Be receiving oral or enteral medications at the time of the first study session 
• Be within 30 percent of ideal body weight 
 
To be included in the study, a control subject must: 
• Have signed appropriate informed consent 
• Be between 18 and 65 years of age 
• Be within 30 percent of ideal body weight 
• Have normal hepatic and renal function (as defined by total bilirubin, AST, ALT, BUN, 
and serum creatinine within normal limits.) 
 
3.14 Exclusion Criteria: List the specific criteria for exclusion of potential subjects 
from participation. 
 
Exclusion criteria (transplant patients and controls): 
To be included in the study, a TRANSPLANT subject must NOT: 
• Be a smoker 
• Have a creatinine clearance less than 30 mL/minute as estimated by the Cockcroft-Gault 
equation 
• Have a hemoglobin value less than 8.5 gm/dL 
• Require supplemental oxygen 
• Have a very high output (> 2500 mL per day) from their transplanted intestinal graft 
• Be undergoing therapy with known CYP3A4/5 and/or p-gp inhibitors or inducers (i.e. 
cyclosporine, azole antifungals, rifampin, phenobarbital, St. John’s Wort) 
• Be undergoing multi-organ transplantation, except for small bowel and pancreas 
combined or modified multivisceral transplant 
• Have had any previous organ transplant or cell infusion 
• Be receiving any non-standard immunosuppression protocol or other non-standard 
treatment that could affect interpretation of the study results 
• Have any known hypersensitivity to benzodiazepines or fexofenadine 
• If female, be pregnant or nursing (as confirmed by pregnancy test at each visit) 
Be under the age of 18 or over the age of 65: 
-The large number of blood samples needed in this study for pharmacokinetic analysis 
would not be practical in pediatric patients (less than 18). 
-In addition, patients over age 65 are generally not transplanted. Therefore, since controls 
are to be age-matched, no control subjects over 65 will be included. 
To be included in the study, a control subject must NOT: 
• Have had any previous organ transplant or cell infusion 
• Have any medical condition known to affect gastrointestinal function or motility, such 
as diabetes mellitus, Crohn’s disease, ulcerative colitis, or short gut syndrome 
• Have liver disease (normal liver function as defined by AST/ALT, total bilirubin, 
albumin, and alkaline phosphatase all within normal limits, and no prior history of liver disease) 
• Be a smoker 
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• Have a creatinine clearance less than 50 mL/minute as estimated by the Cockcroft-Gault 
equation 
• Have a hemoglobin value less than 8.5 gm/dL 
• Have a history of bariatric surgery, such as gastric bypass 
• Be undergoing therapy with known CYP3A4/5 and/or p-gp inhibitors or inducers (i.e. 
cyclosporine, azole antifungals, rifampin, phenobarbital, St. John’s Wort) 
• Be receiving any other investigational drug or be participating in any other 
investigational study 
• Have any known hypersensitivity to benzodiazepines or fexofenadine 
• If female, be pregnant or nursing (as confirmed by pregnancy test at each visit) 
 
3.15 Will HIV serostatus be evaluated specifically for the purpose of participation in 
this research study? 
 
no 
 
4. Recruitment and Informed Consent Procedures 
4.1 Will potential research subjects be identified through the use of advertisements? 
 
yes 
 
4.2 Will potential research subjects be identified and recruited through the use of a 
"honest broker"? 
 
no 
 
4.3 Will you be accessing identifiable medical record information from your patient 
population for subsequent contact? 
 
yes 
 
4.3.1 Are you requesting a waiver of informed consent to access and record 
identifiable medical record information for recruitment purposes only? 
 
No - The respective patients provided previously their written informed consent to permit 
access to their identifiable medical record information for future research study recruitment 
purposes.  Prospective consent will be obtained under IRB #0307037 before transplant. 
 
4.4 Will methods other than advertisements, an honest broker system/process, or the 
review of identifiable medical record information be used for the identification of potential 
research subjects? 
 
no 
  257 
Are you planning on using the CTSI Research Participant Registry as a recruitment 
tool? 
 
yes 
 
4.5 How will potential research subjects be initially contacted to ascertain their 
interest in study participation? 
 
1) Transplant subjects: Interest in and eligibility for study participation will be 
ascertained by the transplant surgeon prior to transplant. This will be accomplished through the 
transplant research registry. IRB # 0307037 
2) Control subjects: Control subjects will be recruited via advertisements posted around 
the University of Pittsburgh and UPMC campuses, the CTSI research participant registry, as well 
as in Audex messages and campus newspapers. 
 
4.6 Are you requesting a waiver to document informed consent for any or all 
participants, for any or all procedures? (e.g., a verbal or computerized consent script will 
be used, but the subjects will not be required to sign a written informed consent document, 
such as with phone screening. 
 
yes 
 
4.6.1 Identify the specific research procedures and/or the specific subject 
populations for which you are requesting a waiver of the requirement to obtain a signed 
consent form. 
 
Telephone screening interview for potential control subjects. 
 
4.6.2 Indicate which of the following regulatory criteria is applicable to your request 
for a waiver of the requirement to obtain a signed consent form. 
 
45 CFR 46.117(c)(2) 
 
4.6.2.1 Address why the specific research procedures for which you are requesting a 
waiver of the requirement to obtain a signed consent form present no more than minimal 
risk of harm to the research subjects: 
 
The pre-screening research procedures for potential control subjects involve the gathering 
of basic demographic and medical information that is necessary to obtain prior to scheduling a 
potential control for a screening session at the CTRC. No research interventions are performed 
during the telephone pre-screening, and all information obtained is kept strictly confidential.  If 
subjects meet basic eligibility criteria, they are scheduled for a screening session, prior to which 
the PI goes through the consent form with them in person. If they then sign the consent form, 
screening procedures are performed. If subjects do not meet the basic eligibility criteria or do not 
wish to participate once the study is described to them, their information is shredded by the 
investigator unless they request otherwise (for example, some participants who are excluded 
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based on weight may ask the investigator to keep their information in case they lose weight or 
the inclusion criteria change.) 
 
4.6.2.2 Justify why the research listed in 4.6.1 involves no procedures for which 
written informed consent is normally required outside of the research context: 
 
The phone screening involves only the gathering of information, which will be kept 
confidential and will be destroyed if the subject does not wish to participate. 
 
4.6.3 Address the procedures that will be used and the information that will be 
provided (i.e., script) in obtaining and documenting the subjects' verbal informed consent 
for study participation: 
 
The study is described to the potential subject and he/she is asked if interested in 
participating and if they have any questions. Potential control subjects are then asked prior to any 
pre-screening questions if it is acceptable to them that they be asked some questions about 
themselves, and assured that their answers will be kept confidential, and that their name and 
information will be kept in a locked cabinet at all times. They are also told that their information 
will be shredded if they are deemed ineligible to participate at this time unless they request 
otherwise (for example, some participants who are excluded based on weight may ask the 
investigator to keep their information in case they lose weight or the inclusion criteria change.) 
Verbal consent to phone screening is documented by the investigator. 
 
4.7 Are you requesting a waiver of the requirement to obtain informed consent 
(from some or all potential subjects) for participation in this minimal risk. research study, 
or any minimal risk procedures associated with the conduct of this research study? 
 
no 
 
4.8 Are you requesting an exception to the requirement to obtain informed consent 
for research involving the evaluation of an 'emergency' procedure? 
 
no 
 
4.9  Consent form documents 
 
See section C.2 and C.3. 
 
4.10 Will all potential adult subjects be capable of providing direct consent for study 
participation? 
 
Yes 
 
4.11 At what point will you obtain the informed consent of potential research 
subjects or their authorized representative? 
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After performing certain of the screening procedures, but prior to performing any of the 
research interventions/interactions 
 
4.11.1 Address why you feel that it is acceptable to defer obtaining written informed 
consent until after the screening procedures have been performed. 
 
We will defer obtaining written informed consent (from control subjects) until after the 
telephone screening has been performed. We will obtain written consent when the potential 
research subject comes into the CTRC for the in-person screening session. This will be prior to 
any invasive screening procedures are done--i.e. prior to drawing labs, physical exam, or detailed 
medical history. 
 
4.11.2 Taking into account the nature of the study and subject population, indicate 
how the research team will ensure that subjects have sufficient time to decide whether to 
participate in this study. In addition, describe the steps that will be taken to minimize the 
possibility of coercion or undue influence. 
 
Potential transplant study subjects will be approached about possible study participation 
in the pre-transplant clinic or while inpatients being worked up for transplant. Potential subjects 
will not be approached immediately prior to transplant--i.e. on the day of surgery. One of the 
investigators will go through the consent form with the potential subject in the clinic or the 
hospital and stress that participation in the study is completely voluntary, that the choice of 
whether or not to participate in the study will have no effect on his/her relationship to the 
medical team or UPMC, and that he/she is free to withdraw from the study at any time after 
signing the consent form. The potential subject will then be free to take home the consent form 
and think about whether or not to participate in the study. 
Control subjects will be recruited via advertisements so they will approach the 
investigators themselves. However, the same considerations will apply--they will be given time 
to think about whether or not to participate, and it will be stressed that participation is completely 
voluntary and they may withdraw from the study at any time for any reason. 
 
4.12 Describe the process that you will employ to ensure the subjects are fully 
informed about this research study. 
 
One of the investigators will go through the consent form with each potential study 
subject, describing each section of the form and each part of the study, including the purpose of 
the study, the procedures to be employed, and the potential risks and benefits of their 
participation in the study, as well as their rights as a research subject. The potential subject will 
be reassured that study participation is completely voluntary, that their decision whether or not to 
participate in the study will have no effect on their relationship with any of the investigators or 
with UPMC, and that even if they do decide to sign the consent form, they may still withdraw 
from the study at any time for any reason. No coercion will occur and the refusal of a potential 
subject to participate in the study will be final. In addition, the potential subject will be given 
ample time to ask questions about the study, and will be given the phone number of a study 
coordinator in case of further questions. 
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4.13 Are you requesting an exception to either IRB policy related to the informed 
consent process? 
 
no 
 
4.14 Will you inform research subjects about the outcome of this research study 
following its completion? 
 
no 
 
5. Potential Risks and Benefits 
5.1 Risks of Screening Procedures: Are there any potential risks (e.g., physical, 
psychological, social, etc.) associated with the screening procedures (i.e., procedures to 
determine research subject eligibility) that will be performed for the purpose of this 
research study? 
 
Yes 
 
5.1.1 Describe potential risks (physical, psychological, social, legal, economic or 
other) associated with screening procedures, research interventions/interactions, and 
follow-up/monitoring procedures performed specifically for this study: 
 
Research Activity: Blood drawn for labs  
Infrequent Risks: Pain Bleeding, bruising, fainting, and risk of infection 
 
5.1.2 Describe the steps that will be taken to prevent or to minimize the severity of 
the potential risks: 
 
All information collected will be kept confidential.  All blood draws will be done by 
appropriate licensed healthcare personnel using sterile techniques and equipment. All data 
collected from subjects will be kept confidential under lock and key. 
 
5.2 Risks of Experimental Interventions: Are there any potential risks (e.g., 
physical, psychological, social, etc.) associated with the experimental interventions that will 
be performed for the purpose of this research study? 
yes 
 
5.2.1 List Expected Incidence of Experimental Intervention Risk: 
 
Research Activity Common risks Infrequent Risks Other risks 
Administration of 
oral fexofenadine 
Fexofenadine 
(Allegra®) is usually 
well tolerated and has 
Infrequent (Occurs in 1-
10% of people): 
Viral infection (cold, flu): 
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a low incidence of 
side effects. However, 
possible side effects 
of fexofenadine (vs. 
placebo) from clinical 
trials for seasonal 
allergic rhinitis (hay 
fever) and chronic 
idiopathic urticaria 
(an allergic skin 
condition) include: 
Common (Occurs in 
10-25% of people): 
headache 10.6% (vs. 
7.5%) and 7.2% (vs. 
6.6%) 
2.5% (vs. 1.5%), 
Nausea: 1.6% (vs. 1.5%), 
Dysmenorrhea (difficult 
menstrual periods): 1.5% 
(vs. 
0.3%), Drowsiness: 1.3% 
(vs. 0.9%) and 2.2% (vs. 
0.0%), Dyspepsia (upset 
stomach): 1.3% (vs. 0.6%), 
Fatigue: 1.3% (vs. 0.9%), 
Upper Respiratory Tract 
Infection: 3.2% (vs. 3.1%) 
and 4.3% (vs. 
1.7%), Back Pain: 2.8% 
(vs. 1.4%) and 2.2% (vs. 
1.1%), Accidental Injury: 
2.9% (vs. 1.3%), 
Coughing: 3.8% (vs. 
1.3%), Fever: 2.4% (vs. 
0.9%), Pain: 2.4% (vs. 
0.4%), Otitis Media (ear 
infection): 2.4% (vs. 
0.0%), Sinusitis (sinus 
infection): 2.2% (vs. 
1.1%), Dizziness: 2.2% 
(vs. 0.0%) Rare (Occurs in 
less than 1% of people): 
none 
Administration of 
oral/intravenous 
midazolam 
Decreased tidal 
volume and/or 
respiratory rate 
decrease (23.3% of 
patients after IV and 
10.8% of patients 
after IM injection), 
apnea 
(15.4% of patients 
after IV 
administration), as 
well as variations in 
blood pressure and 
pulse rate (frequency 
not listed). In 
addition, the 
following adverse 
reactions were seen 
Other adverse effects 
occurring after midazolam 
administration at an 
incidence of <1.0% in 
adults and children 
include: 
Respiratory: 
laryngospasm, 
bronchospasm, dyspnea, 
hyperventilation, 
wheezing, shallow 
respirations, airway 
obstruction, 
Cardiovascular: tachypnea, 
bigeminy, premature 
ventricular contractions, 
vasovagal episode, 
bradycardia, tachycardia, 
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after IV injection of 
midazolam: 
hiccoughs (3.9%), 
vomiting (2.6%), 
coughing 
(1.3%),“oversedation” 
(1.6%), headache 
(1.5%), drowsiness 
(1.2%). Local effects 
at the injection site 
include: tenderness 
(5.6%), pain during 
injection (5.0%), 
redness (2.6%), 
induration (1.7%), 
phlebitis (0.4%). 
nodal rhythm, 
Gastrointestinal: acid taste, 
excessive salivation, 
retching, 
CNS/neuromuscular: 
retrograde amnesia, 
euphoria, hallucination, 
confusion, 
argumentativeness, 
nervousness, anxiety, 
grogginess, restlessness, 
emergence delirium or 
agitation, prolonged 
emergence from 
anesthesia, dreaming 
during emergence, sleep 
disturbance, insomnia, 
nightmares, athetoid 
movements, seizure-like 
activity, ataxia, dizziness, 
dysphoria, slurred speech, 
dysphonia, paresthesia, 
Special Senses: blurred 
vision, diplopia, 
nystagmus, pinpoint 
pupils, cyclic movements 
of eyelids, visual 
disturbance, difficulty 
focusing eyes, ears 
blocked, loss of balance, 
light-headedness,  
Integumentary: hive-like 
elevation at injection site, 
swelling or feeling of 
burning, warmth, or 
coldness at injection site, 
Hypersensitivity: allergic 
reactions including 
anaphylactoid reactions, 
hives, rash, pruritis, 
Miscellaneous: yawning, 
lethargy, chills, weakness, 
toothache, faint feeling 
hematoma. 
Genotyping   There are risks associated with 
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genotyping. 
While the 
investigators will 
have procedures in 
place to ensure that 
all subject 
information is kept 
strictly confidential, 
there is the 
possibility that if 
genotype results 
became generally 
known, this 
information could 
have an impact on 
your future 
insurability, 
employability, 
reproductive plans, 
or could have a 
negative impact on 
family relationships, 
or could result in 
paternity suits or 
stigmatization. 
Removal of two 
extra tissue 
samples during 
biopsy 
 
Small risk of bleeding, 
infection, or intestinal 
perforation (exact 
incidence unknown, but 
rare). Since these subjects 
will be undergoing the 
biopsy as part of routine 
clinical care, we feel it is 
unlikely that the 
acquisition of two extra 
tissue samples beyond the 
usual three obtained as part 
of routine clinical care will 
pose significant extra risk 
to the subject. 
 
 
 
5.2.2 Describe the steps that will be taken to prevent or to minimize the severity of 
the potential risks associated with the experimental interventions: 
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Inpatient subjects (transplant patients at study sessions 1 and 2) will be in monitored 
hospital beds and will be supervised by medical and nursing staff for the duration of the session. 
Outpatient study sessions will take place at the University of Pittsburgh Medical Center Clinical 
and Translational Research Center (CTRC). Study subjects will undergo pulse oximetry 
monitoring for the first two hours after oral midazolam administration while in the CTRC. Vital 
signs and pulse ox will be measured every two hours thereafter for the duration of blood 
sampling. In addition, experienced CTRC nursing staff will continuously monitor each subject 
during the study session to watch for adverse effects from study medications or any other 
medical complications. The Observer's Assessment of Alertness/Sedation (OAA/S) scale will be 
used by the investigators to assess alertness and level of sedation. This assessment will be 
administered at baseline (before administration of study drug), and at 15, 30, 45, 60, and 120 
minutes after each dose of midazolam.  Subjects will be required to remain in bed for six hours 
after midazolam administration (bathroom privileges with assistance). Upon recognition of 
possible adverse events, the patient’s transplant physician will be notified immediately (in the 
case of transplant patients) and appropriate medical care given to the subject (all subjects). 
 
5.3 Risks of Follow Up Procedures: Are there any potential risks (e.g., physical, 
psychological, social, etc.) associated with the follow up procedures (e.g., tests to measure 
the efficacy and/or safety of the experimental intervention(s); to include monitoring 
procedures and/or outcome measures) that will be performed for the purpose of this 
research study? 
 
Yes 
 
5.3.1 List Expected Incidence of Follow Up Procedure Risk: 
 
Research Activity: Blood draws for labs and drug levels 
Common Risks: Pain 
Infrequent Risks: Bruising, bleeding, fainting, and risk of infection 
 
5.3.2 Describe the steps that will be taken to prevent or to minimize the severity of 
the potential risks associated with the follow up procedures: 
 
Patients will have a catheter inserted at the beginning of the study to facilitate blood 
draws.  Blood draws will be performed by qualified CTRC nursing staff using sterile techniques. 
 
5.4 Do any of the research procedures pose a physical or clinically significant 
psychological risk to women who are or may be pregnant or to a fetus? 
 
yes 
 
5.4.1 List the research procedures that pose a risk to pregnant women or fetuses: 
 
Midazolam is classified as Pregnancy Category D by the FDA. An increase in birth 
defects has been seen in infants born to mothers who used benzodiazepine drugs (class of drugs 
that midazolam belongs to) during pregnancy.  Fexofenadine is classified as Pregnancy Category 
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C by the FDA. This means that although animal studies have not shown the drug to cause birth 
defects, no adequate or well-controlled studies have been done in pregnant women to examine 
their effects on the fetus. In addition, midazolam is known to be excreted in breast milk. 
Therefore, being a part of this study while pregnant or breastfeeding may expose the unborn 
child or nursing infant to risks known and unknown. Therefore, pregnant and nursing women 
will not be included in this study. 
 
5.4.2 Describe the steps that will be taken to rule out pregnancy prior to exposing 
women of child-bearing potential to the research procedures that pose a risk to pregnant 
women or fetuses: 
 
A urine pregnancy test will be done on all women of childbearing potential during the 
screening visit and at each study session before administration of study drugs. It must be 
negative before they can enter this study or participate in any of the interventional study sessions. 
 
5.4.3 Describe the measures to prevent pregnancy, and their required duration of 
use, that will be discussed with women of child-bearing potential during and following 
exposure to research procedures: 
 
While enrolled in the study women of childbearing potential must agree to use 
appropriate methods of birth control for the duration of the study as well as for one week after 
the last dose of study drug. Medically acceptable birth control methods include: (1) surgical 
sterilization, (2) approved hormonal contraceptives (such as birth control pills or patches), (3) 
double-barrier methods (such as a condom and diaphragm together) used with a spermicide, (4) 
an intrauterine device (IUD), or (5) abstinence. Women will be advised not to take part in this 
study if they plan to become pregnant within one month after completing this study, are currently 
pregnant, or are currently breast feeding. They will be informed that they must notify their doctor 
and/or the investigators if they suspect they have become pregnant while participating in this 
study. 
 
5.5 Do any of the research procedures pose a potential risk of causing genetic 
mutations that could lead to birth defects? 
 
Unknown 
 
5.5.1 List the research procedures that pose a potential risk of genetic 
mutations/birth defects: 
 
Midazolam is classified as pregnancy category D by the FDA. An increase in birth 
defects has been seen in infants born to mothers who used benzodiazepine drugs during 
pregnancy. Fexofenadine is classified as pregnancy category C by the FDA, meaning that 
although animal studies have not shown the drug to cause birth defects, there are no adequate or 
well-controlled studies in pregnant women to examine its effects on the fetus. 
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5.5.2 Describe the measures to prevent pregnancy, and their required duration of 
use, in female subjects and female partners of male subjects during and following exposure 
to research procedures: 
 
Pregnant and nursing women, or women who plan to become pregnant, are not included 
in the study. The potential risks of the study drugs during pregnancy and lactation are explained 
in the consent forms. Female subjects of childbearing potential must agree to use appropriate 
methods of birth control while enrolled in the study as well as for one week after the last dose of 
study drug.  Acceptable methods of birth control include surgical sterilization, approved 
hormonal contraceptives, double barrier methods (such as condom and diaphragm) used with a 
spermicide, an intrauterine device, or abstinence. In addition, urine pregnancy tests are done at 
each study session before administration of study drugs. 
 
5.6 Are there any alternative procedures or courses of treatment which may be of 
benefit to the subject if they choose not to participate in this study? 
 
Not applicable; the experimental intervention does not involve a diagnostic/treatment 
procedure. 
 
5.7 Describe the specific endpoints (e.g., adverse reactions/events, failure to 
demonstrate effectiveness, disease progression) or other circumstances (e.g., subject's 
failure to follow study procedures) that will result in discontinuing a subject’s 
participation? 
 
Any subject enrolled in the study (transplant patient or control) may withdraw from the 
study at any time if they elect to do so. No cold calling by the investigator or research staff will 
occur. No coercion will occur. Refusal by a subject to participate in the study will be final. 
Subjects will also be withdrawn from the study if they are unable to tolerate the study drugs. 
 
5.8 Will any individuals other than the investigators/research staff involved in the 
conduct of this research study and authorized representatives of the University Research 
Conduct and Compliance Office (RCCO) be permitted access to research data/documents 
(including medical record information) associated with the conduct of this research study? 
 
no 
 
5.9 Has or will a Federal Certificate of Confidentiality be obtained for this research 
study? 
 
no 
 
5.10 Question has been moved to 5.17 
 
5.11 Question has been moved to 5.16 
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5.12 Does participation in this research study offer the potential for direct benefit to 
the research subjects? 
 
There will be no direct benefits to the research subjects participating in this study. 
However, there may be indirect benefits to the transplant patients and to society as a whole from 
this research study because it will allow for a better understanding of the functional and 
metabolic changes occurring in the transplanted small bowel over time as well as the effects of 
certain genetic polymorphisms on these changes. This will enable clinicians who care for small 
bowel transplant patients to optimize drug dosing and potentially improve short- and long-term 
health outcomes in this population. 
 
5.13 Describe the data and safety monitoring plan associated with this study. If the 
research study involves multiple sites, the plan must address both a local and central 
review process. 
 
Study subjects will be closely monitored by the investigators and research personnel. The 
data and safety information obtained for each study subject will be reviewed by the principal 
investigator and the principal investigator's mentor in weekly meetings. The Starzl 
Transplantation Institute’s Protocol Review Committee / DSMB committee will review the 
protocol and progress annually. This will evaluate the recruitment process, any breach of 
confidentiality and data collection. A summary report will be submitted annually to the IRB.  We 
will comply with the IRB’s policies for the reporting of serious and unexpected adverse events 
and breach of confidentiality as detailed in Chapter 3.0, section 3.3 of the IRB Reference 
Manual. If a serious life-threatening event occurs, the event will be reported immediately (i.e., 
within 24 hours) to the IRB. Unexpected reactions of moderate or greater severity will be 
reported to the IRB within 10 calendar days of the reaction. Minor events will be reported to the 
IRB at the time of annual review. All adverse events related to the research intervention will also 
be reported to the Food and Drug Administration (FDA) via the MedWatch adverse event 
reporting system in a timely fashion. 
 
5.14 What precautions will be used to ensure subject privacy is protected? (e.g. the 
research intervention will be conducted in a private room; the collection of sensitive 
information about subjects is limited to the amount necessary to achieve the aims of the 
research, so that no unneeded sensitive information is being collected, drapes or other 
barriers will be used for subjects who are required to disrobe) 
 
Study procedures are conducted in private rooms, either inpatient hospital rooms or 
private rooms in the CTRC. Investigators do not discuss study results or subjects in public areas 
or anywhere where anything may be overheard by non-study personnel. All biological samples 
from subjects are labeled without subject identifiers at all times. 
 
5.15 What precautions will be used to maintain the confidentiality of identifiable 
information? (e.g., paper-based records will be kept in a secure location and only be 
accessible to personnel involved in the study, computer-based files will only be made 
available to personnel involved in the study through the use of access privileges and 
passwords, prior to access to any study-related information, personnel will be required to 
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sign statements agreeing to protect the security and confidentiality of identifiable 
information, whenever feasible, identifiers will be removed from study-related information, 
precautions are in place to ensure the data is secure by using passwords and encryption, 
because the research involves web-based surveys, audio and/or video recordings of subjects 
will be transcribed and then destroyed to eliminate audible identification of subjects) 
 
All study records are and will be kept in a locked cabinet in the Principal Investigator's 
office. Only the PI (Jennifer Bonner) and another co-investigator (Darlene Koritsky) have access 
to the key to open this cabinet. Subjects are assigned numbers based on their order of recruitment 
and the names associated with subject numbers are kept in the aforementioned locked cabinet.  
All biological samples from subjects (blood/plasma/urine/biopsy tissue) are labeled without 
subject identifiers--therefore no laboratory personnel see subject identifiers at any time.  
Laboratory data generated from the above-referenced samples is analyzed without subject 
identifiers. 
 
5.16 If the subject withdraws from the study, describe what, if anything, will happen 
to the subject’s research data or biological specimens. 
 
If a subject decides to withdraw from study participation, research data will be rendered 
anonymous. 
 
5.17 Following the required data retention period, describe the procedures utilized 
to protect subject confidentiality. (e.g., destruction of research records; removal of 
identifiers; destruction of linkage code information; secured long-term retention) 
 
At the end of the data retention period, all research records will be destroyed, including 
linkage code information. 
 
6. Costs and Payments 
6.1 Will research subjects or their insurance providers be charged for any of the 
procedures (e.g., screening procedures, research procedures, follow-up procedures) 
performed for the purpose of this research study? 
 
No 
 
6.2 Will subjects be compensated in any way for their participation in this research 
study? 
 
yes 
 
6.2.1 Describe the amount of payment or other remuneration offered for complete 
participation in this research study. 
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For transplant subjects: $200 for completion of all 3 study sessions. For control subjects: 
$125 upon completion of both study sessions. 
 
6.2.2 Describe the amount and term of payment or other remuneration that will be 
provided for partial completion of this research study. 
 
$100 for completion of each study session during which drug is administered (i.e. study 
sessions 2 and 3)--applicable to transplant patients only. 
 
7. Qualifications and Sources of Support 
7.1 Summarize the qualifications and expertise of the principal investigator and 
listed co-investigators to perform the procedures outlined in this research study. 
 
Kareem Abu-Elmagd, MD, PhD, FACS, is a transplant surgeon at the University of 
Pittsburgh Medical Center, professor of surgery at the University of Pittsburgh, and director of 
the Intestinal Rehabilitation and Transplant Center at UPMC. 
Geoffrey Bond, MD, FRACS, is a transplant surgeon and assistant professor of surgery at 
the University of Pittsburgh. He has extensive clinical and research experience with small bowel 
and multivisceral transplant patients. 
Jennifer Bonner, PharmD, is a clinical pharmacist working with the small bowel 
transplant team at UPMC and a graduate student in the Clinical Pharmaceutical Scientist PhD 
program at the University of Pittsburgh. 
Guillherme Costa, MD, FACS, is a transplant surgeon and assistant professor of surgery 
at the University of Pittsburgh. He has extensive clinical and research experience with small 
bowel and multivisceral transplant patients. 
Darlene Koritsky, RN, is a researcher at the Intestinal Rehabilitation and Transplant 
Center. She has several years’ experience designing clinical research protocols in small bowel 
and multivisceral transplant patients. 
Hossam Kandil, MD, PhD is a gastroenterologist and associate professor of medicine at 
the University of Pittsburgh. He has over 20 years' clinical and research experience working with 
transplant patients. 
Stephen J. O’Keefe, MD, MSc, FRCP is the medical director of the Small Bowel 
Transplantation and Rehabilitation unit at UMPC and professor of medicine at the University of 
Pittsburgh. Dr. O’Keefe has extensive clinical and research experience with small bowel and 
multivisceral transplant patients. 
Raman Venkataramanan, PhD, is a professor in the department of pharmaceutical 
sciences at the University of Pittsburgh School of Pharmacy. He has over 23 years of experience 
working with transplant patients, and has been the principal investigator on several 
pharmacokinetic studies in this patient population. 
Sripal Mada Reddy, Ph.D. is a research assistant professor in the School of Pharmacy. He 
has several years of experience conducting pharmacokinetic studies in human subjects. 
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7.2 Indicate all sources of support for this research study. 
 
Internal funding--this project will be supported by the Clinical Pharmacokinetics 
Laboratory, University of Pittsburgh (Director: Raman Venkataramanan); CTRC 
 
7.3 Does any investigator involved in this study: 
a) possess an equity interest in the publicly-traded entity that either sponsors this 
research or owns the technology being evaluated that exceeds 5% ownership interest or a 
current value of $10,000? 
b) possess any equity interest in the non-publicly-traded entity that either sponsors 
this research or owns the technology being evaluated? 
c) receive salary, consulting fees, honoraria, royalties or other payments from the 
entity that either sponsors this research or owns the technology being evaluated that is 
expected to exceed $10,000 in any twelve-month period? 
d) have rights to the intellectual property (IP) being evaluated, as either the inventor 
of the IP for which a patent has been issued, or as the inventor of the IP that has been 
optioned or licensed to a company? 
e) have a financial relationship with a Licensed Start-up Company (which is being 
monitored by the COI Committee) that has an option or license to utilize the technology 
being evaluated? 
f) receive compensation of any amount when the value of the compensation would 
be affected by the outcome of the research, such as compensation that is explicitly greater 
for a favorable outcome than for an unfavorable outcome or compensation in the form of 
an equity interest in the entity that either sponsors this research or owns the technology 
being evaluated? 
'Investigator' means any member of the study team who participates in the 
design, conduct, or reporting of this research, as well as his/her spouse, registered 
domestic partner, dependents, or other members of his/her household. 
The PI is responsible for ensuring that s/he and all other relevant members of the 
study team review these questions. 
If any of the above are true, select Yes below: 
 
no 
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C.2 CONSENT FORM FOR TRANSPLANT SUBJECTS 
University of Pittsburgh      3459 Fifth Avenue  
School of Medicine       Pittsburgh, PA 15213  
Thomas E. Starzl Transplantation Institute    412-647-1458  
 
CONSENT TO ACT AS PARTICIPANT IN A RESEARCH STUDY 
(TRANSPLANT PATIENT) 
 
TITLE: Short- and long-term evaluation of intestinal CYP3A4/5 and p-glycoprotein 
function in small bowel transplant recipients 
 
PRINCIPAL INVESTIGATOR:  
Jennifer Bonner, PharmD, Clinical Pharmacist  
731 Salk Hall, University of Pittsburgh School of Pharmacy  
3501 Terrace Street, Pittsburgh, PA 15261  
Phone: 412/692-2136  
Co-investigators:  
Raman Venkataramanan, Ph.D, F.C.P., Professor of Pharmaceutical Sciences and Pathology 718 
Salk Hall, University of Pittsburgh School of Pharmacy  
3501 Terrace Street, Pittsburgh, PA 15261  
Phone: 412-648-8547, Fax: 412-383-7436  
Kareem Abu-Elmagd, MD, PhD, Professor of Surgery  
Director, Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax: 412/647-0362  
 
Geoffrey Bond, MD, FRACS, Assistant Professor of Surgery  
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Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax 412/647-0362  
Guilherme Costa, MD, Assistant Professor of Surgery  
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax: 412/647-0362  
Darlene Koritsky, RN, Researcher  
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-4386, Fax: 412/647-0362 
  
Hossam Kandil, MD, PhD Assistant Professor of Medicine  
University of Pittsburgh School of Medicine 
3471 Fifth Ave, Suite 916, Pittsburgh, PA 15213 
  
Stephen J. O’Keefe, MD, MSc, FRCP, Professor of Medicine  
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax: 412/647-0362  
SOURCE OF SUPPORT: Internal (Clinical Pharmacokinetics Laboratory, University of 
Pittsburgh)  
 
Why is this research being done?  
The small intestine (also called the small bowel) is subjected to low temperature during 
transportation from the person who donates the small intestine (the donor) to the person who gets 
it (the recipient). When the small intestine is put inside the recipient it is warmed up to normal 
body temperature and the recipient’s blood begins to flow into it. These changes, combined with 
the effects of surgery and healing, cause the release of substances in the body that may 
temporarily change the way the small intestine works soon after the surgery. However, with time 
the body recovers from the surgery and the new intestine usually begins to function normally. 
The main objective of this study is to look at the time course of this recovery process by 
comparing how three drugs are absorbed immediately after the transplant surgery and at a later 
time point after the transplant surgery. Another objective of this study is to examine the effects 
of certain genetic differences on oral drug absorption after small bowel transplantation. This 
information will then be used in the future to help health professionals such as your doctor 
determine the best dosing of drugs in small bowel transplant patients.  
 
Who is being asked to take part in this research study?  
You are being invited to take part in this research study because you are a small bowel transplant 
candidate and will receive a small bowel or small bowel and pancreas transplantation. Female 
and male small bowel, small bowel-pancreas, and modified multivisceral transplant patients, 
between the ages of 18 and 65 years of age are being asked to participate in this clinical study. 
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This study will take place at the University of Pittsburgh Medical Center, Pittsburgh, PA, and 
will include approximately 25 transplant subjects and 25 control subjects.  
 
How will the study be done?  
If you decide to participate in this study, you will undergo a total of three study sessions. The 
first is a screening visit that will occur at the University of Pittsburgh Medical Center (UPMC) 
during your transplant hospitalization (after your transplant) and will last approximately 2 hours. 
The second study session will take place within 21 days after your transplant surgery and will 
occur while you are still in the hospital. The third study session will require a separate visit to 
UPMC, unless you happen to be an inpatient at the hospital at that time for some other reason. 
The second and third study sessions will last approximately 24 hours each (including the 
overnight stay after the blood draws have been completed). At the second and third study 
sessions you will be administered a single dose of midazolam (an FDA-approved sedative) both 
orally and through a vein (blood vessel). You will also receive a single oral dose of fexofenadine 
(also FDA-approved and marketed under the brand name Allegra® for the treatment of allergy).  
 
First study session - Screening  
If you have signed the informed consent form before your transplant, you will be eligible to 
participate in the first study session. This session will occur after your transplant and will include 
vital signs measurement and clinical laboratory tests that are part of routine clinical care, 
including blood tests to evaluate liver and kidney function. In addition, blood levels of several 
inflammatory and anti-inflammatory substances that are secreted by the body normally and are 
secreted in higher amounts after transplant surgery will be measured. This first session will last 
approximately 2 hours and will take place in the transplant intensive care unit (TICU) of UPMC 
Montefiore hospital.  
After surgery, medical information will be collected that is part of the routine care of small 
bowel transplant surgery which includes daily blood tests to evaluate your liver and kidney 
function, length of the small bowel transplant surgery, any signs or symptoms of injury to your 
transplanted organ, time admitted to the intensive care unit, time spent needing the ventilator 
(breathing machine) and information about the donor small intestine such as age, gender and 
weight. In addition, results of any liver biopsies done before your transplant will be recorded for 
study purposes. Blood levels of the substances associated with inflammation will be measured 
every other day from the first day after surgery until the day of the second study session within 
21 days after your transplant. This will be done using blood left over from other routine lab 
work. No separate blood samples will be taken for this purpose.  
 
Additional procedures  
Small intestinal tissue samples taken during two routine biopsies of your transplanted organ (one 
in the first three weeks after your transplant and one approximately 4 to 9 months after your 
transplant) will be analyzed for levels of the same inflammatory substances. One of these tissue 
samples will also be tested for the presence and type of two specific genes. These two genes 
produce proteins that help the body metabolize (i.e. break down) and transfer drugs in the 
intestine. Finally, these same tissue samples will be analyzed for amounts of these two proteins. 
During each of the two routine biopsy sessions mentioned above, two separate tissue samples 
will be taken for research purposes, in addition to the three that are normally taken as part of 
routine clinical care. A blood sample (approximately 3 mL or 3/5 of a tablespoon) will also be 
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tested for the presence and type of the same genes.  
 
Second and third study sessions  
The second study session will occur in the transplant intensive care unit (TICU) or on Unit 12N 
or 11N of UPMC Montefiore hospital while you are still hospitalized, most likely within 21 days 
after your transplant. The third study session will probably require a separate visit to the CTRC 
approximately four to nine months after your transplant surgery. Before each of these sessions, 
you will be asked not to eat grapefruit or drink grapefruit juice, apple juice, cranberry juice, 
orange juice, or caffeine-containing drinks/foods for 3 days before this study session, because 
these foods may affect intestinal uptake of certain drugs. You will be asked not to drink water or 
consume any food after midnight on the day of the session except small amounts needed to take 
your routine medications. At each study session, you will receive a single dose of 5 milligrams 
(mg) of midazolam by mouth (or through a jejunostomy tube, if you have one at the time) with a 
small amount of water. Sixty minutes later you will receive a dose of 60 mg of fexofenadine by 
mouth with a small amount of water. Seven hours after the oral dose of midazolam you will be 
given a single dose of 2 mg of midazolam through a vein (intravenous). If you are eating a 
regular diet at the time of the study session, you will be given breakfast two hours after the oral 
dose of midazolam and lunch one hour after the intravenous dose of midazolam. Dinner will be 
provided in the early evening of each study session day. If you are receiving enteral feedings 
(feedings through a tube into your intestine) or some other dietary arrangements, they will 
proceed as directed by your physician.  
 
Blood samples will be taken through a small tube that has been placed in your blood vessel (or 
from your central line, if you have one) a total of 16 times over a 20-hour period, starting 
immediately before the first dose of drug. In addition, a blood sample will be taken at the 
beginning of the session to measure levels of the inflammatory substances described above. The 
total amount of blood removed at each study session will be approximately 51 mL 
(approximately 3 tablespoonfuls plus one teaspoonful). For the entire study (both study sessions 
four to six months apart), approximately 102 mL or 7 tablespoonfuls of blood will be removed. 
These same blood samples will also be analyzed for level of tacrolimus (Prograf , an 
immunosuppressive medication you will be receiving after your transplant as part of your routine 
medical care.) Your dose of tacrolimus will not be changed for the purposes of this study, and no 
extra blood samples will be drawn to measure levels of it. In addition, your urine will be 
collected over a 12-hour period during the first study session and 20 hours at the second study 
session, for measurement of study drugs and their metabolites in your urine. You will undergo 
continuous blood pressure monitoring and pulse oximetry (a non-invasive test to measure the 
level of oxygen in your blood to make sure you are breathing adequately) for the first two hours 
after each drug administration. Experienced nursing staff will monitor your progress continually, 
and your level of sedation will be assessed periodically during the session. If you vomit within 4 
hours of taking either of the oral drugs you will be removed from the study, since full absorption 
of the dose may not have taken place. You will be asked to remain overnight in the hospital unit 
or CTRC (wherever the session has taken place) after the second and third study sessions to 
ensure that both study drugs are completely gone from your body before you leave.  
 
If you decide to participate in the study, your medical records will be reviewed for demographic 
information (age, gender, and race), lab results (such as liver and kidney function, done as part of 
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your routine pre- and post-transplant care), and medication information, during the transplant 
follow-up period.  
 
What are the possible risks, side effects, and discomforts of this research study?  
There may be certain risks associated with participation in this study. These may include side 
effects of midazolam and/or fexofenadine (which are described below), the risks associated with 
giving you midazolam, and risk associated with blood sampling for measuring drug levels. These 
include pain, bruising, bleeding, fainting, and risk of infection.  
In addition, there are risks associated with genotyping. While the investigators will have 
procedures in place to ensure that all subject information is kept strictly confidential, there is the 
possibility that if genotype results became generally known, this information could have an 
impact on a subject’s future insurability, employability, reproductive plans, or could have a 
negative impact on family relationships, or could result in paternity suits or stigmatization.  
The doses of midazolam that you will receive (5 mg orally and 2 mg intravenously) are relatively 
low but may be sedating (may cause drowsiness) in some people. These doses of midazolam 
have been used safely for research purposes with minimal side effects in transplant patients. 
However, these are the most common side effects of midazolam seen at a wide range of doses:  
 
The following adverse reactions to midazolam have been reported after intramuscular (IM) or 
intravenous (IV) injection:  
Decreased tidal volume and/or respiratory rate decrease (decrease in breathing rate and volume 
of breath) (23.3% of patients after IV and 10.8% of patients after IM injection), apnea (stopping 
breathing while asleep) (15.4% of patients after IV administration), as well as variations in blood 
pressure and pulse rate (frequency not listed).  
In addition, the following adverse reactions were seen after IV injection of midazolam: 
hiccoughs (hiccups) (3.9%), vomiting (2.6%), coughing (1.3%), “oversedation” (1.6%), 
headache (1.5%), drowsiness (1.2%). Local effects at the injection site include: tenderness 
(5.6%), pain during injection (5.0%), redness (2.6%), induration (indentation of the skin) (1.7%), 
phlebitis (inflammation of blood vessel through which drug was administered) (0.4%).  
 
Other very rare adverse effects occurring after midazolam administration in less than 1.0% in 
adults and children include:  
Respiratory: laryngospasm (tightening or spasm of the throat or airway), bronchospasm (spasm 
or tightening of the lungs), dyspnea (shortness of breath), hyperventilation, wheezing, shallow 
respirations, airway obstruction, tachypnea (rapid breathing).  
Cardiovascular: bigeminy (pulse and heart rate abnormality), premature ventricular contractions 
(type of heart arrhythmia), vasovagal episode (fainting due to drop in blood pressure and heart 
rate), bradycardia (slow heart rate), tachycardia (rapid heart rate), nodal rhythm (type of heart 
arrhythmia).  
Gastrointestinal: acid taste, excessive salivation, retching,  
CNS/neuromuscular: retrograde amnesia (temporary loss of memory), euphoria (elevated mood), 
hallucination, confusion, argumentativeness, nervousness, anxiety, grogginess, restlessness, 
emergence delirium or agitation, prolonged emergence from anesthesia, dreaming during 
emergence, sleep disturbance, insomnia, nightmares, athetoid movements (involuntary writhing 
movements), seizure-like activity, ataxia (unsteady gait), dizziness, dysphoria (unpleasant 
feelings), slurred speech, dysphonia (difficulty speaking), paresthesia (“pins and needles” 
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tingling sensation).  
Special Senses: blurred vision, diplopia (double vision), nystagmus (involuntary rapid movement 
of eyeballs), pinpoint pupils, cyclic movements of eyelids, visual disturbance, difficulty focusing 
eyes, ears blocked, loss of balance, light-headedness,  
Integumentary: hive-like elevation at injection site, swelling or feeling of burning, warmth, or 
coldness at injection site,  
Hypersensitivity: allergic reactions including anaphylactoid reactions, hives, rash, pruritis 
(itching).  
Miscellaneous: yawning, lethargy (low energy), chills, weakness, toothache, faint feeling, 
hematoma (blood clot within a tissue).  
 
Fexofenadine (Allegra®) is usually well tolerated and has a low incidence of side effects.  
However, possible side effects of fexofenadine (vs. placebo) from clinical trials in patients with 
seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (an allergic skin condition) 
include:  
Common (Occurs in 10-25% of people): headache 10.6% (vs. 7.5%) and 7.2% (vs. 6.6%)  
Infrequent (Occurs in 1-10% of people): Viral infection (cold, flu): 2.5% (vs. 1.5%), Nausea: 
1.6% (vs. 1.5%), Dysmenorrhea (difficult menstrual periods): 1.5% (vs. 0.3%), Drowsiness: 
1.3% (vs. 0.9%) and 2.2% (vs. 0.0%), Dyspepsia (upset stomach): 1.3% (vs. 0.6%), Fatigue: 
1.3% (vs. 0.9%), Upper Respiratory Tract Infection: 3.2% (vs. 3.1%) and 4.3% (vs. 1.7%), Back 
Pain: 2.8% (vs. 1.4%) and 2.2% (vs. 1.1%), Accidental Injury: 2.9% (vs. 1.3%), Coughing: 3.8% 
(vs. 1.3%), Fever: 2.4% (vs. 0.9%), Pain: 2.4% (vs. 0.4%), Otitis Media (ear infection): 2.4% (vs. 
0.0%), Sinusitis (sinus infection): 2.2% (vs. 1.1%), Dizziness: 2.2% (vs. 0.0%)  
Rare (Occurs in less than 1% of people): none  
 
In addition, complications of small intestinal biopsy are rare, but may include intestinal bleeding, 
infection, and perforation (puncture) of the intestine.  
 
Pregnancy  
 
Midazolam is classified as Pregnancy Category D by the FDA. An increase in birth defects has 
been seen in infants born to mothers who used benzodiazepine drugs (class of drugs that 
midazolam belongs to) during pregnancy. Fexofenadine is classified as Pregnancy Category C by 
the FDA. This means that although animal studies have not shown the drug to cause birth 
defects, no adequate or well-controlled studies have been done in pregnant women to examine 
their effects on the fetus. In addition, midazolam is known to be excreted in breast milk. 
Therefore, being a part of this study while pregnant or breastfeeding may expose the unborn 
child or nursing infant to risks known and unknown. Therefore, pregnant and nursing women 
will not be included in this study. If you are a woman of childbearing potential, a urine 
pregnancy test will be done at each study session before administration of study drugs. It must be 
negative before you can enter this study. While enrolled in the study you must agree to use 
appropriate methods of birth control as well as for one week after the last dose of study drug. 
Medically acceptable birth control methods include: (1) surgical sterilization, (2) approved 
hormonal contraceptives (such as birth control pills or patches), (3) double barrier methods (such 
as a condom and diaphragm) used with a spermicide, (4) an intrauterine device (IUD), or (5) 
abstinence.  
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You should not take part in this study if you plan to become pregnant within one month after 
completing this study, are currently pregnant, or you are currently breast feeding.  
 
You must notify your doctor if you suspect you have become pregnant while participating in this 
study.  
 
What are possible benefits from taking part in this study?  
There are no direct benefits to you from taking part in this study. However, the information 
learned from this study will be used in the future to help health professionals such as your doctor 
to determine the best dosing of drugs in small bowel transplant recipients after surgery.  
Therefore, your participation may help others in the future by what the doctors learn from your 
involvement in this study.  
 
What treatment or procedures are available if I decide not to take part in this research study?  
If you decide not to take part in this research study, you will undergo normal procedures 
associated with the small bowel transplantation surgery. No routine treatment will be withheld.  
 
If I agree to take part in this research study, will I be told of any new risks that may be found 
during the course of the study?  
You have been informed previously that the personal results of this research study will be 
provided to you upon your request. However, you will be promptly notified if any other 
information about this research study develops during the course of the study which may cause 
you to change your mind about continuing to participate. 
  
Will my insurance provider or I be charged for the costs of any procedures performed as part 
of this research study?  
If you choose to participate in the study, study drugs, nursing care, and meals during study 
sessions will be provided free of charge. Measurement of midazolam and fexofenadine blood 
levels, measurement of inflammatory substances, and genetic testing will also be performed free 
of cost to you. All costs and tests done to treat you before and after your small bowel transplant 
should be covered by your medical insurance. These are tests that would normally be performed 
in patients undergoing small bowel transplant surgery. No compensation will be provided by the 
makers of Versed® (midazolam) or the makers of Allegra® (fexofenadine). This includes no 
financial support for lost wages, disability, pain or discomfort.  
 
Will I be paid if I take part in this research study?  
You will not be paid for taking part in the initial (screening) study session prior to transplant 
surgery. However, you will be paid $100.00 for each of the second and third study visits, up to a 
maximum of $200.00. Your biological sample or genetic material may lead, in the future, to new 
inventions or products. If the research investigators are able to develop new products from the 
use of your biological sample or genetic material, there are currently no plans to share with you 
any money or other rewards that may result from the development of the new product.  
 
Who will pay if I am injured as a result of taking part in this study?  
If you believe that the research procedures have resulted in an injury to you, immediately contact 
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the Principal Investigator who is listed on the first page of this form. Emergency medical 
treatment for injuries solely and directly related to your participation in this research study will 
be provided to you by the hospitals of UPMC. Your insurance provider may be billed for the 
costs of this emergency treatment, but none of those costs will be charged directly to you. If your 
research-related injury requires medical care beyond this emergency treatment, you will be 
responsible for the costs of this follow-up care. At this time, there is no plan for any additional 
financial compensation. 
  
Who will know about my participation in this research study?  
Any information about you obtained from this research will be kept as confidential (private) as 
possible. All records related to your involvement in this research study will be stored in a locked 
file cabinet. Your identity on these records will be indicated by a case number rather than by 
your name, and the information linking these case numbers with your identity will be kept 
separate from the research records. Only the investigators listed on the first page of this consent 
form will have access to information linking your case number to your name, which will be 
stored in a locked cabinet in the Principal Investigator’s office. You will not be identified by 
name in any publication of the research results unless you sign a separate consent form giving 
your permission (release).  
 
Will this research study involve the use or disclosure of my identifiable medical information?  
This research study will involve the recording of current and/or future identifiable medical 
information from your hospital and/or other (e.g., physician office) records. The information that 
will be recorded will be limited to information concerning demographics (age, gender, and race) 
and concurrent conditions and medications you are receiving.  
Your personal research results from this study will not be put in your medical record and you 
will not be identified in any publication of this research study. In addition, your written 
authorization will be obtained prior to providing personal research results to relatives, personal 
physicians, insurance companies, or any other third party.  
 
Who will have access to identifiable information related to my participation in this research 
study?  
In addition to the investigators listed on the first page of this authorization (consent) form and 
their research staff, the following individuals will or may have access to identifiable information 
(which may include your identifiable medical information) related to your participation in this 
research study:  
 
Authorized representatives of the University of Pittsburgh Research Conduct and Compliance 
Office may review your identifiable research information (which may include your identifiable 
medical information) for the purpose of monitoring the appropriate conduct of this research 
study.  
 
Authorized representatives of UPMC hospitals or other affiliated health care providers may have 
access to identifiable information (which may include your identifiable medical information) 
related to your participation in this research study for the purpose of (1) fulfilling orders, made 
by the investigators, for hospital and health care services (e.g., laboratory tests, diagnostic 
procedures) associated with research study participation; (2) addressing correct payment for tests 
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and procedures ordered by the investigators; and/or (3) for internal hospital operations (i.e. 
quality assurance).  
 
In unusual cases, the investigators may be required to release identifiable information (which 
may include your identifiable medical information) related to your participation in this research 
study in response to an order from a court of law. If the investigators learn that you or someone 
with whom you are involved is in serious danger or potential harm, they will need to inform, as 
required by Pennsylvania law, the appropriate agencies.  
 
Authorized representatives of the U.S. Food and Drug Administration may review and/or obtain 
identifiable information (which may include your identifiable medical information) related to 
your participation in this research study for the purpose of monitoring the accuracy of the 
research data. While the U.S. Food and Drug Administration understands the importance of 
maintaining the confidentiality of your identifiable research and medical information, the 
University of Pittsburgh and UPMC cannot guarantee the confidentiality of this information after 
it has been obtained by the U.S. Food and Drug Administration.  
 
For how long will the investigators be permitted to use and disclose identifiable information 
related to my participation in this research study?  
If you agree to participate in the research project, use of your biological sample and genetic 
material will be under the control of the principal investigator of this research project. All the 
blood and tissue samples collected from you will be labeled using an identification number and 
without your name. They will be stored and in the laboratory of the researchers until all the data 
is obtained from these samples. The investigators may continue to use and disclose, for the 
purposes described above, identifiable information (which may include your identifiable medical 
information) related to your participation in this research study for a minimum of 5 years and for 
as long (indefinite) as it may take to complete this research study. The blood and tissue samples 
collected in this study will be kept for an indefinite time period until a complete report of the 
study has been published. The sample with out the identification may be utilized in future studies 
by the investigators. These samples will not be shared with any secondary investigators not listed 
on the current research study.  
 
May I have access to my medical information that results from my participation in this 
research study?  
In accordance with UPMC Notices of Privacy Practices document that you have been given, you 
are permitted access to information (including information resulting from your participation in 
this research study) contained within your medical records filed with your health care provider. 
You will be given the results of your genetic testing related to this study if you request it from 
the investigators. If you request this information from the investigators, you will be given it at 
the end of the research study in a private meeting with one or more of the investigators and the 
information will be kept confidential. If you wish, the investigators will refer you to medical or 
genetic counseling at this time. 
  
Is my participation in this research study voluntary?  
Your participation in this research study is completely voluntary. You do not have to take part in 
this research study and, should you change your mind, you can withdraw from the study at any 
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time. Your current and future care at a UPMC facility and any other benefits for which you 
qualify will be the same whether you participate in this study or not.  
 
Your doctor may be an investigator in this research study, and as an investigator, is interested 
both in your medical care and in the conduct of this research. Before entering this study or at any 
time during the research, you may discuss your care with another doctor who is in no way 
associated with this research project. You are not under any obligation to participate in any 
research study offered by your doctor.  
 
May I withdraw, at a future date, my consent for participation in this research study?  
You may withdraw, at any time, your consent for participation in this research study, to include 
the use and disclosure of your identifiable information for the purposes described above. (Note, 
however, that if you withdraw your consent for the use and disclosure of your identifiable 
medical record information for the purposes described above, you will also be withdrawn, in 
general, from further participation in this research study.) Any identifiable research or medical 
information recorded for, or resulting from, your participation in this research study prior to the 
date that you formally withdrew your consent may continue to be used and disclosed by the 
investigators for the purposes described above. Samples collected before your withdrawal from 
the study will be destroyed, if you so request.  
To formally withdraw your consent for participation in this research study you should provide a 
written and dated notice of this decision to the principal investigator of this research study at the 
address listed on the first page of this form.  
 
If you decide to withdraw your consent for participation in this research study it will have no 
effect on your current or future relationship with the University of Pittsburgh. If you decide to 
withdraw your consent for participation in this research study it will have no affect on your 
current or future medical care at a UPMC hospital or affiliated health care provider or your 
current or future relationship with a health care insurance provider.  
 
If I agree to take part in this research study, can I be removed from the study without my 
consent?  
It is possible that you may be removed from the research study by the researchers if you do not 
follow all the instructions. You may be removed from the study if you experience unexpected 
side effects and in the opinion of the investigators that it is in your best interest. The study may 
also be stopped by the investigators or the sponsor if it felt that it is in the best interest of the 
subjects. 
  
************************************************************************  
VOLUNTARY CONSENT  
All of the above has been explained to me and all of my current questions have been answered. I 
understand that I am encouraged to ask questions about any aspect of this research study during 
the course of this study, and that such future questions will be answered by the researchers listed 
on the first page of this form.  
 
Any questions which I have about my rights as a research participant will be answered by the 
Human Subject Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-
  281 
2668). 
  
I give my permission to use my biological sample or genetic material, with personal identifiers, 
in other research projects involving the study of small bowel transplantation.  
 
Yes ________ No ________  
 
I give my permission to be recontacted to obtain my consent if there is a desire to use my 
biological sample or genetic material, with personal identifiers, in other research projects 
involving the study of different diseases or conditions (i.e. diseases or conditions other than those 
specified in the Description section of this consent form).  
 
Yes ________ No ________  
 
By signing this form, I agree to participate in this research study. A copy of this consent form 
will be given to me. 
  
________________________________ __________________  
Participant’s Signature    Date  
 
CERTIFICATION of INFORMED CONSENT  
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation. 
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise.”  
 
___________________________________ ________________________  
Printed Name of Person Obtaining Consent Role in Research Study 
  
_________________________________ ____________  
Signature of Person Obtaining Consent  Date  
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C.3 CONSENT FORM FOR CONTROL SUBJECTS 
University of Pittsburgh      3459 Fifth Avenue  
School of Medicine       Pittsburgh, PA 15213  
Thomas E. Starzl Transplantation Institute    412-647-1458  
 
CONSENT TO ACT AS PARTICIPANT IN A RESEARCH STUDY (CONTROL 
SUBJECT) 
 
TITLE: Short- and long-term evaluation of intestinal CYP3A4/5 and p-glycoprotein 
function in small bowel transplant recipients 
 
PRINCIPAL INVESTIGATOR:  
Jennifer Bonner, PharmD, Clinical Pharmacist  
731 Salk Hall, University of Pittsburgh School of Pharmacy  
3501 Terrace Street, Pittsburgh, PA 15261  
Phone: 412/692-2136 
  
Co-Investigators:  
Raman Venkataramanan, Ph.D, F.C.P., Professor of Pharmaceutical Sciences and Pathology 718 
Salk Hall, University of Pittsburgh School of Pharmacy  
3501 Terrace Street, Pittsburgh, PA 15261  
Phone: 412-648-8547, Fax: 412-383-7436  
 
Kareem Abu-Elmagd, MD, PhD, Professor of Surgery  
Director, Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax: 412/647-0362 
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Geoffrey Bond, MD, FRACS, Assistant Professor of Surgery  
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax 412/647-0362 
  
Guilherme Costa, MD, Assistant Professor of Surgery  
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax 412/647-0362 
  
Darlene Koritsky, RN, Researcher 
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-4386, Fax: 412/647-0362  
 
Hossam Kandil, MD, PhD Assistant Professor of Medicine  
University of Pittsburgh School of Medicine 3471 Fifth Ave, Suite 916, Pittsburgh, PA 15213  
Phone: 412/647-4932, Fax: 412/647-9268  
 
Stephen J. O’Keefe, MD, MSc, FRCP, Professor of Medicine  
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax: 412/647-0362   
 
SOURCE OF SUPPORT: Internal (Clinical Pharmacokinetics Laboratory, University of 
Pittsburgh)  
 
Why is this research being done?  
The small intestine (also called the small bowel) is subjected to low temperature during 
transportation from the person who donates the small intestine (the donor) to the person who gets 
it (the recipient). When the small intestine is put inside the transplant recipient it is warmed up to 
normal body temperature and the recipient’s blood begins to flow into it. These changes, 
combined with the effects of surgery and healing, cause the release of substances in the body that 
may temporarily change the way the small intestine absorbs oral medications. However, with 
time the body recovers from the surgery and the new intestine usually begins to function 
normally. The main objective of this study is to look at the time course of this recovery process 
by comparing how two drugs are absorbed immediately after the transplant surgery and at a later 
time after the transplant surgery. Another objective of this study is to examine the effects of 
certain genetic differences on oral drug absorption after small bowel transplantation. This 
information will then be used in the future to help health professionals such as your doctor 
determine the best dosing of drugs in small bowel transplant patients. 
  
Who is being asked to take part in this research study?  
You are being invited to take part in this research study to act as a control subject. In addition to 
small bowel transplant subjects, healthy men and women between the ages of 18 and 65 years of 
age are being asked to participate in this clinical study so that we can compare small bowel 
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transplant patients and healthy people of the same age, gender, and race. This study will take 
place at the University of Pittsburgh Medical Center, Pittsburgh, PA, and will include 
approximately 25 transplant subjects and 25 control subjects.  
 
How will the study be done? 
If you decide to participate in this study, you will undergo a total of two study sessions, each of 
which will require a separate visit to the University of Pittsburgh Medical Center (UPMC). The 
first study session is a screening visit that will take approximately 2 hours. The second study 
session involves drug administration and will last approximately 24 hours. At the second session 
you will be administered a single dose of midazolam (an FDA-approved sedative) once by mouth 
and once through a vein (blood vessel). You will also receive fexofenadine (also FDA-approved 
and marketed under the brand name Allegra® for treatment of allergy) one time by mouth.  
 
First study session - Screening  
If you have signed the informed consent form you will be eligible to participate in the first study 
session, a screening session. At this session, the investigators will decide if you are eligible to 
participate in the additional study session. This screening session will include a medical history, 
vital signs measurement, and clinical laboratory tests, including blood tests to evaluate liver and 
kidney function. An electrocardiogram (ECG) will be performed to check for problems with your 
heart rhythm. This first session will last approximately 2 hours and will take place in the Clinical 
and Translational Research Center (CTRC) at the University of Pittsburgh Medical Center 
(UPMC).  
 
Second study session  
The second study session will occur within approximately one month after the first (screening) 
study session. All study sessions will take place at the CTRC of UPMC. Before the second study 
session, you will be asked not to eat grapefruit or drink grapefruit juice, apple juice, cranberry 
juice, orange juice, or caffeine-containing drinks/foods for 3 days before the study session, 
because these foods may affect how certain drugs are taken up by the body. You will be asked 
not to drink liquids or eat any food after midnight on the day of the study, except small amounts 
of water as required to take medications. At the study session, you will receive a single dose of 5 
milligrams (mg) of midazolam by mouth with a small amount of water. Sixty minutes later you 
will receive a dose of 60 mg of fexofenadine by mouth with a small amount of water. Seven 
hours after the oral dose of midazolam you will be given a single dose of 2 mg midazolam 
intravenously (into a blood vessel). You will be given breakfast two hours after the oral dose of 
midazolam, lunch one hour after the intravenous dose of midazolam, and dinner in the early 
evening of the study session day. Blood samples will be taken through a small tube inserted into 
a blood vessel in your forearm over a 20-hour period, starting immediately before the first dose 
of drug, for a total of 16 times. In addition, a 3 mL sample of blood will be taken to measure 
amounts of substances that are secreted by the body normally and are secreted in higher amounts 
after transplant surgery, before any drug is given. That blood sample will also be tested for the 
presence and type of two specific genetic markers. These two genes produce proteins that help 
the body metabolize (i.e. break down) and transport drugs that are taken by mouth. The total 
amount of blood removed at the second study session will be approximately 51 mL 
(approximately 3 tablespoonfuls plus one teaspoonful). If it has been greater than 30 days since 
your screening session, you will also have an additional 3 mL of blood drawn at this session for 
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labs to assess liver and kidney function. In addition, your urine will be collected over a 20-hour 
period during the study session, for measurement of study drugs and their metabolites in your 
urine. You will undergo blood pressure monitoring and pulse oximetry (a non-invasive test to 
measure the level of oxygen in your blood to make sure you are breathing adequately) 
continuously for the first two hours after each drug administration.  
Experienced nursing staff will monitor your progress continually and your level of sedation will 
be assessed periodically during the session. If you vomit within 4 hours of taking either of the 
oral drugs you will be removed from the study, since full absorption of the dose may not have 
taken place. You will be asked to remain overnight in the CTRC in order to complete the blood 
and urine sampling and to make sure that both study drugs are gone from your body before you 
leave.  
 
What are the possible risks, side effects, and discomforts of this research study?  
There may be certain risks associated with participation in this study. These may include side 
effects of midazolam and/or fexofenadine (which are described below), the risks associated with 
giving you the intravenous midazolam, and risk associated with blood sampling for measuring 
drug levels. These include pain, bruising, bleeding, fainting, and risk of infection.  
 
In addition, there are risks associated with genotyping. While the investigators will have 
procedures in place to ensure that all subject information is kept strictly confidential, there is the 
possibility that if genotype results became generally known, this information could have an 
impact on your future insurability, employability, reproductive plans, or could have a negative 
impact on family relationships, or could result in paternity suits or stigmatization.  
 
The doses of midazolam that you will receive (5 mg orally and 2 mg intravenously) are relatively 
low but may be sedating (may cause drowsiness) in some people since midazolam is a sedative 
medication. These doses of midazolam have been used safely for research purposes with minimal 
side effects. However, these are the most common side effects of midazolam seen at a wide 
range of doses:  
 
The following adverse reactions to midazolam have been reported after intramuscular (IM) or 
intravenous (IV) injection:  
 
Decreased tidal volume and/or respiratory rate decrease (decrease in breathing rate and volume 
of breath) (23.3% of patients after IV and 10.8% of patients after IM injection), apnea (stopping 
breathing while asleep) (15.4% of patients after IV administration), as well as variations in blood 
pressure and pulse rate (frequency not listed).  
 
In addition, the following adverse reactions were seen after IV injection of midazolam: 
hiccoughs (hiccups) (3.9%), vomiting (2.6%), coughing (1.3%), “oversedation” (1.6%), 
headache (1.5%), drowsiness (1.2%). Local effects at the injection site include: tenderness 
(5.6%), pain during injection (5.0%), redness (2.6%), induration (indentation of the skin) (1.7%), 
phlebitis (inflammation of blood vessel through which drug was administered) (0.4%).  
 
Other very rare adverse effects occurring after midazolam administration in less than 1.0% in 
adults and children include:  
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Respiratory: laryngospasm (tightening or spasm of the throat or airway), bronchospasm (spasm 
or tightening of the lungs), dyspnea (shortness of breath), hyperventilation, wheezing, shallow 
respirations, airway obstruction, tachypnea (rapid breathing).  
Cardiovascular: bigeminy (pulse and heart rate abnormality), premature ventricular contractions 
(type of heart arrhythmia), vasovagal episode (fainting due to drop in blood pressure and heart 
rate), bradycardia (slow heart rate), tachycardia (rapid heart rate), nodal rhythm (type of heart 
arrhythmia).  
Gastrointestinal: acid taste, excessive salivation, retching,  
CNS/neuromuscular: retrograde amnesia (temporary loss of memory), euphoria (elevated mood), 
hallucination, confusion, argumentativeness, nervousness, anxiety, grogginess, restlessness, 
emergence delirium or agitation, prolonged emergence from anesthesia, dreaming during 
emergence, sleep disturbance, insomnia, nightmares, athetoid movements (involuntary writhing 
movements), seizure-like activity, ataxia (unsteady gait), dizziness, dysphoria (unpleasant 
feelings), slurred speech, dysphonia (difficulty speaking), paresthesia (“pins and needles” 
tingling sensation).  
Special Senses: blurred vision, diplopia (double vision), nystagmus (involuntary rapid movement 
of eyeballs), pinpoint pupils, cyclic movements of eyelids, visual disturbance, difficulty focusing 
eyes, ears blocked, loss of balance, light-headedness,  
Integumentary: hive-like elevation at injection site, swelling or feeling of burning, warmth, or 
coldness at injection site,  
Hypersensitivity: allergic reactions including anaphylactoid reactions, hives, rash, pruritus 
(itching).  
Miscellaneous: yawning, lethargy (low energy), chills, weakness, toothache, faint feeling, 
hematoma (blood clot within a tissue).  
 
Fexofenadine (Allegra®) is usually well tolerated and has a low incidence of side effects.  
However, possible side effects of fexofenadine (vs. placebo) from clinical trials for seasonal 
allergic rhinitis (hay fever) and chronic idiopathic urticaria (an allergic skin condition) include:  
Common (Occurs in 10-25% of people): headache 10.6% (vs. 7.5%) and 7.2% (vs. 6.6%)  
Infrequent (Occurs in 1-10% of people): Viral infection (cold, flu): 2.5% (vs. 1.5%), Nausea: 
1.6% (vs. 1.5%), Dysmenorrhea (difficult menstrual periods): 1.5% (vs. 0.3%), Drowsiness: 
1.3% (vs. 0.9%) and 2.2% (vs. 0.0%), Dyspepsia (upset stomach): 1.3% (vs. 0.6%), Fatigue: 
1.3% (vs. 0.9%), Upper Respiratory Tract Infection: 3.2% (vs. 3.1%) and 4.3% (vs. 1.7%), Back 
Pain: 2.8% (vs. 1.4%) and 2.2% (vs. 1.1%), Accidental Injury: 2.9% (vs. 1.3%), Coughing: 3.8% 
(vs. 1.3%), Fever: 2.4% (vs. 0.9%), Pain: 2.4% (vs. 0.4%), Otitis Media (ear infection): 2.4% (vs. 
0.0%), Sinusitis (sinus infection): 2.2% (vs. 1.1%), Dizziness: 2.2% (vs. 0.0%)  
Rare (Occurs in less than 1% of people): none  
 
Pregnancy  
Midazolam is classified as Pregnancy Category D by the FDA. An increase in birth defects has 
been seen in infants born to mothers who used benzodiazepine drugs (class of drugs that 
midazolam belongs to) during pregnancy. Fexofenadine is classified as Pregnancy Category C by 
the FDA. This means that although animal studies have not shown the drug to cause birth 
defects, no adequate or well-controlled studies have been done in pregnant women to examine 
their effects on the fetus. In addition, midazolam is known to be excreted in breast milk. 
Therefore, being a part of this study while pregnant or breastfeeding may expose the unborn 
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child or nursing infant to risks known and unknown. Therefore, pregnant and nursing women 
will not be included in this study. If you are a woman of childbearing potential, a urine 
pregnancy test will be done during the screening visit and at each study session before 
administration of study drugs. It must be negative before you can enter this study. While enrolled 
in the study you must agree to use appropriate methods of birth control for the duration of the 
study as well as for one week after the last dose of study drug. Medically acceptable birth control 
methods include: (1) surgical sterilization, (2) approved hormonal contraceptives (such as birth 
control pills or patches), (3) double-barrier methods (such as a condom and diaphragm together) 
used with a spermicide, (4) an intrauterine device (IUD), or (5) abstinence.  
 
You should not take part in this study if you plan to become pregnant within one month after 
completing this study, are currently pregnant, or you are currently breast feeding. You must 
notify your doctor if you suspect you have become pregnant while participating in this study.  
 
What are possible benefits from taking part in this study?  
There are no direct benefits to you from taking part in this study. However, the information 
learned from this study will be used in the future to help health professionals such as your doctor 
to determine the best dosing of drugs in small bowel transplant recipients after surgery.  
Therefore, your participation may help others in the future by what the doctors learn from your 
involvement in this study.  
 
If I agree to take part in this research study, will I be told of any new risks that may be found 
during the course of the study?  
You have been informed previously that the personal results of this research study will be 
provided to you upon your request. However, you will be promptly notified if any other 
information about this research study develops during the course of the study which may cause 
you to change your mind about continuing to participate.  
 
Will my insurance provider or I be charged for the costs of any procedures performed as part 
of this research study?  
If you choose to participate in the study, study drugs, nursing care, and meals during the second 
study session will be provided free of charge. Measurement of midazolam and fexofenadine 
blood levels, clinical laboratory testing, and genetic testing will also be performed free of cost to 
you (your insurance will not be billed either). No compensation will be provided by makers of 
Versed® (midazolam) or makers of Allegra® (fexofenadine). This includes no financial support 
for lost wages, disability, pain or discomfort. 
  
Will I be paid if I take part in this research study?  
You will not be paid for taking part in the initial (screening) study session. However, you will be 
paid $125.00 upon completion of the second study session. Your biological sample or genetic 
material may lead, in the future, to new inventions or products. If the research investigators are 
able to develop new products from the use of your biological sample or genetic material, there 
are currently no plans to share with you any money or other rewards that may result from the 
development of the new product.  
 
Who will pay if I am injured as a result of taking part in this study?  
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If you believe that the research procedures have resulted in an injury to you, immediately contact 
the Principal Investigator who is listed on the first page of this form. Emergency medical 
treatment for injuries solely and directly related to your participation in this research study will 
be provided to you by the hospitals of UPMC. Your insurance provider may be billed for the 
costs of this emergency treatment, but none of those costs will be charged directly to you. If your 
research-related injury requires medical care beyond this emergency treatment, you will be 
responsible for the costs of this follow-up care. At this time, there is no plan for any additional 
financial compensation. 
  
Who will know about my participation in this research study?  
Any information about you obtained from this research will be kept as confidential (private) as 
possible. All records related to your involvement in this research study will be stored in a locked 
file cabinet. Your identity on these records will be indicated by a case number rather than by 
your name, and the information linking these case numbers with your identity will be kept 
separate from the research records. Only the investigators listed on the first page of this consent 
form will have access to the information linking your case number to your name, which will be 
stored in a locked cabinet in the Principal Investigator’s office. You will not be identified by 
name in any publication of the research results unless you sign a separate consent form giving 
your permission (release).  
 
Will this research study involve the use or disclosure of my identifiable medical information?  
This research study will involve the recording of current and/or future identifiable medical 
information from your hospital and/or other (e.g., physician office) records. The information that 
will be recorded will be limited to information concerning demographics (age, gender, and race) 
and concurrent conditions and medications you are receiving.  
Your personal research results from this study will not be put in your medical record and you 
will not be identified in any publication of this research study. In addition, your written 
authorization will be obtained prior to providing personal research results to relatives, personal 
physicians, insurance companies, or any other third party. 
  
Who will have access to identifiable information related to my participation in this research 
study?  
In addition to the investigators listed on the first page of this authorization (consent) form and 
their research staff, the following individuals will or may have access to identifiable information 
(which may include your identifiable medical information) related to your participation in this 
research study:  
 
Authorized representatives of the University of Pittsburgh Research Conduct and Compliance 
Office may review your identifiable research information (which may include your identifiable 
medical information) for the purpose of monitoring the appropriate conduct of this research 
study. 
  
Authorized representatives of UPMC hospitals or other affiliated health care providers may have 
access to identifiable information (which may include your identifiable medical information) 
related to your participation in this research study for the purpose of (1) fulfilling orders, made 
by the investigators, for hospital and health care services (e.g., laboratory tests, diagnostic 
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procedures) associated with research study participation; (2) addressing correct payment for tests 
and procedures ordered by the investigators; and/or (3) for internal hospital operations (i.e. 
quality assurance).  
 
In unusual cases, the investigators may be required to release identifiable information (which 
may include your identifiable medical information) related to your participation in this research 
study in response to an order from a court of law. If the investigators learn that you or someone 
with whom you are involved is in serious danger or potential harm, they will need to inform, as 
required by Pennsylvania law, the appropriate agencies. 
  
Authorized representatives of the U.S. Food and Drug Administration may review and/or obtain 
identifiable information (which may include your identifiable medical information) related to 
your participation in this research study for the purpose of monitoring the accuracy of the 
research data. While the U.S. Food and Drug Administration understands the importance of 
maintaining the confidentiality of your identifiable research and medical information, the 
University of Pittsburgh and UPMC cannot guarantee the confidentiality of this information after 
it has been obtained by the U.S. Food and Drug Administration. 
  
For how long will the investigators be permitted to use and disclose identifiable information 
related to my participation in this research study?  
If you agree to participate in the research project, use of your biological sample and genetic 
material will be under the control of the principal investigator of the research project. All the 
blood samples collected from you will be labeled using an identification number and with out 
your name. They will be stored and in the laboratory of the researchers until all the data is 
obtained from these samples. The investigators may continue to use and disclose, for the 
purposes described above, identifiable information (which may include your identifiable medical 
information) related to your participation in this research study for a minimum of 5 years and for 
as long (indefinite) as it may take to complete this research study.  
The blood samples collected in this study will be kept for an indefinite time period until a 
complete report of the study has been published. The sample with out the identification may be 
utilized in future studies by the investigators. These samples will not be shared with any 
secondary investigators not listed on the current research study.  
 
May I have access to my medical information that results from my participation in this 
research study?  
In accordance with UPMC Notices of Privacy Practices document that you have been given, you 
are permitted access to information (including information resulting from your participation in 
this research study) contained within your medical records filed with your health care provider. 
You will be given the results of your genetic testing related to this study if you request it from 
the investigators. If you request this information from the investigators, you will be given it at 
the end of the research study in a private meeting with one or more of the investigators, and the 
information will be kept confidential. If you wish, the investigators will refer you to medical or 
genetic counseling at this time.  
 
Is my participation in this research study voluntary?  
Your participation in this research study is completely voluntary. You do not have to take part in 
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this research study and, should you change your mind, you can withdraw from the study at any 
time. Your current and future care at a UPMC facility and any other benefits for which you 
qualify will be the same whether you participate in this study or not.  
Your doctor may be an investigator in this research study, and as an investigator, is interested 
both in your medical care and in the conduct of this research. Before entering this study or at any 
time during the research, you may discuss your care with another doctor who is in no way 
associated with this research project. You are not under any obligation to participate in any 
research study offered by your doctor. 
  
May I withdraw, at a future date, my consent for participation in this research study?  
You may withdraw, at any time, your consent for participation in this research study, to include 
the use and disclosure of your identifiable information for the purposes described above. (Note, 
however, that if you withdraw your consent for the use and disclosure of your identifiable 
medical record information for the purposes described above, you will also be withdrawn, in 
general, from further participation in this research study.) Any identifiable research or medical 
information recorded for, or resulting from, your participation in this research study prior to the 
date that you formally withdrew your consent may continue to be used and disclosed by the 
investigators for the purposes described above. Samples collected before your withdrawal from 
the study will be destroyed, if you so request.  
 
To formally withdraw your consent for participation in this research study you should provide a 
written and dated notice of this decision to the principal investigator of this research study at the 
address listed on the first page of this form.  
 
If you decide to withdraw your consent for participation in this research study it will have no 
effect on your current or future relationship with the University of Pittsburgh. If you decide to 
withdraw your consent for participation in this research study it will have no affect on your 
current or future medical care at a UPMC hospital or affiliated health care provider or your 
current or future relationship with a health care insurance provider.  
 
If I agree to take part in this research study, can I be removed from the study without my 
consent?  
It is possible that you may be removed from the research study by the researchers if you do not 
follow all the instructions. You may be removed from the study if you experience unexpected 
side effects and in the opinion of the investigators that it is in your best interest. The study may 
also be stopped by the investigators or the sponsor if it felt that it is in the best interest of the 
patients.  
 
************************************************************************  
 
VOLUNTARY CONSENT  
All of the above has been explained to me and all of my current questions have been answered. I 
understand that I am encouraged to ask questions about any aspect of this research study during 
the course of this study, and that such future questions will be answered by the researchers listed 
on the first page of this form. 
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Any questions which I have about my rights as a research participant will be answered by the 
Human Subject Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-
2668).  
 
I give my permission to use my biological samples or genetic material, with personal identifiers, 
in other research projects involving the study of small bowel transplantation.  
 
Yes ________ No ________  
 
I give my permission to be recontacted to obtain my consent if there is a desire to use my 
biological samples or genetic material, with personal identifiers, in other research projects 
involving the study of different diseases or conditions (i.e. diseases or conditions other than those 
specified in the Description section of this consent form).  
 
Yes ________ No ________  
 
By signing this form, I agree to participate in this research study. A copy of this consent form 
will be given to me.  
 
 
________________________________ __________________  
Participant’s Signature    Date 
 
  
CERTIFICATION of INFORMED CONSENT  
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation. 
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise.”  
 
 
___________________________________ ________________________  
Printed Name of Person Obtaining Consent  Role in Research Study  
 
 
_________________________________ ____________  
Signature of Person Obtaining Consent  Date  
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C.4 ADDENDUM TO CONSENT FORM  
University of Pittsburgh     3459 Fifth Avenue  
School of Medicine      Pittsburgh, PA 15213  
Thomas E. Starzl Transplantation Institute   412-647-1458  
 
ADDENDUM 
CONSENT TO ACT AS PARTICIPANT IN A RESEARCH STUDY 
TITLE: Short- and long-term evaluation of intestinal CYP3A4/5 and p-glycoprotein 
function in small bowel transplant recipients 
 
PRINCIPAL INVESTIGATOR:  
Jennifer Bonner, PharmD, Clinical Pharmacist  
731 Salk Hall, University of Pittsburgh School of Pharmacy  
3501 Terrace Street, Pittsburgh, PA 15261  
Phone: 412/692-2136  
 
Co-investigators:  
Raman Venkataramanan, Ph.D, F.C.P., Professor of Pharmaceutical Sciences and Pathology 718 
Salk Hall, University of Pittsburgh School of Pharmacy  
3501 Terrace Street, Pittsburgh, PA 15261  
Phone: 412-648-8547, Fax: 412-383-7436 
  
Kareem Abu-Elmagd, MD, PhD, Professor of Surgery  
Director, Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax: 412/647-0362  
 
Geoffrey Bond, MD, FRACS, Assistant Professor of Surgery  
Intestinal Rehabilitation and Transplant Center  
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3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax 412/647-0362  
 
Guilherme Costa, MD, Assistant Professor of Surgery  
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax: 412/647-0362 
  
Darlene Koritsky, RN, Researcher  
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-4386, Fax: 412/647-0362 
  
Hossam Kandil, MD, PhD Assistant Professor of Medicine  
University of Pittsburgh School of Medicine  
3471 Fifth Ave, Suite 916, Pittsburgh, PA 15213  
 
Stephen J. O’Keefe, MD, MSc, FRCP, Professor of Medicine  
Intestinal Rehabilitation and Transplant Center  
3459 Fifth Avenue, Pittsburgh, PA 15213  
Phone: 412/647-1458, Fax: 412/647-0362  
 
NEW INFORMATION:  
You are currently a participant in a research study to evaluate the effects of small bowel 
transplantation on oral drug absorption. This study includes a total of two pharmacokinetic study 
sessions where study drugs are given and blood and urine samples are collected.  
 
The original consent form you signed reads that we will take a total of sixteen 3-mL blood 
samples from you at each study session, for a total of 48 mL of blood (approximately three 
tablespoonfuls) at each session.  
 
Review of early study results has shown that taking one additional blood sample at each study 
session will improve estimation of peak concentrations of fexofenadine and tacrolimus. 
Therefore, we request your permission to take seventeen blood samples during each study 
session, for a total of 51 mL of blood (approximately three tablespoonfuls plus one teaspoonful) 
at each session.  
 
The risks associated with blood sampling for measuring drug levels include pain, bruising, 
bleeding, fainting, and risk of infection.  
 
There are no direct benefits to you from taking part in this study. However, the information 
learned from this study will be used in the future to help health professionals such as your doctor 
to determine the best dosing of drugs in small bowel transplant recipients after surgery. 
Therefore, your participation may help others in the future by what the doctors learn from your 
involvement in this study.  
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There is no change in the monetary compensation for study participation.  
 
If you believe that the research procedures have resulted in an injury to you, immediately contact 
the Principal Investigator who is listed on the first page of this form. Emergency medical 
treatment for injuries solely and directly related to your participation in this research study will 
be provided to you by the hospitals of UPMC. Your insurance provider may be billed for the 
costs of this emergency treatment, but none of those costs will be charged directly to you. If your 
research-related injury requires medical care beyond this emergency treatment, you will be 
responsible for the costs of this follow-up care. At this time, there is no plan for any additional 
financial compensation.  
 
RIGHT TO WITHDRAW  
You understand that can withdraw from this research study at any time. Your other care and 
benefits will be the same whether you participate in this research study or not. You also 
understand that you may be removed from this research study by the investigators in the event of 
a significant risk to your health.  
 
******************************************************************************
************  
 
VOLUNTARY CONSENT  
 
All of the above has been explained to me and all of my questions have been answered. I 
understand that, if not already done, I may request that my questions be answered by a 
physician involved in the research study. I also understand that any future questions I have 
about this research will be answered by the investigator(s) listed on the first page of this 
addendum to the consent document at the telephone number(s) listed. Any questions I have 
about my rights as a research subject will be answered by the Human Subject Protection 
Advocate of the IRB Office, University of Pittsburgh (1-866-212-2668). By signing this 
form, I agree to continue to participate in this research study.  
 
 
__________________________________ _______________  
Patient/Subject Signature    Date  
 
 
INVESTIGATOR'S CERTIFICATION  
I certify that I have explained this new information and its significance to the above 
individual and that any questions about this information have been answered. 
  
 
__________________________________ ______________  
Investigator's Signature    Date   
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